{"PMC7215165": [["IntroductionViruses infect millions of individuals each year resulting in serious morbidity (Hutchinson, 2018), birth defects (Rasmussen et al., 2016), and mortality (Campos et al., 2015).", [["birth defects", "DISEASE", 112, 125], ["birth defects", "PROBLEM", 112, 125], ["serious", "OBSERVATION_MODIFIER", 74, 81]]], ["Viruses have the ability to rapidly evolve and transmit through multiple modes such as the respiratory tract (Mazur et al., 2015; Young et al., 2015), digestive tract (Ferrari et al., 2017) and skin (Hamel et al., 2015).", [["respiratory tract", "ANATOMY", 91, 108], ["digestive tract", "ANATOMY", 151, 166], ["skin", "ANATOMY", 194, 198], ["digestive", "ORGAN", 151, 160], ["tract", "ORGANISM_SUBDIVISION", 161, 166], ["skin", "ORGAN", 194, 198], ["Viruses", "PROBLEM", 0, 7], ["the respiratory tract", "PROBLEM", 87, 108], ["respiratory tract", "ANATOMY", 91, 108], ["digestive tract", "ANATOMY", 151, 166], ["skin", "ANATOMY", 194, 198]]], ["Despite many discoveries related to the understanding of different aspects in virology, viruses are still a major cause of disease (Suratanee et al., 2010).", [["viruses", "PROBLEM", 88, 95], ["disease", "PROBLEM", 123, 130]]], ["In recent years, life-threatening viruses such as COVID-19 (Corman et al., 2020; Lorusso et al., 2020), Zika virus (ZIKV) (He et al., 2017; Petersen et al., 2016) and Ebola virus (EBOV) (Baize et al., 2014; Gire et al., 2014) have unexpectedly emerged and were difficult to tackle since there were no approved vaccines or effective treatments for the treatment of these viruses.", [["Ebola virus", "DISEASE", 167, 178], ["Zika virus", "ORGANISM", 104, 114], ["Ebola virus", "ORGANISM", 167, 178], ["EBOV", "ORGANISM", 180, 184], ["Zika virus", "SPECIES", 104, 114], ["Ebola virus", "SPECIES", 167, 178], ["Zika virus", "SPECIES", 104, 114], ["ZIKV", "SPECIES", 116, 120], ["Ebola virus", "SPECIES", 167, 178], ["EBOV", "SPECIES", 180, 184], ["life-threatening viruses", "PROBLEM", 17, 41], ["COVID", "TEST", 50, 55], ["Zika virus", "PROBLEM", 104, 114], ["approved vaccines", "TREATMENT", 301, 318], ["effective treatments", "TREATMENT", 322, 342], ["the treatment", "TREATMENT", 347, 360], ["these viruses", "PROBLEM", 364, 377], ["viruses", "OBSERVATION", 370, 377]]], ["In general, viruses cause significant economic burden to society and most are recognized as a public health emergency of international concern (PHEIC) by the World Health Organization (WHO) (Gostin et al., 2014; Gulland, 2016; Patel and Jernigan, 2020).IntroductionTraditional methods used for virus detection mainly involve cell culture (Hematian et al., 2016; Leland and Ginocchio, 2007), nucleic acids (Dominguez et al., 2018; Payungporn et al., 2006) and antigen-antibodies (Liao et al., 2009; Senthilkumaran et al., 2017).", [["cell", "ANATOMY", 325, 329], ["nucleic acids", "CHEMICAL", 391, 404], ["cell", "CELL", 325, 329], ["nucleic acids", "SIMPLE_CHEMICAL", 391, 404], ["antigen-antibodies", "GENE_OR_GENE_PRODUCT", 459, 477], ["antigen-antibodies", "PROTEIN", 459, 477], ["significant economic burden", "PROBLEM", 26, 53], ["Traditional methods", "TREATMENT", 265, 284], ["virus detection", "TEST", 294, 309], ["cell culture", "TEST", 325, 337], ["nucleic acids", "TEST", 391, 404], ["antigen", "TEST", 459, 466], ["viruses", "OBSERVATION", 12, 19], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["economic", "OBSERVATION_MODIFIER", 38, 46], ["burden", "OBSERVATION", 47, 53]]], ["These methods, especially for nucleic acid detection methods, require expensive equipment and well-trained operators (Eivazzadeh-Keihan et al., 2019; Yeh et al., 2020).", [["nucleic acid detection methods", "TREATMENT", 30, 60], ["expensive equipment", "TREATMENT", 70, 89]]], ["Moreover, these methods are unable to meet the needs of clinical diagnosis as well as provide timely details necessary for large viral outbreaks.", [["large viral outbreaks", "PROBLEM", 123, 144], ["large", "OBSERVATION_MODIFIER", 123, 128], ["viral", "OBSERVATION", 129, 134]]], ["The POC device is currently available in the market (Chin et al., 2012), which is expected to reach USD 52.6 BN by 2025 and will experience a robust compound annual growth rate of 9.75% from 2019 to 2026.", [["The POC device", "TREATMENT", 0, 14]]], ["In response to viral outbreaks, advanced POC diagnostic technology must be equipped for both the home and clinical use.IntroductionMicrofluidic chips, or \u201cLab on a chip\u201d, are versatile and promising technology (Bruijns et al., 2016; Koo et al., 2017; Li et al., 2017; Medlin and Orozco, 2017; Tangchaikeeree et al., 2017) that have the ability to integrate sample preparation, reactions and detection on a micron-scale chip (Basha et al., 2017; Kim et al., 2009; Kovarik et al., 2013; Toren et al., 2016).", [["viral outbreaks", "PROBLEM", 15, 30], ["IntroductionMicrofluidic chips", "TREATMENT", 119, 149], ["viral outbreaks", "OBSERVATION", 15, 30]]], ["This advanced technology has both integrated and miniaturized characteristics, which can integrate a traditional laboratory into a small chip.", [["a small chip", "TREATMENT", 129, 141]]], ["It uses a small amount of detection reagents and samples to obtain accurate test results in a short period of time, which is especially suitable for POC.", [["detection reagents", "TREATMENT", 26, 44], ["accurate test", "TEST", 67, 80], ["small", "OBSERVATION_MODIFIER", 10, 15]]], ["Recently, dramatic paper-based microfluidics (Ahn et al., 2018; Reboud et al., 2019), centrifugal chips (Lee et al., 2006; Li et al., 2019a), wearable microfluidic devices (Gao et al., 2017; Koh et al., 2016; Nyein et al., 2018), digital nucleic acid detection chips (Song et al., 2018; Zhu et al., 2014) and others have been proposed for pathogen detection (Tsougeni et al., 2019) as well as disease screenings (Shuler, 2019) and additional applications (Yin et al., 2019).", [["nucleic acid", "CHEMICAL", 238, 250], ["wearable microfluidic devices", "TREATMENT", 142, 171], ["digital nucleic acid detection chips", "PROBLEM", 230, 266], ["dramatic", "OBSERVATION_MODIFIER", 10, 18]]], ["These microfluidic technologies have been systematically classified and summarized by lots of reviews (Bruijns et al., 2016; Kim et al., 2009; Koo et al., 2017; Kumar et al., 2019; Reinholt and Baeumner, 2014) to promote technological innovation of microfluidic systems.IntroductionThis technology is also well-suited in Point of Care Testing (POCT) in viral detection (Yen et al., 2015).", [["microfluidic systems", "OBSERVATION", 249, 269]]], ["After many efforts, microfluidic technology provides a breakthrough in viral detection, leading it possible to efficiently detect viruses that threaten human health.", [["human", "ORGANISM", 152, 157], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["microfluidic technology", "TREATMENT", 20, 43], ["a breakthrough in viral detection", "PROBLEM", 53, 86]]], ["As shown in Fig. 1, the microfluidics system can be used to detect the viruses both for clinical use and personal use.", [["the microfluidics system", "TREATMENT", 20, 44], ["the viruses", "PROBLEM", 67, 78], ["viruses", "OBSERVATION", 71, 78]]], ["In addition, in response to virus detection, it is also necessary to have a full understanding of the virus including its subtypes, genotypes and other notable characteristics.", [["virus detection", "TEST", 28, 43], ["the virus", "PROBLEM", 98, 107]]], ["In this review, we summarize viruses that have been of concern over recent years (Fig. 2) and discuss the application and performance of microfluidics for their detection.", [["viruses", "PROBLEM", 29, 36], ["their detection", "TEST", 155, 170], ["viruses", "OBSERVATION", 29, 36]]], ["Moreover, we summarize the current shortcomings of microfluidics in viral detection and pave ideas for future development.", [["microfluidics in viral detection", "TREATMENT", 51, 83]]], ["We aim to promote technological innovations of microfluidic chips so they exert maximal effects for future virus outbreaks.Ebola virus (EBOV) ::: Microfluidic chips for virus outbreaksEBOV is an enveloped, negative-stranded RNA virus (de La Vega et al., 2015; de Wit et al., 2011) that belongs to the filoviridae family.", [["Ebola virus", "DISEASE", 123, 134], ["Ebola virus", "ORGANISM", 123, 134], ["EBOV", "ORGANISM", 136, 140], ["virus outbreaksEBOV", "ORGANISM", 169, 188], ["filoviridae", "GENE_OR_GENE_PRODUCT", 301, 312], ["filoviridae family", "PROTEIN", 301, 319], ["Ebola virus", "SPECIES", 123, 134], ["Ebola virus", "SPECIES", 123, 134], ["EBOV", "SPECIES", 136, 140], ["microfluidic chips", "TREATMENT", 47, 65], ["future virus outbreaks", "PROBLEM", 100, 122], ["Microfluidic chips", "TREATMENT", 146, 164], ["virus outbreaksEBOV", "PROBLEM", 169, 188], ["stranded RNA virus", "PROBLEM", 215, 233]]], ["It is known as the Ebola Virus Disease (EVD) and has a high mortality (Broadhurst et al., 2016).", [["Ebola Virus Disease", "DISEASE", 19, 38], ["EVD", "DISEASE", 40, 43], ["Ebola Virus", "ORGANISM", 19, 30], ["Ebola Virus", "SPECIES", 19, 30], ["Ebola Virus", "SPECIES", 19, 30], ["the Ebola Virus Disease", "PROBLEM", 15, 38], ["Ebola Virus", "OBSERVATION", 19, 30], ["high", "OBSERVATION_MODIFIER", 55, 59]]], ["EBOV causes damage to blood vessels, the liver, spleen, kidney and immune system (Malvy et al., 2019).", [["blood vessels", "ANATOMY", 22, 35], ["liver", "ANATOMY", 41, 46], ["spleen", "ANATOMY", 48, 54], ["kidney", "ANATOMY", 56, 62], ["immune system", "ANATOMY", 67, 80], ["EBOV", "DISEASE", 0, 4], ["EBOV", "ORGANISM", 0, 4], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 22, 35], ["liver", "ORGAN", 41, 46], ["spleen", "ORGAN", 48, 54], ["kidney", "ORGAN", 56, 62], ["EBOV", "SPECIES", 0, 4], ["EBOV", "PROBLEM", 0, 4], ["damage to blood vessels", "PROBLEM", 12, 35], ["blood vessels", "ANATOMY", 22, 35], ["liver", "ANATOMY", 41, 46], ["spleen", "ANATOMY", 48, 54], ["kidney", "ANATOMY", 56, 62], ["immune system", "ANATOMY", 67, 80]]], ["EVD symptoms such as fever, muscle pain, vomiting, and diarrhea can occur within 2\u201321 days after a person is infected with EBOV (Martines et al., 2015; Richards et al., 2018).", [["muscle", "ANATOMY", 28, 34], ["EVD symptoms", "DISEASE", 0, 12], ["fever", "DISEASE", 21, 26], ["muscle pain", "DISEASE", 28, 39], ["vomiting", "DISEASE", 41, 49], ["diarrhea", "DISEASE", 55, 63], ["EBOV", "DISEASE", 123, 127], ["muscle", "ORGAN", 28, 34], ["EBOV", "ORGANISM", 123, 127], ["person", "SPECIES", 99, 105], ["EBOV", "SPECIES", 123, 127], ["EVD symptoms", "PROBLEM", 0, 12], ["fever", "PROBLEM", 21, 26], ["muscle pain", "PROBLEM", 28, 39], ["vomiting", "PROBLEM", 41, 49], ["diarrhea", "PROBLEM", 55, 63], ["muscle", "ANATOMY", 28, 34], ["pain", "OBSERVATION", 35, 39]]], ["The EVD is mainly prominent in West Africa, where the major 2014 outbreak infected a total of 28,646 people and led to the death of 11,323 individuals (Kinsman et al., 2017).", [["death", "DISEASE", 123, 128], ["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107], ["EVD", "OBSERVATION", 4, 7], ["mainly", "OBSERVATION_MODIFIER", 11, 17], ["prominent", "OBSERVATION_MODIFIER", 18, 27]]], ["This outbreak was the largest EVD epidemic since the discovery of EBOV in 1976 (Wang et al., 2016).", [["EBOV", "DISEASE", 66, 70], ["EBOV", "ORGANISM", 66, 70], ["EBOV", "SPECIES", 66, 70], ["largest", "OBSERVATION_MODIFIER", 22, 29]]], ["During the outbreak, quantitative reverse transcription polymerase chain reaction (qRT-PCR), the gold standard method, was used to detect the virus (Broadhurst et al., 2016), but was found to be time-consuming as well as expensive (Kaushik et al., 2016; Pinsky et al., 2015).Ebola virus (EBOV) ::: Microfluidic chips for virus outbreaksRecently, microfluidics represents a promising technology for the detection of EBOV.", [["Ebola virus", "DISEASE", 275, 286], ["EBOV", "DISEASE", 415, 419], ["Ebola virus", "ORGANISM", 275, 286], ["EBOV", "ORGANISM", 288, 292], ["EBOV", "ORGANISM", 415, 419], ["Ebola virus", "SPECIES", 275, 286], ["Ebola virus", "SPECIES", 275, 286], ["EBOV", "SPECIES", 288, 292], ["EBOV", "SPECIES", 415, 419], ["quantitative reverse transcription polymerase chain reaction", "PROBLEM", 21, 81], ["Microfluidic chips", "TREATMENT", 298, 316], ["virus outbreaks", "PROBLEM", 321, 336], ["EBOV", "PROBLEM", 415, 419], ["EBOV", "OBSERVATION", 415, 419]]], ["One study (Magro et al., 2017) reported a paper microfluidic chip based on reverse transcription recombinase polymerase amplification (RT-RPA).", [["reverse transcription recombinase polymerase", "PROTEIN", 75, 119], ["One study", "TEST", 0, 9], ["a paper microfluidic chip", "TREATMENT", 40, 65], ["reverse transcription recombinase polymerase amplification", "TREATMENT", 75, 133]]], ["This paper chip has both a positive and negative control area and can detect EBOV in 30 min.", [["EBOV", "ORGANISM", 77, 81], ["EBOV", "SPECIES", 77, 81], ["positive", "OBSERVATION", 27, 35]]], ["Moreover, results from 43 patient samples in Guinea showed that this paper chip has a 90% sensitivity compared to RT-PCR.", [["samples", "ANATOMY", 34, 41], ["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["patient samples in Guinea", "TEST", 26, 51], ["this paper chip", "PROBLEM", 64, 79], ["RT-PCR", "TEST", 114, 120]]], ["Du et al., (2017b) proposed a microfluidic platform to extract and capture EBOV RNA using a photocleavable capture probe.", [["EBOV", "ORGANISM", 75, 79], ["EBOV RNA", "RNA", 75, 83], ["EBOV", "SPECIES", 75, 79], ["a microfluidic platform", "TREATMENT", 28, 51], ["EBOV RNA", "TREATMENT", 75, 83], ["a photocleavable capture probe", "TREATMENT", 90, 120]]], ["Qin et al., (2019) proposed an automated and multiplexing system to detect EBOV RNA (Fig. 3A).", [["EBOV", "ORGANISM", 75, 79], ["EBOV RNA", "RNA", 75, 83], ["EBOV", "SPECIES", 75, 79]]], ["This system can complete 24 assays while using use Cas13a to generate fluorescent reporter RNAs resulting in a LOD of 20 pfu/mL from 10 \u03bcL EBOV RNA within 5 min.Ebola virus (EBOV) ::: Microfluidic chips for virus outbreaksThere are five types of EBOV including the Bundibugyo Ebola virus (BDBV), Reston virus (RESTV), Zaire Ebola virus (ZEBOV), Tai Forest Ebola virus (TAFV) and Sudan Ebola virus (SUDV) (Taniguchi et al., 2012).", [["Ebola virus", "DISEASE", 161, 172], ["Ebola virus", "DISEASE", 324, 335], ["Ebola virus", "DISEASE", 356, 367], ["Ebola virus", "DISEASE", 385, 396], ["Cas13a", "GENE_OR_GENE_PRODUCT", 51, 57], ["EBOV", "ORGANISM", 139, 143], ["Ebola virus", "ORGANISM", 161, 172], ["EBOV", "ORGANISM", 174, 178], ["EBOV", "ORGANISM", 246, 250], ["Bundibugyo Ebola virus", "ORGANISM", 265, 287], ["BDBV", "ORGANISM", 289, 293], ["Reston virus", "ORGANISM", 296, 308], ["RESTV", "ORGANISM", 310, 315], ["Zaire Ebola virus", "ORGANISM", 318, 335], ["ZEBOV", "ORGANISM", 337, 342], ["Tai Forest Ebola virus", "ORGANISM", 345, 367], ["TAFV", "ORGANISM", 369, 373], ["Sudan Ebola virus", "ORGANISM", 379, 396], ["Cas13a", "PROTEIN", 51, 57], ["fluorescent reporter RNAs", "RNA", 70, 95], ["EBOV RNA", "RNA", 139, 147], ["Ebola virus", "SPECIES", 161, 172], ["Bundibugyo Ebola virus", "SPECIES", 265, 287], ["Reston virus", "SPECIES", 296, 308], ["Zaire Ebola virus", "SPECIES", 318, 335], ["Forest Ebola virus", "SPECIES", 349, 367], ["Sudan Ebola virus", "SPECIES", 379, 396], ["EBOV", "SPECIES", 139, 143], ["Ebola virus", "SPECIES", 161, 172], ["EBOV", "SPECIES", 174, 178], ["EBOV", "SPECIES", 246, 250], ["Bundibugyo Ebola virus", "SPECIES", 265, 287], ["BDBV", "SPECIES", 289, 293], ["Reston virus", "SPECIES", 296, 308], ["RESTV", "SPECIES", 310, 315], ["Zaire Ebola virus", "SPECIES", 318, 335], ["ZEBOV", "SPECIES", 337, 342], ["Tai Forest Ebola virus", "SPECIES", 345, 367], ["TAFV", "SPECIES", 369, 373], ["Sudan Ebola virus", "SPECIES", 379, 396], ["SUDV", "SPECIES", 398, 402], ["a LOD", "TEST", 109, 114], ["Microfluidic chips", "TREATMENT", 184, 202], ["virus outbreaks", "PROBLEM", 207, 222], ["EBOV", "PROBLEM", 246, 250], ["the Bundibugyo Ebola virus", "TEST", 261, 287], ["BDBV", "TEST", 289, 293], ["Reston virus (RESTV", "TEST", 296, 315], ["Zaire Ebola virus", "PROBLEM", 318, 335], ["ZEBOV", "TEST", 337, 342], ["Tai Forest Ebola virus", "PROBLEM", 345, 367], ["Sudan Ebola virus", "PROBLEM", 379, 396], ["five types", "OBSERVATION_MODIFIER", 232, 242], ["EBOV", "OBSERVATION", 246, 250]]], ["Four (EBOV, SUDV, BDBV, TAFV) of the five subtypes are extremely severe and detrimental to humans (Khan et al., 2015).", [["EBOV", "ORGANISM", 6, 10], ["SUDV", "GENE_OR_GENE_PRODUCT", 12, 16], ["BDBV", "GENE_OR_GENE_PRODUCT", 18, 22], ["TAFV", "GENE_OR_GENE_PRODUCT", 24, 28], ["humans", "ORGANISM", 91, 97], ["BDBV", "PROTEIN", 18, 22], ["TAFV", "PROTEIN", 24, 28], ["humans", "SPECIES", 91, 97], ["EBOV", "SPECIES", 6, 10], ["SUDV", "SPECIES", 12, 16], ["BDBV", "SPECIES", 18, 22], ["humans", "SPECIES", 91, 97], ["EBOV", "TEST", 6, 10], ["SUDV", "TEST", 12, 16], ["extremely", "OBSERVATION_MODIFIER", 55, 64], ["severe", "OBSERVATION", 65, 71]]], ["It is necessary to study microfluidic system capabilities for the detection of various EBOV types.", [["EBOV", "ORGANISM", 87, 91], ["EBOV", "SPECIES", 87, 91], ["various EBOV types", "PROBLEM", 79, 97], ["EBOV types", "OBSERVATION", 87, 97]]], ["Magro et al. also developed a multiplex paper chip to detect three types of EBOV based on RPA (Magro et al., 2017) (Fig. 3 B).", [["EBOV", "ORGANISM", 76, 80], ["EBOV", "SPECIES", 76, 80], ["a multiplex paper chip", "PROBLEM", 28, 50], ["EBOV", "PROBLEM", 76, 80], ["RPA", "TEST", 90, 93], ["EBOV", "OBSERVATION", 76, 80]]], ["Piraino et al., (2016) developed a microfluidic chip that combined digital and analog technologies.", [["a microfluidic chip", "TREATMENT", 33, 52], ["analog technologies", "TREATMENT", 79, 98], ["microfluidic chip", "OBSERVATION", 35, 52]]], ["This chip contains a high dynamic range and can simultaneously detect three types of EBOV with a LOD of 1pM from 5 \u03bcL of serum.", [["serum", "ANATOMY", 121, 126], ["EBOV", "ORGANISM", 85, 89], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["EBOV", "SPECIES", 85, 89], ["This chip", "TEST", 0, 9], ["serum", "TEST", 121, 126], ["high dynamic", "OBSERVATION_MODIFIER", 21, 33], ["EBOV", "OBSERVATION", 85, 89]]], ["Brangel et al. (Brangel et al., 2018) reported a paper and smartphone-based platform to detect IgG antibodies against the virus in sera.", [["sera", "ANATOMY", 131, 135], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 95, 109], ["sera", "ORGANISM_SUBSTANCE", 131, 135], ["IgG antibodies", "PROTEIN", 95, 109], ["IgG antibodies", "TEST", 95, 109], ["the virus in sera", "PROBLEM", 118, 135], ["et al", "OBSERVATION", 8, 13]]], ["Detection results testing 90 survivors and 31 uninfected individuals revealed 100% sensitivity (Fig. 3 C).", [["uninfected individuals", "TEST", 46, 68]]], ["Moreover, this platform was able to detect three types of EBOV.", [["EBOV", "DISEASE", 58, 62], ["EBOV", "ORGANISM", 58, 62], ["EBOV", "SPECIES", 58, 62], ["EBOV", "PROBLEM", 58, 62], ["EBOV", "OBSERVATION", 58, 62]]], ["More recently, Lin et al. (Lin et al., 2019) developed a disc chip to detect the four EBOVs using the reverse transcription loop-mediated isothermal amplification (RT-LAMP) method (Fig. 3 D).", [["a disc chip", "PROBLEM", 55, 66], ["the reverse transcription loop", "TREATMENT", 98, 128], ["mediated isothermal amplification", "TREATMENT", 129, 162], ["RT-LAMP) method", "TREATMENT", 164, 179], ["disc", "ANATOMY", 57, 61]]], ["The LOD of this system is 1 copy/\u03bcL for SUDV, 100 copies/\u03bcL for EBOV, 1000 copies/\u03bcL for BDBV and 10 copies/\u03bcL for TAFV detected in 50 min.Ebola virus (EBOV) ::: Microfluidic chips for virus outbreaksState-of-the art microfluidic detection systems can achieve cost-effective, quick (reported at 5 min) and accurate (as low as 1 copy) detection for EBOV at POC.", [["BDBV", "CHEMICAL", 89, 93], ["TAFV", "CHEMICAL", 115, 119], ["Ebola virus", "DISEASE", 139, 150], ["EBOV", "ORGANISM", 64, 68], ["BDBV", "CANCER", 89, 93], ["Ebola virus", "ORGANISM", 139, 150], ["EBOV", "ORGANISM", 152, 156], ["EBOV", "ORGANISM", 348, 352], ["TAFV", "PROTEIN", 115, 119], ["Ebola virus", "SPECIES", 139, 150], ["EBOV", "SPECIES", 64, 68], ["BDBV", "SPECIES", 89, 93], ["TAFV", "SPECIES", 115, 119], ["Ebola virus", "SPECIES", 139, 150], ["EBOV", "SPECIES", 152, 156], ["EBOV", "SPECIES", 348, 352], ["SUDV", "TEST", 40, 44], ["EBOV", "PROBLEM", 64, 68], ["BDBV", "TEST", 89, 93], ["TAFV", "TEST", 115, 119], ["Microfluidic chips", "TREATMENT", 162, 180], ["virus outbreaks", "PROBLEM", 185, 200], ["the art microfluidic detection systems", "TREATMENT", 209, 247], ["EBOV", "PROBLEM", 348, 352]]], ["However, some chips lack sample preparation or require additional instrumentation, which is not suitable in resource-limited settings for POC.", [["some chips lack sample preparation", "TREATMENT", 9, 43], ["additional instrumentation", "TREATMENT", 55, 81]]], ["Moreover, due to the high contagious rate and characteristics of the multiple EBOV subtypes, low-cost multiplex detection chips should be developed.Human immunodeficiency virus (HIV) ::: Microfluidic chips for virus outbreaksHIV is a single-stranded RNA virus that results in acquired immunodeficiency syndrome (AIDS) (Watts et al., 2009).", [["Human immunodeficiency virus", "DISEASE", 148, 176], ["HIV", "DISEASE", 225, 228], ["acquired immunodeficiency syndrome", "DISEASE", 276, 310], ["AIDS", "DISEASE", 312, 316], ["EBOV", "ORGANISM", 78, 82], ["Human immunodeficiency virus", "ORGANISM", 148, 176], ["HIV", "ORGANISM", 178, 181], ["HIV", "ORGANISM", 225, 228], ["Human immunodeficiency virus", "SPECIES", 148, 176], ["HIV", "SPECIES", 178, 181], ["HIV", "SPECIES", 225, 228], ["EBOV", "SPECIES", 78, 82], ["Human immunodeficiency virus", "SPECIES", 148, 176], ["HIV", "SPECIES", 178, 181], ["HIV", "SPECIES", 225, 228], ["the high contagious rate", "PROBLEM", 17, 41], ["the multiple EBOV subtypes", "PROBLEM", 65, 91], ["low-cost multiplex detection chips", "TREATMENT", 93, 127], ["Human immunodeficiency virus", "PROBLEM", 148, 176], ["Microfluidic chips", "TREATMENT", 187, 205], ["virus outbreaksHIV", "PROBLEM", 210, 228], ["a single-stranded RNA virus", "PROBLEM", 232, 259], ["acquired immunodeficiency syndrome", "PROBLEM", 276, 310], ["multiple", "OBSERVATION_MODIFIER", 69, 77], ["EBOV", "OBSERVATION", 78, 82], ["low", "OBSERVATION_MODIFIER", 93, 96], ["immunodeficiency syndrome", "OBSERVATION", 285, 310]]], ["HIV attacks T lymphocytes and integrates into the chromosomes of its host, which in turn leads to defects in the human immune system causing irreparable damage to the body (Druce et al., 2016; Kuznetsov et al., 2003; Shourian and Qureshi, 2019).", [["T lymphocytes", "ANATOMY", 12, 25], ["chromosomes", "ANATOMY", 50, 61], ["immune system", "ANATOMY", 119, 132], ["body", "ANATOMY", 167, 171], ["HIV", "ORGANISM", 0, 3], ["T lymphocytes", "CELL", 12, 25], ["chromosomes", "CELLULAR_COMPONENT", 50, 61], ["human", "ORGANISM", 113, 118], ["body", "ORGANISM_SUBDIVISION", 167, 171], ["T lymphocytes", "CELL_TYPE", 12, 25], ["chromosomes", "DNA", 50, 61], ["HIV", "SPECIES", 0, 3], ["human", "SPECIES", 113, 118], ["HIV", "SPECIES", 0, 3], ["human", "SPECIES", 113, 118], ["HIV attacks T lymphocytes", "PROBLEM", 0, 25], ["defects in the human immune system", "PROBLEM", 98, 132], ["irreparable damage to the body", "PROBLEM", 141, 171], ["host", "OBSERVATION_MODIFIER", 69, 73], ["defects", "OBSERVATION", 98, 105], ["human immune", "OBSERVATION", 113, 125], ["irreparable", "OBSERVATION_MODIFIER", 141, 152], ["damage", "OBSERVATION", 153, 159], ["body", "ANATOMY", 167, 171]]], ["More than 37 million people live with HIV and infect about 2 million more every year (Anampa et al., 2020).", [["HIV", "DISEASE", 38, 41], ["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 38, 41], ["HIV", "PROBLEM", 38, 41]]], ["This has been occurring since the first case of HIV infection in the early 1980s (Bao and Shao, 2018).", [["HIV infection", "DISEASE", 48, 61], ["HIV", "ORGANISM", 48, 51], ["HIV", "SPECIES", 48, 51], ["HIV", "SPECIES", 48, 51], ["HIV infection", "PROBLEM", 48, 61], ["infection", "OBSERVATION", 52, 61]]], ["Early HIV diagnosis can reduce transmission through behavioral preventive measures and aid in the treatment of infected individuals through treatment strategies such as anti-retroviral therapies (ART) (Choi et al., 2014).", [["HIV", "SPECIES", 6, 9], ["HIV", "SPECIES", 6, 9], ["behavioral preventive measures", "TREATMENT", 52, 82], ["the treatment", "TREATMENT", 94, 107], ["infected individuals", "PROBLEM", 111, 131], ["treatment strategies", "TREATMENT", 140, 160], ["anti-retroviral therapies", "TREATMENT", 169, 194], ["infected", "OBSERVATION", 111, 119]]], ["However, only 10%\u201351% of infected individuals are aware they are infected, most of who live in resource-limited areas where they are not able to readily be tested (WHO, 2010).", [["individuals", "ORGANISM", 34, 45]]], ["Therefore, POC for early diagnosis of HIV is particularly important.Human immunodeficiency virus (HIV) ::: Microfluidic chips for virus outbreaksInvestigators have applied microfluidics to POC for HIV and achieved encouraging results (Mauk et al., 2017).", [["HIV", "DISEASE", 38, 41], ["Human immunodeficiency virus", "DISEASE", 68, 96], ["HIV", "ORGANISM", 38, 41], ["Human immunodeficiency virus", "ORGANISM", 68, 96], ["HIV", "ORGANISM", 98, 101], ["HIV", "ORGANISM", 197, 200], ["Human immunodeficiency virus", "SPECIES", 68, 96], ["HIV", "SPECIES", 98, 101], ["HIV", "SPECIES", 38, 41], ["Human immunodeficiency virus", "SPECIES", 68, 96], ["HIV", "SPECIES", 98, 101], ["HIV", "SPECIES", 197, 200], ["HIV", "PROBLEM", 38, 41], ["Human immunodeficiency virus", "PROBLEM", 68, 96], ["Microfluidic chips", "TREATMENT", 107, 125], ["virus outbreaks", "PROBLEM", 130, 145], ["HIV", "PROBLEM", 197, 200], ["HIV", "OBSERVATION", 38, 41]]], ["Glynn et al. (Glynn et al., 2014) reported a microfluidic chip based on the number of CD4+ cells and magnetophoresis to detect AIDS (Fig. 4A).", [["CD4+ cells", "ANATOMY", 86, 96], ["AIDS", "DISEASE", 127, 131], ["CD4", "GENE_OR_GENE_PRODUCT", 86, 89], ["CD4", "PROTEIN", 86, 89], ["a microfluidic chip", "TREATMENT", 43, 62], ["CD4+ cells", "PROBLEM", 86, 96], ["magnetophoresis", "TREATMENT", 101, 116], ["AIDS", "PROBLEM", 127, 131]]], ["This chip uses CD4+ cell numbers to judge HIV infection in the blood and contains a capture efficiency of 93.0%.", [["CD4+ cell", "ANATOMY", 15, 24], ["blood", "ANATOMY", 63, 68], ["HIV infection", "DISEASE", 42, 55], ["CD4", "GENE_OR_GENE_PRODUCT", 15, 18], ["HIV", "ORGANISM", 42, 45], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["CD4", "PROTEIN", 15, 18], ["HIV", "SPECIES", 42, 45], ["HIV", "SPECIES", 42, 45], ["CD4+ cell numbers", "PROBLEM", 15, 32], ["HIV infection in the blood", "PROBLEM", 42, 68], ["a capture efficiency", "TEST", 82, 102], ["cell numbers", "OBSERVATION", 20, 32], ["HIV", "OBSERVATION_MODIFIER", 42, 45], ["infection", "OBSERVATION", 46, 55], ["blood", "ANATOMY", 63, 68], ["capture efficiency", "OBSERVATION", 84, 102]]], ["It does not need an additional pump and can be operated manually.", [["an additional pump", "TREATMENT", 17, 35]]], ["Liu et al. also proposed microfluidic chips based on the number of CD4 + cells as well as immunomagnetic separation to detect HIV infection.", [["CD4 + cells", "ANATOMY", 67, 78], ["HIV infection", "DISEASE", 126, 139], ["CD4", "GENE_OR_GENE_PRODUCT", 67, 70], ["HIV", "ORGANISM", 126, 129], ["CD4", "PROTEIN", 67, 70], ["HIV", "SPECIES", 126, 129], ["proposed microfluidic chips", "TREATMENT", 16, 43], ["CD4 + cells", "PROBLEM", 67, 78], ["immunomagnetic separation", "TREATMENT", 90, 115], ["HIV infection", "PROBLEM", 126, 139], ["microfluidic chips", "OBSERVATION", 25, 43], ["CD4 + cells", "OBSERVATION", 67, 78], ["HIV", "OBSERVATION_MODIFIER", 126, 129], ["infection", "OBSERVATION", 130, 139]]], ["However, DNA content was used to quantify CD4+ cells.", [["CD4+ cells", "ANATOMY", 42, 52], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["CD4", "GENE_OR_GENE_PRODUCT", 42, 45], ["CD4", "PROTEIN", 42, 45], ["DNA content", "PROBLEM", 9, 20], ["CD4+ cells", "PROBLEM", 42, 52]]], ["This chip can obtain accurate results from 10\u03bcL of whole blood, which is consist with flow cytometry analysis.", [["whole blood", "ANATOMY", 51, 62], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["whole blood", "TEST", 51, 62], ["flow cytometry analysis", "TEST", 86, 109], ["flow cytometry", "OBSERVATION", 86, 100]]], ["Based on the principle of CD4 + cell detection, Alere Pima \u2122 CD4 was launched in 2010 and provides results within 20 min.Human immunodeficiency virus (HIV) ::: Microfluidic chips for virus outbreaksRT-LAMP is widely used for the detection of HIV RNA in a microfluidic system (Jangam et al., 2013; Sun et al., 2013; Zanoli and Spoto, 2013).", [["CD4 + cell", "ANATOMY", 26, 36], ["Human immunodeficiency virus", "DISEASE", 121, 149], ["CD4", "GENE_OR_GENE_PRODUCT", 26, 29], ["Human immunodeficiency virus", "ORGANISM", 121, 149], ["HIV", "ORGANISM", 151, 154], ["HIV", "ORGANISM", 242, 245], ["CD4", "PROTEIN", 26, 29], ["CD4", "PROTEIN", 61, 64], ["HIV RNA", "RNA", 242, 249], ["Human immunodeficiency virus", "SPECIES", 121, 149], ["HIV", "SPECIES", 151, 154], ["HIV", "SPECIES", 242, 245], ["Human immunodeficiency virus", "SPECIES", 121, 149], ["HIV", "SPECIES", 151, 154], ["HIV", "SPECIES", 242, 245], ["Human immunodeficiency virus", "PROBLEM", 121, 149], ["Microfluidic chips", "TREATMENT", 160, 178], ["virus outbreaksRT", "TREATMENT", 183, 200], ["HIV RNA", "PROBLEM", 242, 249], ["cell", "OBSERVATION", 32, 36]]], ["Damhorst et al., (2015) developed a microfluidic platform that integrated RT-LAMP and the smartphone to detect HIV load (Fig. 4 B).", [["HIV", "ORGANISM", 111, 114], ["HIV", "SPECIES", 111, 114], ["the smartphone", "TEST", 86, 100], ["HIV load", "PROBLEM", 111, 119]]], ["Cell lysis buffer combined with a microfluidic chip was used to treat whole blood and complete RT-LAMP On-chip.", [["Cell", "ANATOMY", 0, 4], ["whole blood", "ANATOMY", 70, 81], ["Cell", "CELL", 0, 4], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["Cell lysis buffer", "TREATMENT", 0, 17], ["a microfluidic chip", "TREATMENT", 32, 51], ["whole blood", "PROBLEM", 70, 81], ["LAMP On-chip", "TREATMENT", 98, 110]]], ["As long as a concentration of 670 viral particles are contained in each microliter of whole blood, the virus can be detected.", [["whole blood", "ANATOMY", 86, 97], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["viral particles", "PROBLEM", 34, 49], ["the virus", "PROBLEM", 99, 108], ["viral particles", "OBSERVATION", 34, 49], ["virus", "OBSERVATION", 103, 108]]], ["In more recent studies, Phillips et al. (Phillips et al., 2019) engineered an autonomous analysis device (microRAAD) instrument that detects HIV in whole blood (Fig. 4 C).", [["whole blood", "ANATOMY", 148, 159], ["HIV", "ORGANISM", 141, 144], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["HIV", "SPECIES", 141, 144], ["HIV", "SPECIES", 141, 144], ["an autonomous analysis device (microRAAD) instrument", "TREATMENT", 75, 127], ["HIV", "PROBLEM", 141, 144]]], ["A lateral flow immunoassay (LFIA) was used to visualize the product of RT-LAMP.", [["A lateral flow immunoassay", "TEST", 0, 26]]], ["This instrument achieves a limit of detection (LOD) of 100 HIV-1 RNA copies within 90 min.", [["LOD", "TEST", 47, 50], ["HIV", "PROBLEM", 59, 62]]], ["Chen et al. (Chen et al., 2016) developed a chip that can detect anti-HIV antibodies and HIV RNA, simultaneously.", [["HIV", "ORGANISM", 89, 92], ["anti-HIV antibodies", "PROTEIN", 65, 84], ["HIV RNA", "RNA", 89, 96], ["HIV", "SPECIES", 89, 92], ["HIV", "SPECIES", 89, 92], ["a chip", "PROBLEM", 42, 48], ["anti-HIV antibodies", "PROBLEM", 65, 84], ["HIV RNA", "PROBLEM", 89, 96]]], ["This chip meets serological requirements and detects HIV RNA as low as 103 viral particles/ml from saliva or blood.Human immunodeficiency virus (HIV) ::: Microfluidic chips for virus outbreaksPaper-based microfluidics is also an effective tool for HIV detection.", [["saliva", "ANATOMY", 99, 105], ["blood", "ANATOMY", 109, 114], ["Human immunodeficiency virus", "DISEASE", 115, 143], ["HIV", "ORGANISM", 53, 56], ["saliva", "ORGANISM_SUBSTANCE", 99, 105], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["Human immunodeficiency virus", "ORGANISM", 115, 143], ["HIV", "ORGANISM", 145, 148], ["HIV", "ORGANISM", 248, 251], ["HIV RNA", "RNA", 53, 60], ["Human immunodeficiency virus", "SPECIES", 115, 143], ["HIV", "SPECIES", 145, 148], ["HIV", "SPECIES", 53, 56], ["Human immunodeficiency virus", "SPECIES", 115, 143], ["HIV", "SPECIES", 145, 148], ["HIV", "SPECIES", 248, 251], ["serological requirements", "TEST", 16, 40], ["HIV RNA", "PROBLEM", 53, 60], ["saliva", "PROBLEM", 99, 105], ["blood", "PROBLEM", 109, 114], ["Human immunodeficiency virus", "PROBLEM", 115, 143], ["Microfluidic chips", "TREATMENT", 154, 172], ["virus outbreaks", "PROBLEM", 177, 192], ["HIV detection", "TEST", 248, 261], ["blood", "ANATOMY", 109, 114]]], ["Zhao and Liu, (2016) proposed a paper electrochemical microfluidic system for the diagnosis of an HIV/HCV co-infection.", [["HIV/HCV co-infection", "DISEASE", 98, 118], ["HIV", "ORGANISM", 98, 101], ["HCV", "ORGANISM", 102, 105], ["HIV", "SPECIES", 98, 101], ["HCV", "SPECIES", 102, 105], ["an HIV/HCV co-infection", "PROBLEM", 95, 118], ["HIV", "OBSERVATION", 98, 101], ["HCV co-infection", "OBSERVATION", 102, 118]]], ["This paper system contains multi-channels and uses ELISA to detect antibodies in serum samples.", [["serum samples", "ANATOMY", 81, 94], ["serum samples", "ORGANISM_SUBSTANCE", 81, 94], ["antibodies", "PROTEIN", 67, 77], ["ELISA", "TEST", 51, 56], ["antibodies in serum samples", "TEST", 67, 94]]], ["This system can detect 300 pg/ml HIV and 750 pg/ml Hepatitis C virus (HCV) within 20 min.", [["Hepatitis C", "DISEASE", 51, 62], ["HIV", "ORGANISM", 33, 36], ["Hepatitis C virus", "ORGANISM", 51, 68], ["HCV", "ORGANISM", 70, 73], ["Hepatitis C virus", "SPECIES", 51, 68], ["HIV", "SPECIES", 33, 36], ["Hepatitis C virus", "SPECIES", 51, 68], ["HCV", "SPECIES", 70, 73], ["HIV", "PROBLEM", 33, 36], ["Hepatitis C virus", "PROBLEM", 51, 68]]], ["Kurdekar et al. (Kurdekar et al., 2016) use carbon dots, Whatman filter paper and nitrocellulose paper to detect the HIV antigen.", [["carbon dots", "CHEMICAL", 44, 55], ["carbon", "CHEMICAL", 44, 50], ["nitrocellulose", "CHEMICAL", 82, 96], ["carbon dots", "SIMPLE_CHEMICAL", 44, 55], ["HIV antigen", "PROTEIN", 117, 128], ["HIV", "SPECIES", 117, 120], ["carbon dots", "TREATMENT", 44, 55], ["Whatman filter paper", "TREATMENT", 57, 77], ["the HIV antigen", "PROBLEM", 113, 128]]], ["Results suggest that assays using nitrocellulose paper have higher detection ranges (10 \u03bcg/mL to 250 pg/mL) and sensitivities (fourfold) compared to assays using Whatman filter paper.", [["nitrocellulose", "CHEMICAL", 34, 48], ["nitrocellulose paper", "TREATMENT", 34, 54], ["Whatman filter paper", "TREATMENT", 162, 182]]], ["Li et al. (Li and Liu, 2016) (Fig. 4 D) developed an origami nanobiosensor based on paper and zinc oxide nanowires (ZnO NWs) to detect HIV.", [["Li", "CHEMICAL", 0, 2], ["Li", "CHEMICAL", 11, 13], ["zinc oxide", "CHEMICAL", 94, 104], ["ZnO NWs", "CHEMICAL", 116, 123], ["zinc oxide", "CHEMICAL", 94, 104], ["ZnO", "CHEMICAL", 116, 119], ["zinc oxide nanowires", "SIMPLE_CHEMICAL", 94, 114], ["ZnO NWs", "SIMPLE_CHEMICAL", 116, 123], ["HIV", "ORGANISM", 135, 138], ["HIV", "SPECIES", 135, 138], ["HIV", "SPECIES", 135, 138], ["an origami nanobiosensor", "TREATMENT", 50, 74], ["paper and zinc oxide nanowires (ZnO NWs", "TREATMENT", 84, 123], ["HIV", "PROBLEM", 135, 138], ["HIV", "OBSERVATION", 135, 138]]], ["ZnO NWs was used to increase the surface area of electrodes as well as binding capacity.", [["surface area", "ANATOMY", 33, 45], ["ZnO", "CHEMICAL", 0, 3], ["ZnO", "CHEMICAL", 0, 3], ["ZnO NWs", "SIMPLE_CHEMICAL", 0, 7], ["ZnO NWs", "TREATMENT", 0, 7], ["the surface area of electrodes", "TREATMENT", 29, 59], ["binding capacity", "TEST", 71, 87], ["surface", "OBSERVATION_MODIFIER", 33, 40], ["binding capacity", "OBSERVATION", 71, 87]]], ["This biosensor utilizes an electrochemical impedance spectroscopy (EIS) method to achieve a LOD of 60 fg mL \u22121.", [["an electrochemical impedance spectroscopy (EIS) method", "TREATMENT", 24, 78], ["a LOD", "TEST", 90, 95]]], ["In addition, OraQuick\u00ae, developed by OraSure Technologies\u2122, can detect the HIV antibodies in saliva and the specificity can reach 99.98%.Human immunodeficiency virus (HIV) ::: Microfluidic chips for virus outbreaksWith the goal of detecting HIV, these studies were mainly performed analyzing CD4 + cells, nucleic acids and antigen-antibody reactions in microfluidic chips.", [["CD4 + cells", "ANATOMY", 292, 303], ["Human immunodeficiency virus", "DISEASE", 137, 165], ["nucleic acids", "CHEMICAL", 305, 318], ["OraQuick\u00ae", "SIMPLE_CHEMICAL", 13, 22], ["HIV", "ORGANISM", 75, 78], ["saliva", "ORGANISM_SUBSTANCE", 93, 99], ["Human immunodeficiency virus", "ORGANISM", 137, 165], ["HIV", "ORGANISM", 167, 170], ["HIV", "ORGANISM", 241, 244], ["CD4", "GENE_OR_GENE_PRODUCT", 292, 295], ["nucleic acids", "SIMPLE_CHEMICAL", 305, 318], ["HIV antibodies", "PROTEIN", 75, 89], ["CD4", "PROTEIN", 292, 295], ["HIV", "SPECIES", 75, 78], ["Human immunodeficiency virus", "SPECIES", 137, 165], ["HIV", "SPECIES", 167, 170], ["HIV", "SPECIES", 241, 244], ["HIV", "SPECIES", 75, 78], ["Human immunodeficiency virus", "SPECIES", 137, 165], ["HIV", "SPECIES", 167, 170], ["HIV", "SPECIES", 241, 244], ["the HIV antibodies in saliva", "PROBLEM", 71, 99], ["the specificity", "TEST", 104, 119], ["Human immunodeficiency virus", "PROBLEM", 137, 165], ["Microfluidic chips", "TREATMENT", 176, 194], ["virus", "PROBLEM", 199, 204], ["HIV", "PROBLEM", 241, 244], ["these studies", "TEST", 246, 259], ["nucleic acids", "TEST", 305, 318], ["antigen", "TEST", 323, 330], ["antibody reactions", "PROBLEM", 331, 349], ["microfluidic chips", "TREATMENT", 353, 371], ["microfluidic chips", "OBSERVATION", 353, 371]]], ["Other methods such as RPA (Crannell et al., 2014; Lillis et al., 2016) and helicase dependent amplification (HDA) (Jordan et al., 2012) are also available in microfluidic chips.", [["helicase dependent amplification", "TREATMENT", 75, 107]]], ["These chips demonstrate quicker detection speeds, lower detection limits and more optimal portability when compared to traditional laboratory methods.", [["traditional laboratory methods", "TEST", 119, 149]]], ["However, some chips do not integrate sample preparation and are not suitable for POC.", [["some chips", "TREATMENT", 9, 19]]], ["Moreover, based on the presence of a maternal antibody or absence of a host antibody, methods to detect antibodies cannot be used to accurately diagnose HIV early (Rosenberg et al., 2015; Shafiee et al., 2015; Yan et al., 2019).", [["HIV", "ORGANISM", 153, 156], ["maternal antibody", "PROTEIN", 37, 54], ["host antibody", "PROTEIN", 71, 84], ["antibodies", "PROTEIN", 104, 114], ["HIV", "SPECIES", 153, 156], ["HIV", "SPECIES", 153, 156], ["a maternal antibody", "PROBLEM", 35, 54], ["a host antibody", "PROBLEM", 69, 84], ["antibodies", "PROBLEM", 104, 114]]], ["Therefore, more innovative microfluidic technologies need to be developed, specifically ones that are user-friendly and affordable.Influenza virus ::: Microfluidic chips for virus outbreaksThe influenza virus results in significant morbidity and mortality causing a major public health concern worldwide (Bedford et al., 2015).", [["Influenza virus", "DISEASE", 131, 146], ["influenza virus", "DISEASE", 193, 208], ["Influenza virus", "ORGANISM", 131, 146], ["influenza virus", "ORGANISM", 193, 208], ["Influenza virus", "SPECIES", 131, 146], ["influenza virus", "SPECIES", 193, 208], ["Influenza virus", "SPECIES", 131, 146], ["influenza virus", "SPECIES", 193, 208], ["innovative microfluidic technologies", "TREATMENT", 16, 52], ["Microfluidic chips", "TREATMENT", 151, 169], ["virus outbreaks", "PROBLEM", 174, 189], ["The influenza virus", "PROBLEM", 189, 208], ["influenza virus", "OBSERVATION", 193, 208]]], ["The virulence of the influenza virus is reflected in the immunogen of its enveloped protein (Kaiser, 2006).", [["influenza", "DISEASE", 21, 30], ["influenza virus", "ORGANISM", 21, 36], ["enveloped protein", "PROTEIN", 74, 91], ["influenza virus", "SPECIES", 21, 36], ["influenza virus", "SPECIES", 21, 36], ["the influenza virus", "PROBLEM", 17, 36], ["influenza virus", "OBSERVATION", 21, 36]]], ["Infected individuals suffer from severe viral pneumonia and acute lung injury (Guo and Thomas, 2017).", [["lung", "ANATOMY", 66, 70], ["pneumonia", "DISEASE", 46, 55], ["acute lung injury", "DISEASE", 60, 77], ["individuals", "ORGANISM", 9, 20], ["lung", "ORGAN", 66, 70], ["Infected individuals", "PROBLEM", 0, 20], ["severe viral pneumonia", "PROBLEM", 33, 55], ["acute lung injury", "PROBLEM", 60, 77], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["viral", "OBSERVATION_MODIFIER", 40, 45], ["pneumonia", "OBSERVATION", 46, 55], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["lung", "ANATOMY", 66, 70], ["injury", "OBSERVATION", 71, 77]]], ["The WHO estimates that influenza viruses infect approximately 5\u201315% of the world population and cause 250,000\u2013500,000 deaths each year (Vemula et al., 2016).", [["influenza viruses", "DISEASE", 23, 40], ["deaths", "DISEASE", 118, 124], ["influenza viruses", "ORGANISM", 23, 40], ["influenza viruses infect", "PROBLEM", 23, 47]]], ["There are four types of influenza viruses including influenzas A, B, C and D. Among these, influenza virus A infects humans and other animals such as pigs and birds.", [["influenza viruses", "DISEASE", 24, 41], ["influenza virus A", "DISEASE", 91, 108], ["influenza viruses", "ORGANISM", 24, 41], ["influenzas A", "ORGANISM", 52, 64], ["B, C", "ORGANISM", 66, 70], ["influenza virus A", "ORGANISM", 91, 108], ["humans", "ORGANISM", 117, 123], ["pigs", "ORGANISM", 150, 154], ["birds", "ORGANISM", 159, 164], ["influenza virus", "SPECIES", 91, 106], ["humans", "SPECIES", 117, 123], ["pigs", "SPECIES", 150, 154], ["influenza virus A", "SPECIES", 91, 108], ["humans", "SPECIES", 117, 123], ["pigs", "SPECIES", 150, 154], ["influenza viruses", "PROBLEM", 24, 41], ["influenzas", "TEST", 52, 62], ["influenza virus", "PROBLEM", 91, 106], ["four types", "OBSERVATION_MODIFIER", 10, 20], ["influenza viruses", "OBSERVATION", 24, 41], ["influenza virus", "OBSERVATION", 91, 106]]], ["Influenza viruses B and C only infects humans.", [["Influenza viruses B", "DISEASE", 0, 19], ["Influenza viruses B", "ORGANISM", 0, 19], ["C", "GENE_OR_GENE_PRODUCT", 24, 25], ["humans", "ORGANISM", 39, 45], ["Influenza", "SPECIES", 0, 9], ["humans", "SPECIES", 39, 45], ["humans", "SPECIES", 39, 45], ["Influenza viruses B", "PROBLEM", 0, 19], ["viruses", "OBSERVATION", 10, 17]]], ["Influenza virus A can be presented in 144 various subtypes based on combinations of 18 hemagglutinin (HA,H1\u2013H18) and neuraminidase (NA,N1\u2013N11) (Petrova and Russell, 2018; Tewawong et al., 2017).", [["Influenza virus A", "ORGANISM", 0, 17], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 87, 100], ["HA", "GENE_OR_GENE_PRODUCT", 102, 104], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 117, 130], ["hemagglutinin", "PROTEIN", 87, 100], ["HA", "PROTEIN", 102, 104], ["H1", "PROTEIN", 105, 107], ["H18", "PROTEIN", 108, 111], ["neuraminidase", "PROTEIN", 117, 130], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus A", "PROBLEM", 0, 17], ["18 hemagglutinin (HA", "TREATMENT", 84, 104], ["H1\u2013H18", "TREATMENT", 105, 111], ["neuraminidase (NA", "TREATMENT", 117, 134]]], ["To prevent the spread of influenza and reduce economic and health burdens, accurate and rapid detection methods for the virus are necessary.Influenza virus ::: Microfluidic chips for virus outbreaksCurrently, the influenza virus is a health concern for \u201clab on a chip\u201d (Anderson et al., 2019; Singh et al., 2017; Vemula et al., 2016; Xu et al., 2010; Zhu et al., 2020).", [["influenza", "DISEASE", 25, 34], ["Influenza virus", "DISEASE", 140, 155], ["influenza virus", "DISEASE", 213, 228], ["Influenza virus", "ORGANISM", 140, 155], ["influenza virus", "ORGANISM", 213, 228], ["Influenza virus", "SPECIES", 140, 155], ["Influenza virus", "SPECIES", 140, 155], ["influenza", "PROBLEM", 25, 34], ["economic and health burdens", "PROBLEM", 46, 73], ["rapid detection methods", "TEST", 88, 111], ["the virus", "PROBLEM", 116, 125], ["Microfluidic chips", "TREATMENT", 160, 178], ["virus outbreaks", "PROBLEM", 183, 198], ["the influenza virus", "PROBLEM", 209, 228], ["influenza", "OBSERVATION", 25, 34], ["influenza virus", "OBSERVATION", 213, 228]]], ["In 2016, Lee's group developed an integrated microfluidic method based on the sandwich-based aptamer that could detect H1N1 at a LOD of 0.032 hemagglutination units (HAU) within 30 min (Tseng et al., 2016).", [["an integrated microfluidic method", "TREATMENT", 31, 64], ["the sandwich", "TEST", 74, 86], ["H1N1", "PROBLEM", 119, 123]]], ["In 2020, their group (Lu et al., 2020) also proposed a more automated digital microfluidic platform to detect H1N1 (Fig. 5A).", [["H1N1", "PROBLEM", 110, 114]]], ["This method utilizes electromagnetically-driven magnetic beads and enzyme-linked immunosorbent (ELISA)-like assays on the platform to detect H1N1 viruses.", [["H1N1 viruses", "ORGANISM", 141, 153], ["H1N1 viruses", "SPECIES", 141, 153], ["magnetic beads", "TEST", 48, 62], ["enzyme", "TEST", 67, 73], ["immunosorbent (ELISA", "TEST", 81, 101], ["the platform", "TEST", 118, 130], ["H1N1 viruses", "PROBLEM", 141, 153], ["H1N1", "OBSERVATION", 141, 145]]], ["This system can also reach a LOD of 0.032 HAU within 40 min.", [["a LOD", "TEST", 27, 32]]], ["Ma et al., (2019) proposed a simple self-driven microfluidic chip to detect H1N1 (Fig. 5 B).", [["microfluidic chip", "TREATMENT", 48, 65], ["H1N1", "PROBLEM", 76, 80]]], ["This system integrated nucleic acid extraction and RT-LAMP and was able to detect 3 \u00d7 10\u22124 HAU units/reaction in 40 min through colorimetric detection.", [["nucleic acid", "CHEMICAL", 23, 35], ["nucleic acid extraction", "TREATMENT", 23, 46], ["RT-LAMP", "TREATMENT", 51, 58], ["colorimetric detection", "TEST", 128, 150]]], ["Xia et al., (2019) developed a smartphone-based microfluidic system for the detection of avian influenza virus.", [["avian influenza virus", "DISEASE", 89, 110], ["avian influenza virus", "ORGANISM", 89, 110], ["avian influenza virus", "SPECIES", 89, 110], ["avian influenza virus", "SPECIES", 89, 110], ["the detection", "TEST", 72, 85], ["avian influenza virus", "PROBLEM", 89, 110], ["avian influenza virus", "OBSERVATION", 89, 110]]], ["This system uses gold nanoparticles to detect virus at aLOD of 2.7 \u00d7 104 EID50/mL.Influenza virus ::: Microfluidic chips for virus outbreaksThe various characteristics of the multiple influenza virus strains make development of microfluidic systems more complicated (Zhang and Miller, 2019).", [["Influenza virus", "DISEASE", 82, 97], ["gold nanoparticles", "SIMPLE_CHEMICAL", 17, 35], ["Influenza virus", "ORGANISM", 82, 97], ["influenza virus", "ORGANISM", 184, 199], ["Influenza virus", "SPECIES", 82, 97], ["Influenza virus", "SPECIES", 82, 97], ["gold nanoparticles", "TREATMENT", 17, 35], ["virus", "PROBLEM", 46, 51], ["Microfluidic chips", "TREATMENT", 102, 120], ["virus outbreaks", "PROBLEM", 125, 140], ["the multiple influenza virus strains", "PROBLEM", 171, 207], ["microfluidic systems", "PROBLEM", 228, 248], ["multiple", "OBSERVATION_MODIFIER", 175, 183], ["influenza virus", "OBSERVATION", 184, 199]]], ["More recently, Han et al., (2016) reported a microfluidic electrochemical system to multiplex detect the influenza A virus.", [["influenza A virus", "ORGANISM", 105, 122], ["influenza A virus", "SPECIES", 105, 122], ["influenza A virus", "SPECIES", 105, 122], ["a microfluidic electrochemical system", "PROBLEM", 43, 80], ["the influenza A virus", "PROBLEM", 101, 122], ["influenza", "OBSERVATION", 105, 114]]], ["This group established the electrochemical immunosensor through three electrodes arrangements and ZnO nanorods (NRs) on the inner surface of PDMS.", [["inner surface", "ANATOMY", 124, 137], ["ZnO nanorods", "CHEMICAL", 98, 110], ["ZnO", "CHEMICAL", 98, 101], ["PDMS", "CHEMICAL", 141, 145], ["ZnO nanorods", "SIMPLE_CHEMICAL", 98, 110], ["the electrochemical immunosensor through three electrodes arrangements", "TREATMENT", 23, 93], ["ZnO nanorods (NRs", "TREATMENT", 98, 115], ["the inner surface of PDMS", "TREATMENT", 120, 145]]], ["This system can simultaneously detect the H1N1, H5N1 and H7N9 viruses in the 1 pg/ml - 10 ng/ml range.", [["H5N1", "DISEASE", 48, 52], ["H5N1", "ORGANISM", 48, 52], ["H7N9 viruses", "ORGANISM", 57, 69], ["H5N1", "SPECIES", 48, 52], ["H7N9", "SPECIES", 57, 61], ["the H1N1", "PROBLEM", 38, 46], ["H5N1", "PROBLEM", 48, 52], ["H7N9 viruses", "TREATMENT", 57, 69], ["H1N1", "OBSERVATION", 42, 46]]], ["Wang et al., (2020) developed a microfluidic system based on magnetism mediated separation and size mediated signal detection to multiplex detect influenza A (Fig. 5 C).", [["a microfluidic system", "PROBLEM", 30, 51], ["magnetism mediated separation", "TREATMENT", 61, 90], ["size mediated signal detection", "PROBLEM", 95, 125], ["influenza", "PROBLEM", 146, 155], ["size", "OBSERVATION_MODIFIER", 95, 99]]], ["The LOD of this system reaches 3.4 ng/mL for H7N9 HA and 4.5 ng/mL for H9N2 HA.", [["H7N9 HA", "CHEMICAL", 45, 52], ["H9N2", "ORGANISM", 71, 75], ["H7N9", "SPECIES", 45, 49], ["H7N9 HA", "PROBLEM", 45, 52], ["H9N2 HA", "PROBLEM", 71, 78]]], ["The disc chip proposed by Liu et al., (2018) can detect three avian influenza viruses and two influenza viruses on a single chip within 70 min.", [["influenza viruses", "DISEASE", 68, 85], ["influenza viruses", "DISEASE", 94, 111], ["avian influenza viruses", "SPECIES", 62, 85], ["The disc chip", "TREATMENT", 0, 13], ["three avian influenza viruses", "PROBLEM", 56, 85], ["two influenza viruses", "PROBLEM", 90, 111], ["a single chip", "TREATMENT", 115, 128], ["disc", "ANATOMY", 4, 8], ["influenza viruses", "OBSERVATION", 68, 85]]], ["Shen et al., (2019) also proposed an integrated microfluidic system that contains sample preparation and a RT-PCR module (Fig. 5 D).", [["sample", "ANATOMY", 82, 88], ["an integrated microfluidic system", "TREATMENT", 34, 67], ["sample preparation", "TREATMENT", 82, 100], ["a RT-PCR module", "TREATMENT", 105, 120]]], ["This system uses glycan-coated magnetic beads to capture all influenza viruses in samples and can simultaneously detect twelve influenza subtypes with LODs ranging from 40 to 3000 copies within 100 min.", [["samples", "ANATOMY", 82, 89], ["influenza", "DISEASE", 127, 136], ["samples", "CANCER", 82, 89], ["glycan-coated magnetic beads", "TREATMENT", 17, 45], ["all influenza viruses in samples", "PROBLEM", 57, 89], ["twelve influenza subtypes", "PROBLEM", 120, 145], ["LODs", "TEST", 151, 155], ["influenza viruses", "OBSERVATION", 61, 78]]], ["Wu et al., (2019) developed a digital microarray system to multiplex detect H9N2, H1N1 and H7N9 avian influenza viruses.", [["avian influenza viruses", "DISEASE", 96, 119], ["H9N2", "ORGANISM", 76, 80], ["H1N1", "ORGANISM", 82, 86], ["H7N9 avian influenza viruses", "ORGANISM", 91, 119], ["H7N9 avian influenza", "SPECIES", 91, 111], ["H7N9 avian influenza viruses", "SPECIES", 91, 119], ["a digital microarray system", "PROBLEM", 28, 55], ["H9N2", "PROBLEM", 76, 80], ["H1N1", "PROBLEM", 82, 86], ["H7N9 avian influenza viruses", "PROBLEM", 91, 119], ["influenza viruses", "OBSERVATION", 102, 119]]], ["This system uses antibodies to modify the microarray fluorescent magnetic nanospheres to achieve multiplex detection with a LOD of 0.02 pg/mL.", [["antibodies", "PROTEIN", 17, 27], ["antibodies", "TREATMENT", 17, 27], ["the microarray fluorescent magnetic nanospheres", "TREATMENT", 38, 85], ["multiplex detection", "TEST", 97, 116]]], ["The commercial product Cobas\u00ae has been used for the detection of influenza.", [["Cobas\u00ae", "CHEMICAL", 23, 29], ["influenza", "DISEASE", 65, 74], ["Cobas\u00ae", "SIMPLE_CHEMICAL", 23, 29], ["The commercial product Cobas\u00ae", "TREATMENT", 0, 29], ["influenza", "PROBLEM", 65, 74], ["influenza", "OBSERVATION", 65, 74]]], ["This instrument uses qRT-PCR detection, which can detect and distinguish between influenza A and influenza B viruses within 20 min using RNA detection of nasopharyngeal swab specimens.Influenza virus ::: Microfluidic chips for virus outbreaksMicrofluidic chips have widely focused on the detection of influenza viruses.", [["nasopharyngeal swab specimens", "ANATOMY", 154, 183], ["influenza A", "DISEASE", 81, 92], ["influenza B", "DISEASE", 97, 108], ["Influenza virus", "DISEASE", 184, 199], ["influenza viruses", "DISEASE", 301, 318], ["influenza A", "ORGANISM", 81, 92], ["influenza B viruses", "ORGANISM", 97, 116], ["nasopharyngeal swab specimens", "CANCER", 154, 183], ["Influenza virus", "ORGANISM", 184, 199], ["influenza viruses", "ORGANISM", 301, 318], ["qRT", "DNA", 21, 24], ["influenza B viruses", "SPECIES", 97, 116], ["Influenza virus", "SPECIES", 184, 199], ["influenza A", "SPECIES", 81, 92], ["influenza B viruses", "SPECIES", 97, 116], ["Influenza virus", "SPECIES", 184, 199], ["qRT", "TEST", 21, 24], ["PCR detection", "TEST", 25, 38], ["influenza A", "PROBLEM", 81, 92], ["influenza B viruses", "PROBLEM", 97, 116], ["RNA detection", "TEST", 137, 150], ["nasopharyngeal swab specimens", "TEST", 154, 183], ["Microfluidic chips", "TREATMENT", 204, 222], ["virus outbreaks", "PROBLEM", 227, 242], ["Microfluidic chips", "TREATMENT", 242, 260], ["influenza viruses", "PROBLEM", 301, 318], ["nasopharyngeal", "ANATOMY", 154, 168], ["influenza viruses", "OBSERVATION", 301, 318]]], ["Both detection time and LOD have significantly improved through this advanced technology.", [["this advanced technology", "TREATMENT", 64, 88]]], ["Since there are various subtypes of the influenza viruses, multiplex detection ability of these chips still need improvement.", [["influenza viruses", "DISEASE", 40, 57], ["influenza viruses", "ORGANISM", 40, 57], ["the influenza viruses", "PROBLEM", 36, 57], ["these chips", "TREATMENT", 90, 101], ["various subtypes", "OBSERVATION_MODIFIER", 16, 32], ["influenza viruses", "OBSERVATION", 40, 57]]], ["Moreover, rapid and ongoing evolution of influenza viruses will make this even more challenging.", [["influenza viruses", "DISEASE", 41, 58], ["influenza viruses", "ORGANISM", 41, 58], ["influenza viruses", "PROBLEM", 41, 58], ["rapid", "OBSERVATION_MODIFIER", 10, 15], ["influenza viruses", "OBSERVATION", 41, 58]]], ["Furthermore, portability and cost should be further improved since influenza viruses are common and universal.Zika virus (ZIKV) ::: Microfluidic chips for virus outbreaksZIKV is a single-stranded, RNA virus that belongs to flaviviridae and is a causative agent of Zika fever (Metz et al., 2019; Qadir et al., 2018).", [["influenza viruses", "DISEASE", 67, 84], ["Zika fever", "DISEASE", 264, 274], ["influenza viruses", "ORGANISM", 67, 84], ["Zika virus", "ORGANISM", 110, 120], ["virus outbreaksZIKV", "ORGANISM", 155, 174], ["flaviviridae", "CANCER", 223, 235], ["Zika fever", "ORGANISM", 264, 274], ["Zika virus", "SPECIES", 110, 120], ["Zika virus", "SPECIES", 110, 120], ["ZIKV", "SPECIES", 122, 126], ["influenza viruses", "PROBLEM", 67, 84], ["Microfluidic chips", "TREATMENT", 132, 150], ["virus outbreaksZIKV", "PROBLEM", 155, 174], ["a single-stranded, RNA virus", "PROBLEM", 178, 206], ["flaviviridae", "TREATMENT", 223, 235], ["Zika fever", "PROBLEM", 264, 274]]], ["This mosquito-borne virus was identified in 1947 (Nicolini et al., 2017) and 84 countries so far have been affected (Nelson et al., 2019).", [["mosquito-borne virus", "SPECIES", 5, 25], ["This mosquito-borne virus", "PROBLEM", 0, 25]]], ["The WHO has announced that ZIKV is a PHEIC (Xu et al., 2016).", [["ZIKV", "SPECIES", 27, 31], ["ZIKV", "OBSERVATION", 27, 31]]], ["ZIKV can be transmitted through human contact and has been detected in urine, blood, semen, amniotic fluid, cerebrospinal fluid, saliva and even tears (Paixao et al., 2016; Wu et al., 2018).", [["urine", "ANATOMY", 71, 76], ["blood", "ANATOMY", 78, 83], ["semen", "ANATOMY", 85, 90], ["amniotic fluid", "ANATOMY", 92, 106], ["cerebrospinal fluid", "ANATOMY", 108, 127], ["saliva", "ANATOMY", 129, 135], ["ZIKV", "CHEMICAL", 0, 4], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 32, 37], ["urine", "ORGANISM_SUBSTANCE", 71, 76], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["semen", "ORGANISM_SUBSTANCE", 85, 90], ["amniotic fluid", "ORGANISM_SUBSTANCE", 92, 106], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 108, 127], ["saliva", "ORGANISM_SUBSTANCE", 129, 135], ["human", "SPECIES", 32, 37], ["ZIKV", "SPECIES", 0, 4], ["human", "SPECIES", 32, 37], ["urine", "TEST", 71, 76], ["blood", "TEST", 78, 83], ["semen, amniotic fluid", "TEST", 85, 106], ["cerebrospinal fluid", "TEST", 108, 127], ["even tears", "PROBLEM", 140, 150], ["amniotic fluid", "OBSERVATION", 92, 106], ["cerebrospinal", "ANATOMY", 108, 121], ["fluid", "OBSERVATION", 122, 127]]], ["ZIKV infection is generally asymptomatic.", [["ZIKV infection", "DISEASE", 0, 14], ["ZIKV", "SPECIES", 0, 4], ["ZIKV infection", "PROBLEM", 0, 14], ["generally", "OBSERVATION_MODIFIER", 18, 27], ["asymptomatic", "OBSERVATION_MODIFIER", 28, 40]]], ["A small number of people will have mild clinical symptoms such as mild fever, fatigue, headache, joint pain and a rash, which will rarely lead to serious illness or complications.", [["joint", "ANATOMY", 97, 102], ["fever", "DISEASE", 71, 76], ["fatigue", "DISEASE", 78, 85], ["headache", "DISEASE", 87, 95], ["joint pain", "DISEASE", 97, 107], ["rash", "DISEASE", 114, 118], ["illness", "DISEASE", 154, 161], ["people", "ORGANISM", 18, 24], ["joint", "ORGANISM_SUBDIVISION", 97, 102], ["people", "SPECIES", 18, 24], ["mild clinical symptoms", "PROBLEM", 35, 57], ["mild fever", "PROBLEM", 66, 76], ["fatigue", "PROBLEM", 78, 85], ["headache", "PROBLEM", 87, 95], ["joint pain", "PROBLEM", 97, 107], ["a rash", "PROBLEM", 112, 118], ["serious illness", "PROBLEM", 146, 161], ["complications", "PROBLEM", 165, 178], ["small", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["mild", "OBSERVATION_MODIFIER", 66, 70], ["fever", "OBSERVATION", 71, 76], ["joint", "ANATOMY", 97, 102]]], ["In recent years, it has been found that the virus can cause teratogenicity and Guillain-Barre syndrome (Cugola et al., 2016; van den Berg et al., 2014).", [["Guillain-Barre syndrome", "DISEASE", 79, 102], ["the virus", "PROBLEM", 40, 49], ["teratogenicity", "PROBLEM", 60, 74], ["Barre syndrome", "PROBLEM", 88, 102], ["virus", "OBSERVATION", 44, 49], ["Barre syndrome", "OBSERVATION", 88, 102]]], ["The high contagious rate of the virus led to over 2 million humans being infected globally (Santiago et al., 2018).", [["humans", "ORGANISM", 60, 66], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 60, 66], ["the virus", "PROBLEM", 28, 37], ["high", "OBSERVATION_MODIFIER", 4, 8], ["contagious", "OBSERVATION_MODIFIER", 9, 19]]], ["The most recent outbreak (Petersen et al., 2016) highlights that early diagnosis of ZIKV is extremely important to control epidemic situations, which is extremely challenging (Janahi et al., 2017; Ricotta et al., 2019).Zika virus (ZIKV) ::: Microfluidic chips for virus outbreaksIn recent years, microfluidics has also shown to be an effective tool for the early diagnosis of ZIKV.", [["ZIKV", "DISEASE", 84, 88], ["ZIKV", "DISEASE", 376, 380], ["Zika virus", "ORGANISM", 219, 229], ["ZIKV", "CANCER", 376, 380], ["Zika virus", "SPECIES", 219, 229], ["ZIKV", "SPECIES", 84, 88], ["Zika virus", "SPECIES", 219, 229], ["ZIKV", "SPECIES", 231, 235], ["ZIKV", "SPECIES", 376, 380], ["ZIKV", "PROBLEM", 84, 88], ["Microfluidic chips", "TREATMENT", 241, 259], ["virus outbreaks", "PROBLEM", 264, 279], ["ZIKV", "PROBLEM", 376, 380], ["ZIKV", "OBSERVATION", 84, 88], ["ZIKV", "OBSERVATION", 376, 380]]], ["Microfluidic chips based on nucleic acid detection have important applications in ZIKV detection (Pardee et al., 2016).", [["nucleic acid", "CHEMICAL", 28, 40], ["ZIKV", "SPECIES", 82, 86], ["Microfluidic chips", "TREATMENT", 0, 18], ["nucleic acid detection", "TEST", 28, 50]]], ["For example, Song et al., (2016) reported a cassette microfluidic system based on RT-LAMP (Fig. 6A).", [["a cassette microfluidic system", "TREATMENT", 42, 72]]], ["This chip is chemically heated to eliminate the need for electricity.", [["This chip", "TREATMENT", 0, 9]]], ["Moreover, it uses a visualization method to observe the virus.", [["a visualization method", "TREATMENT", 18, 40], ["the virus", "PROBLEM", 52, 61]]], ["This system also achieved detection of 5 plaque-forming units (PFU) in 40 min.", [["plaque", "ANATOMY", 41, 47], ["5 plaque", "PROBLEM", 39, 47], ["plaque", "OBSERVATION", 41, 47]]], ["Ganguli et al., (2017) generated a microfluidic chip based on a RT-LAMP and smartphone combination.", [["a microfluidic chip", "TREATMENT", 33, 52], ["a RT-LAMP", "TREATMENT", 62, 71], ["smartphone combination", "TREATMENT", 76, 98]]], ["This chip has the ability to multiplex detect ZIKV and other viruses for precise results.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 46, 50], ["ZIKV", "SPECIES", 46, 50], ["ZIKV", "PROBLEM", 46, 50]]], ["The LOD of this system is 1.56e5 PFU/mL in blood under 35 min.", [["blood", "ANATOMY", 43, 48], ["blood", "ORGANISM_SUBSTANCE", 43, 48]]], ["Kaarj et al., (2018) developed a paper microfluidic chip combined with RT-LAMP and a smartphone to detect ZIKV RNA.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 106, 110], ["ZIKV RNA", "RNA", 106, 114], ["ZIKV", "SPECIES", 106, 110], ["a paper microfluidic chip", "TREATMENT", 31, 56], ["RT-LAMP", "TREATMENT", 71, 78], ["ZIKV RNA", "PROBLEM", 106, 114], ["ZIKV RNA", "OBSERVATION", 106, 114]]], ["However, this system requires additional purification steps.", [["additional purification steps", "TREATMENT", 30, 59]]], ["Yang et al., (2019) proposed a wearable microfluidic system to detect the Zika virus (Fig. 6 B).", [["Zika virus", "ORGANISM", 74, 84], ["Zika virus", "SPECIES", 74, 84], ["a wearable microfluidic system", "TREATMENT", 29, 59], ["the Zika virus", "PROBLEM", 70, 84]]], ["This system integrates RPA on a bandage-like sensor.", [["RPA", "GENE_OR_GENE_PRODUCT", 23, 26], ["RPA", "PROTEIN", 23, 26], ["a bandage", "TREATMENT", 30, 39], ["bandage", "OBSERVATION", 32, 39]]], ["Body heat can activate the sensor since the RPA can react at room temperature.", [["Body", "ANATOMY", 0, 4], ["RPA", "GENE_OR_GENE_PRODUCT", 44, 47], ["RPA", "PROTEIN", 44, 47], ["Body heat", "PROBLEM", 0, 9]]], ["If equipped with a sample preparation function in the future, it will have very broad application value.", [["a sample preparation function", "TEST", 17, 46]]], ["More recently, Batule et al. (Batule et al., 2020) reported a two-step paper chip strategy used for RNA extraction and RT-LAMP.", [["a two-step paper chip strategy", "TREATMENT", 60, 90], ["RNA extraction", "TREATMENT", 100, 114], ["RT-LAMP", "TREATMENT", 119, 126]]], ["This method can detect 10 copies in the serum within 1 h.Zika virus (ZIKV) ::: Microfluidic chips for virus outbreaksOn-chip immunological testing remains an important diagnostic measure for Zika virus infection.", [["serum", "ANATOMY", 40, 45], ["Zika virus infection", "DISEASE", 191, 211], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["Zika virus", "ORGANISM", 57, 67], ["Zika virus", "ORGANISM", 191, 201], ["Zika virus", "SPECIES", 57, 67], ["Zika virus", "SPECIES", 57, 67], ["ZIKV", "SPECIES", 69, 73], ["Zika virus", "SPECIES", 191, 201], ["the serum", "TEST", 36, 45], ["Microfluidic chips", "TREATMENT", 79, 97], ["virus outbreaks", "PROBLEM", 102, 117], ["On-chip immunological testing", "TEST", 117, 146], ["Zika virus infection", "PROBLEM", 191, 211]]], ["Draz et al., (2018) reported a paper chip that used platinum nanoparticles.", [["platinum", "CHEMICAL", 52, 60], ["platinum", "CHEMICAL", 52, 60], ["platinum nanoparticles", "SIMPLE_CHEMICAL", 52, 74], ["a paper chip", "TREATMENT", 29, 41], ["platinum nanoparticles", "TREATMENT", 52, 74]]], ["The platinum nanoparticles used antibodies on paper that improved sensitivity and specificity.", [["platinum", "CHEMICAL", 4, 12], ["platinum", "CHEMICAL", 4, 12], ["platinum nanoparticles", "SIMPLE_CHEMICAL", 4, 26], ["antibodies", "PROTEIN", 32, 42], ["The platinum nanoparticles", "TREATMENT", 0, 26], ["specificity", "TEST", 82, 93]]], ["This chip was able to detect ZIKV with a LOD of 101 copies/\u03bcl.", [["ZIKV", "SPECIES", 29, 33], ["ZIKV", "PROBLEM", 29, 33], ["a LOD", "TEST", 39, 44]]], ["Rong et al., (2019) developed a paper microfluidic system based on quantum dot probes and smartphones.", [["a paper microfluidic system", "PROBLEM", 30, 57], ["quantum dot probes", "TREATMENT", 67, 85], ["smartphones", "TEST", 90, 101]]], ["This chip shows limited cross-reactivity with other viruses and can reach a LOD of 0.15 ng/mL in serum within 20 min.", [["serum", "ANATOMY", 97, 102], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["This chip", "TEST", 0, 9], ["other viruses", "PROBLEM", 46, 59], ["a LOD", "TEST", 74, 79], ["cross-reactivity", "OBSERVATION", 24, 40], ["viruses", "OBSERVATION", 52, 59]]], ["Meena et al., (2018) developed an optofluidic chip based on magnetic beads and optical detection to simultaneously detect ZIKV nucleic acids and proteins.", [["ZIKV nucleic acids", "PROTEIN", 122, 140], ["ZIKV", "SPECIES", 122, 126], ["an optofluidic chip", "TREATMENT", 31, 50], ["magnetic beads", "TREATMENT", 60, 74], ["optical detection", "TEST", 79, 96], ["ZIKV nucleic acids", "TEST", 122, 140]]], ["This method contained a LOD of 8 fm and ruled out potential interference from other viruses.Zika virus (ZIKV) ::: Microfluidic chips for virus outbreaksMicrofluidic technology has provided a new route for the detection of ZIKV.", [["Zika virus", "ORGANISM", 92, 102], ["ZIKV", "GENE_OR_GENE_PRODUCT", 222, 226], ["Zika virus", "SPECIES", 92, 102], ["Zika virus", "SPECIES", 92, 102], ["ZIKV", "SPECIES", 104, 108], ["ZIKV", "SPECIES", 222, 226], ["potential interference from other viruses", "PROBLEM", 50, 91], ["Microfluidic chips", "TREATMENT", 114, 132], ["virus outbreaks", "PROBLEM", 137, 152], ["ZIKV", "PROBLEM", 222, 226], ["viruses", "OBSERVATION", 84, 91], ["ZIKV", "OBSERVATION", 222, 226]]], ["Although qRT-PCR is still the gold standard for ZIKV detection, microfluidics has shown fast and accurate advantages and continued development will demonstrate their practical utility in response to ZIVK outbreaks.", [["qRT", "DNA", 9, 12], ["ZIKV", "SPECIES", 48, 52], ["qRT", "TEST", 9, 12], ["PCR", "TEST", 13, 16], ["ZIKV detection", "TEST", 48, 62], ["ZIVK outbreaks", "PROBLEM", 199, 213]]], ["In addition, compared to other viruses such as EBOV and the influenza virus, ZIKV does not have multiple subtypes.", [["influenza virus", "DISEASE", 60, 75], ["EBOV", "ORGANISM", 47, 51], ["influenza virus", "ORGANISM", 60, 75], ["ZIKV", "ORGANISM", 77, 81], ["influenza virus", "SPECIES", 60, 75], ["EBOV", "SPECIES", 47, 51], ["influenza virus", "SPECIES", 60, 75], ["ZIKV", "SPECIES", 77, 81], ["other viruses", "PROBLEM", 25, 38], ["EBOV", "PROBLEM", 47, 51], ["the influenza virus", "PROBLEM", 56, 75], ["ZIKV", "PROBLEM", 77, 81], ["influenza virus", "OBSERVATION", 60, 75]]], ["However, to date, ZIKV infection is still difficult to diagnose because of its cross-reactivity with other flaviviruses, such as dengue virus (Wu et al., 2018).", [["infection", "DISEASE", 23, 32], ["flaviviruses", "DISEASE", 107, 119], ["dengue virus", "DISEASE", 129, 141], ["dengue virus", "ORGANISM", 129, 141], ["ZIKV", "SPECIES", 18, 22], ["dengue virus", "SPECIES", 129, 141], ["ZIKV infection", "PROBLEM", 18, 32], ["its cross-reactivity", "PROBLEM", 75, 95], ["other flaviviruses", "PROBLEM", 101, 119], ["dengue virus", "PROBLEM", 129, 141], ["infection", "OBSERVATION", 23, 32]]], ["Therefore, in the continued development of improved microfluidic methods, the detection of other flaviviruses or arboviruses need to be ruled out for cross-reactivity (Chang et al., 2017).Dengue virus (DENV) ::: Microfluidic chips for virus outbreaksDENV is a mosquito-borne virus that causes dengue fever (DF), dengue hemorrhagic fever and dengue shock syndrome (DSS) (Lang et al., 2016; Nakhapakorn and Tripathi, 2005).", [["arboviruses", "DISEASE", 113, 124], ["Dengue", "DISEASE", 188, 194], ["dengue fever", "DISEASE", 293, 305], ["DF", "DISEASE", 307, 309], ["dengue hemorrhagic fever", "DISEASE", 312, 336], ["dengue shock syndrome", "DISEASE", 341, 362], ["DSS", "DISEASE", 364, 367], ["Dengue virus", "ORGANISM", 188, 200], ["virus outbreaksDENV", "ORGANISM", 235, 254], ["Dengue virus", "SPECIES", 188, 200], ["dengue fever", "SPECIES", 293, 305], ["dengue hemorrhagic fever", "SPECIES", 312, 336], ["Dengue virus", "SPECIES", 188, 200], ["DENV", "SPECIES", 202, 206], ["virus outbreaksDENV", "SPECIES", 235, 254], ["mosquito-borne virus", "SPECIES", 260, 280], ["the detection", "TEST", 74, 87], ["other flaviviruses", "PROBLEM", 91, 109], ["arboviruses", "PROBLEM", 113, 124], ["Dengue virus", "PROBLEM", 188, 200], ["Microfluidic chips", "TREATMENT", 212, 230], ["virus outbreaksDENV", "PROBLEM", 235, 254], ["a mosquito-borne virus", "PROBLEM", 258, 280], ["dengue fever (DF)", "PROBLEM", 293, 310], ["dengue hemorrhagic fever", "PROBLEM", 312, 336], ["dengue shock syndrome", "PROBLEM", 341, 362], ["improved", "OBSERVATION_MODIFIER", 43, 51], ["microfluidic methods", "OBSERVATION", 52, 72], ["flaviviruses", "OBSERVATION", 97, 109], ["hemorrhagic", "OBSERVATION_MODIFIER", 319, 330], ["fever", "OBSERVATION", 331, 336], ["shock syndrome", "OBSERVATION", 348, 362]]], ["DENV belongs to the flaviviridae group and has four serotypes (DENV1-4) (Zonetti et al., 2018).", [["DENV", "ORGANISM", 0, 4], ["flaviviridae", "CANCER", 20, 32], ["DENV1-4", "CELL", 63, 70], ["DENV", "SPECIES", 0, 4], ["DENV", "PROBLEM", 0, 4]]], ["Dengue fever usually has a 10-day incubation period.", [["Dengue fever", "DISEASE", 0, 12], ["Dengue", "ORGANISM", 0, 6], ["Dengue", "SPECIES", 0, 6], ["Dengue fever", "PROBLEM", 0, 12]]], ["Patients usually have typical symptoms such as fever, severe headache, postophthalmic pain, muscle and joint pain, a rash, nausea, abdominal pain and swollen glands (Adimy et al., 2020; Chan and Johansson, 2012; Halstead, 2008).", [["muscle", "ANATOMY", 92, 98], ["joint", "ANATOMY", 103, 108], ["abdominal", "ANATOMY", 131, 140], ["swollen glands", "ANATOMY", 150, 164], ["fever", "DISEASE", 47, 52], ["headache", "DISEASE", 61, 69], ["postophthalmic pain", "DISEASE", 71, 90], ["muscle and joint pain", "DISEASE", 92, 113], ["rash", "DISEASE", 117, 121], ["nausea", "DISEASE", 123, 129], ["abdominal pain", "DISEASE", 131, 145], ["Patients", "ORGANISM", 0, 8], ["muscle", "ORGAN", 92, 98], ["joint", "ORGANISM_SUBDIVISION", 103, 108], ["abdominal", "ORGANISM_SUBDIVISION", 131, 140], ["glands", "ORGAN", 158, 164], ["Patients", "SPECIES", 0, 8], ["typical symptoms", "PROBLEM", 22, 38], ["fever", "PROBLEM", 47, 52], ["severe headache", "PROBLEM", 54, 69], ["postophthalmic pain", "PROBLEM", 71, 90], ["muscle and joint pain", "PROBLEM", 92, 113], ["a rash", "PROBLEM", 115, 121], ["nausea", "PROBLEM", 123, 129], ["abdominal pain", "PROBLEM", 131, 145], ["swollen glands", "PROBLEM", 150, 164], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["headache", "OBSERVATION", 61, 69], ["muscle", "ANATOMY", 92, 98], ["joint", "ANATOMY", 103, 108], ["pain", "OBSERVATION", 109, 113], ["rash", "OBSERVATION", 117, 121], ["abdominal", "ANATOMY", 131, 140], ["pain", "OBSERVATION", 141, 145], ["swollen glands", "ANATOMY", 150, 164]]], ["Currently, the main detection methods used in laboratories for dengue virus rely on cell culture, PCR and ELISA assays.", [["cell", "ANATOMY", 84, 88], ["dengue", "DISEASE", 63, 69], ["cell", "CELL", 84, 88], ["dengue virus", "SPECIES", 63, 75], ["dengue virus", "PROBLEM", 63, 75], ["cell culture", "TEST", 84, 96], ["PCR", "TEST", 98, 101], ["ELISA assays", "TEST", 106, 118]]], ["These time time-consuming, low sensitivity methods cannot quickly respond to DENV outbreaks (Suthanthiraraj et al., 2019).Dengue virus (DENV) ::: Microfluidic chips for virus outbreaksMicrofluidic based methods can give more precise and efficient results compared to electrochemical methods for the early detection of DENV (Eivazzadeh-Keihan et al., 2019).", [["Dengue", "DISEASE", 122, 128], ["DENV", "DISEASE", 318, 322], ["Dengue virus", "ORGANISM", 122, 134], ["DENV", "ORGANISM", 318, 322], ["Dengue virus", "SPECIES", 122, 134], ["DENV", "SPECIES", 77, 81], ["Dengue virus", "SPECIES", 122, 134], ["DENV", "SPECIES", 136, 140], ["DENV", "SPECIES", 318, 322], ["low sensitivity methods", "PROBLEM", 27, 50], ["Dengue virus", "PROBLEM", 122, 134], ["Microfluidic chips", "TREATMENT", 146, 164], ["virus outbreaks", "PROBLEM", 169, 184], ["Microfluidic based methods", "TREATMENT", 184, 210], ["DENV", "PROBLEM", 318, 322], ["DENV", "OBSERVATION", 318, 322]]], ["Recently, Yoo et al., (2020) proposed a microfluidic system that integrated direct sample preparation and LAMP to detect dengue virus (Fig. 7A).", [["sample", "ANATOMY", 83, 89], ["dengue", "DISEASE", 121, 127], ["dengue virus", "ORGANISM", 121, 133], ["dengue virus", "SPECIES", 121, 133], ["a microfluidic system", "TREATMENT", 38, 59], ["LAMP", "TREATMENT", 106, 110], ["dengue virus", "PROBLEM", 121, 133]]], ["This strategy used bead beating and heating procedures to obtain stable RNA directly from whole blood, which could be used to detect viruses.", [["whole blood", "ANATOMY", 90, 101], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["bead beating", "TREATMENT", 19, 31], ["heating procedures", "TREATMENT", 36, 54], ["viruses", "PROBLEM", 133, 140], ["bead beating", "OBSERVATION", 19, 31], ["viruses", "OBSERVATION", 133, 140]]], ["In this system, direct buffer was used to extract RNA from whole blood and obtain a LOD of 102 PFU/200 \u03bcL in less than 1 h.", [["whole blood", "ANATOMY", 59, 70], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["direct buffer", "TREATMENT", 16, 29], ["whole blood", "TEST", 59, 70], ["a LOD", "TEST", 82, 87]]], ["Yin et al., (2020) reported a microfluidic system that integrated RNA extraction and multiplex PCR to detect four DENV serotypes (Fig. 7 B).", [["DENV", "SPECIES", 114, 118], ["a microfluidic system", "TREATMENT", 28, 49], ["integrated RNA extraction", "TREATMENT", 55, 80], ["multiplex PCR", "TEST", 85, 98], ["four DENV serotypes", "PROBLEM", 109, 128], ["DENV serotypes", "OBSERVATION", 114, 128]]], ["In this system, chitosan-modified paper chip to extra RNA and on-chip PCR product was detected using a membrane sensor.", [["membrane", "ANATOMY", 103, 111], ["chitosan", "CHEMICAL", 16, 24], ["chitosan", "SIMPLE_CHEMICAL", 16, 24], ["membrane", "CELLULAR_COMPONENT", 103, 111], ["extra RNA", "RNA", 48, 57], ["chitosan", "TREATMENT", 16, 24], ["modified paper chip to extra RNA", "TREATMENT", 25, 57], ["-chip PCR product", "TREATMENT", 64, 81], ["a membrane sensor", "TREATMENT", 101, 118]]], ["This system detected 100 RNA copies per mL of plasma within 90 min.", [["plasma", "ANATOMY", 46, 52], ["plasma", "ORGANISM_SUBSTANCE", 46, 52], ["plasma", "TEST", 46, 52]]], ["Choi et al., (2017) developed a paper chip that applied agarose into paper to achieve flow control and improve detection sensitivity (Fig. 7 C).", [["a paper chip", "TREATMENT", 30, 42], ["agarose", "TREATMENT", 56, 63], ["flow control", "TREATMENT", 86, 98]]], ["Moreover, this chip integrated RNA extraction and RT-LAMP to detect DENV RNA in blood samples.", [["blood samples", "ANATOMY", 80, 93], ["DENV", "ORGANISM", 68, 72], ["blood samples", "ORGANISM_SUBSTANCE", 80, 93], ["DENV RNA", "RNA", 68, 76], ["DENV", "SPECIES", 68, 72], ["this chip integrated RNA extraction", "TREATMENT", 10, 45], ["RT-LAMP", "TREATMENT", 50, 57], ["DENV RNA", "PROBLEM", 68, 76], ["blood samples", "TEST", 80, 93], ["DENV", "OBSERVATION", 68, 72]]], ["Using this chip, DENV RNA was detected at 50 RNA copies.Dengue virus (DENV) ::: Microfluidic chips for virus outbreaksNon-structural protein 1 (NS1) antigen detection was universally used in serological tests for DENV.", [["Dengue", "DISEASE", 56, 62], ["DENV", "ORGANISM", 17, 21], ["Dengue virus", "ORGANISM", 56, 68], ["Non-structural protein 1", "GENE_OR_GENE_PRODUCT", 118, 142], ["NS1", "GENE_OR_GENE_PRODUCT", 144, 147], ["DENV", "ORGANISM", 213, 217], ["DENV RNA", "RNA", 17, 25], ["Non-structural protein 1", "PROTEIN", 118, 142], ["NS1", "PROTEIN", 144, 147], ["Dengue virus", "SPECIES", 56, 68], ["DENV", "SPECIES", 17, 21], ["Dengue virus", "SPECIES", 56, 68], ["DENV", "SPECIES", 70, 74], ["DENV", "SPECIES", 213, 217], ["this chip", "TREATMENT", 6, 15], ["DENV RNA", "PROBLEM", 17, 25], ["Dengue virus", "PROBLEM", 56, 68], ["Microfluidic chips", "TREATMENT", 80, 98], ["virus outbreaks", "PROBLEM", 103, 118], ["Non-structural protein", "TEST", 118, 140], ["antigen detection", "TEST", 149, 166], ["serological tests", "TEST", 191, 208], ["DENV", "PROBLEM", 213, 217]]], ["NS1 is a highly conserved glycoprotein with a molecular weight of 45\u201355 kDa (Lai et al., 2019).", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS1", "PROTEIN", 0, 3], ["glycoprotein", "PROTEIN", 26, 38]]], ["For immunological tests on chip, Hosseini et al., (2015) fabricated a disk chip equipped with polymethacrylate microspheres and microballoon mixing systems.", [["polymethacrylate microspheres", "SIMPLE_CHEMICAL", 94, 123], ["immunological tests", "TEST", 4, 23], ["a disk chip", "TREATMENT", 68, 79], ["polymethacrylate microspheres", "TREATMENT", 94, 123], ["microballoon mixing systems", "TREATMENT", 128, 155]]], ["This chip can manipulate 54 samples in parallel and can detect 1.9 pfu/mL in serum.", [["samples", "ANATOMY", 28, 35], ["serum", "ANATOMY", 77, 82], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["serum", "TEST", 77, 82]]], ["A dielectrophoresis chip was also proposed by Iswardy et al., (2017) (Fig. 7 D).", [["A dielectrophoresis chip", "TREATMENT", 0, 24]]], ["A dielectrophoresis force was used in this chip to capture beads and an immunoreaction was used to capture the virus.", [["A dielectrophoresis force", "TREATMENT", 0, 25], ["this chip to capture beads", "TREATMENT", 38, 64], ["an immunoreaction", "TREATMENT", 69, 86], ["the virus", "PROBLEM", 107, 116]]], ["This chip only requires 5 min to detect the virus with a LOD of 104 PFU/mL from 15 \u03bcL samples.", [["the virus", "PROBLEM", 40, 49], ["a LOD", "TEST", 55, 60]]], ["Yu-zoon et al. (Yuzon et al., 2019) generated a paper chip using cellulose acetate film and a nitrocellulose membrane to detect the NS1 antigen.", [["membrane", "ANATOMY", 109, 117], ["cellulose acetate", "CHEMICAL", 65, 82], ["nitrocellulose", "CHEMICAL", 94, 108], ["cellulose acetate film", "SIMPLE_CHEMICAL", 65, 87], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["NS1 antigen", "GENE_OR_GENE_PRODUCT", 132, 143], ["NS1 antigen", "PROTEIN", 132, 143], ["a paper chip", "TREATMENT", 46, 58], ["cellulose acetate film", "TREATMENT", 65, 87], ["a nitrocellulose membrane", "TREATMENT", 92, 117], ["the NS1 antigen", "TEST", 128, 143]]], ["This chip reached a LOD 84.66 ng/mL in 2 min.Dengue virus (DENV) ::: Microfluidic chips for virus outbreaksMicrofluidics can be regarded as a capable candidate of POC for DENV.", [["Dengue", "DISEASE", 45, 51], ["Dengue virus", "ORGANISM", 45, 57], ["DENV", "ORGANISM", 171, 175], ["Dengue virus", "SPECIES", 45, 57], ["Dengue virus", "SPECIES", 45, 57], ["DENV", "SPECIES", 59, 63], ["DENV", "SPECIES", 171, 175], ["Dengue virus", "PROBLEM", 45, 57], ["Microfluidic chips", "TREATMENT", 69, 87], ["virus outbreaks", "PROBLEM", 92, 107], ["DENV", "PROBLEM", 171, 175]]], ["Since DENV easily cross-reacts with ZIKV, multiplex and precise detection in microfluidics should be improved.", [["DENV", "ORGANISM", 6, 10], ["DENV", "SPECIES", 6, 10], ["ZIKV", "SPECIES", 36, 40], ["DENV", "PROBLEM", 6, 10], ["ZIKV", "PROBLEM", 36, 40], ["improved", "OBSERVATION_MODIFIER", 101, 109]]], ["Moreover, the four serotypes of DENV should be considered when novel chips are developed in the future.COVID-19 and commercialized products ::: Microfluidic chips for virus outbreaksIn the 21st century, two highly pathogenic human coronaviruses including Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have emerged and triggered global pandemics that resulted in high morbidity and mortality.", [["DENV", "DISEASE", 32, 36], ["COVID-19", "CHEMICAL", 103, 111], ["human coronaviruses", "DISEASE", 225, 244], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 262, 300], ["SARS-CoV)", "DISEASE", 302, 311], ["Middle East Respiratory Syndrome Coronavirus", "DISEASE", 316, 360], ["DENV", "ORGANISM", 32, 36], ["human", "ORGANISM", 225, 230], ["coronaviruses", "ORGANISM", 231, 244], ["Severe Acute Respiratory Syndrome Coronavirus", "ORGANISM", 255, 300], ["SARS-CoV", "ORGANISM", 302, 310], ["Middle East Respiratory Syndrome Coronavirus", "ORGANISM", 316, 360], ["MERS-CoV", "ORGANISM", 362, 370], ["human", "SPECIES", 225, 230], ["DENV", "SPECIES", 32, 36], ["human coronaviruses", "SPECIES", 225, 244], ["Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV", "SPECIES", 255, 310], ["Middle East Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 316, 370], ["DENV", "PROBLEM", 32, 36], ["novel chips", "TREATMENT", 63, 74], ["COVID", "TEST", 103, 108], ["Microfluidic chips", "TREATMENT", 144, 162], ["virus outbreaks", "PROBLEM", 167, 182], ["two highly pathogenic human coronaviruses", "PROBLEM", 203, 244], ["Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)", "PROBLEM", 255, 311], ["Middle East Respiratory Syndrome Coronavirus", "PROBLEM", 316, 360], ["global pandemics", "PROBLEM", 399, 415], ["high morbidity", "PROBLEM", 433, 447], ["DENV", "OBSERVATION", 32, 36], ["highly", "OBSERVATION_MODIFIER", 207, 213], ["pathogenic human coronaviruses", "OBSERVATION", 214, 244], ["Severe", "OBSERVATION_MODIFIER", 255, 261], ["Acute", "OBSERVATION_MODIFIER", 262, 267], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 268, 300], ["Middle", "ANATOMY_MODIFIER", 316, 322], ["Respiratory Syndrome", "OBSERVATION", 328, 348], ["high", "OBSERVATION_MODIFIER", 433, 437], ["morbidity", "OBSERVATION", 438, 447]]], ["COVID-19 is also a type of coronavirus that belongs to the \u03b2-Coronavirus (Kim et al., 2020).", [["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["coronavirus", "ORGANISM", 27, 38], ["\u03b2-Coronavirus", "ORGANISM", 59, 72], ["COVID", "TEST", 0, 5], ["coronavirus", "PROBLEM", 27, 38]]], ["Currently, COVID-19, which is caused by the severe acute SARS-CoV-2, poses a major threat to human health as well as economies world-wide.", [["COVID-19", "CHEMICAL", 11, 19], ["COVID-19", "CELL", 11, 19], ["human", "ORGANISM", 93, 98], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["COVID", "TEST", 11, 16], ["the severe acute SARS", "PROBLEM", 40, 61], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["SARS", "OBSERVATION", 57, 61], ["wide", "OBSERVATION_MODIFIER", 133, 137]]], ["SARS-CoV-2 is believed to infect host cells through the angiotensin-converting enzyme 2 (ACE2), resulting in COVID-19.", [["cells", "ANATOMY", 38, 43], ["SARS", "DISEASE", 0, 4], ["angiotensin", "CHEMICAL", 56, 67], ["SARS-CoV-2", "ORGANISM", 0, 10], ["host cells", "CELL", 33, 43], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 56, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["COVID-19", "GENE_OR_GENE_PRODUCT", 109, 117], ["host cells", "CELL_TYPE", 33, 43], ["angiotensin-converting enzyme 2", "PROTEIN", 56, 87], ["ACE2", "PROTEIN", 89, 93], ["SARS-CoV", "SPECIES", 0, 8], ["the angiotensin", "TEST", 52, 67], ["converting enzyme", "TEST", 68, 85], ["ACE2", "TEST", 89, 93], ["COVID", "TEST", 109, 114]]], ["SARS-CoV-2 has a stronger transmission capacity compared to SARS and has a similar pathogenicity compared to MERS-COV(Zheng et al., 2020).", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 60, 64], ["SARS-CoV-2", "ORGANISM", 0, 10], ["a stronger transmission capacity", "PROBLEM", 15, 47], ["SARS", "PROBLEM", 60, 64], ["a similar pathogenicity", "PROBLEM", 73, 96]]], ["COVID-19 symptoms include a dry cough, fatigue and fever that is followed by anorexia, myalgia and dyspnea.", [["dry cough", "DISEASE", 28, 37], ["fatigue", "DISEASE", 39, 46], ["fever", "DISEASE", 51, 56], ["anorexia", "DISEASE", 77, 85], ["myalgia", "DISEASE", 87, 94], ["dyspnea", "DISEASE", 99, 106], ["COVID", "TEST", 0, 5], ["symptoms", "PROBLEM", 9, 17], ["a dry cough", "PROBLEM", 26, 37], ["fatigue", "PROBLEM", 39, 46], ["fever", "PROBLEM", 51, 56], ["anorexia", "PROBLEM", 77, 85], ["myalgia", "PROBLEM", 87, 94], ["dyspnea", "PROBLEM", 99, 106], ["cough", "OBSERVATION", 32, 37], ["myalgia", "OBSERVATION", 87, 94], ["dyspnea", "OBSERVATION", 99, 106]]], ["In addition, COVID-19 can also cause damage to the myocardium, resulting in chronic cardiovascular issues (Li et al., 2020; Zheng et al., 2020).", [["myocardium", "ANATOMY", 51, 61], ["cardiovascular", "ANATOMY", 84, 98], ["COVID-19", "CHEMICAL", 13, 21], ["damage to the myocardium", "DISEASE", 37, 61], ["COVID-19", "CHEMICAL", 13, 21], ["COVID-19", "GENE_OR_GENE_PRODUCT", 13, 21], ["myocardium", "ORGAN", 51, 61], ["COVID", "TEST", 13, 18], ["damage to the myocardium", "PROBLEM", 37, 61], ["chronic cardiovascular issues", "PROBLEM", 76, 105], ["myocardium", "ANATOMY", 51, 61], ["chronic", "OBSERVATION_MODIFIER", 76, 83], ["cardiovascular", "ANATOMY", 84, 98]]], ["The WHO has declared the COVID-19 epidemic as a PHEIC on January 31, 2020.", [["the COVID", "TEST", 21, 30]]], ["This virus has infected millions of people worldwide in just a few months.", [["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42], ["infected", "OBSERVATION_MODIFIER", 15, 23], ["millions", "OBSERVATION_MODIFIER", 24, 32]]], ["Nucleic acid detection has been used to detect the virus during this outbreak.", [["Nucleic acid", "CHEMICAL", 0, 12], ["Nucleic acid detection", "TEST", 0, 22], ["the virus", "PROBLEM", 47, 56], ["virus", "OBSERVATION", 51, 56]]], ["The National Medical Products Administration (NMPA) announced nucleic acid testing as the gold standard for virus detection.", [["nucleic acid", "CHEMICAL", 62, 74], ["The National Medical Products Administration", "TREATMENT", 0, 44], ["announced nucleic acid testing", "TEST", 52, 82], ["virus detection", "TEST", 108, 123]]], ["Antibody testing is used as a supplementary test for suspected cases where nucleic acid detection was negative and is not used as a basis for initial diagnosis or exclusion of new coronavirus infection.COVID-19 and commercialized products ::: Microfluidic chips for virus outbreaksTo detect the virus, qRT-PCR is still used as the mainstream detection method.", [["nucleic acid", "CHEMICAL", 75, 87], ["coronavirus infection", "DISEASE", 180, 201], ["COVID-19", "CHEMICAL", 202, 210], ["coronavirus", "ORGANISM", 180, 191], ["qRT", "DNA", 302, 305], ["Antibody testing", "TEST", 0, 16], ["a supplementary test", "TEST", 28, 48], ["nucleic acid detection", "TEST", 75, 97], ["new coronavirus infection", "PROBLEM", 176, 201], ["COVID", "TEST", 202, 207], ["Microfluidic chips", "TREATMENT", 243, 261], ["virus outbreaks", "PROBLEM", 266, 281], ["the virus", "PROBLEM", 291, 300], ["qRT", "TEST", 302, 305], ["PCR", "TEST", 306, 309], ["the mainstream detection method", "TEST", 327, 358], ["new", "OBSERVATION_MODIFIER", 176, 179], ["coronavirus", "OBSERVATION_MODIFIER", 180, 191], ["infection", "OBSERVATION", 192, 201], ["virus", "OBSERVATION", 295, 300]]], ["However, due to the rapid development of the epidemic, qRT-PCR can no longer meet the demands associated with needed testing.", [["the epidemic", "PROBLEM", 41, 53], ["needed testing", "TEST", 110, 124]]], ["POC instruments that based on the microfluidic technology play important roles in diagnosing the virus during this epidemic.", [["POC instruments", "TREATMENT", 0, 15], ["the virus", "PROBLEM", 93, 102]]], ["For example, The ID NOW\u00ae instrument proposed by Abbott\u2122 in USA can detect positive samples in 5 min and negative results in 13 min.", [["samples", "ANATOMY", 83, 90]]], ["Filmarray\u00ae, a product of BioFire\u2122, uses microfluidic technology that integrates nucleic acid extraction, purification and PCR amplification into a single chip and results in sequential and accurate detection.", [["Filmarray\u00ae", "CHEMICAL", 0, 10], ["nucleic acid", "CHEMICAL", 80, 92], ["Filmarray\u00ae", "SIMPLE_CHEMICAL", 0, 10], ["Filmarray\u00ae", "TREATMENT", 0, 10], ["microfluidic technology", "TREATMENT", 40, 63], ["nucleic acid extraction", "TREATMENT", 80, 103], ["purification", "TREATMENT", 105, 117], ["PCR amplification", "TEST", 122, 139]]], ["This instrument has been previously used for the detection of EBOV.", [["EBOV", "DISEASE", 62, 66], ["EBOV", "ORGANISM", 62, 66], ["EBOV", "SPECIES", 62, 66], ["This instrument", "TREATMENT", 0, 15], ["EBOV", "PROBLEM", 62, 66], ["EBOV", "OBSERVATION", 62, 66]]], ["Currently, the COVID-19 test kit has been approved by the FDA for EUA based on this system and can be used for rapid detection.", [["the COVID", "TEST", 11, 20], ["rapid detection", "TEST", 111, 126]]], ["The test is specifically designed and ran on existing Filmarray\u00ae 2.0 and Filmarray\u00ae Torch platforms.", [["existing Filmarray", "TEST", 45, 63]]], ["GeneXpert\u00ae developed by Cepheid\u2122 can integrate sample preparation, nucleic acid amplification and detection into a small detection kit, where even those without professional skills can perform complex molecular detection analyses.", [["sample", "ANATOMY", 47, 53], ["GeneXpert\u00ae", "CHEMICAL", 0, 10], ["Cepheid\u2122", "CHEMICAL", 24, 32], ["nucleic acid", "CHEMICAL", 67, 79], ["GeneXpert\u00ae", "SIMPLE_CHEMICAL", 0, 10], ["Cepheid\u2122", "SIMPLE_CHEMICAL", 24, 32], ["GeneXpert\u00ae", "TREATMENT", 0, 10], ["nucleic acid amplification", "TEST", 67, 93], ["a small detection kit", "TEST", 113, 134], ["complex molecular detection analyses", "TEST", 193, 229]]], ["This system has been used for the detection of HIV.", [["HIV", "ORGANISM", 47, 50], ["HIV", "SPECIES", 47, 50], ["HIV", "SPECIES", 47, 50], ["HIV", "PROBLEM", 47, 50], ["HIV", "OBSERVATION", 47, 50]]], ["In response to COVID-19, Xpert SARS-CoV-2 nucleic acid detection reagent has obtained EVA from FDA for the qualitative detection of SARS-CoV-2 nucleic acid.", [["nucleic acid", "CHEMICAL", 42, 54], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 132, 155], ["2 nucleic acid", "SIMPLE_CHEMICAL", 141, 155], ["SARS-CoV", "SPECIES", 132, 140], ["COVID", "TEST", 15, 20], ["Xpert SARS", "TEST", 25, 35], ["CoV", "TEST", 36, 39], ["nucleic acid detection reagent", "TEST", 42, 72], ["the qualitative detection", "TEST", 103, 128], ["SARS", "TEST", 132, 136], ["CoV", "TEST", 137, 140], ["nucleic acid", "TEST", 143, 155]]], ["RTisochip\u00ae proposed by CapitalBio\u2122 in China can detect 6 common respiratory viruses including COVID-19 in a single chip within 1.5 h.", [["CapitalBio\u2122", "CHEMICAL", 23, 34], ["COVID-19", "CHEMICAL", 94, 102], ["RTisochip\u00ae", "TREATMENT", 0, 10], ["6 common respiratory viruses", "PROBLEM", 55, 83], ["COVID", "TEST", 94, 99], ["a single chip", "TREATMENT", 106, 119], ["respiratory viruses", "OBSERVATION", 64, 83]]], ["This system not only detects SARS-CoV-2, but also effectively identifies patients with influenza and COVID-19.", [["influenza", "DISEASE", 87, 96], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["SARS-CoV", "SPECIES", 29, 37], ["SARS", "PROBLEM", 29, 33], ["CoV", "TEST", 34, 37], ["influenza", "PROBLEM", 87, 96], ["COVID", "TEST", 101, 106], ["SARS", "OBSERVATION", 29, 33]]], ["The POC instrument developed by Cannon\u2122 in Japan can detect the SARS-CoV-2 in 35 min.", [["SARS", "DISEASE", 64, 68], ["SARS-CoV", "SPECIES", 64, 72], ["The POC instrument", "TREATMENT", 0, 18], ["the SARS", "TEST", 60, 68]]], ["The instrument only weighs 2.4 kg and DNA can be amplified in as little as 10 min using respiratory samples.COVID-19 and commercialized products ::: Microfluidic chips for virus outbreaksMicrofluidic technology can both be automated and miniaturized to detect viruses.", [["respiratory samples", "ANATOMY", 88, 107], ["COVID-19", "CHEMICAL", 108, 116], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["The instrument", "TREATMENT", 0, 14], ["DNA", "TREATMENT", 38, 41], ["respiratory samples", "TEST", 88, 107], ["COVID", "TEST", 108, 113], ["Microfluidic chips", "TREATMENT", 149, 167], ["virus outbreaks", "PROBLEM", 172, 187], ["viruses", "PROBLEM", 260, 267], ["viruses", "OBSERVATION", 260, 267]]], ["This advanced technology in POC will change current medical methods.", [["current medical methods", "TREATMENT", 44, 67]]], ["Compared to the SARS-CoV and MERS-CoV outbreaks, lab on a chip has played a crucial role in the COVID-19 outbreak.", [["SARS", "DISEASE", 16, 20], ["SARS-CoV", "ORGANISM", 16, 24], ["MERS-CoV", "ORGANISM", 29, 37], ["SARS-CoV", "SPECIES", 16, 24], ["MERS-CoV", "SPECIES", 29, 37], ["the SARS", "TEST", 12, 20], ["the COVID", "TEST", 92, 101]]], ["Countries including the USA, China and Japan have approved the use of this technology, which fully demonstrates the application value of lab on a chip in POC.Other representative viruses ::: Microfluidic chips for virus outbreaksHBV is highly contagious and spreads through bodily fluids such as blood, saliva and semen.", [["bodily fluids", "ANATOMY", 274, 287], ["blood", "ANATOMY", 296, 301], ["saliva", "ANATOMY", 303, 309], ["semen", "ANATOMY", 314, 319], ["HBV", "ORGANISM", 229, 232], ["blood", "ORGANISM_SUBSTANCE", 296, 301], ["saliva", "ORGANISM_SUBSTANCE", 303, 309], ["semen", "ORGANISM_SUBSTANCE", 314, 319], ["HBV", "SPECIES", 229, 232], ["this technology", "TREATMENT", 70, 85], ["Microfluidic chips", "TREATMENT", 191, 209], ["virus outbreaksHBV", "PROBLEM", 214, 232], ["viruses", "OBSERVATION", 179, 186], ["contagious", "OBSERVATION_MODIFIER", 243, 253]]], ["HBV infection can cause cirrhosis, liver failure or hepatocellular carcinoma (Estevez et al., 2017; Lavanchy, 2004; Sarrazin, 2016).Investigators also use microfluidics to perform convenient and accurate diagnoses for these viruses (Chang et al., 2015; Vaghi et al., 2016).", [["liver", "ANATOMY", 35, 40], ["hepatocellular carcinoma", "ANATOMY", 52, 76], ["HBV infection", "DISEASE", 0, 13], ["cirrhosis", "DISEASE", 24, 33], ["liver failure", "DISEASE", 35, 48], ["hepatocellular carcinoma", "DISEASE", 52, 76], ["HBV", "ORGANISM", 0, 3], ["liver", "ORGAN", 35, 40], ["hepatocellular carcinoma", "CANCER", 52, 76], ["HBV", "SPECIES", 0, 3], ["HBV infection", "PROBLEM", 0, 13], ["cirrhosis", "PROBLEM", 24, 33], ["liver failure", "PROBLEM", 35, 48], ["hepatocellular carcinoma", "PROBLEM", 52, 76], ["microfluidics", "TREATMENT", 155, 168], ["these viruses", "PROBLEM", 218, 231], ["infection", "OBSERVATION", 4, 13], ["cirrhosis", "OBSERVATION", 24, 33], ["liver", "ANATOMY", 35, 40], ["failure", "OBSERVATION", 41, 48], ["hepatocellular", "ANATOMY", 52, 66], ["carcinoma", "OBSERVATION", 67, 76]]], ["Li et al. (Li et al., 2019b) described a disc chip to detect HBV in whole blood.", [["whole blood", "ANATOMY", 68, 79], ["Li", "CHEMICAL", 0, 2], ["HBV", "ORGANISM", 61, 64], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["HBV", "SPECIES", 61, 64], ["a disc chip", "PROBLEM", 39, 50], ["HBV in whole blood", "PROBLEM", 61, 79], ["disc", "ANATOMY", 41, 45]]], ["This disc chip integrated sample preparation and qRT-PCR.", [["sample", "ANATOMY", 26, 32], ["This disc chip integrated sample preparation", "TREATMENT", 0, 44], ["qRT", "TEST", 49, 52]]], ["Detection reagents were prestored into the chip and the freeze-dried reagents were kept in 2\u20138 \u00b0C for 6 months in the disc chip.", [["the freeze-dried reagents", "TREATMENT", 52, 77], ["the disc chip", "TREATMENT", 114, 127], ["disc", "ANATOMY", 118, 122]]], ["Moreover, the separation step of plasma or serum is avoided since it is directly detected from whole blood.", [["plasma", "ANATOMY", 33, 39], ["serum", "ANATOMY", 43, 48], ["whole blood", "ANATOMY", 95, 106], ["plasma", "ORGANISM_SUBSTANCE", 33, 39], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["the separation step of plasma or serum", "TEST", 10, 48], ["whole blood", "TEST", 95, 106]]], ["This system can detect 102 copies/mL HBV DNA in \u223c48 min from 500 \u03bcL of whole blood.", [["whole blood", "ANATOMY", 71, 82], ["HBV", "ORGANISM", 37, 40], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["HBV DNA", "DNA", 37, 44], ["HBV", "SPECIES", 37, 40], ["HBV DNA", "TEST", 37, 44], ["whole blood", "TEST", 71, 82]]], ["Our group also proposed a digital isothermal chip for the quantitative detection of HBV.", [["HBV", "ORGANISM", 84, 87], ["HBV", "SPECIES", 84, 87], ["a digital isothermal chip", "TREATMENT", 24, 49], ["HBV", "PROBLEM", 84, 87], ["HBV", "OBSERVATION", 84, 87]]], ["This chip has 120576 reaction chambers and the dynamic range of the detection template is up to 6 orders of magnitude.", [["reaction chambers", "OBSERVATION", 21, 38]]], ["The maximum detectable template amount is 1.13 \u00d7 106 copy numbers in 36 \u03bcL (Wu et al., 2017).", [["copy numbers", "TEST", 53, 65], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["detectable", "OBSERVATION_MODIFIER", 12, 22], ["template", "OBSERVATION_MODIFIER", 23, 31], ["amount", "OBSERVATION_MODIFIER", 32, 38]]], ["Hepatitis C (HCV) is the major cause of chronic liver disease and is often associated with the development of liver cirrhosis, hepatocellular carcinoma, liver failure and death (Pawlotsky, 2016; Petruzziello et al.).", [["liver", "ANATOMY", 48, 53], ["liver", "ANATOMY", 110, 115], ["hepatocellular carcinoma", "ANATOMY", 127, 151], ["liver", "ANATOMY", 153, 158], ["Hepatitis C (HCV)", "DISEASE", 0, 17], ["chronic liver disease", "DISEASE", 40, 61], ["liver cirrhosis", "DISEASE", 110, 125], ["hepatocellular carcinoma", "DISEASE", 127, 151], ["liver failure", "DISEASE", 153, 166], ["death", "DISEASE", 171, 176], ["Hepatitis C", "ORGANISM", 0, 11], ["HCV", "ORGANISM", 13, 16], ["liver", "ORGAN", 48, 53], ["liver", "ORGAN", 110, 115], ["hepatocellular carcinoma", "CANCER", 127, 151], ["liver", "ORGAN", 153, 158], ["HCV", "SPECIES", 13, 16], ["Hepatitis C (HCV", "PROBLEM", 0, 16], ["chronic liver disease", "PROBLEM", 40, 61], ["liver cirrhosis", "PROBLEM", 110, 125], ["hepatocellular carcinoma", "PROBLEM", 127, 151], ["liver failure", "PROBLEM", 153, 166], ["death", "PROBLEM", 171, 176], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["liver", "ANATOMY", 48, 53], ["disease", "OBSERVATION", 54, 61], ["liver", "ANATOMY", 110, 115], ["cirrhosis", "OBSERVATION", 116, 125], ["hepatocellular", "ANATOMY", 127, 141], ["carcinoma", "OBSERVATION", 142, 151], ["liver", "ANATOMY", 153, 158], ["failure", "OBSERVATION", 159, 166]]], ["Mu et al., (2014) developed a paper chip to detect HCV(Fig. 8A).", [["HCV", "ORGANISM", 51, 54], ["HCV", "SPECIES", 51, 54], ["HCV", "PROBLEM", 51, 54]]], ["This method was based on the detection IgG antibodies against HCV and an 8-plex paper chip was designed to yield additional information about the HCV infection.", [["HCV infection", "DISEASE", 146, 159], ["HCV", "ORGANISM", 62, 65], ["HCV", "ORGANISM", 146, 149], ["IgG antibodies", "PROTEIN", 39, 53], ["HCV", "SPECIES", 62, 65], ["HCV", "SPECIES", 146, 149], ["the detection IgG antibodies", "TEST", 25, 53], ["HCV", "PROBLEM", 62, 65], ["an 8-plex paper chip", "TREATMENT", 70, 90], ["the HCV infection", "PROBLEM", 142, 159], ["HCV", "OBSERVATION_MODIFIER", 146, 149], ["infection", "OBSERVATION", 150, 159]]], ["On this chip, 267 amol was detected using chemiluminescence and 26.7 fmol was detected using colorimetry.Other representative viruses ::: Microfluidic chips for virus outbreaksAfrican swine fever virus (ASFV) is a large double stranded DNA virus that contains a high mortality rate in domestic pigs and wild boar (Hubner et al., 2018).", [["swine fever", "DISEASE", 184, 195], ["African swine fever virus", "ORGANISM", 176, 201], ["ASFV", "ORGANISM", 203, 207], ["DNA", "CELLULAR_COMPONENT", 236, 239], ["pigs", "ORGANISM", 294, 298], ["African swine fever virus", "SPECIES", 176, 201], ["pigs", "SPECIES", 294, 298], ["boar", "SPECIES", 308, 312], ["African swine fever virus", "SPECIES", 176, 201], ["ASFV", "SPECIES", 203, 207], ["pigs", "SPECIES", 294, 298], ["chemiluminescence", "TEST", 42, 59], ["fmol", "TEST", 69, 73], ["colorimetry", "TEST", 93, 104], ["Microfluidic chips", "TREATMENT", 138, 156], ["virus outbreaks", "PROBLEM", 161, 176], ["African swine fever virus (ASFV", "PROBLEM", 176, 207], ["a large double stranded DNA virus", "PROBLEM", 212, 245], ["viruses", "OBSERVATION", 126, 133], ["large", "OBSERVATION_MODIFIER", 214, 219], ["double stranded", "OBSERVATION_MODIFIER", 220, 235], ["DNA virus", "OBSERVATION", 236, 245], ["high", "OBSERVATION_MODIFIER", 262, 266], ["mortality", "OBSERVATION_MODIFIER", 267, 276]]], ["Virulence can be divided into high, moderate, low and without clinical symptoms.", [["Virulence", "PROBLEM", 0, 9], ["moderate, low and without clinical symptoms", "PROBLEM", 36, 79], ["high", "OBSERVATION_MODIFIER", 30, 34], ["moderate", "OBSERVATION_MODIFIER", 36, 44], ["low", "OBSERVATION_MODIFIER", 46, 49]]], ["High virulence ASFV can lead to the rapid death of infected animals, where moderate or low virulence may lead to a persistent infection and continuous detoxification (Nurmoja et al., 2017; Tulman et al., 2009).", [["death of infected", "DISEASE", 42, 59], ["infection", "DISEASE", 126, 135], ["ASFV", "ORGANISM", 15, 19], ["ASFV", "SPECIES", 15, 19], ["High virulence ASFV", "PROBLEM", 0, 19], ["the rapid death of infected animals", "PROBLEM", 32, 67], ["moderate or low virulence", "PROBLEM", 75, 100], ["a persistent infection", "PROBLEM", 113, 135], ["rapid", "OBSERVATION_MODIFIER", 36, 41], ["infected", "OBSERVATION", 51, 59], ["moderate", "OBSERVATION_MODIFIER", 75, 83], ["low virulence", "OBSERVATION_MODIFIER", 87, 100], ["persistent", "OBSERVATION_MODIFIER", 115, 125], ["infection", "OBSERVATION", 126, 135]]], ["Recently, He et al., (2020) developed a cartridge system that uses CRISPR-Cas12a and CRISPR RNA to detect ASFV DNA.", [["CRISPR-Cas12a", "GENE_OR_GENE_PRODUCT", 67, 80], ["ASFV", "ORGANISM", 106, 110], ["DNA", "CELLULAR_COMPONENT", 111, 114], ["CRISPR", "DNA", 67, 73], ["Cas12a", "DNA", 74, 80], ["CRISPR RNA", "RNA", 85, 95], ["ASFV DNA", "DNA", 106, 114], ["ASFV", "SPECIES", 106, 110], ["a cartridge system", "TREATMENT", 38, 56], ["CRISPR RNA", "TEST", 85, 95], ["ASFV DNA", "PROBLEM", 106, 114], ["ASFV DNA", "OBSERVATION", 106, 114]]], ["Using this method, the amplification of nucleic acid is not needed.", [["nucleic acid", "CHEMICAL", 40, 52], ["nucleic acid", "SIMPLE_CHEMICAL", 40, 52], ["this method", "TREATMENT", 6, 17], ["nucleic acid", "TREATMENT", 40, 52]]], ["Ye et al., (2019) proposed a portable disc system (Fig. 8 B)to detect the ASFV using a circular fluorescent probe-mediated isothermal nucleic acid amplification (CFPA) method.", [["nucleic acid", "CHEMICAL", 134, 146], ["ASFV", "ORGANISM", 74, 78], ["ASFV", "SPECIES", 74, 78], ["a portable disc system", "TEST", 27, 49], ["the ASFV", "TREATMENT", 70, 78], ["a circular fluorescent probe-mediated isothermal nucleic acid amplification", "TREATMENT", 85, 160]]], ["This system has a LOD of 10 copies/\u03bcL and 100% specificity for pig samples in 10.8 min.Integrated sample preparation ::: Challenges in using microfluidics for viral detectionSample preparation is crucial for precise virus detection.", [["samples", "ANATOMY", 67, 74], ["sample", "ANATOMY", 98, 104], ["pig", "ORGANISM", 63, 66], ["pig", "SPECIES", 63, 66], ["pig", "SPECIES", 63, 66], ["a LOD", "TEST", 16, 21], ["pig samples", "TEST", 63, 74], ["microfluidics", "TREATMENT", 141, 154], ["viral detectionSample preparation", "TREATMENT", 159, 192], ["precise virus detection", "TEST", 208, 231]]], ["Microfluidic systems even have quicker and more accurate advantages compared to traditional methods when it comes to virus outbreaks, where many of these methods ignore sample preparation, which is not suitable for POC.", [["Microfluidic systems", "TEST", 0, 20], ["traditional methods", "TREATMENT", 80, 99]]], ["In addition, compared to other detection objects, nano-level and RNA-coded viruses pose greater challenges for sample preparation.", [["sample", "ANATOMY", 111, 117], ["other detection objects", "TEST", 25, 48], ["nano-level", "TEST", 50, 60], ["RNA", "TEST", 65, 68], ["sample preparation", "TREATMENT", 111, 129]]], ["In recent years, virus sample preparation has also attracted more attention and there have been different proposals for viral sample preparation strategies.", [["sample", "ANATOMY", 23, 29], ["sample", "ANATOMY", 126, 132], ["virus sample preparation", "TREATMENT", 17, 41], ["viral sample preparation strategies", "TREATMENT", 120, 155]]], ["For different detection methods, sample preparation have different meanings such as sample enrichment (Surawathanawises et al., 2016) or nucleic acid extraction (Chen et al., 2019; Zhang et al., 2019).", [["nucleic acid", "CHEMICAL", 137, 149], ["nucleic acid", "SIMPLE_CHEMICAL", 137, 149], ["different detection methods", "TEST", 4, 31], ["sample preparation", "TREATMENT", 33, 51], ["nucleic acid extraction", "TREATMENT", 137, 160]]], ["Recently, Du et al. (Du et al., 2017a) proposed an automated sample preparation microfluidic system that utilized air bubbles and magnetic beads to achieve efficient capture of the Ebola virus.", [["sample", "ANATOMY", 61, 67], ["Ebola", "DISEASE", 181, 186], ["Ebola virus", "ORGANISM", 181, 192], ["Ebola virus", "SPECIES", 181, 192], ["Ebola virus", "SPECIES", 181, 192], ["an automated sample preparation microfluidic system", "TREATMENT", 48, 99], ["air bubbles", "TREATMENT", 114, 125], ["magnetic beads", "TREATMENT", 130, 144], ["the Ebola virus", "PROBLEM", 177, 192], ["air bubbles", "OBSERVATION", 114, 125], ["Ebola virus", "OBSERVATION", 181, 192]]], ["Vaghi et al., (2016) reported a PDMS chip for HCV RNA purification and detection from plasma.", [["plasma", "ANATOMY", 86, 92], ["HCV", "ORGANISM", 46, 49], ["plasma", "ORGANISM_SUBSTANCE", 86, 92], ["HCV RNA", "RNA", 46, 53], ["HCV", "SPECIES", 46, 49], ["a PDMS chip", "TREATMENT", 30, 41], ["HCV RNA purification", "TREATMENT", 46, 66]]], ["Capture efficiency was improved with two orders of magnitude and LOD was improved 10-fold using this system.", [["Capture efficiency", "PROBLEM", 0, 18], ["LOD", "TEST", 65, 68], ["this system", "TREATMENT", 96, 107]]], ["Kim et al., (2019) proposed a microfluidic system to concentrate viral particles.", [["a microfluidic system", "TREATMENT", 28, 49], ["viral particles", "OBSERVATION", 65, 80]]], ["In this system, the poly (ethylene glycol) methacrylate (PEGMA) membrane was integrated into the chip and the virus was concentrated through autonomous and continuous perfusion.", [["poly (ethylene glycol) methacrylate", "CHEMICAL", 20, 55], ["PEGMA", "CHEMICAL", 57, 62], ["poly (ethylene glycol) methacrylate", "CHEMICAL", 20, 55], ["PEGMA", "CHEMICAL", 57, 62], ["poly (ethylene glycol) methacrylate", "SIMPLE_CHEMICAL", 20, 55], ["PEGMA", "SIMPLE_CHEMICAL", 57, 62], ["the poly (ethylene glycol) methacrylate (PEGMA) membrane", "TREATMENT", 16, 72], ["the chip", "TREATMENT", 93, 101], ["the virus", "PROBLEM", 106, 115], ["virus", "OBSERVATION", 110, 115], ["continuous perfusion", "OBSERVATION", 156, 176]]], ["Yeh et al. (Yeh et al., 2020)developed a microfluidic chip for rapid virus capture and in situ detection.", [["a microfluidic chip", "TREATMENT", 39, 58], ["rapid virus capture", "PROBLEM", 63, 82]]], ["This chip uses carbon nanotube arrays with differential filtration porosity to concentrate the virus and uses surface-enhanced Raman spectroscopy (SERS) to detect the virus.", [["carbon nanotube", "CHEMICAL", 15, 30], ["carbon", "CHEMICAL", 15, 21], ["This chip", "TREATMENT", 0, 9], ["carbon nanotube arrays", "TREATMENT", 15, 37], ["differential filtration porosity", "TREATMENT", 43, 75], ["the virus", "PROBLEM", 91, 100], ["surface-enhanced Raman spectroscopy", "TEST", 110, 145], ["the virus", "PROBLEM", 163, 172]]], ["This research demonstrates that an effective virus sample preparation method in chip will give more precise results.Integrated sample preparation ::: Challenges in using microfluidics for viral detectionIn addition, the integration of sample preparation with detection is important especially for nucleic acid-based detection methods (Yin et al., 2019).", [["sample", "ANATOMY", 51, 57], ["sample", "ANATOMY", 127, 133], ["sample", "ANATOMY", 235, 241], ["nucleic acid", "CHEMICAL", 297, 309], ["nucleic acid", "SIMPLE_CHEMICAL", 297, 309], ["an effective virus sample preparation method", "TREATMENT", 32, 76], ["viral detection", "TEST", 188, 203], ["sample preparation with detection", "TEST", 235, 268], ["nucleic acid", "TEST", 297, 309], ["effective", "OBSERVATION_MODIFIER", 35, 44], ["virus", "OBSERVATION", 45, 50]]], ["However, very few studies have been able to integrate virus sample preparation into chips.", [["virus sample preparation", "TREATMENT", 54, 78]]], ["Integrated sample preparation will reduce testing time, improve accuracy and minimize labor.", [["sample", "ANATOMY", 11, 17], ["Integrated sample preparation", "TREATMENT", 0, 29], ["testing time", "TEST", 42, 54], ["accuracy", "TEST", 64, 72], ["labor", "PROBLEM", 86, 91]]], ["Moreover, sample-in-answer-out is the ideal detection process.", [["sample", "TEST", 10, 16]]], ["Therefore, sample preparation should be considered in a single chip.", [["sample", "ANATOMY", 11, 17], ["sample preparation", "TREATMENT", 11, 29], ["a single chip", "TREATMENT", 54, 67]]], ["Whether Lab-on-a-chip is used in the clinic or the home, sample preparation integration is necessary.", [["Lab-on-a-", "CHEMICAL", 8, 17], ["a-chip", "TREATMENT", 15, 21], ["sample preparation integration", "TREATMENT", 57, 87]]], ["Automated and high-throughput microfluidics should also be considered.", [["high-throughput microfluidics", "TREATMENT", 14, 43], ["high", "OBSERVATION_MODIFIER", 14, 18]]], ["Therefore, additional sample preparation methods should be tested and integrated into chips that will be used for virus outbreaks.High throughput and multiplex detection ::: Challenges in using microfluidics for viral detectionVirus outbreaks are characterized by a rapid spread and large scale infection.", [["sample", "ANATOMY", 22, 28], ["infection", "DISEASE", 295, 304], ["additional sample preparation methods", "TREATMENT", 11, 48], ["chips", "TREATMENT", 86, 91], ["virus outbreaks", "PROBLEM", 114, 129], ["microfluidics", "TREATMENT", 194, 207], ["viral detectionVirus outbreaks", "PROBLEM", 212, 242], ["a rapid spread", "PROBLEM", 264, 278], ["large scale infection", "PROBLEM", 283, 304], ["rapid", "OBSERVATION_MODIFIER", 266, 271], ["spread", "OBSERVATION_MODIFIER", 272, 278], ["large", "OBSERVATION_MODIFIER", 283, 288], ["scale", "OBSERVATION_MODIFIER", 289, 294], ["infection", "OBSERVATION", 295, 304]]], ["For example, DENV causes 50\u2013100 million infections, with \u223c2.5% of individuals passing away (Yu et al., 2015).", [["DENV", "DISEASE", 13, 17], ["infections", "DISEASE", 40, 50], ["DENV", "ORGANISM", 13, 17], ["DENV", "SPECIES", 13, 17], ["DENV", "PROBLEM", 13, 17], ["50\u2013100 million infections", "PROBLEM", 25, 50], ["DENV", "OBSERVATION", 13, 17], ["infections", "OBSERVATION", 40, 50]]], ["SARS-CoV-2 has spread to 25 countries across 4 continents and over 40,000 cases have been confirmed in only 3 months (Li and De Clercq, 2020).", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "SPECIES", 0, 8]]], ["These characteristics pose a huge challenge for detection methods.", [["a huge challenge", "TREATMENT", 27, 43], ["detection methods", "TEST", 48, 65]]], ["The gold standard detection method qRT-PCR can achieve a throughput of 96 or 384 samples (Bustin and Mueller, 2005), which is higher than current microfluidic-based methods.", [["PCR", "TEST", 39, 42], ["higher", "OBSERVATION_MODIFIER", 126, 132]]], ["Moreover, studies have shown that when there is a viral outbreak, increased deaths are due to a large number of infections, not increased toxicity (Harris et al., 2008).", [["deaths", "DISEASE", 76, 82], ["infections", "DISEASE", 112, 122], ["toxicity", "DISEASE", 138, 146], ["studies", "TEST", 10, 17], ["a viral outbreak", "PROBLEM", 48, 64], ["increased deaths", "PROBLEM", 66, 82], ["infections", "PROBLEM", 112, 122], ["increased toxicity", "PROBLEM", 128, 146], ["viral", "OBSERVATION_MODIFIER", 50, 55], ["large", "OBSERVATION_MODIFIER", 96, 101], ["number", "OBSERVATION_MODIFIER", 102, 108], ["infections", "OBSERVATION", 112, 122], ["not", "UNCERTAINTY", 124, 127], ["increased", "OBSERVATION_MODIFIER", 128, 137], ["toxicity", "OBSERVATION_MODIFIER", 138, 146]]], ["Therefore, microfluidic chips used for clinically-oriented virus detection face a throughput challenge.High throughput and multiplex detection ::: Challenges in using microfluidics for viral detectionMultiplex detection can improve the accuracy of early detection (Seok et al., 2017) and give additional details for infected patients (Goktas and Sirin, 2016) since most viruses have various subtypes and pathogenicity.", [["patients", "ORGANISM", 325, 333], ["patients", "SPECIES", 325, 333], ["microfluidic chips", "TREATMENT", 11, 29], ["viral detection", "TEST", 185, 200], ["pathogenicity", "PROBLEM", 404, 417], ["pathogenicity", "OBSERVATION", 404, 417]]], ["However, many studies have ignored the fact that there are virus subtypes and only target one or more subtypes, which affects accuracy in practical applications.", [["many studies", "TEST", 9, 21], ["virus subtypes", "PROBLEM", 59, 73], ["virus", "OBSERVATION", 59, 64], ["more subtypes", "OBSERVATION_MODIFIER", 97, 110]]], ["For example, some viruses such as influenza virus have nearly 200 subtypes, which poses a great challenge for microfluidic chip.", [["influenza virus", "DISEASE", 34, 49], ["influenza virus", "ORGANISM", 34, 49], ["influenza virus", "SPECIES", 34, 49], ["influenza virus", "SPECIES", 34, 49], ["some viruses", "PROBLEM", 13, 25], ["influenza virus", "PROBLEM", 34, 49], ["microfluidic chip", "TREATMENT", 110, 127], ["some", "OBSERVATION_MODIFIER", 13, 17], ["viruses", "OBSERVATION", 18, 25], ["influenza virus", "OBSERVATION", 34, 49], ["200 subtypes", "OBSERVATION_MODIFIER", 62, 74], ["microfluidic chip", "OBSERVATION", 110, 127]]], ["To achieve multiple detection in chips, multiple colors or different division areas are used (Gu et al., 2018; Pang et al., 2018; Yan et al., 2017; Zhang et al., 2016).", [["multiple detection in chips", "TREATMENT", 11, 38], ["multiple colors or different division areas", "PROBLEM", 40, 83], ["different", "OBSERVATION_MODIFIER", 59, 68], ["division", "OBSERVATION_MODIFIER", 69, 77], ["areas", "OBSERVATION_MODIFIER", 78, 83]]], ["However, these methods generally need expensive instrument and reagents, which limit the application of the chip.", [["expensive instrument", "TREATMENT", 38, 58], ["reagents", "TREATMENT", 63, 71], ["the chip", "TREATMENT", 104, 112]]], ["Therefore, multiple detection capabilities are challenges in the clinical application of microfluidic chip.Quantitative methods ::: Challenges in using microfluidics for viral detectionThe development of microfluidic technology makes \u201csample-in-answer-out\u201d possible for virus detection.", [["multiple detection capabilities", "TEST", 11, 42], ["microfluidic chip", "TREATMENT", 89, 106], ["viral detection", "TEST", 170, 185], ["\u201csample", "TEST", 234, 241], ["virus detection", "PROBLEM", 270, 285], ["microfluidic chip", "OBSERVATION", 89, 106]]], ["Most research and commercial products obtain results according to the standard curve, which is a relative quantitative method.", [["the standard curve", "TEST", 66, 84]]], ["This type of quantitative method is often limited by several factors including inhibitors and amplification efficiency (Bian et al., 2015).", [["inhibitors", "TREATMENT", 79, 89], ["amplification efficiency", "PROBLEM", 94, 118]]], ["Digital quantitative methods such as digital PCR and digital LAMP can achieve absolute quantification and do not depend on the standard curve to obtain high sensitivity (Sreejith et al., 2018).", [["Digital quantitative methods", "TEST", 0, 28], ["digital PCR", "TEST", 37, 48], ["digital LAMP", "TEST", 53, 65], ["absolute quantification", "TEST", 78, 101], ["the standard curve", "TEST", 123, 141]]], ["However, due to limitations related to instruments, costs and sample preparation, it is difficult to apply this quantitative method in POCT.", [["instruments", "TEST", 39, 50], ["costs and sample preparation", "TREATMENT", 52, 80]]], ["Therefore, the use of digital quantitative methods such as digital RPA and digital Elisa to achieve \u201csample-in-digital-answer-out\u201d results pose great challenges in virus detection.SummaryIn this review, viral outbreaks were introduced as well as a discussion of the advantages and disadvantages of various microfluidic systems in response to these viruses.", [["digital quantitative methods", "TREATMENT", 22, 50], ["digital RPA", "TEST", 59, 70], ["digital Elisa", "TEST", 75, 88], ["\u201csample", "TEST", 100, 107], ["virus detection", "TEST", 164, 179], ["viral outbreaks", "PROBLEM", 203, 218], ["various microfluidic systems", "TREATMENT", 298, 326], ["these viruses", "PROBLEM", 342, 355], ["viruses", "OBSERVATION", 348, 355]]], ["These life-threatening viruses have different characteristics that influence different microfluidic chips in early virus detection.", [["These life-threatening viruses", "PROBLEM", 0, 30], ["different microfluidic chips", "TREATMENT", 77, 105], ["early virus detection", "PROBLEM", 109, 130], ["threatening", "OBSERVATION_MODIFIER", 11, 22], ["viruses", "OBSERVATION", 23, 30], ["microfluidic chips", "OBSERVATION", 87, 105]]], ["In summary, after decades of work, microfluidic technology has made its breakthrough in LOD, time and speed for virus detection.", [["microfluidic technology", "TREATMENT", 35, 58], ["virus detection", "TEST", 112, 127]]], ["This technology will significantly transform virus testing for POC in the home or clinical settings.", [["virus testing", "TEST", 45, 58]]], ["In addition, this article highlights the urgent challenges that microfluidic chips currently face when it comes to virus detection such as sample preparation integration, quantitative methods, the ability to perform throughput and multiplex during a virus outbreak.Future perspectivesDespite many challenges, these technologies are gradually changing the POC of viruses.", [["sample", "ANATOMY", 139, 145], ["the urgent challenges", "TREATMENT", 37, 58], ["microfluidic chips", "TREATMENT", 64, 82], ["virus detection", "TEST", 115, 130], ["quantitative methods", "TEST", 171, 191], ["a virus outbreak", "PROBLEM", 248, 264], ["viruses", "PROBLEM", 362, 369], ["microfluidic chips", "OBSERVATION", 64, 82]]], ["There has been some progress in the detection of viruses such as wearable chips, paper chips, disc chips and the emergence of commercial products such as the Filmarray\u00ae.", [["viruses", "PROBLEM", 49, 56], ["wearable chips", "TREATMENT", 65, 79], ["paper chips", "TREATMENT", 81, 92], ["disc chips", "TREATMENT", 94, 104], ["commercial products", "TREATMENT", 126, 145], ["the Filmarray\u00ae", "TREATMENT", 154, 168], ["some", "OBSERVATION_MODIFIER", 15, 19], ["progress", "OBSERVATION_MODIFIER", 20, 28], ["viruses", "OBSERVATION", 49, 56]]], ["To overcome these challenges, the material and design of microfluidic chips, the innovation of detection methods and the miniaturization of instruments need to all be improved, which requires collaboration between scientists with different expertise.", [["these challenges", "TREATMENT", 12, 28], ["microfluidic chips", "TREATMENT", 57, 75], ["detection methods", "TEST", 95, 112], ["the miniaturization of instruments", "TREATMENT", 117, 151]]], ["If the microfluidic chip is further combined with the \u201cBiological mobile phone\u201d, \u201cMobile detection station\u201d, or \u201cArtificial Intelligence\u201d, its potential for virus detection will be extended even further.Future perspectivesIn the future, microfluidic products that meet the criteria for POC proposed by WHO including (1) being affordable to those at risk of infection, containing (2) high sensitivity, (3) high specificity, (4) user-friendly capabilities, being (5) rapid and robust, (6) equipment free, and (7) delivered to those who need it (Blacksell, 2012; Huppert et al., 2010; Tenforde et al., 2019) will be readily available.", [["infection", "DISEASE", 357, 366], ["the microfluidic chip", "PROBLEM", 3, 24], ["virus detection", "PROBLEM", 157, 172], ["microfluidic products", "TREATMENT", 237, 258], ["infection", "PROBLEM", 357, 366], ["high sensitivity", "PROBLEM", 383, 399], ["microfluidic chip", "OBSERVATION", 7, 24], ["infection", "OBSERVATION", 357, 366]]], ["To apply microfluidic chips clinically, professional users can use microfluidic technology with simple operations and detect a large number of samples in a short time while obtaining accurate information.", [["samples", "ANATOMY", 143, 150], ["microfluidic chips", "TREATMENT", 9, 27], ["microfluidic technology", "TREATMENT", 67, 90], ["simple operations", "TREATMENT", 96, 113]]], ["Early detection of viruses using microfluidic technology can help reduce the scale of viral outbreaks and improve response to infection.Declaration of competing interestThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.", [["infection", "DISEASE", 126, 135], ["viruses", "PROBLEM", 19, 26], ["microfluidic technology", "TREATMENT", 33, 56], ["viral outbreaks", "PROBLEM", 86, 101], ["infection", "PROBLEM", 126, 135], ["viruses", "OBSERVATION", 19, 26], ["infection", "OBSERVATION", 126, 135]]]], "PMC7188620": [], "PMC7371819": [["B. Probleme beim Management des Atemwegs, der Atmung und des Kreislaufs, inkorrekte Sauerstofftherapie, fehlendes Monitoring der Patienten, Vers\u00e4umnis erfahrenere \u00c4rzte anzufordern, mangelnde Kommunikation, schlechtes Teamwork und unzureichende Verwendung von Pl\u00e4nen, die eine Limitierung der Behandlung beschreiben [3, 7].Probleme bei der Akutbehandlung ::: Vermeidung eines innerklinischen KreislaufstillstandsMehrere Studien haben gezeigt, dass \u00c4rzte und Krankenpflegepersonal bei der klinischen Akutversorgung von Notfallpatienten Schwierigkeiten haben.", [["B. Probleme beim Management des Atemwegs, der Atmung und des Kreislaufs, inkorrekte Sauerstofftherapie, fehlendes Monitoring der Patienten, Vers\u00e4umnis erfahrenere \u00c4rzte anzufordern, mangelnde Kommunikation, schlechtes Teamwork und unzureichende Verwendung von Pl\u00e4nen, die eine Limitierung der Behandlung beschreiben", "SPECIES", 0, 315], ["Vermeidung eines innerklinischen KreislaufstillstandsMehrere Studien haben gezeigt, dass \u00c4rzte und Krankenpflegepersonal bei der klinischen Akutversorgung von Notfallpatienten Schwierigkeiten haben", "SPECIES", 359, 556], ["der Atmung und des Kreislaufs", "TREATMENT", 42, 71], ["inkorrekte Sauerstofftherapie", "TREATMENT", 73, 102]]], ["Zum Beispiel wurde gezeigt, dass Assistenz\u00e4rzte Schwierigkeiten haben mit der Einsch\u00e4tzung einer Sauerstofftherapie [10], der Fl\u00fcssigkeits- und Elektrolytbalance [11] der Analgesie [12], der Einverst\u00e4ndniserkl\u00e4rung von Patienten [13], der Pulsoxymetrie [14] und der Dosierung von Medikamenten [15].", [["Zum Beispiel wurde gezeigt, dass Assistenz\u00e4rzte Schwierigkeiten haben mit der Einsch\u00e4tzung einer Sauerstofftherapie [10], der Fl\u00fcssigkeits- und Elektrolytbalance [11] der Analgesie", "SPECIES", 0, 180], ["dass Assistenz\u00e4rzte Schwierigkeiten haben mit der Einsch\u00e4tzung einer Sauerstofftherapie", "TREATMENT", 28, 115]]], ["Studienabsolventen werden im Rahmen ihrer universit\u00e4ren Ausbildung ungen\u00fcgend auf die Probleme ihres Arbeitslebens vorbereitet und insbesondere nicht auf die essenziellen Grandlagen der Pathophysiologie und der Akutbehandlung eingewiesen [17].", [["Studienabsolventen werden im Rahmen ihrer universit\u00e4ren Ausbildung ungen\u00fcgend auf die Probleme ihres Arbeitslebens vorbereitet und insbesondere nicht auf die essenziellen Grandlagen der Pathophysiologie und der Akutbehandlung eingewiesen", "SPECIES", 0, 237], ["Studienabsolventen", "TREATMENT", 0, 18]]], ["\u00c4rzte haben oft wenig Selbstvertrauen, wenn sie akute Probleme behandeln m\u00fcssen und benutzen sehr selten einen systematischen Ansatz, um den Gesundheitszustand eines akut erkrankten Patienten zu beurteilen [20].Erkennen des kritisch erkrankten Patienten ::: Vermeidung eines innerklinischen KreislaufstillstandsIm Allgemeinen sind die klinischen Zeichen einer akuten Erkrankung unabh\u00e4ngig von ihrer Ursache \u00e4hnlich, da sie alle ein Versagen der Atmung, des Kreislaufs und der neurologischen Funktion zeigen.", [["wenn sie akute Probleme behandeln m\u00fcssen und benutzen sehr selten einen systematischen Ansatz, um den Gesundheitszustand eines akut erkrankten Patienten zu beurteilen", "SPECIES", 39, 205], ["Vermeidung eines innerklinischen KreislaufstillstandsIm Allgemeinen sind die klinischen Zeichen einer akuten Erkrankung unabh\u00e4ngig von ihrer Ursache \u00e4hnlich, da sie alle ein Versagen der Atmung, des Kreislaufs und der neurologischen Funktion zeigen", "SPECIES", 258, 506], ["Vermeidung eines innerklinischen", "TREATMENT", 258, 290]]], ["Leider wird die Messung und Dokumentation von wichtigen Ver\u00e4nderungen physiologischer Parameter bei akuten Erkrankungen h\u00e4ufig nicht so oft wie notwendig durchgef\u00fchrt [3, 4, 8].", [["Leider wird die Messung und Dokumentation von wichtigen Ver\u00e4nderungen physiologischer Parameter bei akuten Erkrankungen h\u00e4ufig nicht so oft wie notwendig durchgef\u00fchrt", "SPECIES", 0, 166]]], ["Dies ist \u00fcberraschend, da Ver\u00e4nderungen in der Atemfrequenz einen Kreislaufstillstand m\u00f6glicherweise vorhersagen k\u00f6nnen [22].Erkennen des kritisch erkrankten Patienten ::: Vermeidung eines innerklinischen KreislaufstillstandsUm eine akute Verschlechterung des Krankheitsbilds eines Patienten vorherzusagen, benutzen viele Krankenh\u00e4user mittlerweile ein so genanntes Fr\u00fchalarmsystem bzw. standardisierte Kriterien f\u00fcr die Alarmierung eines Notfallteams [23, 24, 25].", [["Vermeidung eines", "TREATMENT", 172, 188]]], ["Dieser gewichtete Score von einem oder mehreren Vitalzeichen oder dem gesamten Fr\u00fchwarnscore kann benutzt werden, um das Pflegepersonal auf einer Bettenstation darauf hinzuweisen, dass ein Patient sich verschlechtert.", [["Dieser gewichtete Score von einem oder mehreren Vitalzeichen oder dem gesamten Fr\u00fchwarnscore kann benutzt werden, um das Pflegepersonal auf einer Bettenstation darauf hinzuweisen, dass ein Patient sich verschlechtert", "SPECIES", 0, 216]]], ["Dies f\u00fchrt dann zu einem Notruf f\u00fcr den Stationsarzt oder sogar f\u00fcr ein Herzalarmteam der Intensivstation.", [["Dies f\u00fchrt dann zu einem Notruf f\u00fcr den Stationsarzt oder sogar f\u00fcr ein Herzalarmteam der Intensivstation", "SPECIES", 0, 105]]], ["Alternativ dazu k\u00f6nnen Systeme eingef\u00fchrt werden, die auf der Basis einer Routinebeobachtung des akut erkrankten Patienten Notrufkriterien zusammenstellen, wodurch bei Registrierung eines oder mehrerer deutlich phatologischer Vitalparameter ein Notruf ausgel\u00f6st wird [23, 26].Erkennen des kritisch erkrankten Patienten ::: Vermeidung eines innerklinischen KreislaufstillstandsVer\u00e4nderungen in der Atemfrequenz k\u00f6nnen m\u00f6glicherweise einen Kreislaufstillstand vorhersagenErkennen des kritisch erkrankten Patienten ::: Vermeidung eines innerklinischen KreislaufstillstandsEs gibt keine klinischen Daten, die die Vorteile eines Systems gegen\u00fcber einem anderen aufzeigen, aber es scheint von Vorteil zu sein, ein Fr\u00fchwarnscoringsystem zu benutzen, das \u00c4nderungen bei den Vitalparametern verfolgen kann und so m\u00f6glicherweise einen bevorstehenden Kollaps des Herz-Kreislauf-Systems vorhersagen kann, verglichen mit einem Notrufkriteriensystem, das nur getriggert wird, wenn ein bestimmter extremer Messwert bei den Vitalparametern erreicht wird.", [["Basis einer Routinebeobachtung des akut erkrankten Patienten Notrufkriterien zusammenstellen, wodurch bei Registrierung eines oder mehrerer deutlich phatologischer Vitalparameter ein Notruf ausgel\u00f6st wird", "SPECIES", 62, 266], ["Vermeidung eines innerklinischen KreislaufstillstandsEs gibt keine klinischen Daten, die die Vorteile eines Systems gegen\u00fcber einem anderen aufzeigen, aber es scheint von Vorteil zu sein, ein Fr\u00fchwarnscoringsystem zu benutzen, das \u00c4nderungen bei den Vitalparametern verfolgen kann und so m\u00f6glicherweise einen bevorstehenden Kollaps des Herz-Kreislauf-Systems vorhersagen kann, verglichen mit einem Notrufkriteriensystem, das nur getriggert wird, wenn ein bestimmter extremer Messwert bei den Vitalparametern erreicht wird", "SPECIES", 516, 1037], ["Alternativ dazu k\u00f6nnen", "TREATMENT", 0, 22], ["Vermeidung eines innerklinischen", "TREATMENT", 516, 548], ["aufzeigen", "TEST", 656, 665], ["m\u00f6glicherweise einen bevorstehenden", "TREATMENT", 804, 839]]], ["Deren Sensitivit\u00e4t, Spezifit\u00e4t und Genauigkeit im Vorhersagen von akuten Erkrankungen muss noch \u00fcberzeugend validiert werden [27, 28].", [["Spezifit\u00e4t", "TEST", 20, 30]]], ["Mehrere Studien haben abnorme Ver\u00e4nderungen von Herzfrequenz, Blutdruck und Atemfrequenz sowie des Bewusstseins als Parameter identifiziert, um kritische Verschlechterungen des klinischen Zustandsbilds vorherzusagen [22, 23, 29].Erkennen des kritisch erkrankten Patienten ::: Vermeidung eines innerklinischen KreislaufstillstandsDie Meinung, dass das Vorkommen von solchen Verschlechterungsmerkmalen einen voraussagenden Wert hat, muss kritisch hinterfragt werden, da nicht alle wichtigen Vitalparameter auf Bettenstationen kontinuierlich gemessen und dokumentiert werden.", [["Vermeidung eines innerklinischen KreislaufstillstandsDie Meinung, dass das Vorkommen von solchen Verschlechterungsmerkmalen einen voraussagenden Wert hat, muss kritisch hinterfragt werden, da nicht alle wichtigen Vitalparameter auf Bettenstationen kontinuierlich gemessen und dokumentiert werden", "SPECIES", 276, 571], ["Blutdruck und Atemfrequenz sowie des Bewusstseins als Parameter identifiziert", "TREATMENT", 62, 139], ["um kritische Verschlechterungen des", "TREATMENT", 141, 176]]], ["Obwohl das Verwenden von Monitoringsystemen die Erfassung von Vitalparametern verbessern kann [31], k\u00f6nnen sie die Vorhersage des Outcomes nur verbessern, wenn sie auch sehr breit in der Klinik eingesetzt werden.Erkennen des kritisch erkrankten Patienten ::: Vermeidung eines innerklinischen KreislaufstillstandsSelbst wenn \u00c4rzte wegen der akuten Verschlechterung der Vitalparameter eines Patienten alarmiert werden, kommt es oft zu Verz\u00f6gerungen bis der Patient tats\u00e4chlich behandelt wird bzw. auf eine Intensiv- oder Aufwachstation verlegt wird [3, 4, 7].", [["Patient", "SPECIES", 455, 462], ["Vermeidung eines innerklinischen KreislaufstillstandsSelbst wenn \u00c4rzte wegen der akuten Verschlechterung der Vitalparameter eines Patienten alarmiert werden, kommt es oft zu Verz\u00f6gerungen bis der Patient tats\u00e4chlich behandelt wird bzw", "SPECIES", 259, 493], ["Vermeidung eines innerklinischen", "TREATMENT", 259, 291]]], ["Obwohl es Hinweise gibt, dass ein so genanntes Fr\u00fchwarnscoringsystem von sich verschlechternden Vitalparametern attraktiv ist, ist es m\u00f6glich, dass ein eher subjektiver Ansatz, der auf der Erfahrung und Einsch\u00e4tzung des Pflegepersonals basiert, ebenfalls einen hohen Wert haben kann [32].Behandlung der akuten Erkrankung ::: Vermeidung eines innerklinischen KreislaufstillstandsDer traditionelle Ansatz, den Kreislaufstillstand zu behandeln, ist die Entsendung eines Herzalarmteams, das zu dem Patienten mit einen Kreislaufstillstand gerufen wird.", [["Obwohl es Hinweise gibt, dass ein so genanntes Fr\u00fchwarnscoringsystem von sich verschlechternden Vitalparametern attraktiv ist, ist es m\u00f6glich, dass ein eher subjektiver Ansatz, der auf der Erfahrung und Einsch\u00e4tzung des Pflegepersonals basiert, ebenfalls einen hohen Wert haben kann", "SPECIES", 0, 282], ["Vermeidung eines innerklinischen KreislaufstillstandsDer traditionelle Ansatz, den Kreislaufstillstand zu behandeln, ist die Entsendung eines Herzalarmteams, das zu dem Patienten mit einen Kreislaufstillstand gerufen wird", "SPECIES", 325, 546], ["ist es m\u00f6glich", "TREATMENT", 127, 141], ["dass ein eher subjektiver Ansatz", "TREATMENT", 143, 175], ["der auf der Erfahrung und Einsch\u00e4tzung des", "TREATMENT", 177, 219]]], ["So konnten zum Beispiel in einer Studie nur Patienten nach einem Kreislaufstillstand aus dem Krankenhaus entlassen werden, die bereits vor Eintreffen des Herzalarmteams wieder einen Spontankreislauf hatten [34].", [["konnten zum Beispiel", "TREATMENT", 3, 23]]], ["Dieses schlechte Ergebnis, kombiniert mit der \u00dcberlebenschance nach einem Herzstillstand innerhalb der Klinik, zeigt wie wichtig es ist, akut erkrankte bzw. sich akut verschlechternde Patienten zu bemerken und zu verhindern, dass ein Kreislaufstillstand eintritt.", [["kombiniert mit der \u00dcberlebenschance nach einem Herzstillstand innerhalb der Klinik, zeigt wie wichtig es ist, akut erkrankte bzw", "SPECIES", 27, 155], ["sich akut verschlechternde Patienten zu bemerken und zu verhindern, dass ein Kreislaufstillstand eintritt", "SPECIES", 157, 262]]], ["Der Name \u201eHerzalarmteam\u201c bzw. \u201eKreislaufstillstandteam\u201c verdeutlicht, dass dieses Team nur im Falle eines bereits eingetretenen Kreislaufstillstands alarmiert wird.Behandlung der akuten Erkrankung ::: Vermeidung eines innerklinischen KreislaufstillstandsIn manchen Krankenh\u00e4usern ist das Herzalarmteam bzw. das Kreislaufstillstandteam durch ein medizinisches Notfallteam ersetzt worden, das nicht nur Patienten mit einem Kreislaufstillstand behandelt, sondern auch Patienten mit einer akuten Verschlechterung der Vitalparameter [26].", [["Vermeidung eines innerklinischen KreislaufstillstandsIn manchen Krankenh\u00e4usern ist das Herzalarmteam bzw", "SPECIES", 201, 305], ["das Kreislaufstillstandteam durch ein medizinisches Notfallteam ersetzt worden, das nicht nur Patienten mit einem Kreislaufstillstand behandelt, sondern auch Patienten mit einer akuten Verschlechterung der Vitalparameter [26", "SPECIES", 307, 531]]], ["Dieses medizinische Notfallteam besteht meistens aus \u00e4rztlichem und Pflegepersonal von der Intensivstation und/oder aus der Inneren Medizin und wird anhand von spezifischen Einsatzkriterien innerhalb des Krankenhauses angefordert.", [["Dieses medizinische Notfallteam besteht meistens aus \u00e4rztlichem und Pflegepersonal von der Intensivstation und/oder aus der Inneren Medizin und wird anhand von spezifischen Einsatzkriterien innerhalb des Krankenhauses angefordert", "SPECIES", 0, 229], ["aus der Inneren Medizin", "TREATMENT", 116, 139]]], ["Dabei kann jeder Mitarbeiter des Krankenhauses ein medizinisches Notfallteam anfordern.", [["Dabei kann jeder Mitarbeiter des", "TREATMENT", 0, 32]]], ["Eine fr\u00fche Involvierung des medizinischen Notfallteams kann die Anzahl der innerklinischen Kreislaufstillst\u00e4nde, Todesf\u00e4lle und ungeplanter Aufnahmen auf der Intensivstation senken [35, 36].", [["Eine fr\u00fche Involvierung des medizinischen Notfallteams kann die Anzahl der innerklinischen Kreislaufstillst\u00e4nde, Todesf\u00e4lle und ungeplanter Aufnahmen auf der Intensivstation senken", "SPECIES", 0, 180], ["Eine fr\u00fche Involvierung des medizinischen", "TREATMENT", 0, 41]]], ["Das medizinische Notfallteam kann ebenfalls hilfreich sein, um medizinische Fehlerzu entdecken, die Entscheidung zur Therapiebeschr\u00e4nkung zu verbessern und unerwartete Todesf\u00e4lle im postoperativen Verlauf zu reduzieren [37, 38].", [["Das medizinische Notfallteam kann ebenfalls hilfreich sein, um medizinische Fehlerzu entdecken, die Entscheidung zur Therapiebeschr\u00e4nkung zu verbessern und unerwartete Todesf\u00e4lle im postoperativen Verlauf zu reduzieren", "SPECIES", 0, 218]]], ["Weiterhin wurde ein zirkadianer Rhythmus der Alarme von medizinischen Notfallteams berichtet, der darauf hinweisen kann, dass die Identifizierungen und Beantwortung medizinischer Notf\u00e4lle innerhalb des Krankenhauses nicht gleichm\u00e4\u00dfig \u00fcber 24 h am Tag verteilt ist [40].Behandlung der akuten Erkrankung ::: Vermeidung eines innerklinischen KreislaufstillstandsDie genaue Untersuchung des Effekts des Notfallmedizinteams auf das Outcome des Patienten ist sehr schwierig.", [["Weiterhin wurde ein zirkadianer Rhythmus der Alarme von medizinischen Notfallteams berichtet, der darauf hinweisen kann, dass die Identifizierungen und Beantwortung medizinischer Notf\u00e4lle innerhalb des Krankenhauses nicht gleichm\u00e4\u00dfig \u00fcber 24 h am Tag verteilt ist [40", "SPECIES", 0, 267], ["Vermeidung eines innerklinischen KreislaufstillstandsDie genaue Untersuchung des Effekts des Notfallmedizinteams auf das Outcome des Patienten ist sehr schwierig", "SPECIES", 306, 467], ["Weiterhin wurde ein zirkadianer", "TREATMENT", 0, 31], ["Vermeidung eines innerklinischen", "TREATMENT", 306, 338]]], ["Leider muss man viele derzeitige Studien zu diesem Thema auf Grund eines schlechten Studiendesigns kritisieren.", [["man", "SPECIES", 12, 15]]], ["Andererseits konnte diese Studie nicht zeigen, dass die Einf\u00fchrung dieses medizinischen Notfallteams die H\u00e4ufigkeit innerklinischer Kreislaufstillst\u00e4nde, unerwarteter Todesf\u00e4lle oder unerwarteter Aufnahmen auf die Intensivstation signifikant senken konnte [41].Behandlung der akuten Erkrankung ::: Vermeidung eines innerklinischen KreislaufstillstandsIn England hat sich ein vorwiegend aus Intensivkrankenpflegepersonal bestehendes System entwickelt, das entsprechende vorbeugende Ma\u00dfnahmen f\u00fcr die peripheren Bettenstation mit dem Ziel anbietet, die Behandlung von akuten Notf\u00e4llen in diesen Bereichen zu verbessern [42].", [["Vermeidung eines innerklinischen KreislaufstillstandsIn England hat sich ein vorwiegend aus Intensivkrankenpflegepersonal bestehendes System entwickelt, das entsprechende vorbeugende Ma\u00dfnahmen f\u00fcr die peripheren Bettenstation mit dem Ziel anbietet, die Behandlung von akuten Notf\u00e4llen in diesen Bereichen zu verbessern", "SPECIES", 298, 616]]], ["Ein solches Team kann unerwartete Todesf\u00e4lle auf den Bettenstationen ggf. reduzieren, Komplikationen in der postoperativen Phase verhindern sowie die Aufnahmefrequenz und v. a. die Wiederaufnahmen auf die Intensivstation vermindern und so letztendlich das \u00dcberleben erh\u00f6hen [43, 44, 45].Behandlung der akuten Erkrankung ::: Vermeidung eines innerklinischen KreislaufstillstandsAndere Versuche, die Versorgung von Patienten auf Bettenstationen zu verbessern und zu verhindern, dass es zu einer akuten Verschlechterung der Vitalparameter oder sogar zu einem Kreislaufstillstand kommt, sind neue Prozesse bei der Krankenhausaufnahme, fr\u00fches physiologisches Monitoring und Interventionen in der Notfallaufnahme sowie eine bessere Ausbildung der \u00c4rzte.Behandlung der akuten Erkrankung ::: Vermeidung eines innerklinischen KreislaufstillstandsViele dieser Modelle versuchen, das prim\u00e4r aufnehmende \u00c4rzteteam durch notfallmedizinische Experten zu unterst\u00fctzen [46].", [["reduzieren", "CHEMICAL", 74, 84], ["Komplikationen", "CHEMICAL", 86, 100], ["reduzieren", "SIMPLE_CHEMICAL", 74, 84], ["Komplikationen", "SIMPLE_CHEMICAL", 86, 100], ["Phase verhindern sowie die Aufnahmefrequenz und v. a. die Wiederaufnahmen auf die Intensivstation vermindern und so letztendlich das \u00dcberleben erh\u00f6hen", "SPECIES", 123, 273], ["Vermeidung eines innerklinischen KreislaufstillstandsAndere Versuche, die Versorgung von Patienten auf Bettenstationen zu verbessern und zu verhindern, dass es zu einer akuten Verschlechterung der Vitalparameter oder sogar zu einem Kreislaufstillstand kommt, sind neue Prozesse bei der Krankenhausaufnahme, fr\u00fches physiologisches Monitoring und Interventionen in der Notfallaufnahme sowie eine bessere Ausbildung der \u00c4rzte", "SPECIES", 324, 746], ["Vermeidung", "TEST", 784, 794]]], ["Dabei werden die medizinischen und chirurgischen Notaufnahmen als eine Einheit f\u00fcr akut erkrankte Patienten angesehen, bis das erforderliche Ma\u00df der Versorgungsqualit\u00e4t festgestellt werden kann.", [["Dabei werden die medizinischen und chirurgischen Notaufnahmen als eine Einheit f\u00fcr akut erkrankte Patienten angesehen, bis das erforderliche Ma\u00df der Versorgungsqualit\u00e4t festgestellt werden kann", "SPECIES", 0, 193]]], ["Dieser Ansatz der Konzentration erfahrener Kr\u00e4fte im Krankenhaus an einer Stelle der Versorgung von akut erkrankten Patienten schafft eine zentrale Anlauf- und Ansprechstelle f\u00fcr \u00c4rzte, Krankenpflegepersonal und andere Mitarbeiter der gesamten Klinik.", [["Dieser Ansatz der Konzentration erfahrener Kr\u00e4fte im Krankenhaus an einer Stelle der Versorgung von akut erkrankten Patienten schafft eine zentrale Anlauf- und Ansprechstelle f\u00fcr \u00c4rzte, Krankenpflegepersonal und andere Mitarbeiter der gesamten Klinik", "SPECIES", 0, 250], ["erkrankten", "TEST", 105, 115]]], ["Dabei ist zu beachten, dass viele akut erkrankte Patienten in der Notaufnahme aufgenommen werden, wo sie zur Stabilisierung der Parameter oft einer sofortigen Intervention bed\u00fcrfen.", [["Dabei ist zu beachten, dass viele akut erkrankte Patienten in der Notaufnahme aufgenommen werden, wo sie zur Stabilisierung der Parameter oft einer sofortigen Intervention bed\u00fcrfen", "SPECIES", 0, 180], ["Intervention bed\u00fcrfen", "TREATMENT", 159, 180]]], ["Vital bedrohte Patienten k\u00f6nnen durch eine fr\u00fchzeitige, zielgerichtete Therapie in der Notfallaufnahme schnell und erfolgreich behandelt werden kann, was die \u00dcberlebenschancen dieser Patienten wiederum verbessert [48].Ad\u00e4quate Verlegung der Patienten ::: Vermeidung eines innerklinischen KreislaufstillstandsVermutlich werden die am schwersten erkrankten Patienten auf eine Station im Krankenhaus verlegt, die die gr\u00f6\u00dftm\u00f6gliche Versorgungskapazit\u00e4t bzw. die gr\u00f6\u00dftm\u00f6gliche Organersatztherapie anbieten kann und \u00fcber erfahrene \u00c4rzte und Intensivpflegeger\u00e4te verf\u00fcgt.", [["Vermeidung eines innerklinischen KreislaufstillstandsVermutlich werden die am schwersten erkrankten Patienten auf eine Station im Krankenhaus verlegt, die die gr\u00f6\u00dftm\u00f6gliche Versorgungskapazit\u00e4t bzw", "SPECIES", 255, 452], ["Vital bedrohte", "TREATMENT", 0, 14], ["zielgerichtete Therapie", "TREATMENT", 56, 79]]], ["Internationale Organisationen haben Definitionen zum Versorgungsstandard f\u00fcr Aufwach- und Intensivstationen sowie Aufnahme- und Entlassungskriterien f\u00fcr diese Stationen erstellt [50, 51].Personelle Besetzung der Stationen ::: Vermeidung eines innerklinischen KreislaufstillstandsDie personelle Besetzung im Krankenhaus ist am niedrigsten in der Nacht und an Wochenenden, was die Qualit\u00e4t der \u00dcberwachung, der Behandlung und letztendlich des Behandlungserfolgs stark beeinflussen kann.", [["Vermeidung eines innerklinischen KreislaufstillstandsDie personelle Besetzung im Krankenhaus ist am niedrigsten in der Nacht und an Wochenenden, was die Qualit\u00e4t der \u00dcberwachung, der Behandlung und letztendlich des Behandlungserfolgs stark beeinflussen kann", "SPECIES", 226, 483], ["Aufwach", "TEST", 77, 84]]], ["Ebenso hatten Patienten, die nachts von einer Intensivstation auf eine periphere Bettenstation verlegt wurden, ein h\u00f6heres Risiko, einen innerklinischen Kreislaufstillstand zu erleiden, im Vergleich mit Patienten, die tags\u00fcber von der Intensivstation auf eine periphere Station verlegt wurden [54].", [["von einer Intensivstation auf eine periphere Bettenstation verlegt wurden, ein h\u00f6heres Risiko, einen innerklinischen Kreislaufstillstand zu erleiden, im Vergleich mit Patienten, die tags\u00fcber von der Intensivstation auf eine periphere Station verlegt wurden", "SPECIES", 36, 292]]], ["Eine Studie zeigte, dass eine h\u00f6here Anzahl von Pflegekr\u00e4ften auf peripheren Stationen mit einer Reduktion von innerklinischen Kreislaufstillst\u00e4nden sowie weniger Pneumonien, Schockzust\u00e4nden und Todesf\u00e4llen korrelierten [55].Entscheidungen bei der Wiederbelebung ::: Vermeidung eines innerklinischen KreislaufstillstandsDie Entscheidung, den Patienten nicht zu reanimieren, sollte bedacht werden,wenn der Patient dies nicht w\u00fcnscht,wenn der Patient den Kreislaufstillstand nicht \u00fcberleben w\u00fcrde, selbst wenn eine Wiederbelebung versucht w\u00fcrde.\u00c4rzte und Pflegekr\u00e4fte sind oft nicht in der Lage, vern\u00fcnftig einzusch\u00e4tzen, ob ein Reanimationsversuch Sinn macht oder wie in vielen F\u00e4llen v\u00f6llig sinnlos ist [37].", [["dass eine h\u00f6here Anzahl von Pflegekr\u00e4ften auf peripheren Stationen mit einer Reduktion von innerklinischen Kreislaufstillst\u00e4nden sowie weniger Pneumonien, Schockzust\u00e4nden und Todesf\u00e4llen korrelierten", "SPECIES", 20, 219], ["Entscheidungen bei der Wiederbelebung :::", "SPECIES", 225, 266], ["Eine Studie zeigte", "TREATMENT", 0, 18], ["auf peripheren Stationen mit einer Reduktion", "TREATMENT", 62, 106], ["ob", "ANATOMY", 620, 622]]], ["Selbst bei absehbarem Kreislaufstillstand wird h\u00e4ufig nicht entschieden, ob der Patient reanimiert werden soll oder nicht [56].Entscheidungen bei der Wiederbelebung ::: Vermeidung eines innerklinischen KreislaufstillstandsIn vielen europ\u00e4ischen L\u00e4ndern gibt es keine formalen Richtlinien, wie eine DNAR-Entscheidung (\u201eDo not attempt resuscitation\u201c) initiiert und dokumentiert wird.", [["resuscitation", "TREATMENT", 333, 346]]], ["Abschnitt 8).Leitlinien zur Verhinderung innerklinischer Kreislaufstillst\u00e4nde ::: Vermeidung eines innerklinischen KreislaufstillstandsDie folgenden Strategien k\u00f6nnen dazu dienen, vermeidbare innerklinische Kreislaufstillst\u00e4nde zu verhindern:Versorgung von akut erkrankten Patienten bzw. von Patienten, die sich akut verschlechtern, auf einer Aufwach- oder Intensivstation, die \u00fcber die erforderlichen therapeutischen M\u00f6glichkeiten verf\u00fcgt.Akut erkrankte bzw. sich akut verschlechternde Patienten ben\u00f6tigen eine st\u00e4ndige \u00dcberwachung.", [["Vermeidung eines innerklinischen KreislaufstillstandsDie folgenden Strategien k\u00f6nnen dazu dienen, vermeidbare innerklinische Kreislaufstillst\u00e4nde zu verhindern:Versorgung von akut erkrankten Patienten bzw", "SPECIES", 82, 286], ["Akut erkrankte bzw", "SPECIES", 440, 458], ["Abschnitt", "TEST", 0, 9]]], ["Hierbei sollte die H\u00e4ufigkeit und die Art der \u00dcberwachung der Krankheitsschwere und der Wahrscheinlichkeit der klinischen Verschlechterung bis zu einem Kreislaufstillstand angepasst werden.", [["Hierbei sollte die H\u00e4ufigkeit und die Art der \u00dcberwachung der Krankheitsschwere und der Wahrscheinlichkeit der klinischen Verschlechterung bis zu einem Kreislaufstillstand angepasst werden", "SPECIES", 0, 188]]], ["Diese sollten ebenfalls Ratschl\u00e4ge f\u00fcr die weitere klinische Behandlung des Patienten sowie die Definition spezifischer Verantwortlichkeiten von \u00c4rzten und Krankenpflegepersonal enthalten.Das Krankenhaus sollte eine klar definierte Strategie f\u00fcr akut erkrankte bzw. sich akut verschlechternde Patienten haben.", [["Diese sollten ebenfalls Ratschl\u00e4ge f\u00fcr die weitere klinische Behandlung des Patienten sowie die Definition spezifischer Verantwortlichkeiten von \u00c4rzten und Krankenpflegepersonal enthalten", "SPECIES", 0, 187]]], ["Hierbei kann es sich um ein Notfallteam oder ein speziell ausgebildetes Intensivpflegepersonal handeln, welches bei Vorliegen bestimmter Parameter alarmiert wird und die Patienten entsprechend behandelt.", [["Hierbei kann es sich um ein", "TREATMENT", 0, 27], ["Intensivpflegepersonal handeln", "TREATMENT", 72, 102]]], ["Dieser Service muss rund um die Uhr verf\u00fcgbar sein.Alle \u00c4rzte und Pflegekr\u00e4fte m\u00fcssen darin ausgebildet werden, einen akut kranken oder einen sich akut verschlechternden Patienten wahrzunehmen, zu \u00fcberwachen und die Behandlung eines solchen Patienten einzuleiten.", [["Alle \u00c4rzte", "TREATMENT", 51, 61]]], ["Diese Ausbildung beinhaltet Hinweise f\u00fcr die medizinische Behandlung, w\u00e4hrend das Notfallteam auf dem Weg zum Notfallort ist.Pr\u00e4finale Patienten m\u00fcssen identifiziert werden, insbesondere wenn ein Reanimationsversuch nicht indiziert ist.", [["Diese Ausbildung beinhaltet Hinweise f\u00fcr die medizinische Behandlung, w\u00e4hrend das Notfallteam auf dem Weg zum", "SPECIES", 0, 109]]], ["Ebenso muss die Reaktion und die Versorgungsqualit\u00e4t auf diese Ereignisse dokumentiert und ausgewertet werden.Ort des Herzstillstands ::: Innerklinische ReanimationBei monitor\u00fcberwachten Patienten wird der Kreislaufstillstand in der Regel sehr schnell diagnostiziert.", [["Ebenso muss die Reaktion und die Versorgungsqualit\u00e4t auf diese Ereignisse dokumentiert und ausgewertet werden", "SPECIES", 0, 109]]], ["Im Gegensatz dazu hatten Patienten auf Bettenstationen m\u00f6glicherweise eine Phase von sich akut verschlechternden Vitalparametern mit einem darauf folgenden, nicht beobachteten Kreislaufstillstand [3, 4, 6, 8].", [["Im Gegensatz dazu hatten Patienten auf Bettenstationen m\u00f6glicherweise eine Phase von sich akut verschlechternden Vitalparametern mit einem darauf folgenden", "SPECIES", 0, 155], ["auf Bettenstationen m\u00f6glicherweise eine Phase von sich", "TREATMENT", 35, 89], ["Vitalparametern mit einem darauf folgenden", "TREATMENT", 113, 155]]], ["Idealerweise sollten gef\u00e4hrdete Patienten in einer Einheit betreut werden, in denen ihre Vitalparameter kontinuierlich \u00fcberwacht werden k\u00f6nnen, um im Bedarfsfall eine sofortige Reanimation einleiten zu k\u00f6nnen.Ausbildung der zuerst eintreffenden Rettungskr\u00e4fte ::: Innerklinische ReanimationAlle \u00c4rzte, Pflegekr\u00e4fte sowie weitere den Patienten betreuende Berufsgruppen m\u00fcssen in der Lage sein, einen Kreislaufstillstand zu erkennen, Hilfe zu rufen und die Basisma\u00dfnahmen der Reanimation einzuleiten.Ausbildung der zuerst eintreffenden Rettungskr\u00e4fte ::: Innerklinische ReanimationDie Mitarbeiter des Krankenhauses sollten jene Reanimationsma\u00dfnahmen durchf\u00fchren, f\u00fcr die sie ausgebildet wurden.", [["denen ihre Vitalparameter kontinuierlich \u00fcberwacht werden k\u00f6nnen, um im Bedarfsfall eine sofortige Reanimation einleiten zu k\u00f6nnen", "SPECIES", 78, 208], ["Pflegekr\u00e4fte sowie weitere den Patienten betreuende Berufsgruppen m\u00fcssen in der Lage sein, einen Kreislaufstillstand zu erkennen, Hilfe zu rufen und die Basisma\u00dfnahmen der Reanimation einzuleiten", "SPECIES", 302, 497], ["Innerklinische ReanimationAlle \u00c4rzte", "TREATMENT", 264, 300], ["Innerklinische Reanimation", "TREATMENT", 553, 579]]], ["\u00c4rzte und Pflegekr\u00e4fte in der Notfallaufnahme bzw. in der Intensivstation haben zum Beispiel mehr Erfahrung und eine bessere Ausbildung in der Basis- und erweiterten Reanimation im Vergleich mit Krankenhausmitarbeitern, die w\u00e4hrend ihrer normalen Arbeit in der Regel nicht mit der Betreuung von kritisch kranken oder kritisch verletzten Patienten befasst sind.", [["Basis- und erweiterten Reanimation im Vergleich mit Krankenhausmitarbeitern, die w\u00e4hrend ihrer normalen Arbeit in der Regel nicht mit der Betreuung von kritisch kranken oder kritisch verletzten Patienten befasst sind", "SPECIES", 143, 359]]], ["So hat Krankenhauspersonal, das zur Versorgung eines Patienten mit Kreislaufstillstand gerufen wird, in der Regel sehr unterschiedliche Kenntnisse und Erfahrungen im Management der Atemwege sowie von Atmung und Kreislauf.", [["der Regel sehr unterschiedliche Kenntnisse und Erfahrungen im Management der Atemwege sowie von Atmung und Kreislauf", "SPECIES", 104, 220]]], ["Hier ist besonders wichtig, dass nur jene Ma\u00dfnahmen durchgef\u00fchrt werden, in denen eine Ausbildung stattgefunden hat und in denen m\u00f6glichst Erfahrung vorliegt.Anzahl der Rettungskr\u00e4fte ::: Innerklinische ReanimationEin einzelner Helfer muss sicherstellen, dass weitere Hilfe eintrifft und muss deswegen schnellstm\u00f6glich einen Notruf absetzen.", [["Innerklinische Reanimation", "TREATMENT", 188, 214]]], ["Falls weitere Krankenhausmitarbeiter verf\u00fcgbar sind, k\u00f6nnen mehrere Interventionen gleichzeitig durchgef\u00fchrt werden.Verf\u00fcgbares Material ::: Innerklinische ReanimationIn allen Abteilungen des Krankenhauses, in denen Patienten behandelt werden, m\u00fcssen technische Ausr\u00fcstung und Medikamente vorhanden sein, um die schnelle Behandlung eines innerklinischen Kreislaufstillstands zu gew\u00e4hrleisten.", [["m\u00fcssen technische Ausr\u00fcstung und Medikamente vorhanden sein, um die schnelle Behandlung eines innerklinischen Kreislaufstillstands zu gew\u00e4hrleisten", "SPECIES", 244, 391]]], ["Idealerweise sollten die Ausr\u00fcstung f\u00fcr die kardiopulmonale Reanimation (auch die Defibrillatoren) und die Medikamente im gesamten Krankeinhaus standardisiert werden, um ein einheitliches Vorgehen sicher zu stellen [57].Reanimationsteam ::: Innerklinische ReanimationDas Reanimationsteam kann in Form eines traditionellen Herzalarmteam bestehen, das nur gerufen wird, wenn ein Kreislaufstillstand bereits eingetreten ist.", [["Idealerweise sollten die Ausr\u00fcstung f\u00fcr die kardiopulmonale Reanimation (auch die Defibrillatoren) und die Medikamente im gesamten Krankeinhaus standardisiert werden, um ein einheitliches Vorgehen sicher zu stellen", "SPECIES", 0, 214], ["kardiopulmonale Reanimation", "TREATMENT", 44, 71]]], ["Alternativ k\u00f6nnen Krankenh\u00e4user die Strategie eines medizinischen Notfallteams bevorzugen, das gerufen werden kann, bevor sich \u00fcberhaupt ein Kreislaufstilland ereignet [35, 36, 39, 41, 58].", [["Alternativ k\u00f6nnen", "TREATMENT", 0, 17]]], ["Der Ausdruck \u201eReanimationsteam\u201c spiegelt alle Auspr\u00e4gungen der Reaktion wider.Reanimationsteam ::: Innerklinische ReanimationEin innerklinischer Kreislaufstillstand tritt aber selten pl\u00f6tzlich und unvorbereitet ein.", [["Innerklinische Reanimation", "TREATMENT", 99, 125]]], ["Eine Strategie, gef\u00e4hrdete Patienten zu identifizieren, kann m\u00f6glicherweise einige Kreislaufstillst\u00e4nde verhindern, ebenso k\u00f6nnen sinnlose Reanimationsversuche unterlassen werden.Sofortma\u00dfnahmen beim kollabierten Patienten ::: Innerklinische ReanimationEin Algorithmus f\u00fcr das initiale Management eines innerklinischen Kreislaufstillstands ist in Abb.", [["Innerklinische", "TREATMENT", 227, 241]]], ["1 dargestellt:Sicherstellen der pers\u00f6nlichen Sicherheit,\u00dcberpr\u00fcfen der Vitalparameter des Patienten,Wenn Krankenhausmitarbeiter einen Patienten kollabieren sehen oder einen bewusstlosen Patienten auffinden, sollten Sie zuerst den Notruf absetzen und danach \u00fcberpr\u00fcfen, ob der Patient auf Ansprache reagiert.", [["Sie zuerst den Notruf absetzen und danach \u00fcberpr\u00fcfen, ob der Patient auf Ansprache reagiert", "SPECIES", 215, 306], ["Sicherstellen der pers\u00f6nlichen Sicherheit", "TREATMENT", 14, 55], ["ob", "ANATOMY", 269, 271]]], ["Vorsichtiges Sch\u00fctteln an den Schultern und lautes Fragen \u201eGeht es Ihnen gut?\u201c wird empfohlen.Falls andere Krankenhausmitarbeiter zuf\u00e4llig anwesend sind, ist es m\u00f6glich, diese Ma\u00dfnahmen gleichzeitig durchzuf\u00fchren.Der bewusstlose Patient ::: Der wache Patient ::: Innerklinische ReanimationDie exakte Reihenfolge der Reanimationsma\u00dfnahmen beim Management von Atemwegs- und Kreislaufst\u00f6rungen h\u00e4ngt vom Training und der Erfahrung des ersteintreffenden Helfers ab.", [["Patient", "SPECIES", 229, 236], ["Patient", "SPECIES", 251, 258], ["Die exakte Reihenfolge der Reanimationsma\u00dfnahmen beim Management von Atemwegs- und Kreislaufst\u00f6rungen h\u00e4ngt vom Training und der Erfahrung des ersteintreffenden Helfers ab", "SPECIES", 289, 460], ["Falls", "PROBLEM", 94, 99], ["Innerklinische Reanimation", "TREATMENT", 263, 289]]], ["Insbesondere in den ersten Minuten eines Kreislaufstillstands ist eine Schnappatmung sehr h\u00e4ufig und sollte nicht als ein Zeichen normaler Atmung und normaler Kreislauffunktion missverstanden werden.Absetzen des Hilferufs.Danach drehen Sie den Patienten auf den R\u00fccken und machen die Atemwege frei:Freimachen des Atemwegs und Kontrolle der Atmung,\u00dcberstrecken des Halses und Vorschieben des Unterkiefers zum Freimachen des Atemwegs,Untersuchen der Mundh\u00f6hle.", [["den ersten Minuten eines Kreislaufstillstands ist eine Schnappatmung sehr h\u00e4ufig und sollte nicht als ein Zeichen normaler Atmung und normaler Kreislauffunktion missverstanden werden", "SPECIES", 16, 198], ["Danach drehen Sie den Patienten auf den R\u00fccken und machen die Atemwege frei:Freimachen des Atemwegs und Kontrolle der Atmung,\u00dcberstrecken des Halses und Vorschieben des Unterkiefers zum Freimachen des Atemwegs,Untersuchen der Mundh\u00f6hle", "SPECIES", 222, 457], ["Absetzen des Hilferufs", "PROBLEM", 199, 221], ["Freimachen des", "TREATMENT", 298, 312], ["\u00dcberstrecken des", "TREATMENT", 347, 363]]], ["Dabei sollte bedacht werden, dass ein freier Luftweg und die Wiedererlangung der Atmung die wichtigste Priorit\u00e4t bei einer vermuteten Wirbels\u00e4ulenverletzung haben.", [["dass ein freier Luftweg und die Wiedererlangung der Atmung die wichtigste Priorit\u00e4t bei einer vermuteten Wirbels\u00e4ulenverletzung haben", "SPECIES", 29, 162]]], ["Sobald ausreichend Rettungskr\u00e4fte am Einsatzort eingetroffen sind, sollte die Halswirbels\u00e4ule stabilisiert werden, um jegliche Kopfbewegungen zu minimieren.Der bewusstlose Patient ::: Der wache Patient ::: Innerklinische ReanimationNach dem Freimachen des Luftwegs, schauen, horchen und f\u00fchlen Sie, ob eine normale Atmung vorliegt (gelegentliche Schnappatmung und langsame ger\u00e4uschvolle Atemversuche sind nicht normal):untersuchen Sie, ob sich der Thorax hebt und senkt,versuchen Sie, am Mund des Patienten Atemger\u00e4usche zu h\u00f6ren,f\u00fchlen Sie den Ein- und Ausatemluftstrom an der eigenen Wange.Es sollten nicht mehr als 10 s dazu verwendet werden, um zweifelsfrei festzustellen, ob der Patient normal atmet.Der bewusstlose Patient ::: Der wache Patient ::: Innerklinische Reanimation\u00dcberpr\u00fcfung der Vitalzeichen:Es kann schwierig sein, den Puls des Patienten sicher festzustellen.", [["Patient", "SPECIES", 172, 179], ["Patient", "SPECIES", 194, 201], ["Patient", "SPECIES", 721, 728], ["Patient", "SPECIES", 743, 750], ["Innerklinische ReanimationNach dem Freimachen des Luftwegs, schauen, horchen und f\u00fchlen Sie, ob eine normale Atmung vorliegt (gelegentliche Schnappatmung und langsame ger\u00e4uschvolle Atemversuche sind nicht normal):untersuchen Sie, ob sich der Thorax hebt und senkt,versuchen Sie, am Mund des Patienten Atemger\u00e4usche zu h\u00f6ren,f\u00fchlen Sie den Ein- und Ausatemluftstrom an der eigenen", "SPECIES", 206, 585], ["Innerklinische Reanimation", "TREATMENT", 755, 781], ["ob", "ANATOMY", 299, 301], ["Thorax", "ANATOMY", 448, 454], ["ob", "ANATOMY", 677, 679]]], ["Falls der Patient keine Lebenszeichen aufweist (keine Bewegung, keine Atmung, oder kein Husten) m\u00fcssen Reanimationsma\u00dfnahmen sofort begonnen werden, bis erfahrene Hilfe am Notfallort eintrifft oder der Patient Lebenszeichen zeigt.Ausgebildete und erfahrene Rettungskr\u00e4fte im Krankenhaus sollten versuchen, den Karotispuls zu tasten und gleichzeitig nach Lebenszeichen zu suchen, ebenfalls f\u00fcr nicht mehr als 10 s.Auch hier gilt, dass die Reanimationsma\u00dfnahmen sofort begonnen werden sollten, falls der Patient keine oder nur zweifelhafte Lebenszeichen aufweist.", [["Patient", "SPECIES", 10, 17], ["Ausgebildete und erfahrene Rettungskr\u00e4fte im Krankenhaus sollten versuchen, den Karotispuls zu tasten und gleichzeitig nach Lebenszeichen zu suchen, ebenfalls f\u00fcr nicht mehr als 10 s.Auch hier gilt, dass die Reanimationsma\u00dfnahmen sofort begonnen werden sollten", "SPECIES", 230, 490], ["Falls der", "PROBLEM", 0, 9], ["Lebenszeichen zeigt", "TREATMENT", 210, 229]]], ["Verz\u00f6gerungen bei der Diagnose eines Kreislaufstillstands und dem Beginn von Reanimationsma\u00dfnahmen haben einen negativen Einfluss auf den Reanimationserfolg und sind auf jeden Fall zu vermeiden.Der bewusstlose Patient ::: Der wache Patient ::: Innerklinische ReanimationFalls ein Puls getastet werden kann oder sonstige Lebenszeichen bestehen, ist dringende medizinische Hilfe erforderlich.", [["Patient", "SPECIES", 210, 217], ["Patient", "SPECIES", 232, 239], ["Verz\u00f6gerungen bei der Diagnose eines Kreislaufstillstands und dem Beginn von Reanimationsma\u00dfnahmen haben einen negativen Einfluss auf den Reanimationserfolg und sind auf jeden Fall zu vermeiden", "SPECIES", 0, 193], ["Verz\u00f6gerungen", "TREATMENT", 0, 13], ["Innerklinische", "TREATMENT", 244, 258]]], ["Je nach \u00f6rtlichen Gepflogenheiten kann dies durch ein Herzalarmteam oder ein Notfallteam durchgef\u00fchrt werden.", [["Je nach \u00f6rtlichen Gepflogenheiten", "TREATMENT", 0, 33]]], ["W\u00e4hrend diese Teams zum Notfallort eilen, sollte der Patient Sauerstoff bekommen, an einem \u00dcberwachungsmonitor angeschlossen werden und mit einer Venenverweilkan\u00fcle versehen werden.Der bewusstlose Patient ::: Der wache Patient ::: Innerklinische ReanimationFalls der Patient nicht atmet, aber einen tastbaren Puls hat (Atemstillstand) sollte er beatmet werden.", [["Patient", "SPECIES", 197, 204], ["Patient", "SPECIES", 219, 226], ["Patient", "SPECIES", 267, 274]]], ["Alle 10 Atemspenden muss der Karotispuls \u00fcberpr\u00fcft werden.Start der innerklinischen Reanimationsma\u00dfnahmen ::: Innerklinische Reanimation", [["Innerklinische Reanimation", "TREATMENT", 110, 136]]]], "6b0b6f072cebc9e6387289a67768b7acd89d5a1f": [["IntroductionPorcine epidemic diarrhea (PED) is a devastating disease in pigs that is characterized by acute enteritis and lethal watery diarrhea followed by dehydration with high mortality in suckling piglets (Debouck and Pensaert, 1980; Saif et al., 2012; Pijpers et al., 1993) .", [["diarrhea", "DISEASE", 29, 37], ["PED", "DISEASE", 39, 42], ["enteritis", "DISEASE", 108, 117], ["watery diarrhea", "DISEASE", 129, 144], ["dehydration", "DISEASE", 157, 168], ["pigs", "ORGANISM", 72, 76], ["piglets", "ORGANISM", 201, 208], ["pigs", "SPECIES", 72, 76], ["piglets", "SPECIES", 201, 208], ["pigs", "SPECIES", 72, 76], ["IntroductionPorcine epidemic diarrhea", "PROBLEM", 0, 37], ["a devastating disease in pigs", "PROBLEM", 47, 76], ["acute enteritis", "PROBLEM", 102, 117], ["lethal watery diarrhea", "PROBLEM", 122, 144], ["dehydration", "PROBLEM", 157, 168], ["devastating", "OBSERVATION_MODIFIER", 49, 60], ["disease", "OBSERVATION", 61, 68], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["enteritis", "OBSERVATION", 108, 117], ["lethal", "OBSERVATION_MODIFIER", 122, 128], ["high", "OBSERVATION_MODIFIER", 174, 178], ["mortality", "OBSERVATION_MODIFIER", 179, 188]]], ["The disease was initially recognized in England in 1971 and has then spread to swine-producing European countries (Oldham, 1972; Pensaert et al., 1981) .", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["Since the 1990s, PED has become rare in Europe and is more often associated with post-weaning diarrhea in adult pigs (Saif et al., 2012) .", [["diarrhea", "DISEASE", 94, 102], ["pigs", "ORGANISM", 112, 116], ["pigs", "SPECIES", 112, 116], ["pigs", "SPECIES", 112, 116], ["weaning diarrhea", "PROBLEM", 86, 102], ["rare", "OBSERVATION_MODIFIER", 32, 36]]], ["PED was first reported in Asia in 1982 and has since had a great economic impact on the Asian pork industry (Chen et al., 2008; Kweon et al., 1993; Li et al., 2012; Puranaveja et al., 2009; Takahashi et al., 1983) .", [["PED", "DISEASE", 0, 3]]], ["In May 2013, PED outbreaks suddenly appeared in the United States and have rapidly spread nationwide as well as to Canada and Mexico, causing high mortality in newborn piglets and significant financial concerns (Mole, 2013; Stevenson et al., 2013 Vlasova et al., 2014 .IntroductionThe etiological agent of PED, PED virus (PEDV), was identified as a coronavirus in 1978, which is a member of the genus Alphacoronavirus within the family Coronaviridae of the order Nidovirales (Lai et al., 2007; Pensaert and de Bouck, 1978; Saif et al., 2012) .", [["PED", "DISEASE", 306, 309], ["coronavirus", "DISEASE", 349, 360], ["piglets", "ORGANISM", 168, 175], ["PED virus", "ORGANISM", 311, 320], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 401, 417], ["piglets", "SPECIES", 168, 175], ["PED virus", "SPECIES", 311, 320], ["PEDV", "SPECIES", 322, 326], ["PED virus (PEDV", "PROBLEM", 311, 326], ["a coronavirus", "PROBLEM", 347, 360], ["significant", "OBSERVATION_MODIFIER", 180, 191]]], ["PEDV is a large, enveloped virus possessing a single-stranded positivesense RNA genome of approximately 28 kb with a 5 cap and a 3 polyadenylated tail (Pensaert and de Bouck, 1978; Saif et al., 2012) .", [["PEDV", "CHEMICAL", 0, 4], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["single-stranded positivesense RNA genome", "DNA", 46, 86], ["5 cap", "DNA", 117, 122], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["a large, enveloped virus", "PROBLEM", 8, 32], ["large", "OBSERVATION_MODIFIER", 10, 15], ["enveloped", "OBSERVATION_MODIFIER", 17, 26], ["virus", "OBSERVATION", 27, 32], ["28 kb", "OBSERVATION_MODIFIER", 104, 109], ["tail", "OBSERVATION_MODIFIER", 146, 150]]], ["The spike (S) protein of PEDV is the major envelope glycoprotein of the virion and plays pivotal roles in interacting with the cellular receptor for virus entry and mediating neutralizing antibodies in the natural host (Jackwood et al., 2001; Lai et al., 2007; Lee et al., 2010) .", [["cellular", "ANATOMY", 127, 135], ["PEDV", "GENE_OR_GENE_PRODUCT", 25, 29], ["cellular", "CELL", 127, 135], ["spike (S) protein", "PROTEIN", 4, 21], ["PEDV", "PROTEIN", 25, 29], ["major envelope glycoprotein", "PROTEIN", 37, 64], ["cellular receptor", "PROTEIN", 127, 144], ["neutralizing antibodies", "PROTEIN", 175, 198], ["The spike (S) protein", "TEST", 0, 21], ["PEDV", "PROBLEM", 25, 29], ["the cellular receptor", "TREATMENT", 123, 144], ["virus entry", "TREATMENT", 149, 160]]], ["Therefore, the PEDV S glycoprotein is known to be an appropriate viral gene for determining the genetic relatedness among PEDV isolates and for developing diagnostic assays and effective vaccines (Chen et al., 2014; Gerber et al., 2014; Lee et al., 2010; Lee and Lee, 2014; Oh et al., 2014) .IntroductionThe first PED epizootic in Korea was confirmed in 1992 (Kweon et al., 1993) .", [["PEDV S glycoprotein", "GENE_OR_GENE_PRODUCT", 15, 34], ["PEDV S glycoprotein", "PROTEIN", 15, 34], ["viral gene", "DNA", 65, 75], ["PEDV", "SPECIES", 15, 19], ["PEDV", "SPECIES", 122, 126], ["the PEDV S glycoprotein", "TREATMENT", 11, 34], ["diagnostic assays", "TEST", 155, 172], ["effective vaccines", "TREATMENT", 177, 195]]], ["However, a retrospective study revealed that PEDV already existed as early as 1987 (Park and Lee, 1997) .", [["PEDV", "SPECIES", 45, 49], ["a retrospective study", "TEST", 9, 30], ["PEDV", "PROBLEM", 45, 49]]], ["Since the emergence, PED outbreaks occurred every year, resulting in substantial economic losses to the Korean swine industry until early 2010.", [["swine", "SPECIES", 111, 116], ["swine", "SPECIES", 111, 116], ["substantial economic losses", "PROBLEM", 69, 96], ["substantial", "OBSERVATION_MODIFIER", 69, 80], ["economic losses", "OBSERVATION", 81, 96]]], ["After severe outbreaks of foot-and-mouth disease (FMD) during 2010 to 2011, however, the prevalence of PEDV infections was occasional with only sporadic outbreaks in Korea.", [["foot-and-mouth disease", "DISEASE", 26, 48], ["FMD", "DISEASE", 50, 53], ["infections", "DISEASE", 108, 118], ["foot-and-mouth disease", "SPECIES", 26, 48], ["FMD", "SPECIES", 50, 53], ["PEDV", "SPECIES", 103, 107], ["severe outbreaks of foot", "PROBLEM", 6, 30], ["mouth disease", "PROBLEM", 35, 48], ["PEDV infections", "PROBLEM", 103, 118], ["severe", "OBSERVATION_MODIFIER", 6, 12], ["outbreaks", "OBSERVATION", 13, 22], ["foot", "ANATOMY", 26, 30], ["mouth", "ANATOMY", 35, 40], ["disease", "OBSERVATION", 41, 48], ["infections", "OBSERVATION", 108, 118], ["sporadic", "OBSERVATION_MODIFIER", 144, 152], ["outbreaks", "OBSERVATION", 153, 162]]], ["This epidemic situation probably resulted from the mass culling of more than one-third of the entire domestic pig population in Korea during the 2010-2011 FMD outbreaks.", [["FMD", "DISEASE", 155, 158], ["pig", "ORGANISM", 110, 113], ["pig", "SPECIES", 110, 113], ["pig", "SPECIES", 110, 113], ["This epidemic situation", "PROBLEM", 0, 23], ["the mass culling", "PROBLEM", 47, 63], ["mass", "OBSERVATION", 51, 55], ["entire", "OBSERVATION_MODIFIER", 94, 100], ["domestic", "OBSERVATION_MODIFIER", 101, 109], ["pig population", "OBSERVATION", 110, 124]]], ["However, starting in November 2013, severe PED epidemics re-emerged in Korea and swept more than 40% of pig farms Lee et al., 2014a,b) .", [["PED", "DISEASE", 43, 46], ["pig", "ORGANISM", 104, 107], ["pig", "SPECIES", 104, 107], ["pig", "SPECIES", 104, 107], ["severe PED epidemics", "PROBLEM", 36, 56], ["severe", "OBSERVATION_MODIFIER", 36, 42]]], ["Although both modified live and killed vaccines against PED are commercially available in Korea, continuous PED epidemics indicate a low effectiveness of the domestic vaccines.", [["continuous PED epidemics", "PROBLEM", 97, 121], ["the domestic vaccines", "TREATMENT", 154, 175]]], ["This result appears to be due to genetic and antigenic differences between S proteins of vaccine and field strains (Lee et al., 2010; Oh et al., 2014; Lee and Lee, 2014) .", [["S proteins", "PROTEIN", 75, 85], ["genetic and antigenic differences", "PROBLEM", 33, 66], ["vaccine", "TREATMENT", 89, 96], ["appears to be due to", "UNCERTAINTY", 12, 32]]], ["Thus, the lack of effective vaccines enhances the need for the development of next-generation vaccines to control PED.IntroductionPEDV isolation in cell culture is critical for developing effective vaccines for PED prevention as well as performing various PEDV research.", [["cell culture", "ANATOMY", 148, 160], ["PED", "DISEASE", 114, 117], ["cell", "CELL", 148, 152], ["PEDV", "SPECIES", 256, 260], ["effective vaccines", "TREATMENT", 18, 36], ["next-generation vaccines", "TREATMENT", 78, 102], ["IntroductionPEDV isolation", "TREATMENT", 118, 144], ["cell culture", "TEST", 148, 160], ["developing effective vaccines", "TREATMENT", 177, 206], ["PED prevention", "TREATMENT", 211, 225]]], ["However, the cell culture isolation of PEDV has shown to be difficult and even the isolated virus may be unable to maintain infectivity upon further passages in cell culture (Chen et al., 2014) .", [["cell", "ANATOMY", 13, 17], ["cell", "ANATOMY", 161, 165], ["PEDV", "CHEMICAL", 39, 43], ["cell", "CELL", 13, 17], ["PEDV", "ORGANISM", 39, 43], ["cell", "CELL", 161, 165], ["PEDV", "SPECIES", 39, 43], ["the cell culture isolation", "TEST", 9, 35], ["PEDV", "PROBLEM", 39, 43], ["the isolated virus", "PROBLEM", 79, 97], ["cell culture", "TEST", 161, 173]]], ["To date, there have only been two reports in more than two decades on the cultivation of the Korean PEDV strain that is genetically divergent from field PEDVs (Kweon et al., 1999; Song et al., 2003) , while a number of PEDV strains have been recently isolated in the US and successfully grown in cell culture for a year (Chen et al., 2014; Oka et al., 2014) , In the present study, we attempted to isolate PEDV from various PEDV-positive samples using Vero cells.", [["cell culture", "ANATOMY", 296, 308], ["samples", "ANATOMY", 438, 445], ["Vero cells", "ANATOMY", 452, 462], ["PEDV strain", "ORGANISM", 100, 111], ["PEDV strains", "ORGANISM", 219, 231], ["cell culture", "CELL", 296, 308], ["PEDV", "GENE_OR_GENE_PRODUCT", 406, 410], ["PEDV", "GENE_OR_GENE_PRODUCT", 424, 428], ["Vero cells", "CELL", 452, 462], ["PEDV", "PROTEIN", 406, 410], ["Vero cells", "CELL_LINE", 452, 462], ["Korean PEDV strain", "SPECIES", 93, 111], ["PEDV", "SPECIES", 219, 223], ["PEDV", "SPECIES", 406, 410], ["PEDV", "SPECIES", 424, 428], ["the cultivation", "TREATMENT", 70, 85], ["the Korean PEDV strain", "PROBLEM", 89, 111], ["PEDV strains", "PROBLEM", 219, 231], ["PEDV", "PROBLEM", 406, 410], ["various PEDV", "TEST", 416, 428], ["Vero cells", "TREATMENT", 452, 462], ["Vero cells", "OBSERVATION", 452, 462]]], ["At this time, one highly virulent Korean strain KOR/KNU-141112/2014 has been successfully isolated and serially propagated in cell culture for over 30 passages.", [["cell", "ANATOMY", 126, 130], ["KNU-141112/2014", "CHEMICAL", 52, 67], ["KNU-141112/2014", "CELL", 52, 67], ["cell culture", "CELL", 126, 138], ["Korean strain KOR/KNU-141112/2014", "SPECIES", 34, 67], ["KNU", "TEST", 52, 55], ["cell culture", "TEST", 126, 138]]], ["We aimed to characterize the growth and titer of the PEDV isolate KNU-141112 during the serial passages and the pathogenicity of the virus in suckling piglets.", [["KNU-141112", "CHEMICAL", 66, 76], ["KNU-141112", "CELL", 66, 76], ["piglets", "ORGANISM", 151, 158], ["piglets", "SPECIES", 151, 158], ["PEDV", "SPECIES", 53, 57], ["KNU-141112", "SPECIES", 66, 76], ["the PEDV isolate KNU", "TEST", 49, 69], ["the serial passages", "TEST", 84, 103], ["the virus", "PROBLEM", 129, 138], ["virus", "OBSERVATION", 133, 138]]], ["Our in vivo assessment demonstrated that KNU-141112 is highly entero-pathogenic in piglets, exhibiting severe clinical symptoms as well as macroscopic and microscopic lesions typical for PEDV infection.", [["lesions", "ANATOMY", 167, 174], ["KNU-141112", "CHEMICAL", 41, 51], ["infection", "DISEASE", 192, 201], ["KNU-141112", "CHEMICAL", 41, 51], ["KNU-141112", "SIMPLE_CHEMICAL", 41, 51], ["piglets", "ORGANISM", 83, 90], ["lesions", "PATHOLOGICAL_FORMATION", 167, 174], ["piglets", "SPECIES", 83, 90], ["KNU-141112", "SPECIES", 41, 51], ["PEDV", "SPECIES", 187, 191], ["Our in vivo assessment", "TEST", 0, 22], ["KNU", "TEST", 41, 44], ["severe clinical symptoms", "PROBLEM", 103, 127], ["macroscopic and microscopic lesions", "PROBLEM", 139, 174], ["PEDV infection", "PROBLEM", 187, 201], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["microscopic", "OBSERVATION_MODIFIER", 155, 166], ["lesions", "OBSERVATION", 167, 174], ["PEDV", "OBSERVATION_MODIFIER", 187, 191], ["infection", "OBSERVATION", 192, 201]]], ["In addition, the complete genome or full-length S gene sequences of KNU-141112 were determined at selected passages to study the genetic stability and relationship.", [["KNU-141112", "CHEMICAL", 68, 78], ["KNU-141112", "CELL", 68, 78], ["full-length S gene sequences", "DNA", 36, 64], ["KNU-141112", "DNA", 68, 78], ["KNU-141112", "SPECIES", 68, 78], ["KNU", "TEST", 68, 71]]], ["Our data indicated that KNU-141112 isolate is relatively stable during the first 30 passages in cell culture and is classified into subgroup G2b that includes PEDV strains responsible for recent severe outbreaks in Korea and the US.Cells, clinical samples, virus, and antibodyVero cells (ATCC CCL-81) were cultured in alpha minimum essential medium (\u2423-MEM; Invitrogen, Carlsbad, CA) with 5% fetal bovine serum (FBS; Invitrogen) and antibiotic-antimycotic solutions (100\u00d7; Invitrogen) and maintained at 37 \u2022 C in a humidified 5% CO 2 incubator.", [["cell culture", "ANATOMY", 96, 108], ["Cells", "ANATOMY", 232, 237], ["samples", "ANATOMY", 248, 255], ["Vero cells", "ANATOMY", 276, 286], ["ATCC CCL-81", "ANATOMY", 288, 299], ["fetal bovine serum", "ANATOMY", 391, 409], ["FBS", "ANATOMY", 411, 414], ["KNU-141112", "CHEMICAL", 24, 34], ["KNU-141112", "CHEMICAL", 24, 34], ["CO 2", "CHEMICAL", 528, 532], ["KNU-141112", "CELL", 24, 34], ["cell culture", "CELL", 96, 108], ["G2b", "GENE_OR_GENE_PRODUCT", 141, 144], ["PEDV strains", "ORGANISM", 159, 171], ["Cells", "CELL", 232, 237], ["Vero cells", "CELL", 276, 286], ["ATCC CCL-81", "CELL", 288, 299], ["bovine", "ORGANISM", 397, 403], ["serum", "ORGANISM_SUBSTANCE", 404, 409], ["FBS", "ORGANISM_SUBSTANCE", 411, 414], ["Invitrogen", "SIMPLE_CHEMICAL", 416, 426], ["Vero cells", "CELL_LINE", 276, 286], ["ATCC CCL-81", "CELL_LINE", 288, 299], ["bovine", "SPECIES", 397, 403], ["KNU-141112", "SPECIES", 24, 34], ["PEDV", "SPECIES", 159, 163], ["ATCC CCL-81", "SPECIES", 288, 299], ["bovine", "SPECIES", 397, 403], ["Our data", "TEST", 0, 8], ["KNU", "TEST", 24, 27], ["cell culture", "TEST", 96, 108], ["PEDV strains", "PROBLEM", 159, 171], ["recent severe outbreaks", "PROBLEM", 188, 211], ["the US", "TEST", 225, 231], ["Cells", "TEST", 232, 237], ["clinical samples", "TEST", 239, 255], ["virus", "PROBLEM", 257, 262], ["antibody", "TEST", 268, 276], ["Vero cells (ATCC CCL", "TEST", 276, 296], ["MEM", "TEST", 352, 355], ["Invitrogen", "TEST", 357, 367], ["Carlsbad", "TEST", 369, 377], ["CA", "TEST", 379, 381], ["fetal bovine serum", "TEST", 391, 409], ["FBS", "TEST", 411, 414], ["Invitrogen", "TEST", 416, 426], ["antibiotic-antimycotic solutions", "TREATMENT", 432, 464], ["a humidified 5% CO 2 incubator", "TREATMENT", 512, 542], ["relatively", "OBSERVATION_MODIFIER", 46, 56], ["stable", "OBSERVATION_MODIFIER", 57, 63], ["severe", "OBSERVATION_MODIFIER", 195, 201], ["outbreaks", "OBSERVATION", 202, 211]]], ["Seven small intestinal homogenates and 50 stool specimens that tested positive by RT-PCR using an i-TGE/PED Detection Kit (iNtRON Biotechnology, Seongnam, South Korea) were selected for virus isolation experiments.", [["intestinal homogenates", "ANATOMY", 12, 34], ["stool specimens", "ANATOMY", 42, 57], ["intestinal homogenates", "CANCER", 12, 34], ["Seven small intestinal homogenates", "PROBLEM", 0, 34], ["50 stool specimens", "TEST", 39, 57], ["RT", "TEST", 82, 84], ["PCR", "TEST", 85, 88], ["an i-TGE", "TEST", 95, 103], ["virus isolation experiments", "TREATMENT", 186, 213], ["small", "OBSERVATION_MODIFIER", 6, 11], ["intestinal", "ANATOMY", 12, 22]]], ["Intestinal homogenates were prepared to 10% (wt/vol) suspensions with phosphate-buffered saline (PBS) using a MagNA Lyser (Roche Diagnostics, Mannheim, Germany) by three repetitions of 15 s at a speed of 7000 rpm.", [["Intestinal homogenates", "ANATOMY", 0, 22], ["phosphate", "CHEMICAL", 70, 79], ["phosphate", "CHEMICAL", 70, 79], ["Intestinal homogenates", "ORGANISM_SUBSTANCE", 0, 22], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 70, 95], ["Intestinal homogenates", "TREATMENT", 0, 22], ["phosphate-buffered saline (PBS", "TREATMENT", 70, 100], ["a MagNA Lyser", "TREATMENT", 108, 121]]], ["Fecal samples were diluted with PBS to be 10% (wt/vol) suspensions.", [["Fecal samples", "ANATOMY", 0, 13], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["Fecal samples", "TEST", 0, 13], ["PBS", "TREATMENT", 32, 35]]], ["The suspensions were then vortexed and centrifuged for 10 min at 4500 \u00d7 g (Hanil Centrifuge FLETA5, Incheon, South Korea).", [["The suspensions", "TREATMENT", 0, 15]]], ["The supernatant was filtered through a 0.22-m-pore-size syringe filter (Millipore, Billerica, MA) and stored at \u221280 \u2022 C as an inoculum for virus isolation until use.", [["supernatant", "ANATOMY", 4, 15], ["a 0.22-m-pore-size syringe filter (Millipore, Billerica, MA", "TREATMENT", 37, 96], ["an inoculum", "TREATMENT", 123, 134], ["virus isolation", "TREATMENT", 139, 154]]], ["Virus isolation of PEDV was attempted on Vero cells as described previously with some modifications (Hofmann and Wyler, 1988) .", [["Vero cells", "ANATOMY", 41, 51], ["PEDV", "CHEMICAL", 19, 23], ["Virus", "ORGANISM", 0, 5], ["PEDV", "ORGANISM", 19, 23], ["Vero cells", "CELL", 41, 51], ["Vero cells", "CELL_LINE", 41, 51], ["PEDV", "SPECIES", 19, 23], ["Virus isolation", "TREATMENT", 0, 15], ["PEDV", "PROBLEM", 19, 23], ["Vero cells", "TREATMENT", 41, 51], ["PEDV", "OBSERVATION", 19, 23]]], ["Briefly, prior to inoculation, inocula were prepared by adding trypsin (USB, Cleveland, OH) to intestinal or fecal suspensions prepared above to give a final concentration of 10 g/ml.", [["intestinal", "ANATOMY", 95, 105], ["OH", "CHEMICAL", 88, 90], ["trypsin", "GENE_OR_GENE_PRODUCT", 63, 70], ["intestinal", "ORGAN", 95, 105], ["trypsin", "PROTEIN", 63, 70], ["inoculation", "TREATMENT", 18, 29], ["inocula", "TREATMENT", 31, 38], ["trypsin (USB", "TREATMENT", 63, 75], ["intestinal or fecal suspensions", "TREATMENT", 95, 126], ["intestinal", "ANATOMY", 95, 105], ["fecal", "ANATOMY", 109, 114]]], ["Confluent Vero cells grown in 6-well plates were washed with PBS and inoculated with 400 l of each inoculum containing trypsin.", [["Vero cells", "ANATOMY", 10, 20], ["Vero cells", "CELL", 10, 20], ["trypsin", "GENE_OR_GENE_PRODUCT", 119, 126], ["Vero cells", "CELL_LINE", 10, 20], ["trypsin", "PROTEIN", 119, 126], ["Confluent Vero cells", "PROBLEM", 0, 20], ["PBS", "TREATMENT", 61, 64], ["trypsin", "PROBLEM", 119, 126], ["Vero cells", "OBSERVATION", 10, 20], ["grown", "OBSERVATION_MODIFIER", 21, 26], ["inoculum", "OBSERVATION", 99, 107], ["trypsin", "OBSERVATION_MODIFIER", 119, 126]]], ["After incubating at 37 \u2022 C for 1 h, 2 ml of virus growth medium [\u2423-MEM supplemented with antibioticantimycotic solutions, 0.3% tryptose phosphate broth (TPB; Sigma, St. Louis, MO), 0.02% yeast extract (Difco, Detroit, MI), 10 mM HEPES (Invitrogen), and 5 g/ml of trypsin] was added.", [["MEM", "CHEMICAL", 67, 70], ["tryptose phosphate", "CHEMICAL", 127, 145], ["MI", "CHEMICAL", 218, 220], ["tryptose phosphate", "CHEMICAL", 127, 145], ["HEPES", "CHEMICAL", 229, 234], ["antibioticantimycotic", "SIMPLE_CHEMICAL", 89, 110], ["tryptose phosphate broth", "SIMPLE_CHEMICAL", 127, 151], ["St. Louis", "SIMPLE_CHEMICAL", 165, 174], ["Difco", "SIMPLE_CHEMICAL", 202, 207], ["Detroit", "SIMPLE_CHEMICAL", 209, 216], ["trypsin", "GENE_OR_GENE_PRODUCT", 263, 270], ["trypsin", "PROTEIN", 263, 270], ["yeast", "SPECIES", 187, 192], ["yeast", "SPECIES", 187, 192], ["virus growth medium", "TREATMENT", 44, 63], ["antibioticantimycotic solutions", "TREATMENT", 89, 120], ["tryptose phosphate broth", "TREATMENT", 127, 151], ["10 mM HEPES (Invitrogen)", "TREATMENT", 223, 247], ["trypsin", "TREATMENT", 263, 270]]], ["The inoculated cells were maintained at 37 \u2022 C under 5% CO 2 and monitored daily for cytopathic effects (CPE).", [["cells", "ANATOMY", 15, 20], ["CO 2", "CHEMICAL", 56, 60], ["cells", "CELL", 15, 20], ["inoculated cells", "CELL_LINE", 4, 20], ["The inoculated cells", "TEST", 0, 20], ["cytopathic effects", "PROBLEM", 85, 103], ["inoculated cells", "OBSERVATION", 4, 20]]], ["When 70% CPE appeared, inoculated cells were subjected to three rounds of freezing and thawing.", [["cells", "ANATOMY", 34, 39], ["cells", "CELL", 34, 39], ["inoculated cells", "CELL_LINE", 23, 39], ["inoculated cells", "PROBLEM", 23, 39]]], ["The culture supernatants were then collected and centrifuged at 400 \u00d7 g for 10 min.", [["supernatants", "ANATOMY", 12, 24], ["The culture supernatants", "TEST", 0, 24]]], ["The clarified supernatants were aliquoted and stored at \u221280 \u2022 C as 'passage 1 (P1)' viral stocks until use.", [["supernatants", "ANATOMY", 14, 26]]], ["One hundred millimeter diameter tissue culture dishes were used for serial passages of the isolate.", [["tissue", "ANATOMY", 32, 38], ["One hundred millimeter diameter tissue culture dishes", "TREATMENT", 0, 53], ["serial passages", "TEST", 68, 83], ["the isolate", "TREATMENT", 87, 98], ["hundred millimeter", "OBSERVATION_MODIFIER", 4, 22], ["diameter", "OBSERVATION_MODIFIER", 23, 31], ["tissue", "OBSERVATION_MODIFIER", 32, 38], ["culture dishes", "OBSERVATION", 39, 53]]], ["If no CPE was shown in inoculated cells for 7 days, the plates were frozen and thawed three times, and the supernatants were harvested by centrifugation and inoculated on fresh Vero cells for the next passage.", [["cells", "ANATOMY", 34, 39], ["supernatants", "ANATOMY", 107, 119], ["Vero cells", "ANATOMY", 177, 187], ["cells", "CELL", 34, 39], ["Vero cells", "CELL", 177, 187], ["inoculated cells", "CELL_LINE", 23, 39], ["Vero cells", "CELL_LINE", 177, 187], ["CPE", "PROBLEM", 6, 9], ["the plates", "TEST", 52, 62], ["fresh Vero cells", "TREATMENT", 171, 187]]], ["If CPE and RT-PCR results were negative after 6 blind passages, the virus isolation was considered negative.", [["CPE", "TEST", 3, 6], ["RT-PCR", "TEST", 11, 17], ["the virus isolation", "TEST", 64, 83]]], ["The PEDV N protein-specific monoclonal antibody (MAb) was obtained from ChoogAng Vaccine Laboratory (CAVAC; Daejeon, South Korea).Virus titrationVero cells were infected with each passage KNU-141112 virus stock in the presence of trypsin as described above.", [["Vero cells", "ANATOMY", 145, 155], ["KNU-141112", "CHEMICAL", 188, 198], ["PEDV N protein", "GENE_OR_GENE_PRODUCT", 4, 18], ["Virus", "ORGANISM", 130, 135], ["Vero cells", "CELL", 145, 155], ["KNU-141112", "CELL", 188, 198], ["trypsin", "GENE_OR_GENE_PRODUCT", 230, 237], ["PEDV N protein", "PROTEIN", 4, 18], ["monoclonal antibody", "PROTEIN", 28, 47], ["MAb", "PROTEIN", 49, 52], ["Vero cells", "CELL_LINE", 145, 155], ["trypsin", "PROTEIN", 230, 237], ["PEDV", "SPECIES", 4, 8], ["KNU-141112 virus", "SPECIES", 188, 204], ["The PEDV N protein", "TEST", 0, 18], ["specific monoclonal antibody", "TEST", 19, 47], ["Virus titration", "TREATMENT", 130, 145], ["Vero cells", "PROBLEM", 145, 155], ["each passage KNU", "TEST", 175, 191], ["trypsin", "PROBLEM", 230, 237], ["trypsin", "OBSERVATION", 230, 237]]], ["The culture supernatants were collected at 24 or 48 h postinfection (hpi) at which a 70% CPE is commonly developed.", [["supernatants", "ANATOMY", 12, 24], ["The culture supernatants", "TEST", 0, 24]]], ["For growth kinetics experiments, the supernatants were harvested from cells infected with each selected passage virus at different time points (6, 12, 24, 36, and 48 hpi) and stored at \u221280 \u2022 C. Virus titers were measured in 96-well plates by 10-fold serial dilution of the samples in triplicate per dilution to determine the quantity of viruses required to produce CPE in 50% of inoculated Vero cells and calculated as TCID 50 per ml using the Reed-Muench method (Reed and Muench, 1938) .", [["supernatants", "ANATOMY", 37, 49], ["cells", "ANATOMY", 70, 75], ["samples", "ANATOMY", 273, 280], ["Vero cells", "ANATOMY", 390, 400], ["CPE", "CHEMICAL", 365, 368], ["cells", "CELL", 70, 75], ["Virus", "ORGANISM", 194, 199], ["Vero cells", "CELL", 390, 400], ["inoculated Vero cells", "CELL_LINE", 379, 400], ["growth kinetics experiments", "PROBLEM", 4, 31], ["the supernatants", "TREATMENT", 33, 49], ["each selected passage virus", "PROBLEM", 90, 117], ["C. Virus titers", "TEST", 191, 206], ["viruses", "PROBLEM", 337, 344], ["CPE", "TEST", 365, 368], ["inoculated Vero cells", "PROBLEM", 379, 400], ["viruses", "OBSERVATION", 337, 344], ["Vero cells", "OBSERVATION", 390, 400]]], ["The PEDV titer was also determined by a plaque assay using Vero cells and quantified as plaque-forming units (PFU) per ml.Immunofluorescence assay (IFA)Vero cells grown on microscope coverslips placed in 6-well tissue culture plates were mock infected or infected with PEDV at a multiplicity of infection (MOI) of 0.1.", [["plaque", "ANATOMY", 40, 46], ["Vero cells", "ANATOMY", 59, 69], ["plaque", "ANATOMY", 88, 94], ["Vero cells", "ANATOMY", 152, 162], ["tissue", "ANATOMY", 211, 217], ["PEDV", "CHEMICAL", 269, 273], ["infection", "DISEASE", 295, 304], ["PEDV", "GENE_OR_GENE_PRODUCT", 4, 8], ["Vero cells", "CELL", 59, 69], ["Vero cells", "CELL", 152, 162], ["Vero cells", "CELL_LINE", 59, 69], ["Vero cells", "CELL_LINE", 152, 162], ["PEDV", "SPECIES", 4, 8], ["PEDV", "SPECIES", 269, 273], ["The PEDV titer", "TEST", 0, 14], ["a plaque assay", "TEST", 38, 52], ["Vero cells", "TREATMENT", 59, 69], ["Immunofluorescence assay", "TEST", 122, 146], ["Vero cells", "PROBLEM", 152, 162], ["microscope coverslips", "TEST", 172, 193], ["infected", "PROBLEM", 255, 263], ["PEDV", "PROBLEM", 269, 273], ["infection", "PROBLEM", 295, 304], ["plaque", "OBSERVATION", 40, 46], ["plaque", "OBSERVATION", 88, 94], ["well tissue", "OBSERVATION_MODIFIER", 206, 217], ["infection", "OBSERVATION", 295, 304]]], ["The virus-infected cells were subsequently propagated until 24 hpi, fixed with 4% paraformaldehyde for 10 min at room temperature (RT) and permeabilized with 0.2% Triton X-100 in PBS at RT for 10 min.", [["cells", "ANATOMY", 19, 24], ["Triton X-100", "CHEMICAL", 163, 175], ["paraformaldehyde", "CHEMICAL", 82, 98], ["cells", "CELL", 19, 24], ["paraformaldehyde", "SIMPLE_CHEMICAL", 82, 98], ["Triton X-100", "SIMPLE_CHEMICAL", 163, 175], ["virus-infected cells", "CELL_TYPE", 4, 24], ["The virus-infected cells", "PROBLEM", 0, 24], ["4% paraformaldehyde", "TREATMENT", 79, 98], ["virus", "OBSERVATION", 4, 9], ["infected cells", "OBSERVATION", 10, 24]]], ["The cells were blocked with 1% bovine serum albumin (BSA) in PBS for 30 min at RT and then incubated with N-specific MAb for 2 h.", [["cells", "ANATOMY", 4, 9], ["serum", "ANATOMY", 38, 43], ["BSA", "CHEMICAL", 53, 56], ["cells", "CELL", 4, 9], ["bovine", "ORGANISM", 31, 37], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["albumin", "SIMPLE_CHEMICAL", 44, 51], ["BSA", "SIMPLE_CHEMICAL", 53, 56], ["PBS", "SIMPLE_CHEMICAL", 61, 64], ["bovine", "SPECIES", 31, 37], ["1% bovine serum albumin (BSA)", "TREATMENT", 28, 57]]], ["After being washed five times in PBS, the cells were incubated for 1 h at RT with a goat anti-mouse secondary antibody conjugated to Alexa Fluor 488 (Invitrogen), followed by counterstaining with 4 ,6-diamidino-2-phenylindole (DAPI; Sigma).", [["cells", "ANATOMY", 42, 47], ["Alexa Fluor 488", "CHEMICAL", 133, 148], ["4 ,6-diamidino-2-phenylindole", "CHEMICAL", 196, 225], ["Alexa Fluor 488", "CHEMICAL", 133, 148], ["4 ,6-diamidino-2-phenylindole", "CHEMICAL", 196, 225], ["DAPI", "CHEMICAL", 227, 231], ["cells", "CELL", 42, 47], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 133, 148], ["Invitrogen", "SIMPLE_CHEMICAL", 150, 160], ["4 ,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 196, 225], ["DAPI", "SIMPLE_CHEMICAL", 227, 231], ["goat anti-mouse secondary antibody", "PROTEIN", 84, 118], ["Alexa Fluor 488", "PROTEIN", 133, 148], ["goat", "SPECIES", 84, 88], ["goat", "SPECIES", 84, 88], ["Alexa Fluor 488", "SPECIES", 133, 148], ["PBS", "TREATMENT", 33, 36], ["a goat anti-mouse secondary antibody", "TREATMENT", 82, 118], ["Alexa Fluor", "TEST", 133, 144], ["diamidino", "TREATMENT", 201, 210]]], ["The coverslips were mounted on microscope glass slides in mounting buffer and cell staining was visualized using a fluorescence Leica DM IL LED microscope (Leica, Wetzlar, Germany).Quantitative real-time RT-PCRViral RNA was extracted from virus isolates or fecal samples prepared as described above using an i-TGE/PED Detection Kit according to the manufacturer's protocol.", [["coverslips", "ANATOMY", 4, 14], ["cell", "ANATOMY", 78, 82], ["fecal samples", "ANATOMY", 257, 270], ["cell", "CELL", 78, 82], ["fecal samples", "ORGANISM_SUBSTANCE", 257, 270], ["PCRViral RNA", "RNA", 207, 219], ["The coverslips", "TREATMENT", 0, 14], ["microscope glass slides", "TEST", 31, 54], ["cell staining", "PROBLEM", 78, 91], ["a fluorescence Leica DM IL", "TREATMENT", 113, 139], ["PCRViral RNA", "PROBLEM", 207, 219], ["virus isolates", "PROBLEM", 239, 253], ["fecal samples", "TEST", 257, 270], ["an i-TGE/PED Detection Kit", "TREATMENT", 305, 331], ["the manufacturer's protocol", "TREATMENT", 345, 372], ["cell staining", "OBSERVATION", 78, 91], ["PCRViral RNA", "ANATOMY", 207, 219], ["fecal", "ANATOMY", 257, 262]]], ["Quantitative real-time RT-PCR was performed using a One Step SYBR PrimeScript RT-PCR Kit (TaKaRa, Otsu, Japan) as described elsewhere (Kim et al., 2007; Sagong and Lee, 2011) .", [["RT-PCR", "TEST", 23, 29]]], ["The reaction took place using a Thermal Cycler Dice Real Time System (TaKaRa) and the results were analyzed by the system software as described previously (Sagong and Lee, 2011) .Immunization of guinea pigsEight 3-4 month-old guinea pigs (weighing 300-350 g) were randomly allocated into inoculated (n = 6) and control (n = 2) groups.", [["guinea pigsEight 3", "ORGANISM", 195, 213], ["guinea", "ORGANISM", 226, 232], ["pigs", "ORGANISM", 233, 237], ["guinea pigsEight", "SPECIES", 195, 211], ["guinea pigs", "SPECIES", 226, 237], ["The reaction", "PROBLEM", 0, 12], ["Immunization", "TREATMENT", 179, 191], ["old guinea pigs", "TREATMENT", 222, 237]]], ["Six guinea pigs were immunized subcutaneously with 0.5 ml of binary ethylenimine (BEI)-inactivated KNU-141112-P10 virus in the presence of Freund's complete adjuvant (Sigma) and boosted once with a freshly prepared emulsion of the inactivated virus and Freund's incomplete adjuvant (Sigma) at a 2-week interval.", [["subcutaneously", "ANATOMY", 31, 45], ["ethylenimine", "CHEMICAL", 68, 80], ["BEI", "CHEMICAL", 82, 85], ["ethylenimine", "CHEMICAL", 68, 80], ["BEI", "CHEMICAL", 82, 85], ["guinea", "ORGANISM", 4, 10], ["pigs", "ORGANISM", 11, 15], ["ethylenimine", "SIMPLE_CHEMICAL", 68, 80], ["BEI", "SIMPLE_CHEMICAL", 82, 85], ["KNU", "ORGANISM", 99, 102], ["-141112-P10 virus", "ORGANISM", 102, 119], ["guinea pigs", "SPECIES", 4, 15], ["KNU-141112-P10 virus", "SPECIES", 99, 119], ["Six guinea pigs", "TREATMENT", 0, 15], ["binary ethylenimine", "TREATMENT", 61, 80], ["P10 virus", "PROBLEM", 110, 119], ["Freund's complete adjuvant", "TREATMENT", 139, 165], ["a freshly prepared emulsion", "TREATMENT", 196, 223], ["the inactivated virus", "PROBLEM", 227, 248]]], ["Two sham-inoculated guinea pigs were administered and boosted with cell culture media in the presence of the respective adjuvant.", [["cell", "ANATOMY", 67, 71], ["guinea", "ORGANISM", 20, 26], ["pigs", "ORGANISM", 27, 31], ["cell", "CELL", 67, 71], ["guinea pigs", "SPECIES", 20, 31], ["pigs", "SPECIES", 27, 31], ["Two sham-inoculated guinea pigs", "TREATMENT", 0, 31], ["cell culture media", "TREATMENT", 67, 85], ["the respective adjuvant", "TREATMENT", 105, 128], ["guinea pigs", "OBSERVATION", 20, 31], ["adjuvant", "OBSERVATION", 120, 128]]], ["Pre-immune sera were collected before starting the immunization and antisera were collected at 2 weeks after the final boost.Serum neutralizationThe presence of PEDV-specific neutralizing antibodies in serum samples collected from guinea pigs in all groups was determined using a serum neutralization (SN) test in 96-well microtiter plates using PEDV isolate KNU-141112 or vaccine strain SM98-1 as previously described (Oh et al., 2014) with minor modifications.", [["sera", "ANATOMY", 11, 15], ["Serum", "ANATOMY", 125, 130], ["serum samples", "ANATOMY", 202, 215], ["serum", "ANATOMY", 280, 285], ["PEDV", "CHEMICAL", 161, 165], ["KNU-141112", "CHEMICAL", 359, 369], ["sera", "ORGANISM_SUBSTANCE", 11, 15], ["Serum", "ORGANISM_SUBSTANCE", 125, 130], ["PEDV", "GENE_OR_GENE_PRODUCT", 161, 165], ["serum samples", "ORGANISM_SUBSTANCE", 202, 215], ["guinea pigs", "ORGANISM", 231, 242], ["serum", "ORGANISM_SUBSTANCE", 280, 285], ["KNU-141112", "CELL", 359, 369], ["SM98-1", "CELL", 388, 394], ["PEDV", "PROTEIN", 161, 165], ["neutralizing antibodies", "PROTEIN", 175, 198], ["guinea pigs", "SPECIES", 231, 242], ["PEDV", "SPECIES", 161, 165], ["KNU-141112 or vaccine strain SM98-1", "SPECIES", 359, 394], ["Pre-immune sera", "PROBLEM", 0, 15], ["the immunization", "TREATMENT", 47, 63], ["antisera", "TREATMENT", 68, 76], ["Serum neutralization", "TEST", 125, 145], ["PEDV", "PROBLEM", 161, 165], ["specific neutralizing antibodies", "PROBLEM", 166, 198], ["serum samples", "TEST", 202, 215], ["guinea pigs", "TREATMENT", 231, 242], ["a serum neutralization", "TEST", 278, 300], ["test", "TEST", 306, 310], ["PEDV isolate KNU", "TEST", 346, 362], ["PEDV", "OBSERVATION", 161, 165], ["neutralizing", "OBSERVATION_MODIFIER", 175, 187]]], ["Briefly, Vero cells were grown at 2 \u00d7 10 4 /well in 96-well tissue culture plates for 1 day.", [["Vero cells", "ANATOMY", 9, 19], ["tissue", "ANATOMY", 60, 66], ["Vero cells", "CELL", 9, 19], ["Vero cells", "CELL_LINE", 9, 19], ["Vero cells", "PROBLEM", 9, 19]]], ["The KNU-141112-P10 virus stock was diluted in serum-free \u2423-MEM to make 200 TCID in a 50 l volume.", [["serum", "ANATOMY", 46, 51], ["KNU-141112-P10 virus", "ORGANISM", 4, 24], ["serum", "ORGANISM_SUBSTANCE", 46, 51], ["KNU-141112-P10 virus", "SPECIES", 4, 24], ["The KNU", "TEST", 0, 7], ["P10 virus stock", "TREATMENT", 15, 30]]], ["The diluted virus was then mixed with 50 l of 2-fold serial dilutions of individual inactivated sera in 96-well plates and incubated at 37 \u2022 C for 1 h.", [["sera", "ANATOMY", 96, 100], ["sera", "ORGANISM_SUBSTANCE", 96, 100], ["The diluted virus", "TREATMENT", 0, 17], ["2-fold serial dilutions", "TREATMENT", 46, 69], ["individual inactivated sera", "TREATMENT", 73, 100]]], ["The mixture was inoculated into Vero cells and incubated at 37 \u2022 C for 1 h.", [["Vero cells", "ANATOMY", 32, 42], ["Vero cells", "CELL", 32, 42], ["Vero cells", "CELL_LINE", 32, 42], ["Vero cells", "OBSERVATION", 32, 42]]], ["After removing the mixture, the cells were thoroughly rinsed 5 times with PBS and maintained in virus growth medium at 37 \u2022 C in a 5% CO 2 incubator for 2 days.", [["cells", "ANATOMY", 32, 37], ["CO 2", "CHEMICAL", 134, 138], ["cells", "CELL", 32, 37], ["the mixture", "TREATMENT", 15, 26], ["the cells", "TREATMENT", 28, 37], ["PBS", "TREATMENT", 74, 77], ["a 5% CO 2 incubator", "TREATMENT", 129, 148]]], ["For the SN test using the vaccine strain, PEDV strain SM98-1 propagated in the absence of trypsin was diluted in serum-free \u2423-MEM to make 200 PFU in a 50 l volume.", [["serum", "ANATOMY", 113, 118], ["SM98-1", "CHEMICAL", 54, 60], ["PEDV strain", "ORGANISM", 42, 53], ["SM98-1", "CELL", 54, 60], ["trypsin", "GENE_OR_GENE_PRODUCT", 90, 97], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["trypsin", "PROTEIN", 90, 97], ["PEDV", "SPECIES", 42, 46], ["SM98-1", "SPECIES", 54, 60], ["the SN test", "TEST", 4, 15], ["the vaccine strain", "TREATMENT", 22, 40], ["PEDV strain SM98", "TEST", 42, 58], ["trypsin", "PROBLEM", 90, 97]]], ["The diluted virus was then mixed with each serum sample in 96-well plates as described above and incubated at 37 \u2022 C for 1 h.", [["serum sample", "ANATOMY", 43, 55], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["The diluted virus", "TREATMENT", 0, 17], ["each serum sample", "TEST", 38, 55]]], ["Subsequently, approximately 1 \u00d7 10 4 Vero cells in 100 l of \u2423-MEM containing 5% FBS were added to each well and the mixture was maintained at 37 \u2022 C in a 5% CO 2 incubator for 3 days.", [["Vero cells", "ANATOMY", 37, 47], ["FBS", "ANATOMY", 80, 83], ["CO 2", "CHEMICAL", 157, 161], ["Vero cells", "CELL", 37, 47], ["FBS", "ORGANISM_SUBSTANCE", 80, 83], ["Vero cells", "CELL_LINE", 37, 47], ["\u2423-MEM", "TREATMENT", 60, 65], ["5% FBS", "TREATMENT", 77, 83], ["a 5% CO 2 incubator", "TREATMENT", 152, 171]]], ["The neutralization titer was calculated as the reciprocal of the highest dilution of serum that inhibited virus-specific CPE in all of the duplicate wells.Pig infection experimentsThe in vivo swine studies described here were performed at the ImproAH Animal Facility under the guidelines established by its Institutional Animal Care and Use Committee.", [["serum", "ANATOMY", 85, 90], ["infection", "DISEASE", 159, 168], ["serum", "ORGANISM_SUBSTANCE", 85, 90], ["Pig", "ORGANISM", 155, 158], ["Pig", "SPECIES", 155, 158], ["swine", "SPECIES", 192, 197], ["The neutralization titer", "TEST", 0, 24], ["virus", "PROBLEM", 106, 111], ["Pig infection experiments", "PROBLEM", 155, 180], ["The in vivo swine studies", "TEST", 180, 205], ["neutralization titer", "OBSERVATION", 4, 24], ["infection", "OBSERVATION", 159, 168]]], ["A total of 8 suckling piglets of 7 days of age were obtained from a commercial pig farm with no known prior PED outbreak or vaccination with PEDV.", [["PEDV", "CHEMICAL", 141, 145], ["piglets", "ORGANISM", 22, 29], ["pig", "ORGANISM", 79, 82], ["piglets", "SPECIES", 22, 29], ["pig", "SPECIES", 79, 82], ["pig", "SPECIES", 79, 82], ["PEDV", "SPECIES", 141, 145], ["PEDV", "PROBLEM", 141, 145], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["All animals were determined to be free of antibodies to PEDV as well as to transmissible gastroenteritis virus (TGEV) and porcine reproductive and respiratory syndrome virus.", [["transmissible gastroenteritis", "DISEASE", 75, 104], ["porcine reproductive and respiratory syndrome virus", "DISEASE", 122, 173], ["PEDV", "GENE_OR_GENE_PRODUCT", 56, 60], ["transmissible gastroenteritis virus", "ORGANISM", 75, 110], ["TGEV", "ORGANISM", 112, 116], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 122, 173], ["antibodies", "PROTEIN", 42, 52], ["PEDV", "PROTEIN", 56, 60], ["transmissible gastroenteritis virus", "SPECIES", 75, 110], ["porcine", "SPECIES", 122, 129], ["PEDV", "SPECIES", 56, 60], ["transmissible gastroenteritis virus", "SPECIES", 75, 110], ["TGEV", "SPECIES", 112, 116], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 122, 173], ["antibodies", "PROBLEM", 42, 52], ["PEDV", "PROBLEM", 56, 60], ["transmissible gastroenteritis virus", "PROBLEM", 75, 110], ["porcine reproductive and respiratory syndrome virus", "PROBLEM", 122, 173], ["respiratory syndrome", "OBSERVATION", 147, 167]]], ["Pigs were randomly assigned to 3 experimental groups housed in 2 separated rooms: PEDV-inoculated (n = 4) and contact control (n = 2) in room 1 and sham-inoculated control (n = 2) group in room 2.", [["PEDV", "CHEMICAL", 82, 86], ["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 82, 86]]], ["Following a 1 day acclimation period, only piglets in the PEDV-inoculated group orally received a 1 ml dose of 10 3 TCID 50 /ml of KNU-141112-P10 virus.", [["PEDV", "CHEMICAL", 58, 62], ["KNU-141112", "CHEMICAL", 131, 141], ["piglets", "ORGANISM", 43, 50], ["PEDV", "SIMPLE_CHEMICAL", 58, 62], ["KNU-141112-P10 virus", "ORGANISM", 131, 151], ["piglets", "SPECIES", 43, 50]]], ["Two piglets were exposed to the virus by direct contact with inoculated piglets in the same room.", [["piglets", "ORGANISM", 4, 11], ["piglets", "ORGANISM", 72, 79], ["piglets", "SPECIES", 4, 11], ["piglets", "SPECIES", 72, 79]]], ["The sham-inoculated pigs were administered with cell culture media as a placebo.", [["cell", "ANATOMY", 48, 52], ["pigs", "ORGANISM", 20, 24], ["cell", "CELL", 48, 52], ["pigs", "SPECIES", 20, 24], ["pigs", "SPECIES", 20, 24], ["The sham-inoculated pigs", "TREATMENT", 0, 24], ["cell culture media", "TREATMENT", 48, 66], ["a placebo", "TREATMENT", 70, 79], ["inoculated pigs", "OBSERVATION", 9, 24]]], ["Clinical signs of diarrhea and mortality were monitored daily for the duration of the study.", [["diarrhea", "DISEASE", 18, 26], ["diarrhea", "PROBLEM", 18, 26], ["mortality", "PROBLEM", 31, 40], ["the study", "TEST", 82, 91], ["diarrhea", "OBSERVATION", 18, 26]]], ["Stool samples from all groups were collected prior to inoculation and daily with 16 inch, cotton-tipped swabs and subjected to RT-PCR using an i-TGE/PED Detection Kit and real-time RT-PCR as described above.", [["Stool samples", "ANATOMY", 0, 13], ["swabs", "ANATOMY", 104, 109], ["Stool samples", "CANCER", 0, 13], ["Stool samples", "TEST", 0, 13], ["cotton-tipped swabs", "TREATMENT", 90, 109], ["RT", "TEST", 127, 129], ["PCR", "TEST", 130, 133], ["an i-TGE", "TEST", 140, 148], ["PED Detection Kit", "TEST", 149, 166]]], ["PEDV-inoculated piglets were necropsied daily (days 1, 2, 3, and 4) after challenge for post-mortem examinations throughout the study, whereas all pigs from the contact and control groups were euthanized at 4 days post-challenge for post-mortem examinations.", [["piglets", "ANATOMY", 16, 23], ["PEDV", "CHEMICAL", 0, 4], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["piglets", "ORGANISM", 16, 23], ["pigs", "ORGANISM", 147, 151], ["piglets", "SPECIES", 16, 23], ["pigs", "SPECIES", 147, 151], ["PEDV", "SPECIES", 0, 4], ["pigs", "SPECIES", 147, 151], ["PEDV", "PROBLEM", 0, 4], ["post-mortem examinations", "TEST", 88, 112], ["the study", "TEST", 124, 133], ["post-mortem examinations", "TEST", 233, 257]]], ["Small intestinal tissue specimens (<3 mm thick) collected from each piglet were fixed with 10% formalin for 24 h at RT and embedded in paraffin according to standard laboratory procedures.", [["intestinal tissue specimens", "ANATOMY", 6, 33], ["piglet", "ANATOMY", 68, 74], ["formalin", "CHEMICAL", 95, 103], ["formalin", "CHEMICAL", 95, 103], ["paraffin", "CHEMICAL", 135, 143], ["intestinal tissue specimens", "TISSUE", 6, 33], ["piglet", "ORGANISM", 68, 74], ["formalin", "SIMPLE_CHEMICAL", 95, 103], ["Small intestinal tissue specimens", "PROBLEM", 0, 33], ["10% formalin", "TREATMENT", 91, 103], ["paraffin", "TREATMENT", 135, 143], ["standard laboratory procedures", "TREATMENT", 157, 187], ["intestinal tissue", "ANATOMY", 6, 23]]], ["The formalin-fixed paraffin-embedded tissues were cut at 5-8 m thick on a microtome (Leica), floated on a 40 \u2022 C water bath containing distilled water, and transferred onto glass slides.", [["tissues", "ANATOMY", 37, 44], ["formalin", "CHEMICAL", 4, 12], ["formalin", "CHEMICAL", 4, 12], ["paraffin", "CHEMICAL", 19, 27], ["tissues", "TISSUE", 37, 44], ["The formalin-fixed paraffin-embedded tissues", "TREATMENT", 0, 44], ["a microtome (Leica)", "TREATMENT", 72, 91], ["a 40 \u2022 C water bath", "TREATMENT", 104, 123]]], ["The tissues were then deparaffinized in xylene for 5 min and washed in decreasing concentrations of ethanol (100%, 95%, 90%, 80%, and 70%) for 3 min each.", [["tissues", "ANATOMY", 4, 11], ["xylene", "CHEMICAL", 40, 46], ["ethanol", "CHEMICAL", 100, 107], ["xylene", "CHEMICAL", 40, 46], ["ethanol", "CHEMICAL", 100, 107], ["tissues", "TISSUE", 4, 11], ["xylene", "SIMPLE_CHEMICAL", 40, 46], ["ethanol", "SIMPLE_CHEMICAL", 100, 107], ["ethanol", "TREATMENT", 100, 107], ["tissues", "ANATOMY", 4, 11], ["decreasing", "OBSERVATION_MODIFIER", 71, 81], ["concentrations", "OBSERVATION_MODIFIER", 82, 96]]], ["The deparaffinized intestinal tissues sections were stained with hematoxylin and eosin (Sigma) for histopathology or subjected to immunofluorescence assay using PEDV N-specific MAb as described above.ImmunohistochemistryThe paraffin-embedded tissue sections were deparaffinized, treated with 0.01 M citrate buffer (pH 6.0) in a microwave oven for 5 min, chilled at RT for 20 min, and then incubated with 0.3% hydrogen peroxide in DW for 20 min to block endogenous peroxidase.", [["intestinal tissues sections", "ANATOMY", 19, 46], ["tissue sections", "ANATOMY", 242, 257], ["citrate", "CHEMICAL", 299, 306], ["hydrogen peroxide", "CHEMICAL", 409, 426], ["hematoxylin", "CHEMICAL", 65, 76], ["eosin", "CHEMICAL", 81, 86], ["citrate", "CHEMICAL", 299, 306], ["hydrogen peroxide", "CHEMICAL", 409, 426], ["intestinal tissues sections", "MULTI-TISSUE_STRUCTURE", 19, 46], ["hematoxylin", "SIMPLE_CHEMICAL", 65, 76], ["eosin", "SIMPLE_CHEMICAL", 81, 86], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 242, 257], ["citrate", "SIMPLE_CHEMICAL", 299, 306], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 409, 426], ["DW", "SIMPLE_CHEMICAL", 430, 432], ["peroxidase", "GENE_OR_GENE_PRODUCT", 464, 474], ["PEDV N-specific MAb", "PROTEIN", 161, 180], ["endogenous peroxidase", "PROTEIN", 453, 474], ["hematoxylin", "TREATMENT", 65, 76], ["histopathology", "PROBLEM", 99, 113], ["immunofluorescence assay", "TEST", 130, 154], ["PEDV N-specific MAb", "TREATMENT", 161, 180], ["Immunohistochemistry", "TEST", 200, 220], ["0.01 M citrate buffer", "TREATMENT", 292, 313], ["pH", "TEST", 315, 317], ["a microwave oven", "TREATMENT", 326, 342], ["0.3% hydrogen peroxide", "TREATMENT", 404, 426], ["block endogenous peroxidase", "PROBLEM", 447, 474], ["intestinal tissues", "ANATOMY", 19, 37], ["endogenous peroxidase", "OBSERVATION", 453, 474]]], ["After being washed three times in PBS, the sections were blocked with normal horse serum (VECTASTAIN ABC Kit; Vector Laboratories, Burlingame, CA) and incubated 1 h at RT with N-specific MAb.", [["sections", "ANATOMY", 43, 51], ["serum", "ANATOMY", 83, 88], ["horse", "ORGANISM", 77, 82], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["N-specific MAb", "PROTEIN", 176, 190], ["horse", "SPECIES", 77, 82], ["horse", "SPECIES", 77, 82], ["Vector Laboratories", "TEST", 110, 129]]], ["After rinsing in PBS, the samples were reacted for 45 min at RT with a horse anti-mouse secondary antibody (VECTASTAIN ABC Kit), incubated with avidin-biotin peroxidase complex for 45 min (VECTASTAIN ABC Kit), and developed using the DAB substrate Kit (Vector Laboratories) according to the manufacturer's instructions.", [["samples", "ANATOMY", 26, 33], ["biotin", "CHEMICAL", 151, 157], ["avidin-biotin peroxidase", "GENE_OR_GENE_PRODUCT", 144, 168], ["horse anti-mouse secondary antibody", "PROTEIN", 71, 106], ["VECTASTAIN ABC Kit", "PROTEIN", 108, 126], ["avidin", "PROTEIN", 144, 150], ["biotin peroxidase complex", "PROTEIN", 151, 176], ["horse", "SPECIES", 71, 76], ["horse", "SPECIES", 71, 76], ["rinsing in PBS", "TREATMENT", 6, 20], ["the samples", "TEST", 22, 33], ["a horse anti-mouse secondary antibody", "TEST", 69, 106], ["avidin-biotin peroxidase complex", "TREATMENT", 144, 176]]], ["The slides were then counterstained with hematoxylin, dehydrated, cleared with xylene, and mounted on microscope glass slides in mounting buffer and tissue staining was visualized using a microscope.Nucleotide sequence analysisThe complete genomic sequences of the original fecal sample as well as those of the P5 and P10 isolates were determined by nextgeneration sequencing (NGS) technology.", [["tissue", "ANATOMY", 149, 155], ["fecal sample", "ANATOMY", 274, 286], ["xylene", "CHEMICAL", 79, 85], ["hematoxylin", "CHEMICAL", 41, 52], ["xylene", "CHEMICAL", 79, 85], ["hematoxylin", "SIMPLE_CHEMICAL", 41, 52], ["xylene", "SIMPLE_CHEMICAL", 79, 85], ["tissue", "TISSUE", 149, 155], ["hematoxylin", "TREATMENT", 41, 52], ["xylene", "TREATMENT", 79, 85], ["a microscope", "TEST", 186, 198], ["Nucleotide sequence analysis", "TEST", 199, 227], ["the P5 and P10 isolates", "TREATMENT", 307, 330]]], ["Total RNA was extracted from the feces as well as P5 and P10 isolates using a RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions and used as a template to amplify cDNA fragments as described elsewhere Lee et al., 2014b) .", [["feces", "ANATOMY", 33, 38], ["feces", "ORGANISM_SUBDIVISION", 33, 38], ["cDNA fragments", "DNA", 199, 213], ["Total RNA", "PROBLEM", 0, 9], ["a RNeasy Mini Kit", "TREATMENT", 76, 93], ["a template to amplify cDNA fragments", "TREATMENT", 177, 213], ["RNA", "OBSERVATION", 6, 9], ["feces", "OBSERVATION", 33, 38]]], ["Ten overlapping cDNA fragments were generated to encompass the entire genome of each sample, pooled in equimolar amounts, and subjected to NGS using the Ion Torrent Personal Genome Machine (PGM) Sequencer System (Life Technologies, Carlsbad, CA) and a 316 v2 sequencing chip (Life Technologies) as described previously Lee et al., 2014b; Rothberg et al., 2011) .", [["sample", "ANATOMY", 85, 91], ["cDNA fragments", "DNA", 16, 30], ["Ten overlapping cDNA fragments", "PROBLEM", 0, 30], ["NGS", "TEST", 139, 142], ["the Ion Torrent Personal Genome Machine (PGM)", "TREATMENT", 149, 194], ["a 316 v2 sequencing chip (Life Technologies", "TREATMENT", 250, 293], ["cDNA fragments", "OBSERVATION", 16, 30]]], ["The single-nucleotide variants (SNVs) were analyzed using the CLC Genomic Workbench version 7.0 (CLC Bio, Cambridge, MA) and the individual NGS reads were assembled using the complete genome of PEDV reference strain KOR/KNU-1305/2013 (Genbank accession no. KJ662670).", [["KJ662670", "CHEMICAL", 257, 265], ["KJ662670", "CHEMICAL", 257, 265], ["KJ662670", "SIMPLE_CHEMICAL", 257, 265], ["single-nucleotide variants", "DNA", 4, 30], ["NGS reads", "DNA", 140, 149], ["PEDV reference strain KOR/KNU-1305/2013", "DNA", 194, 233]]], ["The 5 and 3 ends of the genomes of the original feces and the P5 and P10 isolates were determined by rapid amplification of cDNA ends (RACE) as described previously .", [["feces", "ANATOMY", 48, 53], ["feces", "ORGANISM_SUBSTANCE", 48, 53], ["P5", "GENE_OR_GENE_PRODUCT", 62, 64], ["5 and 3 ends", "DNA", 4, 16], ["cDNA ends", "DNA", 124, 133], ["RACE", "DNA", 135, 139], ["the P5 and P10 isolates", "TEST", 58, 81]]], ["The full-length genomic nucleotide sequences of the KNU-141112-feces, KNU-141112-P5, and KNU-141112-P10 were deposited in GenBank under accession numbers KR873431, KR873434, and KR873435, respectively.", [["nucleotide", "CHEMICAL", 24, 34], ["nucleotide", "CHEMICAL", 24, 34], ["KNU-141112-feces", "ORGANISM", 52, 68], ["KNU-141112-P5", "CELL", 70, 83], ["KNU-141112-feces, KNU-141112-P5, and KNU-141112", "DNA", 52, 99], ["P10", "DNA", 100, 103], ["KNU-141112-feces", "SPECIES", 52, 68], ["KNU-141112-P10", "SPECIES", 89, 103], ["the KNU", "TEST", 48, 55], ["KNU", "TEST", 70, 73], ["KNU", "TEST", 89, 92], ["KR873434", "TEST", 164, 172]]], ["The S glycoprotein gene sequences of the virus isolates were also determined by the traditional Sanger method.", [["S glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 18], ["S glycoprotein gene sequences", "DNA", 4, 33], ["The S glycoprotein gene sequences", "TREATMENT", 0, 33], ["the virus isolates", "TREATMENT", 37, 55]]], ["Two overlapping cDNA fragments spanning the entire S gene of each isolate were RT-PCR amplified as described previously (Lee et al., 2010) .", [["cDNA fragments", "DNA", 16, 30], ["S gene", "DNA", 51, 57], ["Two overlapping cDNA fragments", "PROBLEM", 0, 30], ["RT-PCR", "TEST", 79, 85], ["cDNA fragments", "OBSERVATION", 16, 30]]], ["The individual cDNA amplicons were gel-purified, cloned into pGEM-T easy (Promega, Madison, WI), and sequenced in both directions using two commercial vector-specific T7 and SP6 primers and the S gene-specific primers.", [["SP6", "GENE_OR_GENE_PRODUCT", 174, 177], ["cDNA amplicons", "DNA", 15, 29], ["pGEM", "DNA", 61, 65], ["T7 and SP6 primers", "DNA", 167, 185], ["S gene", "DNA", 194, 200], ["The individual cDNA amplicons", "TREATMENT", 0, 29], ["specific T7 and SP6 primers", "TREATMENT", 158, 185]]], ["In addition, the complete structural gene sequences of the virus isolate at selected passages (KNU-141112-P3, KNU-141112-P4, KNU-141112-P20, and KNU-141112-P30) were determined by the Sanger method as described above and deposited to the Gen-Bank database under their accession numbers shown in Fig. 5 .Phylogenetic analysisThe sequences of 42 fully sequenced S genes and 25 complete genomes of PEDV isolates were independently used in sequence alignments and phylogenetic analyses.", [["KNU-141112-P3", "CELL", 95, 108], ["KNU-141112-P4", "CELL", 110, 123], ["KNU-141112-P20", "CELL", 125, 139], ["KNU-141112-P30", "CELL", 145, 159], ["PEDV isolates", "CELL", 395, 408], ["structural gene sequences", "DNA", 26, 51], ["KNU-141112", "DNA", 145, 155], ["Gen-Bank database", "DNA", 238, 255], ["S genes", "DNA", 360, 367], ["PEDV", "SPECIES", 395, 399], ["the virus isolate", "TREATMENT", 55, 72], ["KNU", "TEST", 95, 98], ["KNU", "TEST", 110, 113], ["KNU", "TEST", 125, 128], ["KNU", "TEST", 145, 148], ["Phylogenetic analysis", "TEST", 303, 324], ["The sequences", "TEST", 324, 337], ["PEDV isolates", "PROBLEM", 395, 408], ["sequence alignments", "TEST", 436, 455], ["phylogenetic analyses", "TEST", 460, 481]]], ["The multiplesequencing alignments were generated with the ClustalX 2.0 program (Thompson et al., 1997) and the percentages of nucleotide sequence divergences were further assessed with the same software program.", [["nucleotide", "CHEMICAL", 126, 136], ["multiplesequencing alignments", "DNA", 4, 33], ["nucleotide sequence divergences", "PROBLEM", 126, 157]]], ["Phylogenetic trees were constructed from the aligned nucleotide or amino acid sequences by using the neighborjoining method and subsequently subjected to bootstrap analysis with 1000 replicates in order to determine percentage reliability values on each internal node of the tree (Saitou and Nei, 1987) .", [["internal node", "ANATOMY", 254, 267], ["nucleotide", "CHEMICAL", 53, 63], ["amino acid", "CHEMICAL", 67, 77], ["nucleotide", "CHEMICAL", 53, 63], ["amino acid", "CHEMICAL", 67, 77], ["amino acid", "AMINO_ACID", 67, 77], ["internal node", "MULTI-TISSUE_STRUCTURE", 254, 267], ["Phylogenetic trees", "PROBLEM", 0, 18], ["amino acid sequences", "TREATMENT", 67, 87], ["the neighborjoining method", "TREATMENT", 97, 123], ["bootstrap analysis", "TEST", 154, 172], ["internal node", "ANATOMY", 254, 267], ["tree", "ANATOMY_MODIFIER", 275, 279]]], ["All tree figures were produced using Mega 4.0 software (Tamura et al., 2007) .Statistical analysisStudent's t test was used for all statistical analyses, and p-values of less than 0.05 were considered statistically significant.Virus isolation and in vitro characterizationWe attempted to isolate PEDV from PCR-positive clinical samples, including 50 feces and 7 intestinal homogenates on Vero cells.", [["samples", "ANATOMY", 328, 335], ["feces", "ANATOMY", 350, 355], ["intestinal homogenates", "ANATOMY", 362, 384], ["Vero cells", "ANATOMY", 388, 398], ["Virus", "ORGANISM", 227, 232], ["PEDV", "SIMPLE_CHEMICAL", 296, 300], ["feces", "ORGANISM_SUBSTANCE", 350, 355], ["intestinal homogenates", "ORGANISM_SUBSTANCE", 362, 384], ["Vero cells", "CELL", 388, 398], ["Vero cells", "CELL_LINE", 388, 398], ["PEDV", "SPECIES", 296, 300], ["Statistical analysisStudent's t test", "TEST", 78, 114], ["all statistical analyses", "TEST", 128, 152], ["p-values", "TEST", 158, 166], ["Virus isolation", "TREATMENT", 227, 242], ["PEDV", "PROBLEM", 296, 300], ["PCR", "TEST", 306, 309], ["positive clinical samples", "PROBLEM", 310, 335], ["7 intestinal homogenates on Vero cells", "PROBLEM", 360, 398], ["tree", "OBSERVATION_MODIFIER", 4, 8], ["intestinal", "ANATOMY", 362, 372], ["Vero cells", "OBSERVATION", 388, 398]]], ["One PEDV isolate designated KNU-141112 was successfully isolated from the feces of a naturally infected piglet from a commercial farm located in Kyungpook Province obtained on September 29, 2014.", [["KNU-141112", "ANATOMY", 28, 38], ["feces", "ANATOMY", 74, 79], ["piglet", "ANATOMY", 104, 110], ["KNU-141112", "CHEMICAL", 28, 38], ["KNU-141112", "CELL", 28, 38], ["feces", "ORGANISM_SUBDIVISION", 74, 79], ["piglet", "ORGANISM", 104, 110], ["piglet", "SPECIES", 104, 110], ["PEDV", "SPECIES", 4, 8], ["KNU-141112", "SPECIES", 28, 38], ["KNU", "TEST", 28, 31], ["infected piglet", "OBSERVATION", 95, 110]]], ["The KNU-141112 virus was capable of producing distinct CPEs typical for PEDV infection, such as cell fusion, syncytium, and detachment, in infected Vero cells from passage 3 (P3).", [["cell", "ANATOMY", 96, 100], ["syncytium", "ANATOMY", 109, 118], ["Vero cells", "ANATOMY", 148, 158], ["KNU-141112", "CHEMICAL", 4, 14], ["infection", "DISEASE", 77, 86], ["KNU-141112 virus", "ORGANISM", 4, 20], ["CPEs", "GENE_OR_GENE_PRODUCT", 55, 59], ["PEDV", "GENE_OR_GENE_PRODUCT", 72, 76], ["cell", "CELL", 96, 100], ["Vero cells", "CELL", 148, 158], ["infected Vero cells", "CELL_LINE", 139, 158], ["KNU-141112 virus", "SPECIES", 4, 20], ["PEDV", "SPECIES", 72, 76], ["The KNU", "TEST", 0, 7], ["virus", "PROBLEM", 15, 20], ["distinct CPEs", "PROBLEM", 46, 59], ["PEDV infection", "PROBLEM", 72, 86], ["cell fusion", "TREATMENT", 96, 107], ["syncytium", "PROBLEM", 109, 118], ["detachment", "PROBLEM", 124, 134], ["infected Vero cells", "PROBLEM", 139, 158], ["typical for", "UNCERTAINTY", 60, 71], ["PEDV infection", "OBSERVATION", 72, 86], ["cell fusion", "OBSERVATION", 96, 107], ["detachment", "OBSERVATION", 124, 134], ["infected", "OBSERVATION_MODIFIER", 139, 147], ["Vero cells", "OBSERVATION", 148, 158]]], ["We then investigated whether the isolate can be efficiently cultivated and maintained in cell culture.", [["cell", "ANATOMY", 89, 93], ["cell culture", "CELL", 89, 101], ["cell culture", "TEST", 89, 101]]], ["Thus, the isolated PEDV strain KNU-141112 was further serially passaged in Vero cells for a total of 30 passages (P1 to P30).", [["Vero cells", "ANATOMY", 75, 85], ["KNU-141112", "CHEMICAL", 31, 41], ["KNU-141112", "CHEMICAL", 31, 41], ["KNU-141112", "CELL", 31, 41], ["Vero cells", "CELL", 75, 85], ["Vero cells", "CELL_LINE", 75, 85], ["KNU-141112", "SPECIES", 31, 41], ["the isolated PEDV strain KNU", "TEST", 6, 34], ["Vero cells", "TREATMENT", 75, 85]]], ["The time of CPE onset was at 24 hpi and, accordingly, prominent CPE was observed within 48 hpi in the first 2 productive passages (P3 and P4).", [["CPE onset", "PROBLEM", 12, 21], ["prominent CPE", "PROBLEM", 54, 67], ["prominent", "OBSERVATION_MODIFIER", 54, 63], ["CPE", "OBSERVATION", 64, 67]]], ["In the later passages, visible CPE appeared at 12 hpi and became predominant by 24 hpi.", [["visible CPE", "PROBLEM", 23, 34]]], ["Virus propagation was confirmed by detecting PEDV antigens by IFA using a PEDV N protein-specific MAb.", [["Virus", "ORGANISM", 0, 5], ["PEDV antigens", "GENE_OR_GENE_PRODUCT", 45, 58], ["IFA", "SIMPLE_CHEMICAL", 62, 65], ["PEDV antigens", "PROTEIN", 45, 58], ["PEDV N protein", "PROTEIN", 74, 88], ["specific MAb", "PROTEIN", 89, 101], ["PEDV", "SPECIES", 45, 49], ["PEDV", "SPECIES", 74, 78], ["Virus propagation", "PROBLEM", 0, 17], ["a PEDV N protein", "TREATMENT", 72, 88]]], ["The distinct staining was distributed in the cytoplasm of typical syncytial cells.", [["cytoplasm", "ANATOMY", 45, 54], ["syncytial cells", "ANATOMY", 66, 81], ["cytoplasm", "ORGANISM_SUBSTANCE", 45, 54], ["syncytial cells", "CELL", 66, 81], ["syncytial cells", "CELL_TYPE", 66, 81], ["The distinct staining", "PROBLEM", 0, 21], ["typical syncytial cells", "PROBLEM", 58, 81], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["staining", "OBSERVATION", 13, 21], ["cytoplasm", "OBSERVATION_MODIFIER", 45, 54], ["typical", "OBSERVATION_MODIFIER", 58, 65], ["syncytial cells", "OBSERVATION", 66, 81]]], ["In contrast, no CPE and N-specific staining was evident in mock-inoculated Vero cells.", [["Vero cells", "ANATOMY", 75, 85], ["Vero cells", "CELL", 75, 85], ["mock-inoculated Vero cells", "CELL_LINE", 59, 85], ["CPE", "PROBLEM", 16, 19], ["specific staining", "PROBLEM", 26, 43], ["no", "UNCERTAINTY", 13, 15], ["CPE", "OBSERVATION", 16, 19], ["inoculated Vero cells", "OBSERVATION", 64, 85]]], ["Examples of CPE and corresponding IFA images in selected passages are shown in Fig. 1 .", [["CPE", "PROBLEM", 12, 15], ["corresponding IFA images", "TEST", 20, 44], ["CPE", "OBSERVATION", 12, 15]]], ["The level of viral genome in each selected passage was further assessed by real-time RT-PCR and the mean cycle threshold (Ct) value was determined to be 16.7, ranging from 15.3 (P10) to 18.7 (P5).", [["viral genome", "DNA", 13, 25], ["viral genome", "PROBLEM", 13, 25], ["PCR", "TEST", 88, 91], ["the mean cycle threshold", "TEST", 96, 120], ["Ct) value", "TEST", 122, 131], ["viral genome", "OBSERVATION", 13, 25]]], ["The infectious titer of the isolate ranged from 10 5.1 to 10 6.1 TCID 50 /ml up to P5, whereas it was determined to be approximately 10 7 TCID 50 /ml in the later passages.", [["The infectious titer", "TEST", 0, 20], ["the isolate", "TEST", 24, 35], ["infectious", "OBSERVATION", 4, 14]]], ["The peak viral titer reached 10 7.8 TCID 50 /ml (equivalent to 10 7.5 PFU/ml) or more since passage 10 ( Fig. 2A) .", [["The peak viral titer", "TEST", 0, 20]]], ["The growth kinetics study further showed that KNU-141112 replicated rapidly and efficiently in Vero cells, reaching a maximum titer >10 7 TCID 50 /ml by 24 dpi (Fig. 2B) .Antibody response and pathogenicity of KNU-141112Guinea pig antisera were collected before immunization (preimmune) and at 2 weeks after the final boost and tested for their neutralizing activity against the isolate KNU-141112 or vaccine strain.", [["Vero cells", "ANATOMY", 95, 105], ["KNU-141112", "CHEMICAL", 46, 56], ["KNU-141112", "CHEMICAL", 210, 220], ["KNU-141112", "CHEMICAL", 387, 397], ["KNU-141112", "CHEMICAL", 46, 56], ["KNU-141112", "CHEMICAL", 210, 220], ["KNU-141112", "SIMPLE_CHEMICAL", 46, 56], ["Vero cells", "CELL", 95, 105], ["KNU-141112", "CELL", 210, 220], ["pig", "ORGANISM", 227, 230], ["KNU-141112", "CELL", 387, 397], ["Vero cells", "CELL_LINE", 95, 105], ["Guinea pig", "SPECIES", 220, 230], ["KNU-141112", "SPECIES", 46, 56], ["KNU-141112", "SPECIES", 210, 220], ["pig", "SPECIES", 227, 230], ["KNU-141112", "SPECIES", 387, 397], ["The growth kinetics study", "TEST", 0, 25], ["KNU", "TEST", 46, 49], ["a maximum titer", "TEST", 116, 131], ["Antibody response", "TEST", 171, 188], ["KNU", "TEST", 210, 213], ["Guinea pig antisera", "TREATMENT", 220, 239], ["immunization (preimmune)", "TREATMENT", 262, 286], ["the final boost", "TREATMENT", 308, 323], ["the isolate KNU", "TEST", 375, 390], ["vaccine strain", "PROBLEM", 401, 415], ["Vero cells", "OBSERVATION", 95, 105]]], ["As shown in Fig. 3 , the guinea pig antisera were highly effective in inhibiting KNU-141112 infection with mean neutralizing antibody (NA) titers of 1:112, whereas the antisera at relatively low dilution fully protect Vero cells from SM98-1 infection with mean NA titers of 1:37.", [["Vero cells", "ANATOMY", 218, 228], ["KNU-141112", "CHEMICAL", 81, 91], ["infection", "DISEASE", 92, 101], ["infection", "DISEASE", 241, 250], ["KNU-141112", "CHEMICAL", 81, 91], ["guinea pig", "ORGANISM", 25, 35], ["KNU-141112", "CELL", 81, 91], ["Vero cells", "CELL", 218, 228], ["SM98-1", "GENE_OR_GENE_PRODUCT", 234, 240], ["Vero cells", "CELL_LINE", 218, 228], ["guinea pig", "SPECIES", 25, 35], ["pig", "SPECIES", 32, 35], ["KNU-141112", "SPECIES", 81, 91], ["SM98-1", "SPECIES", 234, 240], ["the guinea pig antisera", "TREATMENT", 21, 44], ["KNU", "TEST", 81, 84], ["infection", "PROBLEM", 92, 101], ["mean neutralizing antibody", "TEST", 107, 133], ["NA) titers", "TEST", 135, 145], ["the antisera", "TEST", 164, 176], ["Vero cells", "TEST", 218, 228], ["SM98", "TEST", 234, 238], ["1 infection", "PROBLEM", 239, 250], ["mean NA titers", "TEST", 256, 270], ["Vero cells", "OBSERVATION", 218, 228]]], ["In contrast, none of the pre-immune and nonimmunized sera showed neutralizing activity against either strain.", [["sera", "ANATOMY", 53, 57], ["pre-immune", "ORGANISM", 25, 35], ["sera", "ORGANISM_SUBSTANCE", 53, 57], ["the pre-immune and nonimmunized sera", "TEST", 21, 57], ["neutralizing activity", "PROBLEM", 65, 86], ["strain", "PROBLEM", 102, 108], ["neutralizing activity", "OBSERVATION", 65, 86]]], ["Taken together, our data indicated that the isolate KNU-141112 elicits potent antibody responses in immunized animals.", [["KNU-141112", "CHEMICAL", 52, 62], ["KNU-141112", "CHEMICAL", 52, 62], ["KNU-141112", "SIMPLE_CHEMICAL", 52, 62], ["KNU-141112", "SPECIES", 52, 62], ["the isolate KNU", "TEST", 40, 55]]], ["However, the antisera strongly recognized the homologous field isolate, but inefficiently the heterologous PEDV vaccine strain, suggesting the antigenic variations between the vaccine strain and field PEDVs.Antibody response and pathogenicity of KNU-141112Four piglets were challenged orally with the KNU-141112 virus, while 2 control animals were inoculated with cell culture media.", [["cell", "ANATOMY", 364, 368], ["KNU-141112", "CHEMICAL", 246, 256], ["KNU-141112", "CHEMICAL", 301, 311], ["KNU-141112", "CHEMICAL", 246, 256], ["PEDV vaccine", "ORGANISM", 107, 119], ["KNU-141112", "CELL", 246, 256], ["piglets", "ORGANISM", 261, 268], ["KNU-141112 virus", "ORGANISM", 301, 317], ["animals", "ORGANISM", 335, 342], ["cell", "CELL", 364, 368], ["piglets", "SPECIES", 261, 268], ["PEDV", "SPECIES", 107, 111], ["KNU-141112", "SPECIES", 246, 256], ["KNU-141112 virus", "SPECIES", 301, 317], ["the heterologous PEDV vaccine strain", "PROBLEM", 90, 126], ["the antigenic variations", "PROBLEM", 139, 163], ["the vaccine strain", "TREATMENT", 172, 190], ["Antibody response", "TEST", 207, 224], ["KNU", "TEST", 246, 249], ["the KNU", "TEST", 297, 304], ["cell culture media", "TREATMENT", 364, 382]]], ["Two piglets were housed together with inoculated piglets in the same room for direct contact exposure.", [["piglets", "ORGANISM", 4, 11], ["piglets", "ORGANISM", 49, 56], ["piglets", "SPECIES", 4, 11], ["piglets", "SPECIES", 49, 56]]], ["During the acclimation period, all piglets were active and had normal fecal consistency.", [["piglets", "ORGANISM", 35, 42], ["fecal", "ORGANISM_SUBSTANCE", 70, 75], ["piglets", "SPECIES", 35, 42], ["active", "OBSERVATION_MODIFIER", 48, 54], ["fecal consistency", "OBSERVATION_MODIFIER", 70, 87]]], ["PEDV-challenged piglets exhibited clinical signs including lethargy and diarrheic feces by 1 day post-inoculation (DPI) and experienced severe watery diarrhea with vomiting thereafter.", [["feces", "ANATOMY", 82, 87], ["PEDV", "CHEMICAL", 0, 4], ["lethargy", "DISEASE", 59, 67], ["diarrheic feces", "DISEASE", 72, 87], ["DPI", "CHEMICAL", 115, 118], ["watery diarrhea", "DISEASE", 143, 158], ["vomiting", "DISEASE", 164, 172], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["piglets", "ORGANISM", 16, 23], ["feces", "ORGANISM_SUBSTANCE", 82, 87], ["piglets", "SPECIES", 16, 23], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["clinical signs", "PROBLEM", 34, 48], ["lethargy", "PROBLEM", 59, 67], ["diarrheic feces", "PROBLEM", 72, 87], ["severe watery diarrhea", "PROBLEM", 136, 158], ["vomiting", "PROBLEM", 164, 172], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["watery", "OBSERVATION_MODIFIER", 143, 149], ["diarrhea", "OBSERVATION", 150, 158]]], ["PEDV-associated mortality occurred in one of the inoculated pigs at 1 DPI.", [["PEDV", "CHEMICAL", 0, 4], ["pigs", "ORGANISM", 60, 64], ["pigs", "SPECIES", 60, 64], ["PEDV", "SPECIES", 0, 4], ["pigs", "SPECIES", 60, 64], ["PEDV", "PROBLEM", 0, 4], ["mortality", "OBSERVATION", 16, 25]]], ["Contact piglets housed with the inoculated group exhibited diarrheic feces with vomiting by 2 DPI and the progression of clinical signs was similar to that of the inoculated animals.", [["feces", "ANATOMY", 69, 74], ["diarrheic feces", "DISEASE", 59, 74], ["vomiting", "DISEASE", 80, 88], ["DPI", "CHEMICAL", 94, 97], ["piglets", "ORGANISM", 8, 15], ["feces", "ORGANISM_SUBDIVISION", 69, 74], ["piglets", "SPECIES", 8, 15], ["diarrheic feces", "PROBLEM", 59, 74], ["vomiting", "PROBLEM", 80, 88], ["clinical signs", "PROBLEM", 121, 135]]], ["Furthermore, all inoculated and contact piglets were positive for PEDV, as determined by RT-PCR, by 1 or 2 DPI and shed PEDV in feces with mean Ct values of 18.7 (range 16.4-21.0) and 20.1 (range 15.4-23.1), respectively.", [["feces", "ANATOMY", 128, 133], ["DPI", "CHEMICAL", 107, 110], ["piglets", "ORGANISM", 40, 47], ["PEDV", "GENE_OR_GENE_PRODUCT", 66, 70], ["DPI", "SIMPLE_CHEMICAL", 107, 110], ["feces", "ORGANISM_SUBSTANCE", 128, 133], ["piglets", "SPECIES", 40, 47], ["PEDV", "SPECIES", 66, 70], ["PEDV", "SPECIES", 120, 124], ["PEDV", "PROBLEM", 66, 70], ["PCR", "TEST", 92, 95], ["shed PEDV in feces", "TEST", 115, 133], ["mean Ct values", "TEST", 139, 153], ["PEDV", "OBSERVATION", 120, 124]]], ["Negative control pigs remained active with normal feces and continued to be undetectable for fecal shedding of PEDV throughout the study period.Antibody response and pathogenicity of KNU-141112One piglet died from PEDV and was subsequently necropsied at 1 DPI and the remaining inoculated piglets were randomly selected for necropsy thereafter.", [["feces", "ANATOMY", 50, 55], ["fecal", "ANATOMY", 93, 98], ["piglet", "ANATOMY", 197, 203], ["KNU-141112", "CHEMICAL", 183, 193], ["KNU-141112", "CHEMICAL", 183, 193], ["pigs", "ORGANISM", 17, 21], ["feces", "ORGANISM_SUBSTANCE", 50, 55], ["fecal", "ORGANISM_SUBSTANCE", 93, 98], ["PEDV", "SIMPLE_CHEMICAL", 111, 115], ["KNU-141112", "CELL", 183, 193], ["piglet", "ORGANISM", 197, 203], ["piglets", "ORGANISM", 289, 296], ["pigs", "SPECIES", 17, 21], ["piglets", "SPECIES", 289, 296], ["pigs", "SPECIES", 17, 21], ["PEDV", "SPECIES", 111, 115], ["KNU-141112", "SPECIES", 183, 193], ["PEDV", "SPECIES", 214, 218], ["fecal shedding of PEDV", "PROBLEM", 93, 115], ["Antibody response", "TEST", 144, 161], ["KNU", "TEST", 183, 186], ["PEDV", "PROBLEM", 214, 218], ["active", "OBSERVATION_MODIFIER", 31, 37], ["feces", "OBSERVATION", 50, 55], ["undetectable", "OBSERVATION", 76, 88], ["piglet", "OBSERVATION_MODIFIER", 197, 203], ["died", "OBSERVATION", 204, 208], ["PEDV", "OBSERVATION", 214, 218]]], ["All contact and control animals were euthanized at the end of the study for postmortem assessments.", [["animals", "ORGANISM", 24, 31], ["the study", "TEST", 62, 71], ["postmortem assessments", "TEST", 76, 98]]], ["All inoculated and na\u00efve contact pigs macroscopically displayed typical PED-like lesions.", [["PED-like lesions", "ANATOMY", 72, 88], ["pigs", "ORGANISM", 33, 37], ["PED-like lesions", "PATHOLOGICAL_FORMATION", 72, 88], ["pigs", "SPECIES", 33, 37], ["typical PED-like lesions", "PROBLEM", 64, 88], ["inoculated", "OBSERVATION", 4, 14], ["typical", "OBSERVATION_MODIFIER", 64, 71], ["PED", "OBSERVATION_MODIFIER", 72, 75], ["-like", "OBSERVATION_MODIFIER", 75, 80], ["lesions", "OBSERVATION", 81, 88]]], ["The small intestine was dilated and accumulated with yellow fluid and its wall was thin and transparent, due to the villous atrophy (Fig. 4, panel A) .", [["small intestine", "ANATOMY", 4, 19], ["yellow fluid", "ANATOMY", 53, 65], ["wall", "ANATOMY", 74, 78], ["villous", "ANATOMY", 116, 123], ["villous atrophy", "DISEASE", 116, 131], ["small intestine", "ORGAN", 4, 19], ["fluid", "ORGANISM_SUBSTANCE", 60, 65], ["wall", "TISSUE", 74, 78], ["villous", "TISSUE", 116, 123], ["dilated", "PROBLEM", 24, 31], ["yellow fluid", "PROBLEM", 53, 65], ["the villous atrophy", "PROBLEM", 112, 131], ["small intestine", "ANATOMY", 4, 19], ["dilated", "OBSERVATION", 24, 31], ["yellow fluid", "OBSERVATION", 53, 65], ["wall", "ANATOMY_MODIFIER", 74, 78], ["thin", "OBSERVATION_MODIFIER", 83, 87], ["transparent", "OBSERVATION_MODIFIER", 92, 103], ["villous", "ANATOMY_MODIFIER", 116, 123], ["atrophy", "OBSERVATION", 124, 131]]], ["The stomach was distended and filled with curdled and undigested milk.", [["stomach", "ANATOMY", 4, 11], ["milk", "ANATOMY", 65, 69], ["stomach", "ORGAN", 4, 11], ["milk", "ORGANISM_SUBSTANCE", 65, 69], ["distended", "PROBLEM", 16, 25], ["stomach", "ANATOMY", 4, 11], ["distended", "OBSERVATION", 16, 25], ["filled", "OBSERVATION", 30, 36], ["undigested milk", "OBSERVATION", 54, 69]]], ["In contrast, the other intestinal organs appeared grossly normal.", [["intestinal organs", "ANATOMY", 23, 40], ["intestinal organs", "ORGAN", 23, 40], ["intestinal organs", "ANATOMY", 23, 40], ["grossly", "OBSERVATION_MODIFIER", 50, 57], ["normal", "OBSERVATION", 58, 64]]], ["Microscopic intestinal observations consistent with viral enteritis were developed in all inoculated and contact piglets, which included vacuolation of small intestinal enterocytes and shortening and fusion of small intestinal villi (Fig. 4, panels B and C) .", [["intestinal", "ANATOMY", 12, 22], ["intestinal enterocytes", "ANATOMY", 158, 180], ["intestinal villi", "ANATOMY", 216, 232], ["viral enteritis", "DISEASE", 52, 67], ["intestinal", "ORGAN", 12, 22], ["piglets", "ORGANISM", 113, 120], ["intestinal enterocytes", "MULTI-TISSUE_STRUCTURE", 158, 180], ["intestinal villi", "MULTI-TISSUE_STRUCTURE", 216, 232], ["piglets", "SPECIES", 113, 120], ["Microscopic intestinal observations", "TEST", 0, 35], ["viral enteritis", "PROBLEM", 52, 67], ["small intestinal enterocytes", "PROBLEM", 152, 180], ["shortening", "PROBLEM", 185, 195], ["fusion", "TREATMENT", 200, 206], ["small intestinal villi", "PROBLEM", 210, 232], ["intestinal", "ANATOMY", 12, 22], ["consistent with", "UNCERTAINTY", 36, 51], ["viral", "OBSERVATION_MODIFIER", 52, 57], ["enteritis", "OBSERVATION", 58, 67], ["small", "OBSERVATION_MODIFIER", 152, 157], ["intestinal enterocytes", "ANATOMY", 158, 180], ["shortening", "OBSERVATION_MODIFIER", 185, 195], ["fusion", "OBSERVATION", 200, 206], ["small", "OBSERVATION_MODIFIER", 210, 215], ["intestinal villi", "ANATOMY", 216, 232]]], ["Similar microscopic lesions were continuously present in the challenged and contact pigs through 4 DPI.", [["lesions", "ANATOMY", 20, 27], ["DPI", "CHEMICAL", 99, 102], ["lesions", "PATHOLOGICAL_FORMATION", 20, 27], ["pigs", "ORGANISM", 84, 88], ["pigs", "SPECIES", 84, 88], ["Similar microscopic lesions", "PROBLEM", 0, 27], ["microscopic", "OBSERVATION_MODIFIER", 8, 19], ["lesions", "OBSERVATION", 20, 27]]], ["Furthermore, both IFA and IHC staining revealed that the viral antigen was predominantly detected in the cytoplasm of epithelial cells on atrophied villi in all segments of the small intestines (Fig. 4 , panels D-F).", [["cytoplasm", "ANATOMY", 105, 114], ["epithelial cells", "ANATOMY", 118, 134], ["atrophied villi", "ANATOMY", 138, 153], ["small intestines", "ANATOMY", 177, 193], ["IHC", "GENE_OR_GENE_PRODUCT", 26, 29], ["cytoplasm", "ORGANISM_SUBSTANCE", 105, 114], ["epithelial cells", "CELL", 118, 134], ["atrophied villi", "TISSUE", 138, 153], ["intestines", "ORGAN", 183, 193], ["viral antigen", "PROTEIN", 57, 70], ["epithelial cells", "CELL_TYPE", 118, 134], ["both IFA", "TEST", 13, 21], ["IHC staining", "TEST", 26, 38], ["the viral antigen", "TEST", 53, 70], ["epithelial cells", "PROBLEM", 118, 134], ["atrophied villi", "PROBLEM", 138, 153], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["epithelial cells", "OBSERVATION", 118, 134], ["atrophied villi", "OBSERVATION", 138, 153], ["all segments", "ANATOMY_MODIFIER", 157, 169], ["small intestines", "ANATOMY", 177, 193]]], ["These finding are comparable to those in pigs naturally or experimentally infected with virulent strains of PEDV (Debouck et isolates.", [["pigs", "ORGANISM", 41, 45], ["PEDV", "ORGANISM", 108, 112], ["Debouck et isolates", "ORGANISM", 114, 133], ["pigs", "SPECIES", 41, 45], ["pigs", "SPECIES", 41, 45], ["PEDV", "SPECIES", 108, 112], ["PEDV", "PROBLEM", 108, 112]]], ["PEDV-specific CPEs were observed daily and were photographed at 24 hpi using an inverted microscope at a magnification of 200\u00d7 (first panels).", [["CPEs", "ANATOMY", 14, 18], ["PEDV", "CHEMICAL", 0, 4], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["CPEs", "CELL", 14, 18], ["PEDV", "PROTEIN", 0, 4], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["specific CPEs", "PROBLEM", 5, 18], ["an inverted microscope", "TEST", 77, 99]]], ["For immunostaining, infected cells were fixed at 24 hpi and incubated with MAb against the N protein, followed by Alexa green-conjugated goat anti-mouse secondary antibody (second panels).", [["cells", "ANATOMY", 29, 34], ["Alexa green", "CHEMICAL", 114, 125], ["Alexa green", "CHEMICAL", 114, 125], ["cells", "CELL", 29, 34], ["Alexa green", "SIMPLE_CHEMICAL", 114, 125], ["infected cells", "CELL_TYPE", 20, 34], ["N protein", "PROTEIN", 91, 100], ["Alexa green-conjugated goat anti-mouse secondary antibody", "PROTEIN", 114, 171], ["goat", "SPECIES", 137, 141], ["anti-mouse", "SPECIES", 142, 152], ["goat", "SPECIES", 137, 141], ["immunostaining", "PROBLEM", 4, 18], ["infected cells", "PROBLEM", 20, 34], ["MAb", "TREATMENT", 75, 78], ["the N protein", "TEST", 87, 100], ["Alexa green", "TEST", 114, 125], ["infected cells", "OBSERVATION", 20, 34]]], ["The cells were then counterstained with DAPI (third panels) and examined using a fluorescence microscope at 200\u00d7 magnification.", [["cells", "ANATOMY", 4, 9], ["DAPI", "CHEMICAL", 40, 44], ["cells", "CELL", 4, 9], ["DAPI", "SIMPLE_CHEMICAL", 40, 44], ["DAPI (third panels", "TREATMENT", 40, 58], ["a fluorescence microscope", "TEST", 79, 104]]], ["Neither macroscopic nor microscopic intestinal lesions were observed in the negative control piglets during the experiment.Complete genomic characterization of KNU-141112Entire genome sequence data of the original fecal sample (KNU-141112-feces) and cell culture-passaged KNU-141112-P5 and -P10 viruses were determined using the NGS technology.", [["intestinal lesions", "ANATOMY", 36, 54], ["fecal sample", "ANATOMY", 214, 226], ["KNU-141112-feces", "ANATOMY", 228, 244], ["cell", "ANATOMY", 250, 254], ["KNU-141112", "CHEMICAL", 160, 170], ["KNU-141112", "CHEMICAL", 228, 238], ["KNU-141112", "CHEMICAL", 160, 170], ["intestinal lesions", "PATHOLOGICAL_FORMATION", 36, 54], ["piglets", "ORGANISM", 93, 100], ["KNU-141112", "CELL", 160, 170], ["KNU-141112-feces", "CELL", 228, 244], ["cell", "CELL", 250, 254], ["KNU-141112-P5", "CELL", 272, 285], ["-P10 viruses", "ORGANISM", 290, 302], ["piglets", "SPECIES", 93, 100], ["KNU-141112", "SPECIES", 160, 170], ["KNU-141112-feces", "SPECIES", 228, 244], ["microscopic intestinal lesions", "PROBLEM", 24, 54], ["KNU", "TEST", 160, 163], ["Entire genome sequence data", "TEST", 170, 197], ["the original fecal sample", "TEST", 201, 226], ["KNU", "TEST", 228, 231], ["cell culture", "TEST", 250, 262], ["KNU", "TEST", 272, 275], ["P10 viruses", "PROBLEM", 291, 302], ["the NGS technology", "TEST", 325, 343], ["microscopic", "OBSERVATION_MODIFIER", 24, 35], ["intestinal", "ANATOMY", 36, 46], ["lesions", "OBSERVATION", 47, 54]]], ["The full-length genome of KOR/KNU-1305/2013 PEDV was used as the initial reference for each NGS read and the individual complete genome sequences were successfully obtained by the assembly of respective NGS reads.", [["KOR", "GENE_OR_GENE_PRODUCT", 26, 29], ["full-length genome", "DNA", 4, 22], ["KOR", "DNA", 26, 29], ["KNU-1305/2013 PEDV", "DNA", 30, 48], ["NGS reads", "DNA", 203, 212], ["PEDV", "PROBLEM", 44, 48], ["each NGS", "TEST", 87, 95]]], ["The 5 and 3 ends of their genomes were also sequenced by RACE.", [["5 and 3 ends", "DNA", 4, 16], ["RACE", "DNA", 57, 61], ["genomes", "OBSERVATION", 26, 33]]], ["All three genomes were 28,038 nucleotides (nt) in length, excluding the 3 poly(A) tail and exhibited the genomic organization typical of all previously sequenced PEDV strains, consisting of the 292-nt 5 UTR, the 20,345-nt ORF1a/1b (nt 293 to 12,601 for 1a and nt 12,601 to 20,637 for 1b), the 4161-nt S gene (nt 20,634 to 24,794), the 675-nt ORF3 (nt 24,794 to 25,468), the 231-nt E gene (nt 25,449 to 25,679) , the 681-nt membrane (M) gene (nt 25,687 to 26,367), the 1326-nt N gene (nt 26,379 to 27,704), and the 334- Fig. 3 .", [["nucleotides", "CHEMICAL", 30, 41], ["PEDV", "GENE_OR_GENE_PRODUCT", 162, 166], ["membrane", "CELLULAR_COMPONENT", 423, 431], ["poly(A) tail", "DNA", 74, 86], ["292-nt 5 UTR", "DNA", 194, 206], ["20,345-nt ORF1a/1b", "DNA", 212, 230], ["nt 293 to 12,601 for 1a", "DNA", 232, 255], ["nt 12,601 to 20,637", "DNA", 260, 279], ["4161-nt S gene", "DNA", 293, 307], ["nt 20,634 to 24,794", "DNA", 309, 328], ["675-nt ORF3", "DNA", 335, 346], ["nt 24,794 to 25,468", "DNA", 348, 367], ["231-nt E gene", "DNA", 374, 387], ["nt 25,449 to 25,679", "DNA", 389, 408], ["681-nt membrane (M) gene", "DNA", 416, 440], ["nt 25,687 to 26,367", "DNA", 442, 461], ["1326-nt N gene", "DNA", 468, 482], ["nt 26,379 to 27,704", "DNA", 484, 503], ["334- Fig. 3", "DNA", 514, 525], ["nucleotides (nt) in length", "TEST", 30, 56], ["all previously sequenced PEDV strains", "PROBLEM", 137, 174], ["nt ORF1a", "TEST", 219, 227], ["nt", "TEST", 232, 234], ["nt", "TEST", 260, 262], ["nt S gene", "TEST", 298, 307], ["nt", "TEST", 309, 311], ["nt ORF3", "TEST", 339, 346], ["nt", "TEST", 348, 350], ["nt E gene", "TEST", 378, 387], ["nt", "TEST", 389, 391], ["nt", "TEST", 442, 444], ["nt", "TEST", 484, 486], ["tail", "ANATOMY", 82, 86]]], ["Virus-neutralizing antibody titers in the sera of guinea pigs inoculated with a PEDV KNU-141112 isolate.", [["sera", "ANATOMY", 42, 46], ["PEDV KNU-141112", "CHEMICAL", 80, 95], ["Virus", "ORGANISM", 0, 5], ["sera", "ORGANISM_SUBSTANCE", 42, 46], ["guinea pigs", "ORGANISM", 50, 61], ["KNU-141112 isolate", "CELL", 85, 103], ["guinea pigs", "SPECIES", 50, 61], ["guinea pigs", "SPECIES", 50, 61], ["PEDV KNU-141112", "SPECIES", 80, 95], ["Virus", "TEST", 0, 5], ["neutralizing antibody titers", "TEST", 6, 34], ["guinea pigs", "TREATMENT", 50, 61], ["a PEDV KNU", "TEST", 78, 88], ["neutralizing antibody", "OBSERVATION", 6, 27]]], ["Guinea pigs were immunized twice with inactivated KNU-141112-P10 virus by subcutaneous injection.", [["subcutaneous", "ANATOMY", 74, 86], ["KNU-141112", "CHEMICAL", 50, 60], ["pigs", "ORGANISM", 7, 11], ["KNU-141112-P10 virus", "ORGANISM", 50, 70], ["Guinea pigs", "SPECIES", 0, 11], ["KNU-141112-P10 virus", "SPECIES", 50, 70], ["Guinea pigs", "TREATMENT", 0, 11]]], ["Blood samples were collected prior to immunization and at 2 weeks after the second immunization and subjected to the virus neutralization assay using homologous (KNU-141112; solid circles) and heterologous (SM98-1; solid diamonds) strains.", [["Blood samples", "ANATOMY", 0, 13], ["KNU-141112", "CHEMICAL", 162, 172], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13], ["immunization", "TREATMENT", 38, 50], ["the second immunization", "TREATMENT", 72, 95], ["the virus neutralization assay", "TEST", 113, 143], ["KNU", "TEST", 162, 165], ["heterologous", "TEST", 193, 205], ["SM98", "TEST", 207, 211], ["solid diamonds) strains", "PROBLEM", 215, 238]]], ["Neutralizing antibody titers for individual infected animals were spotted as a log2 scale.", [["Neutralizing antibody titers", "TEST", 0, 28], ["individual infected animals", "PROBLEM", 33, 60], ["a log2 scale", "TEST", 77, 89]]], ["Values are representative of the mean from three independent experiments in duplicate and error bars denote standard deviations. nt 3 UTR.", [["nt 3 UTR", "DNA", 129, 137], ["standard deviations", "PROBLEM", 108, 127], ["standard deviations", "OBSERVATION", 108, 127]]], ["The slippery heptamer sequence, TTTAAAC, followed by a stem-loop structure was present at the 3 end of ORF1a in the PEDV genome, which is a potential signal for a ribosomal frame shift during translation to generate the pp1ab.Complete genomic characterization of KNU-141112The complete genome sequences of all three viruses were compared, and the results are summarized in Table 1 .", [["ribosomal", "ANATOMY", 163, 172], ["KNU-141112", "CHEMICAL", 263, 273], ["KNU-141112", "CHEMICAL", 263, 273], ["ORF1a", "GENE_OR_GENE_PRODUCT", 103, 108], ["PEDV", "GENE_OR_GENE_PRODUCT", 116, 120], ["ribosomal", "CELLULAR_COMPONENT", 163, 172], ["pp1ab", "GENE_OR_GENE_PRODUCT", 220, 225], ["KNU-141112", "CELL", 263, 273], ["slippery heptamer sequence", "DNA", 4, 30], ["ORF1a", "PROTEIN", 103, 108], ["PEDV genome", "DNA", 116, 127], ["pp1ab", "PROTEIN", 220, 225], ["KNU-141112", "SPECIES", 263, 273], ["The slippery heptamer sequence", "TREATMENT", 0, 30], ["TTTAAAC", "TREATMENT", 32, 39], ["a stem-loop structure", "TREATMENT", 53, 74], ["KNU", "TEST", 263, 266], ["slippery heptamer", "OBSERVATION", 4, 21], ["stem", "ANATOMY", 55, 59], ["PEDV genome", "ANATOMY", 116, 127]]], ["Compared to the KNU-141112-feces, KNU-141112-P5 showed one different nt at position 21,756 resulting in one amino acid (aa) change (Leu to Phe) in the S protein, while KNU-141112-P10 gained two additional nt changes at positions 21,448 and 24,492 causing two aa mutations located in the S protein.", [["KNU-141112-feces", "ANATOMY", 16, 32], ["KNU-141112", "CHEMICAL", 16, 26], ["KNU-141112-P5", "CHEMICAL", 34, 47], ["amino acid", "CHEMICAL", 108, 118], ["Phe", "CHEMICAL", 139, 142], ["KNU-141112-P5", "CHEMICAL", 34, 47], ["amino acid", "CHEMICAL", 108, 118], ["Leu", "CHEMICAL", 132, 135], ["Phe", "CHEMICAL", 139, 142], ["amino acid", "AMINO_ACID", 108, 118], ["Phe", "AMINO_ACID", 139, 142], ["KNU-141112-P5", "DNA", 34, 47], ["S protein", "PROTEIN", 151, 160], ["KNU", "PROTEIN", 168, 171], ["141112", "PROTEIN", 172, 178], ["S protein", "PROTEIN", 287, 296], ["KNU-141112", "SPECIES", 16, 26], ["the KNU", "TEST", 12, 19], ["KNU", "TEST", 34, 37], ["one amino acid", "TEST", 104, 118], ["the S protein", "TEST", 147, 160], ["KNU", "TEST", 168, 171], ["two additional nt changes", "PROBLEM", 190, 215], ["two aa mutations", "PROBLEM", 255, 271], ["aa mutations", "OBSERVATION", 259, 271]]], ["The full-length S genes of the original feces and KNU-141112 viruses at selected passages (P3, P4, P5, P10, P20, and P30) were also sequenced using the traditional sequencing method.", [["feces", "ANATOMY", 40, 45], ["feces", "ORGANISM", 40, 45], ["KNU-141112 viruses", "ORGANISM", 50, 68], ["P5", "GENE_OR_GENE_PRODUCT", 99, 101], ["P20", "GENE_OR_GENE_PRODUCT", 108, 111], ["P30", "GENE_OR_GENE_PRODUCT", 117, 120], ["full-length S genes", "DNA", 4, 23], ["P3", "DNA", 91, 93], ["P4", "DNA", 95, 97], ["P5", "DNA", 99, 101], ["P10", "DNA", 103, 106], ["P20", "DNA", 108, 111], ["P30", "DNA", 117, 120], ["KNU-141112 viruses", "SPECIES", 50, 68], ["KNU", "TEST", 50, 53], ["viruses", "PROBLEM", 61, 68], ["P4", "TEST", 95, 97], ["P5", "TEST", 99, 101], ["P10", "TEST", 103, 106], ["P20", "TEST", 108, 111], ["the traditional sequencing method", "TEST", 148, 181]]], ["The S protein sequences of KNU-141112-feces, -P5, and -P10 were completely identical to those determined by NGS.", [["KNU-141112", "CHEMICAL", 27, 37], ["-P5", "CELL", 45, 48], ["S protein sequences", "DNA", 4, 23], ["KNU-141112-feces, -P5, and -P10", "DNA", 27, 58], ["The S protein sequences", "TEST", 0, 23], ["KNU", "TEST", 27, 30], ["feces", "TEST", 38, 43], ["NGS", "TEST", 108, 111]]], ["One nt change present in the S gene of KNU-141112-P5 had been acquired since passage 3 (KNU-141112-P3).", [["KNU-141112", "CHEMICAL", 39, 49], ["S gene", "DNA", 29, 35], ["KNU", "DNA", 39, 42], ["141112", "DNA", 43, 49], ["P5", "DNA", 50, 52], ["P3", "DNA", 99, 101], ["One nt change", "PROBLEM", 0, 13], ["KNU", "TEST", 39, 42], ["KNU", "TEST", 88, 91], ["nt", "OBSERVATION_MODIFIER", 4, 6], ["change", "OBSERVATION", 7, 13]]], ["A total of three nt mutations, identified at passage 10 compared to the feces, were sustained through passage 30 (KNU-141112-30) .", [["feces", "ANATOMY", 72, 77], ["KNU-141112-30", "CHEMICAL", 114, 127], ["KNU-141112-30", "CHEMICAL", 114, 127], ["feces", "ORGANISM_SUBDIVISION", 72, 77], ["three nt mutations", "PROBLEM", 11, 29], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["In addition, compared to KNU-141112-P10, we were able to detect two independent mutations at positions 24,869 and 25,656, resulting in amino acid changes in ORF3 (Asp to Tyr) and E (Pro to Ser) of KNU-141112-P20, respectively, which were maintained at passage 30.", [["KNU-141112", "CHEMICAL", 25, 35], ["amino acid", "CHEMICAL", 135, 145], ["KNU-141112-P10", "CHEMICAL", 25, 39], ["amino acid", "CHEMICAL", 135, 145], ["Asp", "CHEMICAL", 163, 166], ["Tyr", "CHEMICAL", 170, 173], ["Pro", "CHEMICAL", 182, 185], ["Ser", "CHEMICAL", 189, 192], ["KNU-141112-P20", "CHEMICAL", 197, 211], ["amino acid", "AMINO_ACID", 135, 145], ["ORF3", "GENE_OR_GENE_PRODUCT", 157, 161], ["Tyr", "AMINO_ACID", 170, 173], ["ORF3", "DNA", 157, 161], ["KNU", "TEST", 25, 28], ["amino acid changes", "PROBLEM", 135, 153], ["Asp", "TEST", 163, 166], ["KNU", "TEST", 197, 200], ["amino acid", "OBSERVATION", 135, 145]]], ["Altogether, our results revealed that the PEDV isolate KNU-141112 is genetically stable during serial passages in cell culture.Complete genomic characterization of KNU-141112The entire genome sequences of PEDVs determined in this study were further compared to those of 3 other Korean and 8 non-Korean PEDV strains available in GenBank, and the nucleotide homology and difference data are described in Table 2 .", [["cell culture", "ANATOMY", 114, 126], ["KNU-141112", "CHEMICAL", 55, 65], ["KNU-141112", "CHEMICAL", 164, 174], ["KNU-141112", "CHEMICAL", 164, 174], ["KNU-141112", "CELL", 55, 65], ["cell culture", "CELL", 114, 126], ["KNU-141112", "CELL", 164, 174], ["PEDVs", "GENE_OR_GENE_PRODUCT", 205, 210], ["PEDVs", "DNA", 205, 210], ["KNU-141112", "SPECIES", 55, 65], ["KNU-141112", "SPECIES", 164, 174], ["PEDV", "SPECIES", 302, 306], ["the PEDV isolate KNU", "TEST", 38, 58], ["serial passages in cell culture", "TEST", 95, 126], ["KNU", "TEST", 164, 167], ["this study", "TEST", 225, 235], ["8 non-Korean PEDV strains", "TREATMENT", 289, 314], ["stable", "OBSERVATION_MODIFIER", 81, 87]]], ["KNU-141112 isolates (feces, P5, and P10) had the highest nucleotide identity (99.9%) with the Korean re-emergent strain KOR-KNU-1305 and US strains, IN17846 and MN, showing 8 to 46 different nt at the genomic level.", [["feces", "ANATOMY", 21, 26], ["KNU-141112", "CHEMICAL", 0, 10], ["nucleotide", "CHEMICAL", 57, 67], ["nucleotide", "CHEMICAL", 57, 67], ["KNU-141112", "GENE_OR_GENE_PRODUCT", 0, 10], ["feces", "ORGANISM_SUBSTANCE", 21, 26], ["P5", "GENE_OR_GENE_PRODUCT", 28, 30], ["KNU-1305", "CELL", 124, 132], ["US strains", "CELL", 137, 147], ["IN17846", "CELL", 149, 156], ["MN", "CELL", 161, 163], ["KNU-141112", "SPECIES", 0, 10], ["Korean re-emergent strain KOR-KNU-1305", "SPECIES", 94, 132], ["KNU", "TEST", 0, 3], ["isolates", "TEST", 11, 19], ["feces", "TEST", 21, 26], ["P5", "TEST", 28, 30], ["KNU", "TEST", 124, 127], ["US strains", "TEST", 137, 147], ["MN", "TEST", 161, 163]]], ["All three viruses were genetically distinct from the Korean vaccine strains, SM98-1 and DR-13, and the prototype CV777 strain and exhibited relatively low nucleotide identity ranging from 96.3% to 96.8%.", [["nucleotide", "CHEMICAL", 155, 165], ["nucleotide", "CHEMICAL", 155, 165], ["SM98-1", "ORGANISM", 77, 83], ["DR-13", "ORGANISM", 88, 93], ["CV777 strain", "ORGANISM", 113, 125], ["DR-13", "SPECIES", 88, 93], ["All three viruses", "PROBLEM", 0, 17], ["the Korean vaccine strains", "TEST", 49, 75], ["SM98", "TEST", 77, 81], ["DR", "TEST", 88, 90], ["relatively low nucleotide identity", "PROBLEM", 140, 174], ["viruses", "OBSERVATION", 10, 17]]], ["By alignment of the global PEDV strains, a single-nucleotide insertion between nucleotides 20,204 and 20,205 has been previously identified in one Chinese AH2012 and three US strains, Table 1 Nucleotide and amino acid changes of KNU-141112 during serial passages in cell culture.Genome region (nucleotide length)Nucleotide Amino acid Position feces P3 P4 P5 P10 P20 P30 Position feces P3 P4 P5 P10 P20 P30 5 UTR (292) -a -N D b ND --ND ND --ND ND --ND ND ORF1a (12,354) --ND ND --ND ND --ND ND --ND ND ORF1ab (20,345) --N D ND --ND ND --ND ND --ND ND S (4,161) 21448 A A A A C C C 272 K K K K T T T 21756 C T T T T T TGenome region (nucleotide length)resulting in the shorter pp1ab protein in length (Chen et al., 2014) .", [["cell culture", "ANATOMY", 266, 278], ["nucleotide", "CHEMICAL", 50, 60], ["amino acid", "CHEMICAL", 207, 217], ["KNU-141112", "CHEMICAL", 229, 239], ["nucleotide", "CHEMICAL", 294, 304], ["Amino acid", "CHEMICAL", 323, 333], ["nucleotide", "CHEMICAL", 50, 60], ["nucleotides", "CHEMICAL", 79, 90], ["amino acid", "CHEMICAL", 207, 217], ["KNU-141112", "CHEMICAL", 229, 239], ["nucleotide", "CHEMICAL", 294, 304], ["Amino acid", "CHEMICAL", 323, 333], ["nucleotide", "CHEMICAL", 633, 643], ["amino acid", "AMINO_ACID", 207, 217], ["cell culture", "CELL", 266, 278], ["pp1ab", "GENE_OR_GENE_PRODUCT", 676, 681], ["nucleotides 20,204 and 20,205", "DNA", 79, 108], ["Genome region", "DNA", 279, 292], ["P3 P4 P5 P10 P20 P30 5 UTR", "DNA", 385, 411], ["pp1ab protein", "PROTEIN", 676, 689], ["Chinese AH2012", "SPECIES", 147, 161], ["KNU-141112", "SPECIES", 229, 239], ["the global PEDV strains", "PROBLEM", 16, 39], ["a single-nucleotide insertion between nucleotides", "TREATMENT", 41, 90], ["three US strains", "TEST", 166, 182], ["amino acid changes", "TEST", 207, 225], ["KNU", "TEST", 229, 232], ["serial passages in cell culture", "TEST", 247, 278], ["Genome region (nucleotide length)", "TREATMENT", 279, 312], ["Nucleotide Amino acid Position feces P3 P4 P5 P10", "TEST", 312, 361], ["Position feces", "TEST", 370, 384], ["ORF1ab", "TEST", 502, 508], ["C", "TEST", 579, 580], ["K K", "TEST", 585, 588], ["K", "TEST", 589, 590], ["K", "TEST", 591, 592], ["T", "TEST", 593, 594], ["T", "TEST", 595, 596], ["T", "TEST", 597, 598], ["C", "TEST", 605, 606], ["T", "TEST", 607, 608], ["T", "TEST", 609, 610], ["T", "TEST", 611, 612], ["nucleotide length", "TEST", 633, 650], ["global", "OBSERVATION_MODIFIER", 20, 26], ["PEDV strains", "OBSERVATION", 27, 39]]], ["However, none of the genomes of the three PEDVs included such an insertion, and this result was further confirmed by the traditional Sanger sequencing method (data not shown).Genome region (nucleotide length)In agreement with previous results (Lee et al., 2010; Lee and Lee, 2014; Lee et al., 2014a,b) , the full-length S gene-based phylogenetic tree revealed that the global PEDV strains were clearly defined into 2 separate clusters, designated genogroup 1 (G1; classical) and genogroup 2 (G2; field epidemic).", [["PEDVs", "CANCER", 42, 47], ["PEDV", "GENE_OR_GENE_PRODUCT", 376, 380], ["PEDVs", "DNA", 42, 47], ["Genome region", "DNA", 175, 188], ["S gene", "DNA", 320, 326], ["PEDV", "SPECIES", 376, 380], ["an insertion", "TREATMENT", 62, 74], ["the full-length S gene", "TEST", 304, 326], ["the global PEDV strains", "PROBLEM", 365, 388]]], ["All original feces and passaged PEDV viruses through passages 30 were classified into subgroup 2b along with the recent Korean field isolates, which were most closely clustered together with the emergent US strains in an adjacent clade with the same subgroup.", [["feces", "ANATOMY", 13, 18], ["feces", "ORGANISM_SUBSTANCE", 13, 18], ["PEDV viruses", "ORGANISM", 32, 44], ["PEDV", "SPECIES", 32, 36], ["the emergent US strains", "TEST", 191, 214], ["feces", "OBSERVATION", 13, 18]]], ["Subsequent phylogenetic analysis of the S1 region showed the same grouping structure as the S gene-based tree (data not shown).", [["S1 region", "DNA", 40, 49], ["S gene", "DNA", 92, 98], ["Subsequent phylogenetic analysis", "TEST", 0, 32], ["S1", "ANATOMY", 40, 42], ["tree", "ANATOMY_MODIFIER", 105, 109]]], ["In addition, phylogenetic analysis based on the entire genome sequences demonstrated that strain KNU-141112 is grouped within the same cluster with the recent Korean and US stains (Fig. 5B ).DiscussionIn Korea, three PEDV strains, SM98-1, DR-13, and Chinju99, were initially isolated almost two decades ago in Korea.", [["KNU-141112", "CHEMICAL", 97, 107], ["KNU-141112", "CELL", 97, 107], ["SM98-1", "ORGANISM", 231, 237], ["DR-13", "GENE_OR_GENE_PRODUCT", 239, 244], ["Chinju99", "GENE_OR_GENE_PRODUCT", 250, 258], ["entire genome sequences", "DNA", 48, 71], ["KNU-141112", "SPECIES", 97, 107], ["phylogenetic analysis", "TEST", 13, 34], ["the entire genome sequences", "TEST", 44, 71], ["strain KNU", "TEST", 90, 100], ["US stains", "TEST", 170, 179], ["three PEDV strains", "TEST", 211, 229], ["SM98", "TEST", 231, 235], ["DR", "TEST", 239, 241]]], ["Genetic and phylogenetic analyses revealed that SM98-1 and DR-13 belong to the classical group 1, whereas Chinju99 is classified into the field epidemic group 2.", [["SM98-1", "GENE_OR_GENE_PRODUCT", 48, 54], ["DR-13", "GENE_OR_GENE_PRODUCT", 59, 64], ["Chinju99", "GENE_OR_GENE_PRODUCT", 106, 114], ["SM98-1 and DR-13", "DNA", 48, 64], ["Chinju99", "DNA", 106, 114], ["Genetic and phylogenetic analyses", "TEST", 0, 33], ["SM98", "TEST", 48, 52], ["DR", "TEST", 59, 61]]], ["Of these, only SM98-1 and DR-13 isolates can be grown in cell culture and, accordingly, have been used as commercial vaccine seeds.", [["cell culture", "ANATOMY", 57, 69], ["SM98-1", "GENE_OR_GENE_PRODUCT", 15, 21], ["DR-13", "GENE_OR_GENE_PRODUCT", 26, 31], ["cell culture", "CELL", 57, 69], ["SM98", "TEST", 15, 19], ["DR", "TEST", 26, 28], ["cell culture", "TEST", 57, 69], ["commercial vaccine seeds", "TREATMENT", 106, 130]]], ["Since 2008, we have been monitoring the genetic diversity of PEDV prevalent in the field based on the S gene.", [["PEDV", "CHEMICAL", 61, 65], ["PEDV", "CANCER", 61, 65], ["S gene", "DNA", 102, 108], ["PEDV", "SPECIES", 61, 65], ["PEDV", "PROBLEM", 61, 65], ["PEDV", "OBSERVATION", 61, 65]]], ["Our data demonstrated the existence of antigenic and genetic variations between vaccine and field strains, exhibiting a more than 10% amino acid difference in the S1 domain (Lee et al., 2010; Lee and Lee, 2014; Oh et al., 2014) .", [["amino acid", "CHEMICAL", 134, 144], ["amino acid", "CHEMICAL", 134, 144], ["amino acid", "AMINO_ACID", 134, 144], ["S1 domain", "PROTEIN", 163, 172], ["Our data", "TEST", 0, 8], ["antigenic and genetic variations between vaccine and field strains", "PROBLEM", 39, 105], ["10% amino acid difference in the S1 domain", "PROBLEM", 130, 172], ["S1", "ANATOMY", 163, 165]]], ["This may be one of the reasons for the incomplete efficacy of current vaccines in Korea, suggesting that the isolation of field PEDV is required for the development of a next-generation vaccine.", [["PEDV", "CHEMICAL", 128, 132], ["PEDV", "SPECIES", 128, 132], ["current vaccines", "TREATMENT", 62, 78], ["the isolation of field PEDV", "PROBLEM", 105, 132], ["a next-generation vaccine", "TREATMENT", 168, 193]]], ["Although virus isolation in cell culture from clinical samples of naturally or experimentally infected pigs is fastidious, recent studies reported the successful isolation and propagation of several US original PEDV strains using Vero cells (Chen et al., 2014; Oka et al., 2014) .", [["cell culture", "ANATOMY", 28, 40], ["samples", "ANATOMY", 55, 62], ["Vero cells", "ANATOMY", 230, 240], ["cell culture", "CELL", 28, 40], ["pigs", "ORGANISM", 103, 107], ["Vero cells", "CELL", 230, 240], ["Vero cells", "CELL_LINE", 230, 240], ["pigs", "SPECIES", 103, 107], ["pigs", "SPECIES", 103, 107], ["PEDV", "SPECIES", 211, 215], ["virus isolation", "PROBLEM", 9, 24], ["cell culture", "TEST", 28, 40], ["clinical samples", "TEST", 46, 62], ["experimentally infected pigs", "PROBLEM", 79, 107], ["recent studies", "TEST", 123, 137], ["the successful isolation", "TREATMENT", 147, 171], ["virus", "OBSERVATION", 9, 14]]], ["In this study, we initially sought to isolate PEDV efficiently propagated in vitro from 7 intestine homogenates and 50 fecal samples of naturally infected piglets (field cases) and were able to obtain only 1 isolate from feces in Vero cell culture.", [["intestine homogenates", "ANATOMY", 90, 111], ["fecal samples", "ANATOMY", 119, 132], ["feces", "ANATOMY", 221, 226], ["cell", "ANATOMY", 235, 239], ["PEDV", "CELL", 46, 50], ["intestine homogenates", "ORGANISM_SUBSTANCE", 90, 111], ["piglets", "ORGANISM", 155, 162], ["feces", "ORGANISM_SUBSTANCE", 221, 226], ["Vero cell", "CELL", 230, 239], ["Vero cell culture", "CELL_LINE", 230, 247], ["piglets", "SPECIES", 155, 162], ["PEDV", "SPECIES", 46, 50], ["this study", "TEST", 3, 13], ["PEDV", "PROBLEM", 46, 50], ["fecal samples", "TEST", 119, 132], ["naturally infected piglets", "PROBLEM", 136, 162], ["Vero cell culture", "TEST", 230, 247], ["Vero cell", "OBSERVATION", 230, 239]]], ["The virus isolation rate, in the present study, was less than 2% and was relatively lower than that in recent US studies ranging from 5 to 10% (Chen et al., 2014; Oka et al., 2014) .", [["The virus isolation rate", "TEST", 0, 24], ["the present study", "TEST", 29, 46], ["recent US studies", "TEST", 103, 120], ["virus isolation", "OBSERVATION", 4, 19], ["lower", "OBSERVATION_MODIFIER", 84, 89]]], ["In previous studies, all isolated PEDV strains originated from intestinal contents of naturally infected or experimentally inoculated pigs, suggesting that intestine samples may be a better source for virus isolation (Chen et al., 2014; Oka et al., 2014) .", [["intestinal", "ANATOMY", 63, 73], ["intestine samples", "ANATOMY", 156, 173], ["PEDV strains", "ORGANISM", 34, 46], ["intestinal", "ORGAN", 63, 73], ["pigs", "ORGANISM", 134, 138], ["intestine samples", "MULTI-TISSUE_STRUCTURE", 156, 173], ["pigs", "SPECIES", 134, 138], ["PEDV", "SPECIES", 34, 38], ["pigs", "SPECIES", 134, 138], ["previous studies", "TEST", 3, 19], ["all isolated PEDV strains", "PROBLEM", 21, 46], ["intestine samples", "PROBLEM", 156, 173], ["virus isolation", "TREATMENT", 201, 216], ["PEDV strains", "OBSERVATION", 34, 46], ["intestinal", "ANATOMY", 63, 73], ["naturally", "OBSERVATION_MODIFIER", 86, 95], ["infected", "OBSERVATION_MODIFIER", 96, 104], ["inoculated pigs", "OBSERVATION", 123, 138], ["intestine", "ANATOMY", 156, 165]]], ["However, we failed to isolate PEDV from intestine homogenates, which may be due to the number of intestinal contents (n = 7) included in our study and be responsible for the low isolation rate.", [["intestine homogenates", "ANATOMY", 40, 61], ["intestinal", "ANATOMY", 97, 107], ["PEDV", "SIMPLE_CHEMICAL", 30, 34], ["intestine homogenates", "TISSUE", 40, 61], ["intestinal", "ORGAN", 97, 107], ["PEDV", "SPECIES", 30, 34], ["PEDV from intestine homogenates", "PROBLEM", 30, 61], ["our study", "TEST", 137, 146], ["the low isolation rate", "TREATMENT", 170, 192], ["intestine", "ANATOMY", 40, 49], ["may be due to", "UNCERTAINTY", 69, 82], ["intestinal", "ANATOMY", 97, 107], ["contents", "OBSERVATION", 108, 116]]], ["Although PEDV isolation might be affected by multiple factors, it appears to depend on the number of samples with good quality rather than the type of samples (intestinal contents or feces).", [["samples", "ANATOMY", 101, 108], ["samples", "ANATOMY", 151, 158], ["intestinal", "ANATOMY", 160, 170], ["feces", "ANATOMY", 183, 188], ["samples", "TISSUE", 151, 158], ["intestinal", "ORGAN", 160, 170], ["feces", "ORGANISM_SUBDIVISION", 183, 188], ["PEDV", "SPECIES", 9, 13], ["PEDV isolation", "TREATMENT", 9, 23], ["PEDV", "OBSERVATION", 9, 13], ["multiple", "OBSERVATION_MODIFIER", 45, 53], ["factors", "OBSERVATION", 54, 61], ["intestinal", "ANATOMY", 160, 170]]], ["Further studies are needed to improve the isolation methodology or to determine the contributing factor(s) to enhance the success rate of PEDV isolation in cell culture.", [["cell culture", "ANATOMY", 156, 168], ["PEDV", "CHEMICAL", 138, 142], ["PEDV", "SIMPLE_CHEMICAL", 138, 142], ["cell culture", "CELL", 156, 168], ["PEDV", "SPECIES", 138, 142], ["Further studies", "TEST", 0, 15], ["the isolation methodology", "TEST", 38, 63], ["PEDV isolation", "PROBLEM", 138, 152], ["cell culture", "TEST", 156, 168]]], ["The PEDV isolate, KNU-141112, was cytopathogenic in Vero cells from passage 3 and after passage 5, exhibited more severe and rapid CPE characterized by fusion of infected cells (syncytium or polykaryon formation).", [["KNU-141112", "ANATOMY", 18, 28], ["Vero cells", "ANATOMY", 52, 62], ["cells", "ANATOMY", 171, 176], ["syncytium", "ANATOMY", 178, 187], ["polykaryon", "ANATOMY", 191, 201], ["KNU-141112", "CHEMICAL", 18, 28], ["KNU-141112", "CELL", 18, 28], ["Vero cells", "CELL", 52, 62], ["cells", "CELL", 171, 176], ["syncytium", "CELL", 178, 187], ["polykaryon", "TISSUE", 191, 201], ["Vero cells", "CELL_LINE", 52, 62], ["infected cells", "CELL_TYPE", 162, 176], ["PEDV", "SPECIES", 4, 8], ["KNU-141112", "SPECIES", 18, 28], ["The PEDV isolate", "TEST", 0, 16], ["KNU", "TEST", 18, 21], ["cytopathogenic in Vero cells", "PROBLEM", 34, 62], ["rapid CPE", "PROBLEM", 125, 134], ["infected cells", "PROBLEM", 162, 176], ["Vero cells", "OBSERVATION", 52, 62], ["more severe", "OBSERVATION_MODIFIER", 109, 120], ["rapid", "OBSERVATION_MODIFIER", 125, 130], ["infected cells", "OBSERVATION", 162, 176]]], ["The initial viral infectious titers ranged from approximately 5 to 6 log 10 TCID 50 /ml and increased after several more passages reaching to 8 log 10 TCID 50 /ml or more.", [["The initial viral infectious titers", "TEST", 0, 35], ["viral", "OBSERVATION_MODIFIER", 12, 17], ["infectious", "OBSERVATION", 18, 28]]], ["These growth characteristics, including cytopathology, infectious titer, and growth kinetics were unchanged or even more efficient throughout the experiment (30 passages), indicating that the isolate KNU-141112 is phenotypically stable during serial passages in Vero cells.DiscussionSince the antibody response is a critical indicator to prove the cause of viral infection, we immunized guinea pigs twice with the inactivated isolate (KNU-141112-P10) and determined whether the animals developed humoral immunity using an SN test.", [["Vero cells", "ANATOMY", 262, 272], ["KNU-141112", "CHEMICAL", 200, 210], ["viral infection", "DISEASE", 357, 372], ["KNU-141112", "CHEMICAL", 435, 445], ["KNU-141112", "CHEMICAL", 200, 210], ["KNU-141112", "CELL", 200, 210], ["Vero cells", "CELL", 262, 272], ["guinea pigs", "ORGANISM", 387, 398], ["KNU-141112-P10", "CELL", 435, 449], ["animals", "ORGANISM", 478, 485], ["Vero cells", "CELL_LINE", 262, 272], ["guinea pigs", "SPECIES", 387, 398], ["KNU-141112", "SPECIES", 200, 210], ["guinea pigs", "SPECIES", 387, 398], ["cytopathology", "TEST", 40, 53], ["infectious titer", "TEST", 55, 71], ["growth kinetics", "PROBLEM", 77, 92], ["the isolate KNU", "TEST", 188, 203], ["serial passages in Vero cells", "PROBLEM", 243, 272], ["viral infection", "PROBLEM", 357, 372], ["KNU", "TEST", 435, 438], ["an SN test", "TEST", 519, 529], ["infectious", "OBSERVATION_MODIFIER", 55, 65], ["unchanged", "OBSERVATION_MODIFIER", 98, 107], ["stable", "OBSERVATION_MODIFIER", 229, 235], ["Vero cells", "OBSERVATION", 262, 272], ["viral", "OBSERVATION_MODIFIER", 357, 362], ["infection", "OBSERVATION", 363, 372]]], ["The guinea pig sera raised against the isolate contained high levels of NA (6.4 log 2 ), demonstrating the ability of KNU-141112 to elicit immune responses.", [["sera", "ANATOMY", 15, 19], ["NA", "CHEMICAL", 72, 74], ["KNU-141112", "CHEMICAL", 118, 128], ["KNU-141112", "CHEMICAL", 118, 128], ["guinea", "ORGANISM", 4, 10], ["pig", "ORGANISM", 11, 14], ["sera", "ORGANISM_SUBSTANCE", 15, 19], ["NA", "SIMPLE_CHEMICAL", 72, 74], ["KNU-141112", "CELL", 118, 128], ["guinea pig", "SPECIES", 4, 14], ["pig", "SPECIES", 11, 14], ["KNU-141112", "SPECIES", 118, 128], ["The guinea pig sera", "TEST", 0, 19], ["the isolate", "TEST", 35, 46], ["NA", "TEST", 72, 74], ["KNU", "TEST", 118, 121], ["high", "OBSERVATION_MODIFIER", 57, 61]]], ["On the other hand, the antisera showed a relatively weak neutralizing response (an almost 2-log 2 reduction), when the heterologous vaccine strain SM98-1 was used for an SN test.", [["SM98-1", "CELL", 147, 153], ["the antisera", "TEST", 19, 31], ["a relatively weak neutralizing response", "PROBLEM", 39, 78], ["the heterologous vaccine strain SM98", "TEST", 115, 151], ["an SN test", "TEST", 167, 177]]], ["This weak neutralizing activity of the anti-KNU-141112 guinea pig sera against SM98-1 was somewhat expected because of a high degree of genetic diversity between the S proteins of the vaccine strain and field isolates (Lee et al., 2010; Lee and Lee, 2014; Oh et al., 2014) .DiscussionExperimental oral inoculation of nursery pigs with PEDV isolate KNU-141112 induced severe clinical disease typical of acute enteritis throughout the study, demonstrating that the isolate was highly enteropathogenic in neonatal piglets.", [["sera", "ANATOMY", 66, 70], ["oral", "ANATOMY", 297, 301], ["anti-KNU-141112", "CHEMICAL", 39, 54], ["SM98-1", "CHEMICAL", 79, 85], ["PEDV", "CHEMICAL", 335, 339], ["KNU-141112", "CHEMICAL", 348, 358], ["enteritis", "DISEASE", 408, 417], ["KNU-141112", "CHEMICAL", 348, 358], ["anti-KNU-141112 guinea", "ORGANISM", 39, 61], ["pig", "ORGANISM", 62, 65], ["sera", "ORGANISM_SUBSTANCE", 66, 70], ["SM98-1", "GENE_OR_GENE_PRODUCT", 79, 85], ["oral", "ORGANISM_SUBDIVISION", 297, 301], ["pigs", "ORGANISM", 325, 329], ["KNU-141112", "CELL", 348, 358], ["piglets", "ORGANISM", 511, 518], ["S proteins", "PROTEIN", 166, 176], ["guinea pig", "SPECIES", 55, 65], ["pigs", "SPECIES", 325, 329], ["piglets", "SPECIES", 511, 518], ["anti-KNU-141112 guinea pig", "SPECIES", 39, 65], ["PEDV", "SPECIES", 335, 339], ["KNU-141112", "SPECIES", 348, 358], ["the anti-KNU", "TEST", 35, 47], ["guinea pig sera", "TEST", 55, 70], ["SM98", "TEST", 79, 83], ["a high degree of genetic diversity", "PROBLEM", 119, 153], ["the vaccine strain", "TREATMENT", 180, 198], ["severe clinical disease", "PROBLEM", 367, 390], ["acute enteritis", "PROBLEM", 402, 417], ["the study", "TEST", 429, 438], ["weak", "OBSERVATION_MODIFIER", 5, 9], ["neutralizing", "OBSERVATION", 10, 22], ["high degree", "OBSERVATION_MODIFIER", 121, 132], ["severe", "OBSERVATION_MODIFIER", 367, 373], ["acute", "OBSERVATION_MODIFIER", 402, 407], ["enteritis", "OBSERVATION", 408, 417], ["highly", "OBSERVATION_MODIFIER", 475, 481], ["enteropathogenic", "OBSERVATION", 482, 498]]], ["Onset of clinical signs including lethargy and watery diarrhea in inoculated pigs was found as early as 1 DPI.", [["lethargy", "DISEASE", 34, 42], ["watery diarrhea", "DISEASE", 47, 62], ["watery", "ORGANISM_SUBDIVISION", 47, 53], ["pigs", "ORGANISM", 77, 81], ["pigs", "SPECIES", 77, 81], ["pigs", "SPECIES", 77, 81], ["clinical signs", "PROBLEM", 9, 23], ["lethargy", "PROBLEM", 34, 42], ["watery diarrhea", "PROBLEM", 47, 62]]], ["The PEDV genome was detected in feces in 100% of challenged pigs on DPI 1 and virus quantities from fecal shedding were maintained thereafter in all challenged pigs throughout the study period, leading to the source for direct transmission of virus to other animals.", [["feces", "ANATOMY", 32, 37], ["fecal", "ANATOMY", 100, 105], ["DPI", "CHEMICAL", 68, 71], ["PEDV", "GENE_OR_GENE_PRODUCT", 4, 8], ["feces", "ORGANISM_SUBSTANCE", 32, 37], ["pigs", "ORGANISM", 60, 64], ["DPI 1", "ORGANISM", 68, 73], ["fecal", "ORGANISM_SUBSTANCE", 100, 105], ["pigs", "ORGANISM", 160, 164], ["PEDV genome", "DNA", 4, 15], ["pigs", "SPECIES", 60, 64], ["pigs", "SPECIES", 160, 164], ["PEDV", "SPECIES", 4, 8], ["pigs", "SPECIES", 60, 64], ["pigs", "SPECIES", 160, 164], ["The PEDV genome", "PROBLEM", 0, 15], ["DPI", "TREATMENT", 68, 71], ["virus quantities", "TREATMENT", 78, 94], ["fecal shedding", "PROBLEM", 100, 114], ["direct transmission of virus", "PROBLEM", 220, 248], ["PEDV genome", "OBSERVATION", 4, 15], ["fecal", "ANATOMY", 100, 105]]], ["This result is inconsistent with a previous study using a US PEDV strain that demonstrated virus fecal shedding on DPI 1 in only one-fourth of the challenged pigs (Madson Fig. 5 .", [["fecal", "ANATOMY", 97, 102], ["DPI", "CHEMICAL", 115, 118], ["fecal", "ORGANISM_SUBSTANCE", 97, 102], ["pigs", "ORGANISM", 158, 162], ["pigs", "SPECIES", 158, 162], ["pigs", "SPECIES", 158, 162], ["a previous study", "TEST", 33, 49], ["a US PEDV strain", "TEST", 56, 72], ["virus fecal shedding", "PROBLEM", 91, 111], ["DPI", "TREATMENT", 115, 118]]], ["Phylogenetic analyses based on the nucleotide sequences of the spike genes (A) and the full-length genomes (B) of PEDV strains.", [["PEDV", "GENE_OR_GENE_PRODUCT", 114, 118], ["spike genes", "DNA", 63, 74], ["A", "DNA", 76, 77], ["full-length genomes", "DNA", 87, 106], ["PEDV", "SPECIES", 114, 118], ["Phylogenetic analyses", "TEST", 0, 21], ["the nucleotide sequences", "TEST", 31, 55], ["PEDV strains", "PROBLEM", 114, 126]]], ["A putative similar region of the spike protein and the complete genome sequence of TGEV was included as an outgroup in each panel.", [["TGEV", "ORGANISM", 83, 87], ["spike protein", "PROTEIN", 33, 46], ["TGEV", "SPECIES", 83, 87], ["the spike protein", "PROBLEM", 29, 46], ["TGEV", "PROBLEM", 83, 87], ["spike", "OBSERVATION_MODIFIER", 33, 38]]], ["Multiple-sequencing alignments were performed using ClustalX program and the phylogenetic tree was constructed from the aligned nucleotide sequences by using the neighbor-joining method.", [["nucleotide", "CHEMICAL", 128, 138], ["aligned nucleotide sequences", "DNA", 120, 148], ["Multiple-sequencing alignments", "TEST", 0, 30], ["ClustalX program", "TREATMENT", 52, 68]]], ["Numbers at each branch represent bootstrap values greater than 50% of 1000 replicates.", [["bootstrap values", "TEST", 33, 49], ["branch", "ANATOMY_MODIFIER", 16, 22], ["bootstrap values", "OBSERVATION", 33, 49]]], ["Names of the strains, countries and years of isolation, GenBank accession numbers, and genogroups and subgroups proposed in this study are shown.", [["isolation", "TREATMENT", 45, 54], ["this study", "TEST", 124, 134]]], ["The PEDV isolates identified in this study are indicated by solid circles.", [["PEDV", "SPECIES", 4, 8], ["The PEDV isolates", "TEST", 0, 17], ["this study", "TEST", 32, 42], ["solid circles", "OBSERVATION", 60, 73]]], ["Scale bars indicate nucleotide substitutions per site. et al., 2014) .", [["nucleotide", "CHEMICAL", 20, 30], ["nucleotide", "CHEMICAL", 20, 30], ["nucleotide substitutions per site", "PROBLEM", 20, 53], ["nucleotide substitutions", "OBSERVATION", 20, 44]]], ["The difference between the current and previous studies is the age of the pigs: 1-week-old neonatal pigs and 3-week-old weaned pigs used in the present and previous experiments, respectively.", [["pigs", "ORGANISM", 74, 78], ["pigs", "ORGANISM", 100, 104], ["pigs", "ORGANISM", 127, 131], ["pigs", "SPECIES", 74, 78], ["pigs", "SPECIES", 100, 104], ["pigs", "SPECIES", 127, 131], ["previous studies", "TEST", 39, 55], ["neonatal pigs", "TREATMENT", 91, 104], ["old weaned pigs", "TREATMENT", 116, 131], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["Therefore, younger piglets in this study were more sensitive to PEDV infection shedding virus in feces earlier than older pigs, probably due to an age-dependent disease severity as previously described (Shibata et al., 2000) .", [["PEDV", "CHEMICAL", 64, 68], ["infection", "DISEASE", 69, 78], ["piglets", "ORGANISM", 19, 26], ["PEDV", "GENE_OR_GENE_PRODUCT", 64, 68], ["feces", "ORGANISM_SUBDIVISION", 97, 102], ["pigs", "ORGANISM", 122, 126], ["piglets", "SPECIES", 19, 26], ["pigs", "SPECIES", 122, 126], ["PEDV", "SPECIES", 64, 68], ["pigs", "SPECIES", 122, 126], ["this study", "TEST", 30, 40], ["PEDV infection shedding virus in feces", "PROBLEM", 64, 102], ["an age-dependent disease severity", "PROBLEM", 144, 177], ["infection", "OBSERVATION", 69, 78], ["probably due to", "UNCERTAINTY", 128, 143], ["dependent", "OBSERVATION_MODIFIER", 151, 160], ["disease", "OBSERVATION", 161, 168]]], ["IHC and IFA revealed that viral antigen in villous enterocytes were observed at 1 DPI in all segments of the small intestine of inoculated piglets.", [["villous enterocytes", "ANATOMY", 43, 62], ["small intestine", "ANATOMY", 109, 124], ["piglets", "ANATOMY", 139, 146], ["DPI", "CHEMICAL", 82, 85], ["villous enterocytes", "CELL", 43, 62], ["small intestine", "ORGAN", 109, 124], ["piglets", "ORGANISM", 139, 146], ["viral antigen", "PROTEIN", 26, 39], ["villous enterocytes", "CELL_TYPE", 43, 62], ["piglets", "SPECIES", 139, 146], ["IHC", "TEST", 0, 3], ["IFA", "TEST", 8, 11], ["viral antigen in villous enterocytes", "PROBLEM", 26, 62], ["viral", "OBSERVATION_MODIFIER", 26, 31], ["villous enterocytes", "OBSERVATION", 43, 62], ["all segments", "ANATOMY_MODIFIER", 89, 101], ["small intestine", "ANATOMY", 109, 124], ["inoculated piglets", "OBSERVATION", 128, 146]]], ["The onset of clinical signs and viral fecal shedding and the detection time of viral antigen in the target tissue were similar to recent independent reports using different US PEDV strains Jung et al., 2014) .", [["fecal", "ANATOMY", 38, 43], ["tissue", "ANATOMY", 107, 113], ["fecal", "ORGANISM_SUBDIVISION", 38, 43], ["tissue", "TISSUE", 107, 113], ["viral antigen", "PROTEIN", 79, 92], ["clinical signs", "PROBLEM", 13, 27], ["viral fecal shedding", "PROBLEM", 32, 52], ["viral antigen", "TEST", 79, 92]]], ["Two non-challenged piglets were included in this study for direct contact to inoculated piglets in the same space.", [["piglets", "ORGANISM", 19, 26], ["piglets", "ORGANISM", 88, 95], ["piglets", "SPECIES", 19, 26], ["piglets", "SPECIES", 88, 95], ["Two non-challenged piglets", "TREATMENT", 0, 26], ["this study", "TEST", 44, 54]]], ["All contact piglets displayed PED-like symptoms within 24 h after the onset of clinical signs in inoculated piglets.", [["piglets", "ORGANISM", 12, 19], ["piglets", "ORGANISM", 108, 115], ["piglets", "SPECIES", 108, 115], ["PED-like symptoms", "PROBLEM", 30, 47], ["clinical signs in inoculated piglets", "PROBLEM", 79, 115], ["inoculated piglets", "OBSERVATION", 97, 115]]], ["The presence of PEDV in feces and infected tissues was further verified in contact piglets, showing 100% morbidity in our study.", [["feces", "ANATOMY", 24, 29], ["tissues", "ANATOMY", 43, 50], ["PEDV", "CHEMICAL", 16, 20], ["PEDV", "GENE_OR_GENE_PRODUCT", 16, 20], ["feces", "ORGANISM_SUBSTANCE", 24, 29], ["tissues", "TISSUE", 43, 50], ["piglets", "ORGANISM", 83, 90], ["PEDV", "PROTEIN", 16, 20], ["PEDV", "SPECIES", 16, 20], ["PEDV in feces", "PROBLEM", 16, 29], ["infected tissues", "PROBLEM", 34, 50], ["our study", "TEST", 118, 127], ["PEDV", "OBSERVATION", 16, 20], ["feces", "OBSERVATION_MODIFIER", 24, 29], ["infected tissues", "OBSERVATION", 34, 50]]], ["Mortality averages 50% in suckling piglets up to 1 week of age, often approaching 100% in 1-to 3-dayold piglets, and decreases to 10% thereafter (Saif et al., 2012) .", [["piglets", "ORGANISM", 35, 42], ["piglets", "ORGANISM", 104, 111], ["piglets", "SPECIES", 35, 42]]], ["In our study, mortality was observed only in one out of four inoculated piglets, resulting in 25% mortality in the current study involving 8-day-old piglets.", [["piglets", "ORGANISM", 72, 79], ["piglets", "ORGANISM", 149, 156], ["piglets", "SPECIES", 72, 79], ["piglets", "SPECIES", 149, 156], ["our study", "TEST", 3, 12], ["the current study", "TEST", 111, 128]]], ["For reproducible challenge studies in vivo using the isolate in the future, a neonatal swine bioassay will be needed to determine either the median pig diarrhea dose or lethal dose as a standardized dose and this aspect is currently under investigation.DiscussionWhole-genome sequences of 3 Korean PEDV strains (KNU-141112-feces, P5, and P10) were determined using NGS approaches coupled with RACE experiments.", [["diarrhea", "DISEASE", 152, 160], ["KNU-141112", "CHEMICAL", 312, 322], ["pig", "ORGANISM", 148, 151], ["KNU-141112-feces", "CELL", 312, 328], ["P5", "CELL", 330, 332], ["DiscussionWhole-genome sequences", "DNA", 253, 285], ["swine", "SPECIES", 87, 92], ["swine", "SPECIES", 87, 92], ["pig", "SPECIES", 148, 151], ["the isolate", "TREATMENT", 49, 60], ["a neonatal swine bioassay", "TREATMENT", 76, 101], ["the median pig diarrhea dose", "TREATMENT", 137, 165], ["a standardized dose", "TREATMENT", 184, 203], ["Korean PEDV strains", "TEST", 291, 310], ["KNU", "TEST", 312, 315], ["NGS approaches", "TREATMENT", 365, 379], ["RACE experiments", "TREATMENT", 393, 409]]], ["Regions covering the structural genes were also sequenced at the selected passages by the Sanger method for confirmation.", [["structural genes", "DNA", 21, 37], ["the Sanger method", "TEST", 86, 103], ["structural genes", "OBSERVATION", 21, 37]]], ["Compared to the original feces (KNU-141112-feces), only one nt difference at position 21,756 was identified for the first 5 passages (KNU-141112-P5) in cell culture, which led to a non-synonymous mutation at the corresponding position 375 of the S protein.", [["feces", "ANATOMY", 25, 30], ["cell culture", "ANATOMY", 152, 164], ["KNU-141112", "CHEMICAL", 32, 42], ["KNU-141112-P5", "CHEMICAL", 134, 147], ["feces", "ORGANISM_SUBDIVISION", 25, 30], ["KNU-141112-feces", "ORGANISM", 32, 48], ["KNU-141112-P5", "CELL", 134, 147], ["cell culture", "CELL", 152, 164], ["S protein", "PROTEIN", 246, 255], ["the original feces", "TEST", 12, 30], ["KNU", "TEST", 32, 35], ["KNU", "TEST", 134, 137], ["cell culture", "TEST", 152, 164], ["a non-synonymous mutation", "PROBLEM", 179, 204], ["the S protein", "TEST", 242, 255], ["difference", "OBSERVATION_MODIFIER", 63, 73], ["non-synonymous mutation", "OBSERVATION", 181, 204]]], ["This nt change was initially found at passage 3 and further maintained through passage 30.", [["This nt change", "PROBLEM", 0, 14]]], ["However, we were unable to investigate whether this mutation had been acquired at the beginning of the Vero cell culture since infectious virus was not obtained during the first two passages.", [["cell", "ANATOMY", 108, 112], ["Vero cell", "CELL", 103, 112], ["Vero cell culture", "CELL_LINE", 103, 120], ["this mutation", "PROBLEM", 47, 60], ["the Vero cell culture", "TEST", 99, 120], ["infectious virus", "PROBLEM", 127, 143]]], ["Interestingly, the identical C21756T mutation at the whole-genome level (L375F at the aa level of S) has been previously reported in a US PEDV isolate ISU-19338E during cell culture passage (Chen et al., 2014) , suggesting its potential importance for adaption of the field virus to growth in vitro.", [["cell", "ANATOMY", 169, 173], ["ISU-19338E", "CHEMICAL", 151, 161], ["C21756T", "GENE_OR_GENE_PRODUCT", 29, 36], ["L375F", "GENE_OR_GENE_PRODUCT", 73, 78], ["ISU-19338E", "CELL", 151, 161], ["cell", "CELL", 169, 173], ["L375F", "DNA", 73, 78], ["ISU-19338E", "SPECIES", 151, 161], ["a US PEDV isolate ISU", "TEST", 133, 154], ["the field virus", "TREATMENT", 264, 279]]], ["At passage 10, two more nt differences at positions 21,448 and 24,492 of the genome (A21448C and G24492C) were detected when compared to KNU-141112-feces.", [["KNU-141112", "CHEMICAL", 137, 147], ["KNU-141112", "CHEMICAL", 137, 147], ["genome", "CELLULAR_COMPONENT", 77, 83], ["feces", "ORGANISM_SUBSTANCE", 148, 153], ["KNU-141112", "SPECIES", 137, 147], ["KNU", "TEST", 137, 140]]], ["All of the changes acquired in KNU-141112-P10 led to non-synonymous mutations at the respective positions 272 and 1287 of the S protein (K272T and E1287Q).", [["KNU-141112", "CHEMICAL", 31, 41], ["KNU-141112-P10", "CHEMICAL", 31, 45], ["S protein", "PROTEIN", 126, 135], ["E1287Q", "PROTEIN", 147, 153], ["KNU", "TEST", 31, 34], ["non-synonymous mutations", "PROBLEM", 53, 77], ["the S protein", "TEST", 122, 135], ["K272T", "TEST", 137, 142]]], ["These findings were similar to recent data reported by Chen et al. (2014) that two US isolates individually gained the 4 mutations located in ORF1b, S, and E through passage 9 in cell culture.", [["cell culture", "ANATOMY", 179, 191], ["ORF1b", "GENE_OR_GENE_PRODUCT", 142, 147], ["cell culture", "CELL", 179, 191], ["ORF1b", "DNA", 142, 147], ["two US isolates", "TEST", 79, 94], ["the 4 mutations", "PROBLEM", 115, 130], ["cell culture", "TEST", 179, 191]]], ["However, no nucleotide changes were identified in ORF1b and E for the first 10 passages in Vero cells.", [["Vero cells", "ANATOMY", 91, 101], ["nucleotide", "CHEMICAL", 12, 22], ["nucleotide", "CHEMICAL", 12, 22], ["ORF1b", "GENE_OR_GENE_PRODUCT", 50, 55], ["Vero cells", "CELL", 91, 101], ["ORF1b", "DNA", 50, 55], ["E", "DNA", 60, 61], ["Vero cells", "CELL_LINE", 91, 101], ["nucleotide changes", "PROBLEM", 12, 30], ["no", "UNCERTAINTY", 9, 11], ["Vero cells", "OBSERVATION", 91, 101]]], ["The 3 mutations in the S protein were persistent for 30 passages in cell culture.", [["cell culture", "ANATOMY", 68, 80], ["cell culture", "CELL", 68, 80], ["S protein", "PROTEIN", 23, 32], ["The 3 mutations", "PROBLEM", 0, 15], ["the S protein", "TEST", 19, 32], ["cell culture", "TEST", 68, 80], ["persistent", "OBSERVATION_MODIFIER", 38, 48]]], ["Celladapted PEDV vaccine strains, SM98-1 and DR-13, are known to contain a 52-nt deletion spanned from the end of S to the start of ORF3 and a 49-nt deletion in the middle of ORF3.", [["SM98-1", "GENE_OR_GENE_PRODUCT", 34, 40], ["DR-13", "GENE_OR_GENE_PRODUCT", 45, 50], ["ORF3", "GENE_OR_GENE_PRODUCT", 132, 136], ["ORF3", "GENE_OR_GENE_PRODUCT", 175, 179], ["52-nt deletion", "DNA", 75, 89], ["S", "DNA", 114, 115], ["ORF3", "DNA", 132, 136], ["49-nt deletion", "DNA", 143, 157], ["ORF3", "DNA", 175, 179], ["Celladapted PEDV vaccine strains", "TREATMENT", 0, 32], ["SM98", "TEST", 34, 38], ["DR", "TEST", 45, 47], ["a 52-nt deletion", "PROBLEM", 73, 89], ["a 49-nt deletion", "TREATMENT", 141, 157], ["middle", "ANATOMY_MODIFIER", 165, 171]]], ["Thus, we further sequenced structural genes of KNU-141112-P20 and -P30 and identified two additional nucleotide changes (G24869T and C25656T) acquiring non-synonymous amino acid mutations in ORF3 and E, respectively.", [["amino acid", "CHEMICAL", 167, 177], ["nucleotide", "CHEMICAL", 101, 111], ["amino acid", "CHEMICAL", 167, 177], ["KNU-141112-P20", "GENE_OR_GENE_PRODUCT", 47, 61], ["amino acid", "AMINO_ACID", 167, 177], ["structural genes", "DNA", 27, 43], ["KNU", "DNA", 47, 50], ["141112", "DNA", 51, 57], ["P20", "DNA", 58, 61], ["P30", "DNA", 67, 70], ["ORF3", "DNA", 191, 195], ["E", "DNA", 200, 201], ["KNU", "TEST", 47, 50], ["two additional nucleotide changes", "PROBLEM", 86, 119], ["non-synonymous amino acid mutations", "PROBLEM", 152, 187], ["acid mutations", "OBSERVATION", 173, 187]]], ["Except for those nucleotide substitutions, the isolate had no extra change, including such large deletions in structural genes through passage 30, indicating the genetic stability of KNU-141112 during serial passages in Vero cells.", [["Vero cells", "ANATOMY", 220, 230], ["nucleotide", "CHEMICAL", 17, 27], ["KNU-141112", "CHEMICAL", 183, 193], ["nucleotide", "CHEMICAL", 17, 27], ["KNU-141112", "CHEMICAL", 183, 193], ["KNU-141112", "CELL", 183, 193], ["Vero cells", "CELL", 220, 230], ["structural genes", "DNA", 110, 126], ["Vero cells", "CELL_LINE", 220, 230], ["KNU-141112", "SPECIES", 183, 193], ["those nucleotide substitutions", "PROBLEM", 11, 41], ["extra change", "PROBLEM", 62, 74], ["such large deletions in structural genes through passage", "PROBLEM", 86, 142], ["KNU", "TEST", 183, 186], ["serial passages in Vero cells", "PROBLEM", 201, 230], ["no", "UNCERTAINTY", 59, 61], ["extra change", "OBSERVATION", 62, 74], ["large", "OBSERVATION_MODIFIER", 91, 96], ["deletions", "OBSERVATION", 97, 106], ["Vero cells", "OBSERVATION", 220, 230]]], ["Sequence comparisons with other PEDV strains showed that KNU-141112 isolates are genetically most similar to recent Korean and US epidemic strains with 99.8-99.9% identities, but most distinctly related to classical strains, CV777, SM98-1, and DR-13, with 96.3-96.8% identities at the genomic level.", [["KNU-141112", "CHEMICAL", 57, 67], ["KNU-141112 isolates", "CELL", 57, 76], ["CV777", "CELL", 225, 230], ["SM98-1", "CELL", 232, 238], ["DR-13", "CELL", 244, 249], ["KNU-141112", "SPECIES", 57, 67], ["DR-13", "SPECIES", 244, 249], ["Sequence comparisons", "TEST", 0, 20], ["other PEDV strains", "TEST", 26, 44], ["KNU", "TEST", 57, 60], ["US epidemic strains", "TEST", 127, 146], ["classical strains", "PROBLEM", 206, 223], ["SM98", "TEST", 232, 236], ["DR", "TEST", 244, 246], ["strains", "OBSERVATION", 216, 223]]], ["All phylogenetic analyses based on the complete genome, the full-length S gene, and the S1 portion formed the similar tree structure, revealing that the Korean KNU-141112 strains are clustered together with the re-emergent Korean strains in subgroup 2b that also includes 2013 emergent US strains and 2011-2012 field epidemic Chinese strains.DiscussionIn conclusion, we isolated and serially propagated PEDV in cell culture that is phenotypically and genotypically identical to field strains responsible for the recent severe PED outbreaks in Korea.", [["cell culture", "ANATOMY", 411, 423], ["KNU-141112", "CHEMICAL", 160, 170], ["PEDV", "CHEMICAL", 403, 407], ["PED", "DISEASE", 526, 529], ["KNU-141112 strains", "CELL", 160, 178], ["PEDV", "CELL", 403, 407], ["cell culture", "CELL", 411, 423], ["full-length S gene", "DNA", 60, 78], ["S1 portion", "DNA", 88, 98], ["PEDV", "DNA", 403, 407], ["Korean KNU-141112", "SPECIES", 153, 170], ["PEDV", "SPECIES", 403, 407], ["All phylogenetic analyses", "TEST", 0, 25], ["the Korean KNU", "TEST", 149, 163], ["strains", "PROBLEM", 171, 178], ["emergent US strains", "TEST", 277, 296], ["PEDV in cell culture", "TEST", 403, 423], ["the recent severe PED outbreaks in Korea", "PROBLEM", 508, 548], ["similar", "OBSERVATION", 110, 117], ["tree structure", "OBSERVATION", 118, 132], ["severe", "OBSERVATION_MODIFIER", 519, 525]]], ["To our knowledge, this is the first report describing the isolation and in vitro and in vivo characterization of Korean PEDV associated with the field epidemic.", [["PEDV", "CHEMICAL", 120, 124], ["PEDV", "SPECIES", 120, 124], ["the isolation", "TREATMENT", 54, 67], ["Korean PEDV", "PROBLEM", 113, 124]]], ["With the availability of the Korean isolate, we are now able to spur the development of new effective and safe vaccines for PED prevention.", [["PED", "DISEASE", 124, 127], ["the Korean isolate", "TREATMENT", 25, 43], ["safe vaccines", "TREATMENT", 106, 119], ["PED prevention", "TREATMENT", 124, 138], ["new", "OBSERVATION_MODIFIER", 88, 91]]], ["Indeed, our PEDV isolate has been used for the development of an inactivated vaccine that is currently being evaluated under experimental and field conditions.", [["PEDV", "CHEMICAL", 12, 16], ["PEDV", "SPECIES", 12, 16], ["our PEDV isolate", "TREATMENT", 8, 24], ["an inactivated vaccine", "TREATMENT", 62, 84]]], ["Furthermore, we are continuing to passage the isolate in Vero cells to develop a live attenuated vaccine that generally prove to provide a more efficient protective immunity than killed viral vaccines.", [["Vero cells", "ANATOMY", 57, 67], ["Vero cells", "CELL", 57, 67], ["Vero cells", "CELL_LINE", 57, 67], ["the isolate in Vero cells", "TREATMENT", 42, 67], ["a live attenuated vaccine", "TREATMENT", 79, 104], ["a more efficient protective immunity", "TREATMENT", 137, 173], ["viral vaccines", "TREATMENT", 186, 200]]], ["For this purpose, pathogenic and molecular characterization of the isolates at selected passages will be assessed to determine their phenotypes in pigs and to identify the genetic changes involved in PEDV attenuation.", [["pigs", "ORGANISM", 147, 151], ["PEDV", "SIMPLE_CHEMICAL", 200, 204], ["pigs", "SPECIES", 147, 151], ["pigs", "SPECIES", 147, 151], ["PEDV", "SPECIES", 200, 204], ["pathogenic", "PROBLEM", 18, 28], ["the isolates", "PROBLEM", 63, 75], ["PEDV attenuation", "PROBLEM", 200, 216], ["PEDV attenuation", "OBSERVATION", 200, 216]]]], "f174e535b5e88cadd50d5684bed11710973f598e": [["IntroductionVaccines are among the most outstanding achievements in human medical history.", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["IntroductionVaccines", "TREATMENT", 0, 20]]], ["Through their power to prevent or reduce the burden of infectious diseases they make an enormous global impact by improving the life quality of both humans and animals.", [["infectious diseases", "DISEASE", 55, 74], ["humans", "ORGANISM", 149, 155], ["humans", "SPECIES", 149, 155], ["humans", "SPECIES", 149, 155], ["infectious diseases", "PROBLEM", 55, 74], ["infectious", "OBSERVATION", 55, 65], ["enormous", "OBSERVATION_MODIFIER", 88, 96], ["global", "OBSERVATION_MODIFIER", 97, 103], ["impact", "OBSERVATION_MODIFIER", 104, 110]]], ["Vaccines may save up to three million children's lives and up to six million total lives each year [1, 2] .", [["children", "ORGANISM", 38, 46], ["children", "SPECIES", 38, 46], ["Vaccines", "TREATMENT", 0, 8]]], ["In addition to their contribution to an increased survival rate, vaccines are also an essential medical tool to protect against cancers and devastating sequelae derived from viral and bacterial infections, such as human papillomavirus (HPV) or meningitis, allergies, autoimmune diseases, or even drug dependencies.IntroductionHowever, there are many important pathogens against which vaccines do not yet exist, and some current vaccines could be improved.", [["cancers", "ANATOMY", 128, 135], ["cancers", "DISEASE", 128, 135], ["viral and bacterial infections", "DISEASE", 174, 204], ["human papillomavirus (HPV) or meningitis", "DISEASE", 214, 254], ["allergies", "DISEASE", 256, 265], ["autoimmune diseases", "DISEASE", 267, 286], ["cancers", "CANCER", 128, 135], ["human", "ORGANISM", 214, 219], ["papillomavirus", "ORGANISM", 220, 234], ["HPV", "ORGANISM", 236, 239], ["human", "SPECIES", 214, 219], ["papillomavirus", "SPECIES", 220, 234], ["human papillomavirus", "SPECIES", 214, 234], ["HPV", "SPECIES", 236, 239], ["an increased survival rate", "PROBLEM", 37, 63], ["vaccines", "TREATMENT", 65, 73], ["cancers", "PROBLEM", 128, 135], ["devastating sequelae", "PROBLEM", 140, 160], ["viral and bacterial infections", "PROBLEM", 174, 204], ["human papillomavirus (HPV)", "PROBLEM", 214, 240], ["meningitis", "PROBLEM", 244, 254], ["allergies", "PROBLEM", 256, 265], ["autoimmune diseases", "PROBLEM", 267, 286], ["vaccines", "TREATMENT", 384, 392], ["some current vaccines", "TREATMENT", 415, 436], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["survival", "OBSERVATION", 50, 58], ["viral", "OBSERVATION_MODIFIER", 174, 179], ["bacterial", "OBSERVATION_MODIFIER", 184, 193], ["infections", "OBSERVATION", 194, 204], ["meningitis", "OBSERVATION", 244, 254], ["improved", "OBSERVATION_MODIFIER", 446, 454]]], ["For example, some vaccines do not protect against all circulating strains of a pathogen because many microbes have developed sophisticated mechanisms to escape the host immune system.", [["immune system", "ANATOMICAL_SYSTEM", 169, 182], ["some vaccines", "TREATMENT", 13, 26], ["all circulating strains", "PROBLEM", 50, 73], ["a pathogen", "PROBLEM", 77, 87], ["host immune system", "OBSERVATION", 164, 182]]], ["Mutations on the antigens of microbes such as influenza (flu), human immunodeficiency virus (HIV), or meningococcus constitute a rapidly changing 'disguise' to avoid recognition by trained immune cells that might otherwise prevent infection or disease.", [["immune cells", "ANATOMY", 189, 201], ["influenza (flu", "DISEASE", 46, 60], ["human immunodeficiency virus (HIV)", "DISEASE", 63, 97], ["infection", "DISEASE", 231, 240], ["influenza (flu)", "ORGANISM", 46, 61], ["human immunodeficiency virus", "ORGANISM", 63, 91], ["HIV", "ORGANISM", 93, 96], ["immune cells", "CELL", 189, 201], ["immune cells", "CELL_TYPE", 189, 201], ["human immunodeficiency virus (HIV", "SPECIES", 63, 96], ["human immunodeficiency virus", "SPECIES", 63, 91], ["HIV", "SPECIES", 93, 96], ["Mutations", "PROBLEM", 0, 9], ["influenza (flu)", "PROBLEM", 46, 61], ["human immunodeficiency virus (HIV)", "PROBLEM", 63, 97], ["meningococcus", "PROBLEM", 102, 115], ["trained immune cells", "TREATMENT", 181, 201], ["infection", "PROBLEM", 231, 240], ["disease", "PROBLEM", 244, 251], ["infection", "OBSERVATION", 231, 240]]], ["Further, some vaccine antigens do not elicit sufficiently durable or potent immunity.", [["vaccine antigens", "PROTEIN", 14, 30], ["some vaccine antigens", "TREATMENT", 9, 30]]], ["In addition to this, the rise of drug-resistant pathogenic entities such as those causing shigellosis demands our attention in the search for proficient vaccines [3] .", [["shigellosis", "DISEASE", 90, 101], ["drug-resistant pathogenic entities", "PROBLEM", 33, 67], ["shigellosis", "PROBLEM", 90, 101], ["proficient vaccines", "TREATMENT", 142, 161]]], ["Therefore, a major research focus is to seek ways to boost vaccine-induced host protection against pathogens, by developing novel antigens that evoke a more robust and protective immune response.IntroductionMany effective vaccines developed in the past used live-attenuated strains of a pathogen, or inactivated killed pathogens [4] .", [["boost vaccine", "TREATMENT", 53, 66], ["pathogens", "PROBLEM", 99, 108], ["Introduction", "TREATMENT", 195, 207], ["Many effective vaccines", "TREATMENT", 207, 230], ["a pathogen", "PROBLEM", 285, 295], ["inactivated killed pathogens", "PROBLEM", 300, 328]]], ["Liveattenuated vaccine strains are typically highly immunogenic, but carry inherent safety concerns, given the potential of these weakened viral particles to revert into disease-causing viruses.", [["Liveattenuated vaccine strains", "PROBLEM", 0, 30], ["these weakened viral particles", "PROBLEM", 124, 154], ["viruses", "PROBLEM", 186, 193], ["viruses", "OBSERVATION", 186, 193]]], ["Additionally, mutagenic events within the host organism may generate more virulent strains.", [["mutagenic events within the host organism", "PROBLEM", 14, 55], ["more virulent strains", "PROBLEM", 69, 90]]], ["Conversely, while inactivated or killed vaccine pathogens cannot replicate nor revert into more virulent forms, they tend to stimulate a weaker immune reaction, and thus may require the administration of multiple dosages, an important practical limitation.", [["killed vaccine pathogens", "PROBLEM", 33, 57], ["a weaker immune reaction", "PROBLEM", 135, 159], ["multiple dosages", "TREATMENT", 204, 220]]], ["An effective way to address these limitations has gradually emerged through studies of self-assembling proteins, which can be used as nanoparticles mediating multi-copy antigen display.IntroductionOne of the earliest examples of a self-associating protein particle was reported in the 1950s: a protein extracted from the tobacco mosaic virus (TMV) was found to form rod-shaped particles, which morphologically resembled the original TMV but which did not contain genetic material [5] .", [["multi-copy antigen", "GENE_OR_GENE_PRODUCT", 158, 176], ["tobacco mosaic virus", "ORGANISM", 321, 341], ["TMV", "ORGANISM", 343, 346], ["TMV", "ORGANISM", 433, 436], ["self-assembling proteins", "PROTEIN", 87, 111], ["tobacco mosaic virus", "SPECIES", 321, 341], ["tobacco mosaic virus", "SPECIES", 321, 341], ["TMV", "SPECIES", 343, 346], ["a protein", "TEST", 292, 301], ["mosaic virus", "OBSERVATION", 329, 341], ["shaped", "OBSERVATION_MODIFIER", 370, 376], ["particles", "OBSERVATION_MODIFIER", 377, 386]]], ["Later, in the 1970s, the hepatitis B virus (HBV) surface antigen (HBsAg) was purified from infected human serum [6] .", [["serum", "ANATOMY", 106, 111], ["hepatitis B", "DISEASE", 25, 36], ["HBsAg", "CHEMICAL", 66, 71], ["hepatitis B virus", "ORGANISM", 25, 42], ["(HBV) surface antigen", "GENE_OR_GENE_PRODUCT", 43, 64], ["HBsAg", "GENE_OR_GENE_PRODUCT", 66, 71], ["human", "ORGANISM", 100, 105], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["hepatitis B virus (HBV) surface antigen", "PROTEIN", 25, 64], ["HBsAg", "PROTEIN", 66, 71], ["hepatitis B virus", "SPECIES", 25, 42], ["human", "SPECIES", 100, 105], ["hepatitis B virus", "SPECIES", 25, 42], ["HBV", "SPECIES", 44, 47], ["human", "SPECIES", 100, 105], ["the hepatitis B virus (HBV) surface antigen", "TEST", 21, 64], ["HBsAg", "TEST", 66, 71], ["infected human serum", "TEST", 91, 111]]], ["Electron microscopy (EM) and ultraviolet absorption studies revealed that HBsAg formed spherical particles with an average diameter of~22 nm and which, importantly, like the TMV protein particle, lacked nucleic acid and hence were non-infectious.", [["HBsAg", "CHEMICAL", 74, 79], ["nucleic acid", "CHEMICAL", 203, 215], ["HBsAg", "GENE_OR_GENE_PRODUCT", 74, 79], ["TMV", "ORGANISM", 174, 177], ["HBsAg", "PROTEIN", 74, 79], ["TMV protein particle", "PROTEIN", 174, 194], ["Electron microscopy", "TEST", 0, 19], ["ultraviolet absorption studies", "TEST", 29, 59], ["HBsAg formed spherical particles", "PROBLEM", 74, 106], ["the TMV protein particle", "TEST", 170, 194], ["nucleic acid", "TEST", 203, 215], ["non-infectious", "PROBLEM", 231, 245], ["HBsAg", "OBSERVATION", 74, 79], ["spherical particles", "OBSERVATION", 87, 106], ["average", "OBSERVATION_MODIFIER", 115, 122], ["diameter", "OBSERVATION_MODIFIER", 123, 131], ["22 nm", "OBSERVATION_MODIFIER", 135, 140], ["TMV protein particle", "OBSERVATION", 174, 194], ["nucleic acid", "OBSERVATION", 203, 215], ["non-infectious", "OBSERVATION", 231, 245]]], ["Preparations of such virus-derived 'nanoparticles' formed the first efficacious HBV vaccine, licensed in 1981 [7] , and represented a milestone that created a new focus in the field of vaccinology.", [["HBV", "ORGANISM", 80, 83], ["HBV", "SPECIES", 80, 83], ["such virus-derived 'nanoparticles'", "TREATMENT", 16, 50], ["new", "OBSERVATION_MODIFIER", 159, 162], ["focus", "OBSERVATION", 163, 168]]], ["Indeed, antigen nanoparticles, first exemplified by HBsAg, have now emerged as a leading strategy in the development of safe and potent vaccines.IntroductionWhat are the advantages of nanoparticle antigens?", [["HBsAg", "CHEMICAL", 52, 57], ["HBsAg", "GENE_OR_GENE_PRODUCT", 52, 57], ["nanoparticle antigens", "GENE_OR_GENE_PRODUCT", 184, 205], ["HBsAg", "PROTEIN", 52, 57], ["nanoparticle antigens", "PROTEIN", 184, 205], ["HBsAg", "TEST", 52, 57], ["safe and potent vaccines", "TREATMENT", 120, 144], ["nanoparticle antigens", "PROBLEM", 184, 205], ["HBsAg", "OBSERVATION", 52, 57]]], ["Key parameters governing the elicitation of an efficient immune response to a microbe include both antigen density and distribution on the pathogen surface [8] .", [["surface", "ANATOMY", 148, 155], ["the pathogen surface", "TEST", 135, 155], ["antigen density", "OBSERVATION_MODIFIER", 99, 114], ["distribution", "OBSERVATION_MODIFIER", 119, 131]]], ["B-and T-cell stimulation and activation, and the subsequent secretion of antigen-specific antibodies by plasma cells, rely on effective cross-linking between B-cell surface immunoglobulins (the B-cell receptor, BCR) and the recognition pattern presented by the pathogen.", [["T-cell", "ANATOMY", 6, 12], ["plasma cells", "ANATOMY", 104, 116], ["B-cell surface", "ANATOMY", 158, 172], ["B-cell", "ANATOMY", 194, 200], ["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["T-cell", "CELL", 6, 12], ["plasma cells", "CELL", 104, 116], ["B-cell surface immunoglobulins", "GENE_OR_GENE_PRODUCT", 158, 188], ["B-cell receptor", "GENE_OR_GENE_PRODUCT", 194, 209], ["BCR", "GENE_OR_GENE_PRODUCT", 211, 214], ["antigen-specific antibodies", "PROTEIN", 73, 100], ["plasma cells", "CELL_TYPE", 104, 116], ["B-cell surface immunoglobulins", "PROTEIN", 158, 188], ["B-cell receptor", "PROTEIN", 194, 209], ["BCR", "PROTEIN", 211, 214], ["B", "TEST", 0, 1], ["T-cell stimulation", "TREATMENT", 6, 24], ["the subsequent secretion of antigen", "TEST", 45, 80], ["plasma cells", "TEST", 104, 116], ["B-cell surface immunoglobulins", "TREATMENT", 158, 188], ["the B-cell receptor", "TREATMENT", 190, 209], ["BCR", "PROBLEM", 211, 214], ["the pathogen", "PROBLEM", 257, 269]]], ["The high density and structurally ordered antigenic array presented by a nanoparticle provides a molecular scenario where multiple binding events occur simultaneously between the nanoparticle and the host cell BCRs (Fig. 1 ).", [["cell", "ANATOMY", 205, 209], ["cell", "CELL", 205, 209], ["The high density and structurally ordered antigenic array", "PROBLEM", 0, 57], ["multiple binding events", "PROBLEM", 122, 145], ["high", "OBSERVATION_MODIFIER", 4, 8], ["density", "OBSERVATION", 9, 16], ["host cell BCRs", "OBSERVATION", 200, 214]]], ["This multivalent molecular and cellular setting favors the fruitful network of stimulatory interactions, as opposed to the weaker effect of monovalent binding afforded by single soluble recombinant antigens.", [["cellular", "ANATOMY", 31, 39], ["cellular", "CELL", 31, 39], ["recombinant antigens", "PROTEIN", 186, 206], ["monovalent binding", "PROBLEM", 140, 158], ["single soluble recombinant antigens", "TREATMENT", 171, 206], ["cellular setting", "OBSERVATION", 31, 47]]], ["Indeed, the high avidity for the nanoparticle provided by the multivalent interaction constitutes a critical step in the induction of a potent immune reaction (Fig. 1) .", [["a potent immune reaction", "PROBLEM", 134, 158]]], ["Because of these advantageous Fig. 1 .", [["these advantageous Fig", "TREATMENT", 11, 33], ["advantageous Fig", "OBSERVATION", 17, 33]]], ["Multivalent nanoparticles favor the generation of potent, long-lived immunoprotection in germinal centers.", [["germinal centers", "ANATOMY", 89, 105], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 89, 105], ["Multivalent nanoparticles", "TREATMENT", 0, 25], ["long-lived immunoprotection in germinal centers", "TREATMENT", 58, 105], ["nanoparticles", "OBSERVATION", 12, 25], ["potent", "OBSERVATION_MODIFIER", 50, 56], ["germinal centers", "OBSERVATION", 89, 105]]], ["Recombinant nanoparticles loaded with the desired antigen are designed thoroughly to present multiple copies of a pathogen epitope in a highly ordered manner on the surface of a self-assembling nanoparticle.", [["surface", "ANATOMY", 165, 172], ["surface", "CELLULAR_COMPONENT", 165, 172], ["Recombinant nanoparticles", "TREATMENT", 0, 25], ["a pathogen epitope", "PROBLEM", 112, 130], ["pathogen epitope", "OBSERVATION", 114, 130]]], ["As opposed to single recombinant antigens that provide brief half-life 1:1 interactions with the BCRs (A), the polydentate nature, i.e. avidity, of the interaction with the nanoparticle enables tighter and prolonged bindings: the dissociation of one antigen molecule can be compensated by the binding of a new antigen molecule or re-association with a new BCR (B).", [["BCRs", "GENE_OR_GENE_PRODUCT", 97, 101], ["BCR", "GENE_OR_GENE_PRODUCT", 356, 359], ["B", "GENE_OR_GENE_PRODUCT", 361, 362], ["recombinant antigens", "PROTEIN", 21, 41], ["BCRs", "PROTEIN", 97, 101], ["antigen molecule", "PROTEIN", 250, 266], ["antigen molecule", "PROTEIN", 310, 326], ["BCR (B)", "PROTEIN", 356, 363], ["a new antigen molecule", "PROBLEM", 304, 326], ["a new BCR", "PROBLEM", 350, 359]]], ["This scenario enables the clustering of BCRs for multiple and simultaneous engagement with the antigen epitopes.", [["BCRs", "GENE_OR_GENE_PRODUCT", 40, 44], ["BCRs", "PROTEIN", 40, 44], ["antigen epitopes", "PROTEIN", 95, 111], ["the antigen epitopes", "TREATMENT", 91, 111]]], ["Thus, the B-cell traps the antigen-loaded nanoparticle to establish a durable, localized and strong recognition that translates into B-cell intracellular signaling, internalization and processing of the antigen for presentation, via molecules of the MHC complex, to the T follicular helper cells (Tfh) within the germinal centers.", [["B-cell", "ANATOMY", 10, 16], ["B-cell", "ANATOMY", 133, 139], ["intracellular", "ANATOMY", 140, 153], ["T follicular helper cells", "ANATOMY", 270, 295], ["Tfh", "ANATOMY", 297, 300], ["germinal centers", "ANATOMY", 313, 329], ["B-cell", "CELL", 10, 16], ["B-cell", "CELL", 133, 139], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 140, 153], ["T follicular helper cells", "CELL", 270, 295], ["Tfh", "CELL", 297, 300], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 313, 329], ["MHC complex", "PROTEIN", 250, 261], ["T follicular helper cells", "CELL_TYPE", 270, 295], ["Tfh", "CELL_TYPE", 297, 300], ["the B-cell traps", "TEST", 6, 22], ["the antigen", "TEST", 199, 210], ["germinal", "ANATOMY_MODIFIER", 313, 321]]], ["This new recognition evokes the secretion of regulatory cytokines by the Tfh cell and ultimately the evolution of B cells into plasma cells that can secrete antigen-specific neutralizing Abs. immunological and physicochemical properties, and their suitability for large-scale manufacturing via Escherichia coli (E. coli) or eukaryotic systems, nanoparticles are at the frontline of new vaccine therapeutics.IntroductionA variety of naturally occurring proteins can self-assemble into nanoparticles that are highly symmetric, stable, and structurally organized, with diameters of 10-150 nm [9, 10] , a highly suitable size range for optimal interactions with various cells of the immune system [8, 11] .", [["Tfh cell", "ANATOMY", 73, 81], ["B cells", "ANATOMY", 114, 121], ["plasma cells", "ANATOMY", 127, 139], ["cells", "ANATOMY", 666, 671], ["immune system", "ANATOMY", 679, 692], ["Tfh cell", "CELL", 73, 81], ["B cells", "CELL", 114, 121], ["plasma cells", "CELL", 127, 139], ["antigen", "GENE_OR_GENE_PRODUCT", 157, 164], ["Escherichia coli", "ORGANISM", 294, 310], ["E. coli", "ORGANISM", 312, 319], ["cells", "CELL", 666, 671], ["regulatory cytokines", "PROTEIN", 45, 65], ["Tfh cell", "CELL_TYPE", 73, 81], ["B cells", "CELL_TYPE", 114, 121], ["plasma cells", "CELL_TYPE", 127, 139], ["neutralizing Abs", "PROTEIN", 174, 190], ["Escherichia coli", "SPECIES", 294, 310], ["E. coli", "SPECIES", 312, 319], ["Escherichia coli", "SPECIES", 294, 310], ["E. coli", "SPECIES", 312, 319], ["the secretion of regulatory cytokines", "PROBLEM", 28, 65], ["B cells into plasma cells", "PROBLEM", 114, 139], ["secrete antigen", "TEST", 149, 164], ["large-scale manufacturing", "TREATMENT", 264, 289], ["Escherichia coli", "PROBLEM", 294, 310], ["E. coli", "PROBLEM", 312, 319], ["eukaryotic systems", "PROBLEM", 324, 342], ["nanoparticles", "TREATMENT", 344, 357], ["new vaccine therapeutics", "TREATMENT", 382, 406], ["diameters", "TEST", 566, 575], ["Tfh cell", "OBSERVATION", 73, 81], ["neutralizing Abs", "OBSERVATION", 174, 190], ["physicochemical properties", "OBSERVATION", 210, 236], ["Escherichia coli", "OBSERVATION", 294, 310], ["highly", "OBSERVATION_MODIFIER", 507, 513], ["symmetric", "OBSERVATION", 514, 523], ["stable", "OBSERVATION_MODIFIER", 525, 531], ["structurally", "OBSERVATION_MODIFIER", 537, 549], ["organized", "OBSERVATION_MODIFIER", 550, 559], ["diameters", "OBSERVATION_MODIFIER", 566, 575]]], ["These nanoparticles normally play diverse physiological roles, but are of particular interest in the context of vaccine design because they can be used as self-assembling platforms for the display of an arranged and well-ordered matrix of a particular immunogen, thereby mimicking the repetitive surface architecture of a natural microbe, e.g. a spherical virus capsid [12] .IntroductionWhile many natural proteins have acquired self-assembling properties during evolution [13] , the de novo engineering of protein assemblies is challenging.", [["surface", "ANATOMY", 296, 303], ["matrix", "CELLULAR_COMPONENT", 229, 235], ["vaccine design", "TREATMENT", 112, 126], ["a particular immunogen", "TREATMENT", 239, 261], ["a spherical virus capsid", "PROBLEM", 344, 368], ["the de novo engineering of protein assemblies", "TREATMENT", 480, 525]]], ["Early proposals to rationally perform atomic and molecular manipulations to generate interesting new materials were mentioned by Richard Feynman in 1960 [14, 15] .", [["atomic and molecular manipulations", "TREATMENT", 38, 72]]], ["Later, the idea of combining proteins as building blocks into higher-order structures via selfassembly was advanced [15, 16] .", [["combining proteins", "PROBLEM", 19, 37]]], ["More recently, the feasibility of designing self-assembling proteins has improved via new computational approaches [17] .", [["self-assembling proteins", "PROTEIN", 44, 68]]], ["Consequently, using natural or engineered protein nanoparticle scaffolds, vaccinologists can now aim to add heterologous epitopes or antigens onto the 'plain' nanoparticle, thus representing a limitless source of possible 'chimeric' nanoparticle antigens.", [["chimeric' nanoparticle antigens", "GENE_OR_GENE_PRODUCT", 223, 254], ["heterologous epitopes", "PROTEIN", 108, 129], ["antigens", "PROTEIN", 133, 141], ["chimeric' nanoparticle antigens", "PROTEIN", 223, 254], ["natural or engineered protein nanoparticle scaffolds", "TREATMENT", 20, 72], ["vaccinologists", "TREATMENT", 74, 88], ["heterologous epitopes", "TREATMENT", 108, 129], ["'chimeric' nanoparticle antigens", "PROBLEM", 222, 254]]], ["Such chimeric nanoparticles can be obtained by self-assembly, or by covalent chemical attachment of an antigen to a nanoparticle.IntroductionSince the emergence of nanoparticle vaccine antigens in the 1970s, numerous attempts to generate plain or chimeric nanoparticles with scaffolds from many origins have been described.", [["Such chimeric nanoparticles", "PROBLEM", 0, 27], ["nanoparticle vaccine antigens", "TREATMENT", 164, 193], ["plain or chimeric nanoparticles with scaffolds", "TREATMENT", 238, 284]]], ["Some of these are virus-like particles (VLPs) composed of single or multiple viral antigens, in some cases anchored in a lipid bilayer.", [["lipid bilayer", "ANATOMY", 121, 134], ["VLPs", "ORGANISM", 40, 44], ["lipid bilayer", "CELLULAR_COMPONENT", 121, 134], ["viral antigens", "PROTEIN", 77, 91], ["virus", "PROBLEM", 18, 23], ["single or multiple viral antigens", "PROBLEM", 58, 91], ["virus", "OBSERVATION", 18, 23], ["particles", "OBSERVATION_MODIFIER", 29, 38], ["multiple", "OBSERVATION_MODIFIER", 68, 76], ["viral antigens", "OBSERVATION", 77, 91]]], ["Structural proteins from different microorganisms have served as templates for the production of such nanoparticles and for the presentation of immunogenic epitopes: the protein pIII of the filamentous phage f1 [18] , the Ty component from Saccharomyces cerevisiae [19] , the surface and core antigens of the hepatitis B virus [20, 21] , surface or coat proteins of bluetongue virus [22] , human parvovirus B19 [23] , tobacco mosaic virus [24] , the Picornaviridae virus [25] , Sindbis virus [26] , and papillomavirus [27, 28] are just some examples.", [["surface", "ANATOMY", 276, 283], ["surface", "ANATOMY", 338, 345], ["hepatitis B", "DISEASE", 309, 320], ["bluetongue virus", "DISEASE", 366, 382], ["parvovirus B19", "DISEASE", 396, 410], ["tobacco mosaic virus", "DISEASE", 418, 438], ["Sindbis virus", "DISEASE", 478, 491], ["pIII", "GENE_OR_GENE_PRODUCT", 178, 182], ["filamentous phage f1 [18", "GENE_OR_GENE_PRODUCT", 190, 214], ["Ty", "GENE_OR_GENE_PRODUCT", 222, 224], ["Saccharomyces cerevisiae", "ORGANISM", 240, 264], ["surface", "CELLULAR_COMPONENT", 276, 283], ["hepatitis B virus", "ORGANISM", 309, 326], ["surface", "CELLULAR_COMPONENT", 338, 345], ["bluetongue virus", "ORGANISM", 366, 382], ["human", "ORGANISM", 390, 395], ["parvovirus B19", "ORGANISM", 396, 410], ["[23", "ORGANISM", 411, 414], ["tobacco mosaic virus", "ORGANISM", 418, 438], ["Picornaviridae virus", "ORGANISM", 450, 470], ["Sindbis virus", "ORGANISM", 478, 491], ["papillomavirus", "ORGANISM", 503, 517], ["immunogenic epitopes", "PROTEIN", 144, 164], ["protein pIII", "PROTEIN", 170, 182], ["Ty component", "PROTEIN", 222, 234], ["core antigens", "PROTEIN", 288, 301], ["coat proteins", "PROTEIN", 349, 362], ["Saccharomyces cerevisiae", "SPECIES", 240, 264], ["hepatitis B virus", "SPECIES", 309, 326], ["bluetongue virus", "SPECIES", 366, 382], ["human", "SPECIES", 390, 395], ["parvovirus B19", "SPECIES", 396, 410], ["tobacco mosaic virus", "SPECIES", 418, 438], ["Picornaviridae virus", "SPECIES", 450, 470], ["Sindbis virus", "SPECIES", 478, 491], ["Saccharomyces cerevisiae", "SPECIES", 240, 264], ["hepatitis B virus", "SPECIES", 309, 326], ["bluetongue virus", "SPECIES", 366, 382], ["human parvovirus B19", "SPECIES", 390, 410], ["tobacco mosaic virus", "SPECIES", 418, 438], ["Picornaviridae virus", "SPECIES", 450, 470], ["Sindbis virus", "SPECIES", 478, 491], ["Structural proteins", "PROBLEM", 0, 19], ["different microorganisms", "PROBLEM", 25, 49], ["such nanoparticles", "TREATMENT", 97, 115], ["immunogenic epitopes", "PROBLEM", 144, 164], ["the protein pIII", "TREATMENT", 166, 182], ["the filamentous phage f1", "TREATMENT", 186, 210], ["Saccharomyces cerevisiae", "TEST", 240, 264], ["the surface", "TEST", 272, 283], ["core antigens", "TEST", 288, 301], ["the hepatitis B virus", "TEST", 305, 326], ["coat proteins", "TEST", 349, 362], ["bluetongue virus", "PROBLEM", 366, 382], ["human parvovirus B19", "TEST", 390, 410], ["tobacco mosaic virus", "PROBLEM", 418, 438], ["the Picornaviridae virus", "PROBLEM", 446, 470], ["Sindbis virus", "PROBLEM", 478, 491], ["papillomavirus", "TEST", 503, 517], ["bluetongue virus", "OBSERVATION", 366, 382]]], ["This mini-review will focus on a subset of such studies.", [["such studies", "TEST", 43, 55]]], ["Structural vaccinology is an emerging discipline that uses insights from structural and computational biology studies with neighboring fields such as formulation science, immunology, animal studies, and serology in order to design, evaluate, optimize, and deliver leading candidate vaccine antigens [29, 30] .", [["animal studies", "TEST", 183, 197], ["serology", "TEST", 203, 211]]], ["As a minor note, synthetic nanoparticles made from non-polypeptide polymers, metals, or other solid supports, and the use of encapsulating particles as vaccine delivery systems are beyond the scope of the current review, and the reader is directed to alternative sources [31] [32] [33] .Viral proteins and virus-like particles (VLPs)Many viruses encode proteins that form stable nanoparticle structures, which self-assemble in infected host cells in order to package the viral genomes as a pre-requisite for propagation.", [["cells", "ANATOMY", 441, 446], ["metals", "CHEMICAL", 77, 83], ["non-polypeptide polymers", "SIMPLE_CHEMICAL", 51, 75], ["metals", "SIMPLE_CHEMICAL", 77, 83], ["[31] [32] [33]", "SIMPLE_CHEMICAL", 271, 285], ["virus-like particles", "ORGANISM", 306, 326], ["VLPs", "ORGANISM", 328, 332], ["host cells", "CELL", 436, 446], ["Viral proteins", "PROTEIN", 287, 301], ["infected host cells", "CELL_TYPE", 427, 446], ["viral genomes", "DNA", 471, 484], ["synthetic nanoparticles", "TREATMENT", 17, 40], ["non-polypeptide polymers", "TREATMENT", 51, 75], ["encapsulating particles", "TREATMENT", 125, 148], ["vaccine delivery systems", "TREATMENT", 152, 176], ["Viral proteins", "TEST", 287, 301], ["virus", "PROBLEM", 306, 311], ["like particles", "PROBLEM", 312, 326], ["Many viruses encode proteins", "PROBLEM", 333, 361], ["infected host cells", "PROBLEM", 427, 446], ["the viral genomes", "PROBLEM", 467, 484], ["virus", "OBSERVATION", 306, 311], ["particles", "OBSERVATION_MODIFIER", 317, 326], ["stable", "OBSERVATION_MODIFIER", 372, 378], ["nanoparticle structures", "OBSERVATION", 379, 402], ["infected host cells", "OBSERVATION", 427, 446], ["viral genomes", "OBSERVATION", 471, 484]]], ["However, if scaffold proteins are assembled in the absence of genetic material, then non-infectious non-replicating virus-like particles (VLPs) that closely resemble intact virions can be obtained.", [["virions", "ANATOMY", 173, 180], ["virus-like particles", "ORGANISM", 116, 136], ["VLPs", "ORGANISM", 138, 142], ["scaffold proteins", "PROTEIN", 12, 29], ["scaffold proteins", "PROBLEM", 12, 29], ["genetic material", "PROBLEM", 62, 78], ["non-infectious non-replicating virus", "PROBLEM", 85, 121]]], ["Consequently, viral nanoparticles or VLPs composed of one, or a few, recombinant self-assembling proteins were among the first antigen-nanoparticle candidates, some of which have indeed been developed into successfully marketed vaccines [4] .", [["recombinant self-assembling proteins", "PROTEIN", 69, 105], ["viral nanoparticles", "PROBLEM", 14, 33], ["VLPs", "PROBLEM", 37, 41], ["assembling proteins", "PROBLEM", 86, 105]]], ["Indeed, the earliest VLPs were relatively simply obtained by self-assembly of single recombinant HBV or HPV capsid proteins.", [["VLPs", "ORGANISM", 21, 25], ["HBV", "ORGANISM", 97, 100], ["HPV capsid", "ORGANISM", 104, 114], ["single recombinant HBV or HPV capsid proteins", "PROTEIN", 78, 123], ["HBV", "SPECIES", 97, 100], ["HPV", "SPECIES", 104, 107], ["the earliest VLPs", "TEST", 8, 25], ["single recombinant HBV", "PROBLEM", 78, 100], ["HPV capsid proteins", "PROBLEM", 104, 123]]], ["After excellent results obtained with these first 'plain' VLPs, several 'chimeric' VLPs were explored as platforms for the display of heterologous epitopes or antigens.", [["VLPs", "ORGANISM", 83, 87], ["heterologous epitopes", "PROTEIN", 134, 155], ["antigens", "PROTEIN", 159, 167], ["these first 'plain' VLPs", "TREATMENT", 38, 62], ["several 'chimeric' VLPs", "TREATMENT", 64, 87], ["heterologous epitopes", "PROBLEM", 134, 155]]], ["We will also briefly discuss the more complex VLPs representing enveloped viruses.", [["VLPs", "ORGANISM", 46, 50], ["the more complex VLPs", "PROBLEM", 29, 50], ["enveloped", "OBSERVATION_MODIFIER", 64, 73], ["viruses", "OBSERVATION", 74, 81]]], ["In contrast to VLPs made from highly purified protein capsids, enveloped VLPs (virosomes) are assembled by budding from the host cell membrane.", [["cell membrane", "ANATOMY", 129, 142], ["VLPs", "GENE_OR_GENE_PRODUCT", 73, 77], ["virosomes", "GENE_OR_GENE_PRODUCT", 79, 88], ["cell membrane", "CELLULAR_COMPONENT", 129, 142], ["enveloped VLPs", "PROTEIN", 63, 77], ["virosomes", "PROTEIN", 79, 88], ["VLPs", "TREATMENT", 15, 19], ["highly purified protein capsids", "PROBLEM", 30, 61], ["protein capsids", "OBSERVATION", 46, 61], ["host cell membrane", "OBSERVATION", 124, 142]]], ["More extensive reviews of viral or VLP vaccines, with a focus on the challenges of their industrial development and manufacturing, can be found elsewhere [34, 35] .Viral proteins and virus-like particles (VLPs)In the second half of the 20th century, the first genetically engineered vaccine was developed by cloning the VP 3 capsid protein of the foot-and-mouth disease virus (FMDV), which was demonstrated to be a safe, stable and effective polypeptide vaccine for cattle and swine [36] .", [["virus-like particles", "ORGANISM", 183, 203], ["VP 3", "GENE_OR_GENE_PRODUCT", 320, 324], ["foot-and-mouth disease virus", "ORGANISM", 347, 375], ["FMDV", "ORGANISM", 377, 381], ["Viral proteins", "PROTEIN", 164, 178], ["VP 3 capsid protein", "PROTEIN", 320, 339], ["foot-and-mouth disease virus", "SPECIES", 347, 375], ["FMDV", "SPECIES", 377, 381], ["cattle", "SPECIES", 466, 472], ["swine", "SPECIES", 477, 482], ["foot-and-mouth disease virus", "SPECIES", 347, 375], ["FMDV", "SPECIES", 377, 381], ["cattle", "SPECIES", 466, 472], ["swine", "SPECIES", 477, 482], ["viral or VLP vaccines", "TREATMENT", 26, 47], ["Viral proteins", "TEST", 164, 178], ["virus", "PROBLEM", 183, 188], ["the first genetically engineered vaccine", "TREATMENT", 250, 290], ["mouth disease virus", "PROBLEM", 356, 375], ["effective polypeptide vaccine", "TREATMENT", 432, 461], ["virus", "OBSERVATION", 183, 188], ["particles", "OBSERVATION_MODIFIER", 194, 203], ["foot", "ANATOMY", 347, 351], ["mouth", "ANATOMY", 356, 361]]], ["The breakthrough of the genetic FMDV animal vaccine, coupled with the discovery of the HBsAg vaccine antigen purified from human serum, stimulated the search for a safe, genetic in vitro-produced vaccine to protect humans against HBV.", [["serum", "ANATOMY", 129, 134], ["HBsAg", "CHEMICAL", 87, 92], ["FMDV", "ORGANISM", 32, 36], ["HBsAg", "GENE_OR_GENE_PRODUCT", 87, 92], ["human", "ORGANISM", 123, 128], ["serum", "ORGANISM_SUBSTANCE", 129, 134], ["humans", "ORGANISM", 215, 221], ["HBV", "ORGANISM", 230, 233], ["HBsAg vaccine antigen", "PROTEIN", 87, 108], ["FMDV", "SPECIES", 32, 36], ["human", "SPECIES", 123, 128], ["humans", "SPECIES", 215, 221], ["FMDV", "SPECIES", 32, 36], ["human", "SPECIES", 123, 128], ["humans", "SPECIES", 215, 221], ["HBV", "SPECIES", 230, 233], ["the genetic FMDV animal vaccine", "TREATMENT", 20, 51], ["the HBsAg vaccine antigen", "TREATMENT", 83, 108], ["human serum", "TEST", 123, 134], ["vitro-produced vaccine", "TREATMENT", 181, 203], ["HBV", "PROBLEM", 230, 233]]], ["In 1986, licensure was obtained for the first human vaccine based on a recombinant protein subunit antigen (HBsAg), which self-assembles into nanoparticles [37, 38] .", [["HBsAg", "CHEMICAL", 108, 113], ["human", "ORGANISM", 46, 51], ["recombinant protein subunit antigen", "GENE_OR_GENE_PRODUCT", 71, 106], ["HBsAg", "GENE_OR_GENE_PRODUCT", 108, 113], ["recombinant protein subunit antigen", "PROTEIN", 71, 106], ["HBsAg", "PROTEIN", 108, 113], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["the first human vaccine", "TREATMENT", 36, 59], ["a recombinant protein subunit antigen", "TEST", 69, 106], ["HBsAg", "TEST", 108, 113]]], ["Although these assemblies form nanoparticles, they do not very closely resemble the intact HBV virion and thus are not fully considered VLPs.", [["HBV", "ORGANISM", 91, 94], ["HBV", "SPECIES", 91, 94], ["the intact HBV virion", "PROBLEM", 80, 101], ["HBV", "OBSERVATION", 91, 94]]], ["Nevertheless, recombinant HBsAg nanoparticles are included in two safe and efficacious vaccines (marketed as Engerix-B [39] and Recombivax-HB), now globally implemented to protect against HBV.Viral proteins and virus-like particles (VLPs)Perhaps the first real VLP human vaccine is the successful story of two similar vaccines protecting against HPV infection, a major cause of anogenital disease and, especially, cervical cancer [40] .", [["anogenital", "ANATOMY", 378, 388], ["cervical cancer", "ANATOMY", 414, 429], ["HBsAg", "CHEMICAL", 26, 31], ["Engerix-B [39] and Recombivax-HB", "CHEMICAL", 109, 141], ["HPV infection", "DISEASE", 346, 359], ["anogenital disease", "DISEASE", 378, 396], ["cervical cancer", "DISEASE", 414, 429], ["HBsAg", "GENE_OR_GENE_PRODUCT", 26, 31], ["Engerix-B [39]", "ORGANISM", 109, 123], ["Recombivax-HB", "SIMPLE_CHEMICAL", 128, 141], ["HBV", "ORGANISM", 188, 191], ["virus-like particles", "ORGANISM", 211, 231], ["VLPs", "ORGANISM", 233, 237], ["VLP", "ORGANISM", 261, 264], ["human", "ORGANISM", 265, 270], ["HPV", "ORGANISM", 346, 349], ["anogenital disease", "CANCER", 378, 396], ["cervical cancer", "CANCER", 414, 429], ["Viral proteins", "PROTEIN", 192, 206], ["human", "SPECIES", 265, 270], ["HBV", "SPECIES", 188, 191], ["human", "SPECIES", 265, 270], ["HPV", "SPECIES", 346, 349], ["recombinant HBsAg nanoparticles", "TEST", 14, 45], ["efficacious vaccines", "TREATMENT", 75, 95], ["Engerix", "TEST", 109, 116], ["Recombivax", "TREATMENT", 128, 138], ["HBV", "PROBLEM", 188, 191], ["Viral proteins", "PROBLEM", 192, 206], ["virus", "PROBLEM", 211, 216], ["the first real VLP human vaccine", "TREATMENT", 246, 278], ["two similar vaccines", "TREATMENT", 306, 326], ["HPV infection", "PROBLEM", 346, 359], ["anogenital disease", "PROBLEM", 378, 396], ["cervical cancer", "PROBLEM", 414, 429], ["virus", "OBSERVATION", 211, 216], ["particles", "OBSERVATION_MODIFIER", 222, 231], ["infection", "OBSERVATION", 350, 359], ["cervical", "ANATOMY", 414, 422], ["cancer", "OBSERVATION", 423, 429]]], ["Both vaccines were launched in the first decade of the 21st century (marketed as Cervarix and Gardasil) and contain recombinant HPV L1 major capsid protein VLPs [27, 28] .", [["HPV L1", "ORGANISM", 128, 134], ["recombinant HPV L1 major capsid protein VLPs", "PROTEIN", 116, 160], ["HPV", "SPECIES", 128, 131], ["Both vaccines", "TREATMENT", 0, 13], ["Cervarix and Gardasil)", "TREATMENT", 81, 103]]], ["The development of these vaccines followed work in the 1980s, when the first reports emerged describing the selfassembly of recombinant forms of the major capsid proteins of several viruses, including hepatitis B [37] , polyoma [41] , and parvovirus [42] .", [["hepatitis B", "DISEASE", 201, 212], ["hepatitis B [37]", "ORGANISM", 201, 217], ["polyoma", "ORGANISM", 220, 227], ["parvovirus", "ORGANISM", 239, 249], ["major capsid proteins", "PROTEIN", 149, 170], ["hepatitis B", "SPECIES", 201, 212], ["these vaccines", "TREATMENT", 19, 33], ["several viruses", "PROBLEM", 174, 189], ["hepatitis B", "TEST", 201, 212], ["polyoma", "TEST", 220, 227], ["parvovirus", "PROBLEM", 239, 249], ["several", "OBSERVATION_MODIFIER", 174, 181], ["viruses", "OBSERVATION", 182, 189]]], ["Studies in the early 1990s then revealed that recombinant L1 from bovine and human papillomaviruses could self-assemble into empty capsid-like nanoparticles of~50 nm diameter and, importantly, L1 nanoparticles could raise high-titer neutralizing antibodies in animals, with an immunogenicity profile similar to that of infectious HPV virions [43, 44] .", [["infectious HPV virions", "DISEASE", 319, 341], ["bovine", "ORGANISM", 66, 72], ["human", "ORGANISM", 77, 82], ["papillomaviruses", "ORGANISM", 83, 99], ["L1 nanoparticles", "SIMPLE_CHEMICAL", 193, 209], ["HPV virions", "ORGANISM", 330, 341], ["recombinant L1", "PROTEIN", 46, 60], ["neutralizing antibodies", "PROTEIN", 233, 256], ["bovine", "SPECIES", 66, 72], ["human", "SPECIES", 77, 82], ["bovine", "SPECIES", 66, 72], ["human papillomaviruses", "SPECIES", 77, 99], ["HPV", "SPECIES", 330, 333], ["Studies", "TEST", 0, 7], ["recombinant L1 from bovine and human papillomaviruses", "PROBLEM", 46, 99], ["L1 nanoparticles", "TEST", 193, 209], ["high-titer neutralizing antibodies in animals", "PROBLEM", 222, 267], ["an immunogenicity profile", "PROBLEM", 274, 299], ["infectious HPV virions", "PROBLEM", 319, 341], ["50 nm", "OBSERVATION_MODIFIER", 160, 165], ["diameter", "OBSERVATION_MODIFIER", 166, 174], ["infectious", "OBSERVATION_MODIFIER", 319, 329]]], ["Notably, the denatured non-assembled form of L1 did not induce neutralizing antibodies [40] , highlighting the importance of the correct nanoparticulate structure of the protective epitopes in the L1 VLPs.Viral proteins and virus-like particles (VLPs)Several high-resolution crystal structures of different HPV L1 proteins have been determined, revealing the molecular basis for their oligomerization into the pentameric assembly unit of the viral shell [45] .", [["virus-like particles", "ORGANISM", 224, 244], ["HPV", "ORGANISM", 307, 310], ["L1", "PROTEIN", 45, 47], ["neutralizing antibodies", "PROTEIN", 63, 86], ["L1 VLPs", "PROTEIN", 197, 204], ["Viral proteins", "PROTEIN", 205, 219], ["VLPs", "PROTEIN", 246, 250], ["HPV L1 proteins", "PROTEIN", 307, 322], ["pentameric assembly unit", "PROTEIN", 410, 434], ["the denatured non-assembled form of L1", "PROBLEM", 9, 47], ["neutralizing antibodies", "PROBLEM", 63, 86], ["the protective epitopes in the L1 VLPs", "PROBLEM", 166, 204], ["Viral proteins", "TEST", 205, 219], ["virus", "TEST", 224, 229], ["VLPs", "TEST", 246, 250], ["Several high-resolution crystal structures of different HPV L1 proteins", "PROBLEM", 251, 322], ["L1", "ANATOMY", 45, 47], ["nanoparticulate structure", "OBSERVATION", 137, 162], ["protective epitopes", "OBSERVATION", 170, 189], ["L1 VLPs", "ANATOMY", 197, 204], ["virus", "OBSERVATION", 224, 229], ["particles", "OBSERVATION_MODIFIER", 235, 244], ["high", "OBSERVATION_MODIFIER", 259, 263], ["viral shell", "OBSERVATION", 442, 453]]], ["Further, cryoEM studies have enabled reconstructions of the entire HPV type 16 capsid alone or bound to neutralizing Fab fragments [46] [47] [48] .", [["Further, cryoEM studies", "TEST", 0, 23]]], ["Together, these structural studies have provided a deep understanding of the HPV L1 structure, antigenic specificity, and assembly into nanoparticles.", [["these structural studies", "TEST", 10, 34], ["L1", "ANATOMY", 81, 83]]], ["Such L1 VLPs derived from HPV types 16 and 18 (in the bivalent Cervarix) and additionally types 6, 11 (in the first quadrivalent Gardasil), 31, 33, 45, 52, and 58 (in the nonavalent Gardasil 9) form the basis of safe and highly efficacious vaccines [49] (Table 1) .", [["Gardasil", "CHEMICAL", 129, 137], ["Gardasil 9", "CHEMICAL", 182, 192], ["HPV", "ORGANISM", 26, 29], ["HPV types", "TEST", 26, 35], ["highly efficacious vaccines", "TREATMENT", 221, 248], ["L1 VLPs", "ANATOMY", 5, 12]]], ["Both HPV vaccines currently have relatively high production costs and their strain coverage efficacy is specific only for these L1 types included in the formulation, thus leaving room for improvement of potential second-generation vaccines.", [["HPV", "ORGANISM", 5, 8], ["HPV", "SPECIES", 5, 8], ["Both HPV vaccines", "TREATMENT", 0, 17], ["relatively high production costs", "PROBLEM", 33, 65], ["their strain coverage efficacy", "TREATMENT", 70, 100], ["potential second-generation vaccines", "TREATMENT", 203, 239], ["high", "OBSERVATION_MODIFIER", 44, 48]]], ["Nevertheless, the HPV L1 VLPs represent a shining example that encouraged the development and implementation of additional nanoparticle vaccines.Viral proteins and virus-like particles (VLPs)In addition to the research and clinical development of the HPV nanoparticle vaccines, numerous other viruses (for example, rotavirus [50] , poliovirus [51] , herpesvirus [52] , and parvovirus [53] ) have been used to generate non-infectious VLPs as vaccine candidates, although currently mostly without successful clinical development.", [["HPV L1 VLPs", "ORGANISM", 18, 29], ["virus-like particles", "ORGANISM", 164, 184], ["VLPs", "ORGANISM", 186, 190], ["HPV", "ORGANISM", 251, 254], ["rotavirus [50", "ORGANISM", 315, 328], ["poliovirus [51]", "ORGANISM", 332, 347], ["herpesvirus [52", "ORGANISM", 350, 365], ["parvovirus", "ORGANISM", 373, 383], ["VLPs", "ORGANISM", 433, 437], ["Viral proteins", "PROTEIN", 145, 159], ["HPV", "SPECIES", 18, 21], ["HPV", "SPECIES", 251, 254], ["the HPV L1 VLPs", "PROBLEM", 14, 29], ["additional nanoparticle vaccines", "TREATMENT", 112, 144], ["Viral proteins", "TEST", 145, 159], ["virus", "PROBLEM", 164, 169], ["the HPV nanoparticle vaccines", "TREATMENT", 247, 276], ["numerous other viruses", "PROBLEM", 278, 300], ["rotavirus", "TEST", 315, 324], ["poliovirus", "TEST", 332, 342], ["herpesvirus", "PROBLEM", 350, 361], ["parvovirus", "PROBLEM", 373, 383], ["non-infectious VLPs", "TREATMENT", 418, 437], ["virus", "OBSERVATION", 164, 169], ["particles", "OBSERVATION_MODIFIER", 175, 184]]], ["However, the increased understanding of the self-assembly of these nanoparticles and VLP production technology led to new opportunities in making chimeric VLPs that display heterologous epitopes or antigens attached to the VLP either by covalent modification (chemical cross-linking) or through genetic engineering, discussed further below.Viral proteins and virus-like particles (VLPs)The first viral nanoparticles to be discovered, efficiently produced recombinantly and characterized were those from HBV, composed either of the surface antigen (HBsAg) [37] , as described above, or the core antigen (HBcAg) [54] .", [["HBsAg", "CHEMICAL", 548, 553], ["VLPs", "ORGANISM", 155, 159], ["virus-like particles", "ORGANISM", 359, 379], ["VLPs", "ORGANISM", 381, 385], ["HBV", "ORGANISM", 503, 506], ["HBsAg", "GENE_OR_GENE_PRODUCT", 548, 553], ["HBcAg", "GENE_OR_GENE_PRODUCT", 603, 608], ["chimeric VLPs", "PROTEIN", 146, 159], ["heterologous epitopes", "PROTEIN", 173, 194], ["antigens", "PROTEIN", 198, 206], ["Viral proteins", "PROTEIN", 340, 354], ["VLPs", "PROTEIN", 381, 385], ["surface antigen", "PROTEIN", 531, 546], ["HBsAg", "PROTEIN", 548, 553], ["core antigen", "PROTEIN", 589, 601], ["HBcAg", "PROTEIN", 603, 608], ["HBV", "SPECIES", 503, 506], ["these nanoparticles", "TREATMENT", 61, 80], ["VLP production technology", "TREATMENT", 85, 110], ["chimeric VLPs", "TREATMENT", 146, 159], ["heterologous epitopes", "PROBLEM", 173, 194], ["the VLP", "TREATMENT", 219, 226], ["Viral proteins", "TEST", 340, 354], ["virus", "PROBLEM", 359, 364], ["like particles (VLPs", "PROBLEM", 365, 385], ["The first viral nanoparticles", "PROBLEM", 386, 415], ["HBV", "PROBLEM", 503, 506], ["the surface antigen", "TEST", 527, 546], ["HBsAg", "TEST", 548, 553], ["the core antigen", "TEST", 585, 601], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["virus", "OBSERVATION", 359, 364], ["particles", "OBSERVATION_MODIFIER", 370, 379]]], ["The HBcAg was first shown to selfassemble into particles of 24-31 nm diameter, which resembled the viral cores obtained from HBV-infected human liver, and which were highly immunogenic in animals.", [["liver", "ANATOMY", 144, 149], ["HBcAg", "GENE_OR_GENE_PRODUCT", 4, 9], ["HBV", "ORGANISM", 125, 128], ["human", "ORGANISM", 138, 143], ["liver", "ORGAN", 144, 149], ["HBcAg", "PROTEIN", 4, 9], ["human", "SPECIES", 138, 143], ["HBV", "SPECIES", 125, 128], ["human", "SPECIES", 138, 143], ["The HBcAg", "TEST", 0, 9], ["the viral cores", "TEST", 95, 110], ["HBV", "PROBLEM", 125, 128], ["infected human liver", "PROBLEM", 129, 149], ["viral cores", "OBSERVATION", 99, 110], ["HBV", "OBSERVATION", 125, 128], ["infected", "OBSERVATION", 129, 137], ["liver", "ANATOMY", 144, 149], ["highly", "OBSERVATION_MODIFIER", 166, 172], ["immunogenic", "OBSERVATION_MODIFIER", 173, 184]]], ["Later cryoEM studies revealed that HBcAg produced in E. coli self-assembles into two classes of differently sized nanoparticles of 300 \u00c5 and 360 \u00c5 diameter, corresponding to 180 or 240 protomers [55, 56] .", [["HBcAg", "GENE_OR_GENE_PRODUCT", 35, 40], ["E. coli", "ORGANISM", 53, 60], ["HBcAg", "PROTEIN", 35, 40], ["E. coli", "SPECIES", 53, 60], ["E. coli", "SPECIES", 53, 60], ["Later cryoEM studies", "TEST", 0, 20], ["HBcAg", "TEST", 35, 40], ["E. coli", "PROBLEM", 53, 60], ["E. coli", "OBSERVATION", 53, 60], ["sized", "OBSERVATION_MODIFIER", 108, 113], ["nanoparticles", "OBSERVATION_MODIFIER", 114, 127]]], ["A landmark study by Brown and coworkers showed that a chimeric recombinant form of HBcAg genetically fused to the foreign FMDV peptide epitope could be produced in a viral expression system and self-assembled into nanoparticles displaying the FMDV epitope.", [["HBcAg", "GENE_OR_GENE_PRODUCT", 83, 88], ["HBcAg", "PROTEIN", 83, 88], ["FMDV epitope", "PROTEIN", 243, 255], ["FMDV", "SPECIES", 122, 126], ["FMDV", "SPECIES", 243, 247], ["FMDV", "SPECIES", 122, 126], ["FMDV", "SPECIES", 243, 247], ["A landmark study", "TEST", 0, 16], ["HBcAg genetically fused", "PROBLEM", 83, 106], ["the foreign FMDV peptide epitope", "PROBLEM", 110, 142], ["a viral expression system", "PROBLEM", 164, 189], ["the FMDV epitope", "PROBLEM", 239, 255], ["foreign FMDV", "OBSERVATION", 114, 126], ["FMDV epitope", "OBSERVATION", 243, 255]]], ["This chimera was significantly more potent than the free FMDV peptide or the same peptide coupled to a beta-galactosidase carrier protein, and was highly potent in raising neutralizing antibodies against both FMDV and HBV [20] .", [["beta-galactosidase", "GENE_OR_GENE_PRODUCT", 103, 121], ["FMDV", "ORGANISM", 209, 213], ["HBV", "ORGANISM", 218, 221], ["chimera", "PROTEIN", 5, 12], ["beta-galactosidase carrier protein", "PROTEIN", 103, 137], ["neutralizing antibodies", "PROTEIN", 172, 195], ["FMDV", "SPECIES", 57, 61], ["FMDV", "SPECIES", 209, 213], ["FMDV", "SPECIES", 57, 61], ["FMDV", "SPECIES", 209, 213], ["HBV", "SPECIES", 218, 221], ["the free FMDV peptide", "PROBLEM", 48, 69], ["a beta-galactosidase carrier protein", "TEST", 101, 137], ["neutralizing antibodies", "TREATMENT", 172, 195], ["HBV", "TEST", 218, 221]]], ["Many analogous studies were subsequently performed, for example, showing that a human rhinovirus peptide presented on the HBcAg particle was 100-fold more immunogenic than uncoupled peptide [57] .", [["human", "ORGANISM", 80, 85], ["rhinovirus", "ORGANISM", 86, 96], ["HBcAg", "GENE_OR_GENE_PRODUCT", 122, 127], ["human", "SPECIES", 80, 85], ["human rhinovirus", "SPECIES", 80, 96], ["Many analogous studies", "TEST", 0, 22], ["a human rhinovirus peptide", "PROBLEM", 78, 104], ["the HBcAg particle", "TEST", 118, 136]]], ["Overall, many such studies revealed a number of sites on HBV nanoparticles suitable for insertion and display of foreign epitopes, in order to ensure optimal presentation to the immune system.", [["immune system", "ANATOMY", 178, 191], ["HBV", "ORGANISM", 57, 60], ["foreign epitopes", "PROTEIN", 113, 129], ["HBV", "SPECIES", 57, 60], ["many such studies", "TEST", 9, 26], ["HBV nanoparticles", "TREATMENT", 57, 74], ["insertion", "TREATMENT", 88, 97], ["foreign epitopes", "PROBLEM", 113, 129], ["foreign epitopes", "OBSERVATION", 113, 129]]], ["It also emerged that carrier-specific immunosuppression and pre-existing immunity to HBcAg did not significantly alter the immunogenicity of the chimeric particles, thus potentially allowing repeated immunizations with the same nanoparticle platform [58] .", [["HBcAg", "GENE_OR_GENE_PRODUCT", 85, 90], ["HBcAg", "PROTEIN", 85, 90], ["specific immunosuppression", "TREATMENT", 29, 55], ["pre-existing immunity to HBcAg", "PROBLEM", 60, 90], ["the chimeric particles", "PROBLEM", 141, 163], ["repeated immunizations", "TREATMENT", 191, 213]]], ["Collectively, these findings supported the use of HBcAg nanoparticles or similar VLPs as efficient scaffolds for the presentation of heterologous ('foreign') epitopes as vaccine antigens.Viral proteins and virus-like particles (VLPs)Indeed, in the long search for a vaccine against malaria, successful clinical trials have been performed using chimeric nanoparticle antigens containing epitopes from the circumsporozoite protein (CSP) of the Plasmodium falciparum (P. falciparum) malaria parasite genetically fused either to HBcAg [59] (in Malarivax) or to HBsAg (in Mosquirix) [60] .", [["malaria", "DISEASE", 282, 289], ["Plasmodium falciparum", "DISEASE", 442, 463], ["P. falciparum) malaria", "DISEASE", 465, 487], ["HBsAg", "CHEMICAL", 557, 562], ["HBcAg", "GENE_OR_GENE_PRODUCT", 50, 55], ["VLPs", "ORGANISM", 81, 85], ["virus-like particles", "ORGANISM", 206, 226], ["VLPs", "ORGANISM", 228, 232], ["circumsporozoite protein", "GENE_OR_GENE_PRODUCT", 404, 428], ["CSP", "GENE_OR_GENE_PRODUCT", 430, 433], ["Plasmodium falciparum", "ORGANISM", 442, 463], ["P. falciparum", "ORGANISM", 465, 478], ["malaria parasite", "ORGANISM", 480, 496], ["HBcAg", "GENE_OR_GENE_PRODUCT", 525, 530], ["HBsAg", "GENE_OR_GENE_PRODUCT", 557, 562], ["epitopes", "PROTEIN", 158, 166], ["vaccine antigens", "PROTEIN", 170, 186], ["Viral proteins", "PROTEIN", 187, 201], ["chimeric nanoparticle antigens", "PROTEIN", 344, 374], ["epitopes", "PROTEIN", 386, 394], ["circumsporozoite protein", "PROTEIN", 404, 428], ["CSP", "PROTEIN", 430, 433], ["HBsAg", "PROTEIN", 557, 562], ["Plasmodium falciparum", "SPECIES", 442, 463], ["P. falciparum", "SPECIES", 465, 478], ["Plasmodium falciparum", "SPECIES", 442, 463], ["P. falciparum", "SPECIES", 465, 478], ["HBcAg nanoparticles", "TREATMENT", 50, 69], ["similar VLPs", "TREATMENT", 73, 85], ["efficient scaffolds", "TREATMENT", 89, 108], ["heterologous ('foreign') epitopes", "TREATMENT", 133, 166], ["vaccine antigens", "TREATMENT", 170, 186], ["Viral proteins", "TEST", 187, 201], ["virus", "PROBLEM", 206, 211], ["a vaccine", "TREATMENT", 264, 273], ["malaria", "PROBLEM", 282, 289], ["chimeric nanoparticle antigens", "TREATMENT", 344, 374], ["the circumsporozoite protein", "TEST", 400, 428], ["CSP", "TEST", 430, 433], ["the Plasmodium falciparum (P. falciparum)", "TREATMENT", 438, 479], ["malaria parasite", "PROBLEM", 480, 496], ["HBcAg", "TEST", 525, 530], ["HBsAg", "TEST", 557, 562], ["virus", "OBSERVATION", 206, 211], ["particles", "OBSERVATION_MODIFIER", 217, 226]]], ["This latter construct, presenting CSP residues 207-395 of P. falciparum NF54, is the key component of the RTS,S (Mosquirix) vaccine for which in mid-2015 the European Medicines Agency expressed a positive scientific opinion, following large-scale safety and efficacy data from phase III clinical trials [61] [62] [63] (Table 1) .", [["CSP residues 207-395", "CHEMICAL", 34, 54], ["P. falciparum", "ORGANISM", 58, 71], ["NF54", "ORGANISM", 72, 76], ["P. falciparum", "SPECIES", 58, 71], ["P. falciparum", "SPECIES", 58, 71], ["P. falciparum NF54", "TREATMENT", 58, 76], ["S (Mosquirix) vaccine", "TREATMENT", 110, 131], ["large-scale safety", "TREATMENT", 235, 253], ["efficacy data", "TEST", 258, 271]]], ["Although the latter is probably the most notable and clinically advanced new application, the literature contains many other examples of other nanoparticles or VLPs used as carriers for epitopes, some of which have entered clinical trials.", [["VLPs", "ORGANISM", 160, 164], ["epitopes", "PROTEIN", 186, 194], ["other nanoparticles", "PROBLEM", 137, 156], ["VLPs", "TREATMENT", 160, 164], ["epitopes", "PROBLEM", 186, 194], ["probably the", "UNCERTAINTY", 23, 35], ["most notable", "OBSERVATION_MODIFIER", 36, 48], ["advanced", "OBSERVATION_MODIFIER", 64, 72], ["new", "OBSERVATION_MODIFIER", 73, 76]]], ["For example, the NicQ\u03b2 vaccine, which presents hundreds of copies of a nicotine hapten covalently attached to a self-assembling nanoparticle made of the bacteriophage Q\u03b2 coat protein, was shown to be safe and able to generate antibody responses potentially beneficial for smoking cessation [64] .", [["NicQ\u03b2", "CHEMICAL", 17, 22], ["nicotine", "CHEMICAL", 71, 79], ["smoking", "CHEMICAL", 272, 279], ["nicotine", "CHEMICAL", 71, 79], ["NicQ\u03b2", "GENE_OR_GENE_PRODUCT", 17, 22], ["nicotine", "SIMPLE_CHEMICAL", 71, 79], ["Q\u03b2", "GENE_OR_GENE_PRODUCT", 167, 169], ["bacteriophage Q\u03b2 coat protein", "PROTEIN", 153, 182], ["the NicQ\u03b2 vaccine", "TREATMENT", 13, 30], ["a nicotine hapten", "TREATMENT", 69, 86], ["the bacteriophage", "TREATMENT", 149, 166]]], ["Similarly, Q\u03b2 entered clinical trials as a platform on which a peptide representing the A\u03b2 1-6 epitope was conjugated for display as an immunotherapy against Alzheimer disease [65] .Viral proteins and virus-like particles (VLPs)Interestingly, HBcAg was recently used in successful preclinical studies as a nanoparticle scaffold presenting a structurally optimized antigen against respiratory syncytial virus (RSV), a leading cause of severe respiratory tract disease in children worldwide [66] .", [["respiratory tract", "ANATOMY", 441, 458], ["A\u03b2 1-6", "CHEMICAL", 88, 94], ["Alzheimer disease", "DISEASE", 158, 175], ["respiratory syncytial virus (RSV)", "DISEASE", 380, 413], ["respiratory tract disease", "DISEASE", 441, 466], ["Q\u03b2", "SIMPLE_CHEMICAL", 11, 13], ["virus-like particles", "GENE_OR_GENE_PRODUCT", 201, 221], ["VLPs", "ORGANISM", 223, 227], ["HBcAg", "GENE_OR_GENE_PRODUCT", 243, 248], ["respiratory syncytial virus", "ORGANISM", 380, 407], ["RSV", "ORGANISM", 409, 412], ["tract", "ORGANISM_SUBDIVISION", 453, 458], ["children", "ORGANISM", 470, 478], ["Q\u03b2", "PROTEIN", 11, 13], ["A\u03b2 1-6 epitope", "PROTEIN", 88, 102], ["Viral proteins", "PROTEIN", 182, 196], ["VLPs", "PROTEIN", 223, 227], ["HBcAg", "PROTEIN", 243, 248], ["respiratory syncytial virus", "SPECIES", 380, 407], ["children", "SPECIES", 470, 478], ["respiratory syncytial virus", "SPECIES", 380, 407], ["RSV", "SPECIES", 409, 412], ["an immunotherapy", "TREATMENT", 133, 149], ["Alzheimer disease", "PROBLEM", 158, 175], ["Viral proteins", "TEST", 182, 196], ["virus", "PROBLEM", 201, 206], ["a nanoparticle scaffold", "TREATMENT", 304, 327], ["respiratory syncytial virus", "PROBLEM", 380, 407], ["severe respiratory tract disease", "PROBLEM", 434, 466], ["virus", "OBSERVATION", 201, 206], ["particles", "OBSERVATION_MODIFIER", 212, 221], ["syncytial virus", "OBSERVATION", 392, 407], ["severe", "OBSERVATION_MODIFIER", 434, 440], ["respiratory tract disease", "OBSERVATION", 441, 466]]], ["Many previous efforts to design vaccine antigens to protect against RSV focused on the surfaceexposed fusion glycoprotein, F, a highly conserved target of neutralizing antibodies [67] .", [["RSV", "DISEASE", 68, 71], ["RSV", "ORGANISM", 68, 71], ["F", "GENE_OR_GENE_PRODUCT", 123, 124], ["surfaceexposed fusion glycoprotein", "PROTEIN", 87, 121], ["F", "PROTEIN", 123, 124], ["neutralizing antibodies", "PROTEIN", 155, 178], ["RSV", "SPECIES", 68, 71], ["design vaccine antigens", "TREATMENT", 25, 48], ["RSV", "PROBLEM", 68, 71], ["neutralizing antibodies", "TEST", 155, 178]]], ["Schief and co-workers performed a pioneering study by using insights from the crystal structure of a neutralizing epitope of the F antigen in order to computationally design and optimize its stabilized conformation for conjugation and presentation on HBcAg nanoparticles.", [["F antigen", "GENE_OR_GENE_PRODUCT", 129, 138], ["HBcAg nanoparticles", "SIMPLE_CHEMICAL", 251, 270], ["F antigen", "PROTEIN", 129, 138], ["a pioneering study", "TEST", 32, 50], ["HBcAg nanoparticles", "TREATMENT", 251, 270]]], ["The antigen alone was moderately immunogenic, but showed a much higher ability to induce protective RSV-neutralizing antibodies in several animal models including rhesus macaques when it was presented in multiple copies on the HBcAg scaffold [68] .", [["RSV", "ORGANISM", 100, 103], ["rhesus", "ORGANISM", 163, 169], ["macaques", "ORGANISM", 170, 178], ["HBcAg", "GENE_OR_GENE_PRODUCT", 227, 232], ["RSV-neutralizing antibodies", "PROTEIN", 100, 127], ["rhesus macaques", "SPECIES", 163, 178], ["RSV", "SPECIES", 100, 103], ["rhesus macaques", "SPECIES", 163, 178], ["moderately immunogenic", "PROBLEM", 22, 44], ["protective RSV", "PROBLEM", 89, 103], ["neutralizing antibodies", "PROBLEM", 104, 127], ["rhesus macaques", "TREATMENT", 163, 178], ["the HBcAg scaffold", "TREATMENT", 223, 241], ["RSV", "OBSERVATION", 100, 103]]], ["For this formulation, the designed RSV F epitope was chemically conjugated to a form of HBcAg produced in E. coli and which exposes a reactive Lys genetically engineered into the major immunodominant region of HBcAg [69] .", [["Lys", "CHEMICAL", 143, 146], ["Lys", "CHEMICAL", 143, 146], ["RSV", "ORGANISM", 35, 38], ["HBcAg", "GENE_OR_GENE_PRODUCT", 88, 93], ["E. coli", "ORGANISM", 106, 113], ["HBcAg", "GENE_OR_GENE_PRODUCT", 210, 215], ["RSV F epitope", "PROTEIN", 35, 48], ["HBcAg", "PROTEIN", 88, 93], ["major immunodominant region", "PROTEIN", 179, 206], ["HBcAg", "PROTEIN", 210, 215], ["E. coli", "SPECIES", 106, 113], ["RSV", "SPECIES", 35, 38], ["E. coli", "SPECIES", 106, 113], ["this formulation", "TREATMENT", 4, 20], ["the designed RSV F epitope", "TREATMENT", 22, 48], ["HBcAg", "PROBLEM", 88, 93], ["E. coli", "PROBLEM", 106, 113], ["a reactive Lys", "PROBLEM", 132, 146], ["HBcAg", "TEST", 210, 215], ["E. coli", "OBSERVATION", 106, 113], ["reactive Lys", "OBSERVATION", 134, 146]]], ["This bipartite approach of separately producing and purifying the optimized antigen and carrier components, followed by their conjugation, avoids the potential size limitation of antigens that can be incorporated into a nanoparticle via genetic fusion [70] .", [["antigens", "PROTEIN", 179, 187], ["a nanoparticle via genetic fusion", "TREATMENT", 218, 251], ["size", "OBSERVATION_MODIFIER", 160, 164]]], ["Although this production process was thus rather complicated, the neutralizing activity elicited was comparable to the titers induced by natural human infection, suggesting that this proof of principle for epitope-focused structure-based antigen design combined with self-assembling nanoparticle display holds great promise for future vaccines (Fig. 2) .Viral proteins and virus-like particles (VLPs)Hepatitis E virus (HEV) constitutes another successful example of the generation of recombinant VLPs with efficacy in preventing the progress of the infection.", [["infection", "DISEASE", 151, 160], ["Hepatitis E", "DISEASE", 400, 411], ["infection", "DISEASE", 549, 558], ["human", "ORGANISM", 145, 150], ["virus-like particles", "ORGANISM", 373, 393], ["VLPs)", "ORGANISM", 395, 400], ["Hepatitis E virus", "ORGANISM", 400, 417], ["HEV", "ORGANISM", 419, 422], ["VLPs", "ORGANISM", 496, 500], ["Viral proteins", "PROTEIN", 354, 368], ["human", "SPECIES", 145, 150], ["Hepatitis E virus", "SPECIES", 400, 417], ["human", "SPECIES", 145, 150], ["Hepatitis E virus", "SPECIES", 400, 417], ["HEV", "SPECIES", 419, 422], ["the neutralizing activity", "PROBLEM", 62, 87], ["natural human infection", "PROBLEM", 137, 160], ["epitope", "PROBLEM", 206, 213], ["self-assembling nanoparticle display", "TREATMENT", 267, 303], ["future vaccines", "TREATMENT", 328, 343], ["Viral proteins", "TEST", 354, 368], ["virus", "TEST", 373, 378], ["like particles", "PROBLEM", 379, 393], ["Hepatitis E virus", "PROBLEM", 400, 417], ["recombinant VLPs", "TREATMENT", 484, 500], ["the infection", "PROBLEM", 545, 558], ["infection", "OBSERVATION", 151, 160], ["virus", "OBSERVATION", 373, 378], ["particles", "OBSERVATION_MODIFIER", 384, 393], ["infection", "OBSERVATION", 549, 558]]], ["While insect cells have been used to prepare HEV particles of a truncated version of the HEV viral capsid protein that yielded an antigenicity similar to that of original HEV viral particles [71] , a bacteria-derived HEV particle with a shorter polypeptidic subunit rendered up to 86.8% efficacy and is currently in phase IV clinical trials (Hecolin) [72, 73] .", [["cells", "ANATOMY", 13, 18], ["Hecolin", "CHEMICAL", 342, 349], ["insect cells", "CELL", 6, 18], ["HEV", "ORGANISM", 45, 48], ["HEV", "ORGANISM", 89, 92], ["HEV", "ORGANISM", 171, 174], ["HEV", "ORGANISM", 217, 220], ["Hecolin", "SIMPLE_CHEMICAL", 342, 349], ["insect cells", "CELL_TYPE", 6, 18], ["HEV viral capsid protein", "PROTEIN", 89, 113], ["polypeptidic subunit", "PROTEIN", 245, 265], ["HEV", "SPECIES", 45, 48], ["HEV", "SPECIES", 89, 92], ["HEV", "SPECIES", 171, 174], ["HEV", "SPECIES", 217, 220], ["a truncated version", "TREATMENT", 62, 81], ["the HEV viral capsid protein", "TEST", 85, 113], ["an antigenicity", "PROBLEM", 127, 142], ["original HEV viral particles", "TEST", 162, 190], ["a bacteria", "PROBLEM", 198, 208], ["HEV particle", "TEST", 217, 229], ["a shorter polypeptidic subunit", "TREATMENT", 235, 265]]], ["The need for next-generation vaccines against influenza has been one of the biggest drivers of research into novel VLP antigens.", [["influenza", "DISEASE", 46, 55], ["influenza", "ORGANISM", 46, 55], ["VLP antigens", "GENE_OR_GENE_PRODUCT", 115, 127], ["VLP antigens", "PROTEIN", 115, 127], ["next-generation vaccines", "TREATMENT", 13, 37], ["influenza", "PROBLEM", 46, 55]]], ["For several decades, influenza vaccines have been successfully produced using embryonated chicken eggs [4] .", [["chicken", "ORGANISM", 90, 97], ["chicken", "SPECIES", 90, 97], ["chicken", "SPECIES", 90, 97], ["influenza vaccines", "TREATMENT", 21, 39], ["embryonated chicken eggs", "TREATMENT", 78, 102]]], ["Nevertheless, considerable efforts have been invested to devise alternative production methods for recombinant influenza antigens that might increase the vaccine manufacturing speed, yields, volume, purity and safety, and overcome the potential inability to provide sufficient vaccine doses in the event of future widespread epidemics or pandemics.", [["recombinant influenza antigens", "PROTEIN", 99, 129], ["alternative production methods", "TREATMENT", 64, 94], ["recombinant influenza antigens", "PROBLEM", 99, 129], ["sufficient vaccine doses", "TREATMENT", 266, 290], ["pandemics", "PROBLEM", 338, 347], ["widespread", "OBSERVATION_MODIFIER", 314, 324], ["epidemics", "OBSERVATION", 325, 334]]], ["In particular, several groups have explored influenza virus-like particles (VLPs): self-assemblies of the hemagglutinin (HA) and neuraminidase (NA) antigens on a lipid bilayer supported by the M1 matrix protein, generating non-infectious particles of approximately 100-150 nm diameter, thus resembling influenza virions [10, 74] .", [["lipid bilayer", "ANATOMY", 162, 175], ["influenza virions", "DISEASE", 302, 319], ["influenza virus", "ORGANISM", 44, 59], ["VLPs", "ORGANISM", 76, 80], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 106, 119], ["neuraminidase (NA) antigens", "GENE_OR_GENE_PRODUCT", 129, 156], ["M1", "GENE_OR_GENE_PRODUCT", 193, 195], ["matrix", "CELLULAR_COMPONENT", 196, 202], ["hemagglutinin", "PROTEIN", 106, 119], ["HA", "PROTEIN", 121, 123], ["neuraminidase (NA) antigens", "PROTEIN", 129, 156], ["M1 matrix protein", "PROTEIN", 193, 210], ["influenza virus", "SPECIES", 44, 59], ["influenza virus", "PROBLEM", 44, 59], ["the hemagglutinin (HA)", "PROBLEM", 102, 124], ["neuraminidase (NA) antigens", "PROBLEM", 129, 156], ["a lipid bilayer", "TREATMENT", 160, 175], ["influenza virions", "PROBLEM", 302, 319], ["influenza virus", "OBSERVATION", 44, 59], ["non-infectious", "OBSERVATION_MODIFIER", 223, 237], ["influenza virions", "OBSERVATION", 302, 319]]], ["Following progress in making recombinant selfassembling VLPs from Sf9 insect cells [75] , influenza VLPs were shown to be promising immunogens [76] .", [["cells", "ANATOMY", 77, 82], ["VLPs", "ORGANISM", 56, 60], ["Sf9 insect cells", "CELL", 66, 82], ["influenza VLPs", "ORGANISM", 90, 104], ["Sf9 insect cells", "CELL_LINE", 66, 82], ["Sf9", "SPECIES", 66, 69], ["recombinant selfassembling VLPs", "TREATMENT", 29, 60], ["influenza VLPs", "PROBLEM", 90, 104]]], ["This recombinant system enables tailored antigen expression levels, overcoming the issues of low abundance of NA or M1 in the traditional egg-based influenza vaccines.", [["NA", "CHEMICAL", 110, 112], ["NA", "SIMPLE_CHEMICAL", 110, 112], ["egg", "ORGANISM_SUBDIVISION", 138, 141], ["low abundance of NA", "PROBLEM", 93, 112], ["influenza vaccines", "TREATMENT", 148, 166], ["low abundance", "OBSERVATION_MODIFIER", 93, 106], ["influenza vaccines", "OBSERVATION", 148, 166]]], ["Using this system, a recombinant VLP designed to protect against the avian influenza A H7N9 strain was generated [77] .", [["VLP", "ORGANISM", 33, 36], ["avian", "ORGANISM", 69, 74], ["influenza A H7N9", "ORGANISM", 75, 91], ["avian influenza A H7N9", "SPECIES", 69, 91], ["A H7N9 strain", "SPECIES", 85, 98], ["this system", "TREATMENT", 6, 17], ["a recombinant VLP", "TREATMENT", 19, 36], ["the avian influenza A H7N9 strain", "PROBLEM", 65, 98]]], ["The latter induced protective immunity in ferrets [78] and showed positive phase I clinical results [79] .", [["ferrets", "ORGANISM", 42, 49], ["ferrets", "SPECIES", 42, 49]]], ["Moreover, several similar VLP vaccines have been tested in preclinical studies; for example, H7N9 VLPs were produced in mammalian 293T cells, and raised high titers of neutralizing antibodies in mice [80] .", [["293T cells", "ANATOMY", 130, 140], ["VLP", "ORGANISM", 26, 29], ["H7N9 VLPs", "ORGANISM", 93, 102], ["mammalian 293T cells", "CELL", 120, 140], ["mice", "ORGANISM", 195, 199], ["mammalian 293T cells", "CELL_LINE", 120, 140], ["neutralizing antibodies", "PROTEIN", 168, 191], ["mice", "SPECIES", 195, 199], ["H7N9", "SPECIES", 93, 97], ["mice", "SPECIES", 195, 199], ["several similar VLP vaccines", "TREATMENT", 10, 38], ["preclinical studies", "TEST", 59, 78], ["H7N9 VLPs", "PROBLEM", 93, 102], ["neutralizing antibodies", "TEST", 168, 191], ["293T cells", "OBSERVATION", 130, 140]]], ["Further, mice were broadly protected by a vaccine cocktail of VLPs displaying H1, H3, H5 and H7 hemagglutinin antigens [81] .", [["mice", "ORGANISM", 9, 13], ["VLPs", "ORGANISM", 62, 66], ["H3", "GENE_OR_GENE_PRODUCT", 82, 84], ["H1", "PROTEIN", 78, 80], ["H3", "PROTEIN", 82, 84], ["H5", "PROTEIN", 86, 88], ["H7 hemagglutinin antigens", "PROTEIN", 93, 118], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["H1", "SPECIES", 78, 80], ["a vaccine cocktail", "TREATMENT", 40, 58], ["VLPs", "PROBLEM", 62, 66], ["H1", "PROBLEM", 78, 80], ["H3", "PROBLEM", 82, 84], ["H5", "PROBLEM", 86, 88], ["H7 hemagglutinin antigens", "TEST", 93, 118]]], ["These data suggest that the influenza VLP approach may be applicable as a rapid response to potentially pandemic strains and, moreover, they can also be used to prepare seasonal quadrivalent influenza vaccines (QIV), for which clinical trials are ongoing.Viral proteins and virus-like particles (VLPs)Nevertheless, a novel approach for the prevention of influenza in individuals aged 18 and older has been achieved with the development of Flublok, the first recombinant influenza vaccine to have been licensed.", [["influenza", "DISEASE", 354, 363], ["Flublok", "CHEMICAL", 439, 446], ["virus-like particles", "ORGANISM", 274, 294], ["VLPs", "ORGANISM", 296, 300], ["Flublok", "SIMPLE_CHEMICAL", 439, 446], ["Viral proteins", "PROTEIN", 255, 269], ["QIV", "SPECIES", 211, 214], ["These data", "TEST", 0, 10], ["the influenza VLP approach", "TREATMENT", 24, 50], ["pandemic strains", "PROBLEM", 104, 120], ["seasonal quadrivalent influenza vaccines", "TREATMENT", 169, 209], ["Viral proteins", "TEST", 255, 269], ["virus", "PROBLEM", 274, 279], ["influenza", "PROBLEM", 354, 363], ["Flublok", "TREATMENT", 439, 446], ["the first recombinant influenza vaccine", "TREATMENT", 448, 487], ["virus", "OBSERVATION", 274, 279], ["particles", "OBSERVATION_MODIFIER", 285, 294]]], ["This trivalent vaccine contains recombinant HA proteins of three strains of seasonal influenza virus [82] and its higher antigen load has been reported to improve immunogenicity and efficacy [83] .", [["trivalent", "CHEMICAL", 5, 14], ["influenza virus", "DISEASE", 85, 100], ["seasonal influenza virus", "ORGANISM", 76, 100], ["recombinant HA proteins", "PROTEIN", 32, 55], ["seasonal influenza virus", "SPECIES", 76, 100], ["seasonal influenza virus", "SPECIES", 76, 100], ["This trivalent vaccine", "TREATMENT", 0, 22], ["recombinant HA proteins", "TREATMENT", 32, 55], ["seasonal influenza virus", "PROBLEM", 76, 100], ["its higher antigen load", "PROBLEM", 110, 133]]], ["Produced in insect cells, these proteins adopt multimeric nanoparticulate structures of 20-40 nm in diameter as characterized by dynamic light scattering and electron microscopy.Viral proteins and virus-like particles (VLPs)While influenza is one of the most promising targets for recombinant VLP technology, other viral targets have proved more challenging, especially when several viral proteins are required for VLP assembly [34, 35] .", [["cells", "ANATOMY", 19, 24], ["influenza", "DISEASE", 230, 239], ["insect cells", "CELL", 12, 24], ["virus-like particles", "ORGANISM", 197, 217], ["insect cells", "CELL_TYPE", 12, 24], ["Viral proteins", "PROTEIN", 178, 192], ["viral proteins", "PROTEIN", 383, 397], ["electron microscopy", "TEST", 158, 177], ["Viral proteins", "TEST", 178, 192], ["virus", "PROBLEM", 197, 202], ["influenza", "PROBLEM", 230, 239], ["recombinant VLP technology", "TREATMENT", 281, 307], ["other viral targets", "TEST", 309, 328], ["several viral proteins", "PROBLEM", 375, 397], ["insect cells", "OBSERVATION", 12, 24], ["nanoparticulate", "OBSERVATION_MODIFIER", 58, 73], ["20-40 nm", "OBSERVATION_MODIFIER", 88, 96], ["dynamic light scattering", "OBSERVATION", 129, 153], ["virus", "OBSERVATION", 197, 202], ["particles", "OBSERVATION_MODIFIER", 208, 217]]], ["Although the currently licensed rotavirus (RV) vaccines are very efficacious, improved RV vaccines are needed to provide greater protection in developing countries and to improve protection against mild gastroenteritis.", [["gastroenteritis", "DISEASE", 203, 218], ["rotavirus", "ORGANISM", 32, 41], ["rotavirus", "SPECIES", 32, 41], ["RV", "SPECIES", 43, 45], ["RV", "SPECIES", 87, 89], ["rotavirus (RV) vaccines", "TREATMENT", 32, 55], ["very efficacious", "PROBLEM", 60, 76], ["RV vaccines", "TREATMENT", 87, 98], ["mild gastroenteritis", "PROBLEM", 198, 218], ["mild", "OBSERVATION_MODIFIER", 198, 202], ["gastroenteritis", "OBSERVATION", 203, 218]]], ["To this end, several rotavirus VLPs have been tested in preclinical models.", [["rotavirus", "ORGANISM", 21, 30], ["VLPs", "ORGANISM", 31, 35], ["rotavirus", "SPECIES", 21, 30], ["several rotavirus VLPs", "TREATMENT", 13, 35]]], ["For example, double-layered RV VLPs (~60 nm diameter, obtained using insect cell expression) made of recombinant VP2 and VP6 proteins, the most abundant RV antigens, conferred partial protection in animals, but required adjuvant or priming with liveattenuated RV vaccine [84] .", [["cell", "ANATOMY", 76, 80], ["insect cell", "CELL", 69, 80], ["VP2", "GENE_OR_GENE_PRODUCT", 113, 116], ["VP6", "GENE_OR_GENE_PRODUCT", 121, 124], ["recombinant VP2 and VP6 proteins", "PROTEIN", 101, 133], ["RV antigens", "PROTEIN", 153, 164], ["double-layered RV VLPs", "TREATMENT", 13, 35], ["insect cell expression", "TREATMENT", 69, 91], ["recombinant VP2", "TREATMENT", 101, 116], ["VP6 proteins", "PROBLEM", 121, 133], ["adjuvant", "TREATMENT", 220, 228], ["liveattenuated RV vaccine", "TREATMENT", 245, 270], ["RV VLPs", "ANATOMY", 28, 35], ["RV", "ANATOMY", 153, 155], ["partial", "OBSERVATION_MODIFIER", 176, 183], ["protection", "OBSERVATION", 184, 194]]], ["More recently, progress has been made using E. coli as a suitable low-cost scalable production system for VP2-VP6 rotavirus VLPs that elicited a strong antibody response and protection against RV-induced diarrhea in mice [85] .", [["diarrhea", "DISEASE", 204, 212], ["E. coli", "ORGANISM", 44, 51], ["VP2", "ORGANISM", 106, 109], ["VP6 rotavirus VLPs", "ORGANISM", 110, 128], ["mice", "ORGANISM", 216, 220], ["VP2", "PROTEIN", 106, 109], ["E. coli", "SPECIES", 44, 51], ["mice", "SPECIES", 216, 220], ["E. coli", "SPECIES", 44, 51], ["VP2-VP6 rotavirus", "SPECIES", 106, 123], ["RV", "SPECIES", 193, 195], ["mice", "SPECIES", 216, 220], ["E. coli", "PROBLEM", 44, 51], ["a suitable low-cost scalable production system", "TREATMENT", 55, 101], ["VP2-VP6 rotavirus VLPs", "TREATMENT", 106, 128], ["RV", "PROBLEM", 193, 195], ["diarrhea", "PROBLEM", 204, 212]]], ["These RV studies suggest that such VLPs hold promise, but likely require additional optimization of composition, immunization route, and effective adjuvants to be efficacious in humans.Viral proteins and virus-like particles (VLPs)Attempts to make HIV vaccines have also included various different VLPs, mostly involving lipid-enveloped assemblies where the internal HIV Gag p24 provides support for exposure of trimers of Env, the crucial HIV target antigen for neutralizing antibodies.", [["VLPs", "ORGANISM", 35, 39], ["humans", "ORGANISM", 178, 184], ["virus-like particles", "ORGANISM", 204, 224], ["VLPs", "ORGANISM", 226, 230], ["HIV", "ORGANISM", 248, 251], ["p24", "GENE_OR_GENE_PRODUCT", 375, 378], ["Env", "GENE_OR_GENE_PRODUCT", 423, 426], ["HIV", "ORGANISM", 440, 443], ["Viral proteins", "PROTEIN", 185, 199], ["internal HIV Gag p24", "PROTEIN", 358, 378], ["Env", "PROTEIN", 423, 426], ["HIV target antigen", "PROTEIN", 440, 458], ["neutralizing antibodies", "PROTEIN", 463, 486], ["humans", "SPECIES", 178, 184], ["HIV", "SPECIES", 248, 251], ["humans", "SPECIES", 178, 184], ["HIV", "SPECIES", 248, 251], ["HIV", "SPECIES", 367, 370], ["HIV", "SPECIES", 440, 443], ["These RV studies", "TEST", 0, 16], ["additional optimization of composition", "TREATMENT", 73, 111], ["immunization route", "TREATMENT", 113, 131], ["effective adjuvants", "TREATMENT", 137, 156], ["Viral proteins", "PROBLEM", 185, 199], ["virus", "PROBLEM", 204, 209], ["HIV vaccines", "TREATMENT", 248, 260], ["various different VLPs", "TREATMENT", 280, 302], ["the internal HIV Gag p24", "TREATMENT", 354, 378], ["exposure of trimers of Env", "TREATMENT", 400, 426], ["neutralizing antibodies", "PROBLEM", 463, 486], ["virus", "OBSERVATION", 204, 209], ["particles", "OBSERVATION_MODIFIER", 215, 224]]], ["A number of preclinical studies have shown the potential of this approach to efficiently induce humoral and cellular immune responses [86] .", [["cellular", "ANATOMY", 108, 116], ["cellular", "CELL", 108, 116], ["preclinical studies", "TEST", 12, 31], ["this approach", "TREATMENT", 60, 73]]], ["The initiation of future human clinical trials using emerging HIV VLP vaccine candidates should be facilitated by the clinical development experience (manufacturing, safety, etc.) accrued in the generation of influenza and rotavirus vaccines described above.Viral proteins and virus-like particles (VLPs)Human norovirus (NoV) causes endemic viral diarrheal disease and may cause up to half of all gastroenteritis outbreaks worldwide, and therefore is gaining increasing attention as another pathogen causing a globally significant healthcare burden [87, 88] .", [["influenza", "DISEASE", 209, 218], ["norovirus (NoV)", "DISEASE", 310, 325], ["viral diarrheal disease", "DISEASE", 341, 364], ["gastroenteritis", "DISEASE", 397, 412], ["human", "ORGANISM", 25, 30], ["HIV VLP", "ORGANISM", 62, 69], ["rotavirus", "ORGANISM", 223, 232], ["virus-like particles", "ORGANISM", 277, 297], ["VLPs", "ORGANISM", 299, 303], ["Human norovirus", "ORGANISM", 304, 319], ["NoV", "ORGANISM", 321, 324], ["Viral proteins", "PROTEIN", 258, 272], ["human", "SPECIES", 25, 30], ["Human", "SPECIES", 304, 309], ["human", "SPECIES", 25, 30], ["HIV", "SPECIES", 62, 65], ["rotavirus", "SPECIES", 223, 232], ["Human norovirus", "SPECIES", 304, 319], ["NoV", "SPECIES", 321, 324], ["future human clinical trials", "TREATMENT", 18, 46], ["emerging HIV VLP vaccine", "TREATMENT", 53, 77], ["influenza", "PROBLEM", 209, 218], ["rotavirus vaccines", "TREATMENT", 223, 241], ["Viral proteins", "TEST", 258, 272], ["virus", "PROBLEM", 277, 282], ["Human norovirus", "PROBLEM", 304, 319], ["endemic viral diarrheal disease", "PROBLEM", 333, 364], ["all gastroenteritis outbreaks", "PROBLEM", 393, 422], ["another pathogen", "PROBLEM", 483, 499], ["a globally significant healthcare burden", "PROBLEM", 508, 548], ["virus", "OBSERVATION", 277, 282], ["particles", "OBSERVATION_MODIFIER", 288, 297], ["endemic", "OBSERVATION_MODIFIER", 333, 340], ["viral diarrheal disease", "OBSERVATION", 341, 364], ["gastroenteritis", "OBSERVATION", 397, 412]]], ["Candidate NoV VLP vaccines have been developed using the recombinant VP1 protein (the major NoV antigen) which self-assembles into nanoparticles (diameter 30 nm) closely resembling the native virion [89] .", [["NoV VLP", "ORGANISM", 10, 17], ["VP1", "GENE_OR_GENE_PRODUCT", 69, 72], ["NoV antigen", "GENE_OR_GENE_PRODUCT", 92, 103], ["recombinant VP1 protein", "PROTEIN", 57, 80], ["major NoV antigen", "PROTEIN", 86, 103], ["NoV VLP vaccines", "TREATMENT", 10, 26], ["the recombinant VP1 protein", "TREATMENT", 53, 80]]], ["A number of clinical trials have been performed ( Table 1 ) and showed that NoV VLP vaccines are well tolerated and can induce rapid, robust immune response in adults [88] .", [["NoV VLP", "ORGANISM", 76, 83], ["NoV", "SPECIES", 76, 79], ["NoV VLP vaccines", "TREATMENT", 76, 92]]], ["However, in the clinical trials reported to date, results demonstrate modest protection from infection and disease and some prevention of severe gastroenteritis in healthy subjects, while efficacy data for the key 'at risk' groups have not yet emerged [87] .", [["infection", "DISEASE", 93, 102], ["gastroenteritis", "DISEASE", 145, 160], ["infection", "PROBLEM", 93, 102], ["disease", "PROBLEM", 107, 114], ["severe gastroenteritis in healthy subjects", "PROBLEM", 138, 180], ["modest", "OBSERVATION_MODIFIER", 70, 76], ["protection", "OBSERVATION", 77, 87], ["infection", "OBSERVATION", 93, 102], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["gastroenteritis", "OBSERVATION", 145, 160]]], ["While the VLP platform appears promising, a key question for NoV vaccine development is the breadth of protection against multiple variant genotype strains, potentially resolvable using multivalent NoV VLP cocktails.Viral proteins and virus-like particles (VLPs)The viral examples described above clearly demonstrate the success, and future promise, of using highly purified non-enveloped viral capsid proteins as plain or chimeric antigen nanoparticles.", [["NoV", "ORGANISM", 61, 64], ["virus-like particles", "ORGANISM", 235, 255], ["VLPs", "ORGANISM", 257, 261], ["Viral proteins", "PROTEIN", 216, 230], ["VLPs", "PROTEIN", 257, 261], ["non-enveloped viral capsid proteins", "PROTEIN", 375, 410], ["NoV", "SPECIES", 61, 64], ["NoV", "SPECIES", 198, 201], ["the VLP platform", "TEST", 6, 22], ["NoV vaccine", "TREATMENT", 61, 72], ["multiple variant genotype strains", "PROBLEM", 122, 155], ["multivalent NoV VLP cocktails", "TREATMENT", 186, 215], ["Viral proteins", "TEST", 216, 230], ["virus", "PROBLEM", 235, 240], ["The viral examples", "TEST", 262, 280], ["non-enveloped viral capsid proteins", "TREATMENT", 375, 410], ["chimeric antigen nanoparticles", "TREATMENT", 423, 453], ["virus", "OBSERVATION", 235, 240], ["particles", "OBSERVATION_MODIFIER", 246, 255]]], ["However, enveloped VLPs, due to the inclusion of a lipid bilayer in addition to the structural protein antigens, represent a more complex challenge that is now being partly overcome via breakthroughs in mammalian and insect cell expression technologies.", [["lipid bilayer", "ANATOMY", 51, 64], ["cell", "ANATOMY", 224, 228], ["enveloped VLPs", "ORGANISM", 9, 23], ["insect cell", "CELL", 217, 228], ["structural protein antigens", "PROTEIN", 84, 111], ["enveloped VLPs", "PROBLEM", 9, 23], ["a lipid bilayer", "PROBLEM", 49, 64], ["the structural protein antigens", "PROBLEM", 80, 111], ["VLPs", "OBSERVATION", 19, 23], ["protein antigens", "OBSERVATION", 95, 111], ["insect cell expression", "OBSERVATION", 217, 239]]], ["Unlike the simpler nonenveloped viral protein nanoparticles, enveloped VLPs have more inherent safety issues due to potential contaminations from the expression system used, and may be more challenging to formulate with longterm stability profiles.", [["the simpler nonenveloped viral protein nanoparticles", "TREATMENT", 7, 59], ["potential contaminations", "PROBLEM", 116, 140], ["viral protein nanoparticles", "OBSERVATION", 32, 59]]], ["Nevertheless, several enveloped VLP candidates are now in clinical trials.Bacterial protein platformsIn addition to viral nanoparticles or VLPs, there are many other naturally occurring self-assembling protein nanoparticles that have been identified from a wide variety of sources [9] .", [["several enveloped VLP candidates", "TREATMENT", 14, 46], ["Bacterial protein platforms", "PROBLEM", 74, 101], ["viral nanoparticles", "PROBLEM", 116, 135], ["VLPs", "PROBLEM", 139, 143], ["self-assembling protein nanoparticles", "TREATMENT", 186, 223], ["protein platforms", "OBSERVATION", 84, 101], ["viral nanoparticles", "OBSERVATION", 116, 135], ["wide", "OBSERVATION_MODIFIER", 257, 261], ["variety", "OBSERVATION_MODIFIER", 262, 269]]], ["For example, almost all living organisms produce ferritin, a protein whose main function is intracellular iron storage.", [["intracellular", "ANATOMY", 92, 105], ["iron", "CHEMICAL", 106, 110], ["iron", "CHEMICAL", 106, 110], ["ferritin", "GENE_OR_GENE_PRODUCT", 49, 57], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 105], ["iron", "SIMPLE_CHEMICAL", 106, 110], ["ferritin", "PROTEIN", 49, 57], ["ferritin", "TEST", 49, 57], ["intracellular iron storage", "PROBLEM", 92, 118], ["ferritin", "OBSERVATION", 49, 57], ["intracellular", "OBSERVATION", 92, 105], ["iron storage", "OBSERVATION", 106, 118]]], ["Ferritin is made of 24 subunits, each composed of a four-alpha-helix bundle, that self-assemble in a quaternary structure with octahedral symmetry (Fig. 3) .", [["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Ferritin", "PROTEIN", 0, 8], ["alpha-helix bundle", "PROTEIN", 57, 75], ["Ferritin", "TEST", 0, 8], ["octahedral symmetry", "OBSERVATION", 127, 146]]], ["Several high-resolution structures of ferritin have been determined, confirming that Helicobacter pylori ferritin is made of 24 identical protomers [90] , whereas in animals, there are ferritin light and heavy chains that can assemble alone or combine with different ratios into particles of 24 subunits [91, 92] .Bacterial protein platformsFerritin self-assembles into nanoparticles with robust thermal and chemical stability.", [["ferritin", "GENE_OR_GENE_PRODUCT", 38, 46], ["Helicobacter pylori", "ORGANISM", 85, 104], ["ferritin", "GENE_OR_GENE_PRODUCT", 105, 113], ["ferritin", "GENE_OR_GENE_PRODUCT", 185, 193], ["Ferritin", "GENE_OR_GENE_PRODUCT", 341, 349], ["ferritin", "PROTEIN", 38, 46], ["Helicobacter pylori ferritin", "PROTEIN", 85, 113], ["ferritin light and heavy chains", "PROTEIN", 185, 216], ["Helicobacter pylori", "SPECIES", 85, 104], ["Helicobacter pylori", "SPECIES", 85, 104], ["Several high-resolution structures of ferritin", "PROBLEM", 0, 46], ["Helicobacter pylori ferritin", "TEST", 85, 113], ["Bacterial protein platformsFerritin", "TEST", 314, 349], ["high", "OBSERVATION_MODIFIER", 8, 12], ["-resolution", "OBSERVATION_MODIFIER", 12, 23], ["chemical stability", "OBSERVATION", 408, 426]]], ["Hence, the ferritin nanoparticle is potentially wellsuited to carry and expose immunogens.", [["ferritin", "GENE_OR_GENE_PRODUCT", 11, 19], ["the ferritin nanoparticle", "TREATMENT", 7, 32]]], ["Moreover, since ferritin is composed of eight units each with three-fold axis symmetry, it is a convenient scaffold for the presentation of trimeric antigens.", [["ferritin", "GENE_OR_GENE_PRODUCT", 16, 24], ["ferritin", "PROTEIN", 16, 24], ["trimeric antigens", "PROTEIN", 140, 157], ["ferritin", "TEST", 16, 24], ["three-fold axis symmetry", "TREATMENT", 62, 86], ["a convenient scaffold", "TREATMENT", 94, 115], ["trimeric antigens", "PROBLEM", 140, 157]]], ["Indeed, Nabel and co-workers reported an elegant structure-based design strategy to generate ferritin nanoparticles genetically engineered to present a multivalent array of the flu virus hemagglutinin (HA) with its native trimeric conformation intact.", [["Nabel", "CHEMICAL", 8, 13], ["ferritin", "GENE_OR_GENE_PRODUCT", 93, 101], ["flu virus hemagglutinin", "ORGANISM", 177, 200], ["HA", "PROTEIN", 202, 204], ["flu virus hemagglutinin", "SPECIES", 177, 200], ["flu virus", "SPECIES", 177, 186], ["ferritin nanoparticles", "TREATMENT", 93, 115], ["the flu virus hemagglutinin (HA", "TREATMENT", 173, 204], ["intact", "OBSERVATION", 244, 250]]], ["HA is the key antigenic component of flu vaccines, and immunization of mice with these HA-ferritin nanoparticles yielded a very promising outcome: compared to a current commercial vaccine, the animals responded with a more potent immune response, as illustrated by the notably higher number of neutralizing antibodies, enhanced breadth of coverage against unmatched H1N1 viruses and increased generation of neutralizing Abs against two H1N1 highly conserved, yet independent, flu epitopes [93] .", [["HA", "GENE_OR_GENE_PRODUCT", 0, 2], ["mice", "ORGANISM", 71, 75], ["HA-ferritin nanoparticles", "SIMPLE_CHEMICAL", 87, 112], ["animals", "ORGANISM", 193, 200], ["H1N1 viruses", "ORGANISM", 366, 378], ["neutralizing antibodies", "PROTEIN", 294, 317], ["neutralizing Abs", "PROTEIN", 407, 423], ["flu epitopes", "PROTEIN", 476, 488], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["H1N1 viruses", "SPECIES", 366, 378], ["flu vaccines", "TREATMENT", 37, 49], ["immunization of mice", "TREATMENT", 55, 75], ["these HA", "TEST", 81, 89], ["ferritin nanoparticles", "PROBLEM", 90, 112], ["a current commercial vaccine", "TREATMENT", 159, 187], ["neutralizing antibodies", "PROBLEM", 294, 317], ["unmatched H1N1 viruses", "PROBLEM", 356, 378], ["neutralizing Abs", "TREATMENT", 407, 423], ["two H1N1", "PROBLEM", 432, 440], ["flu epitopes", "TEST", 476, 488], ["neutralizing antibodies", "OBSERVATION", 294, 317], ["H1N1 viruses", "OBSERVATION", 366, 378]]], ["This work was one of the first clear examples of how the structurally optimized presentation of ordered arrays of a well-folded immunogen can induce stronger protection.", [["a well-folded immunogen", "TREATMENT", 114, 137]]], ["In more recent work aiming towards a universal flu vaccine by providing broad coverage of protection against different subtypes of the flu virus, Yassine et al. reported a refined structure-based generation of a ferritin-based nanoparticle that displayed only the Fig. 3 .", [["flu virus", "ORGANISM", 135, 144], ["ferritin", "GENE_OR_GENE_PRODUCT", 212, 220], ["ferritin", "PROTEIN", 212, 220], ["flu virus", "SPECIES", 135, 144], ["a universal flu vaccine", "TREATMENT", 35, 58], ["broad coverage of protection", "TREATMENT", 72, 100], ["the flu virus", "PROBLEM", 131, 144], ["a refined structure", "PROBLEM", 170, 189], ["a ferritin", "TEST", 210, 220], ["flu virus", "OBSERVATION", 135, 144]]], ["Generation of chimeric nanoparticles with surface-exposed arrays of immunogenic epitopes.", [["surface", "ANATOMY", 42, 49], ["immunogenic epitopes", "PROTEIN", 68, 88], ["chimeric nanoparticles", "TREATMENT", 14, 36], ["immunogenic epitopes", "PROBLEM", 68, 88], ["immunogenic epitopes", "OBSERVATION", 68, 88]]], ["Recombinant DNA technology can be used to make genes that encode self-assembling polypeptides fused with the desired immunogenic epitope for subsequent production in a chosen cell expression system.", [["cell", "ANATOMY", 175, 179], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["cell", "CELL", 175, 179], ["Recombinant DNA technology", "TREATMENT", 0, 26], ["a chosen cell expression system", "TREATMENT", 166, 197]]], ["The chimeric polypeptide then self-assembles within the cell, with an ordered pattern of surface exposed epitopes.", [["cell", "ANATOMY", 56, 60], ["surface", "ANATOMY", 89, 96], ["cell", "CELL", 56, 60], ["surface exposed epitopes", "PROTEIN", 89, 113], ["The chimeric polypeptide", "TREATMENT", 0, 24], ["surface exposed epitopes", "PROBLEM", 89, 113]]], ["Here, we depict a model of ferritin shown as a grey isosurface (PDB: 3bve) that self-assembles in eight identical units, each composed of trimeric ferritin.", [["ferritin", "GENE_OR_GENE_PRODUCT", 27, 35], ["ferritin", "GENE_OR_GENE_PRODUCT", 147, 155], ["ferritin", "PROTEIN", 27, 35], ["grey isosurface", "PROTEIN", 47, 62], ["trimeric ferritin", "PROTEIN", 138, 155], ["a model of ferritin", "TEST", 16, 35], ["a grey isosurface", "TEST", 45, 62], ["PDB", "TEST", 64, 67], ["trimeric ferritin", "PROBLEM", 138, 155], ["trimeric ferritin", "OBSERVATION", 138, 155]]], ["On the left panel, one of the trimers can be visualized within one of the nanoparticle units.", [["the left panel", "TEST", 3, 17], ["the nanoparticle units", "TREATMENT", 70, 92], ["left", "ANATOMY_MODIFIER", 7, 11]]], ["The monomers are colored in orange, green, and cyan.", [["monomers", "OBSERVATION_MODIFIER", 4, 12], ["colored", "OBSERVATION", 17, 24], ["green", "OBSERVATION_MODIFIER", 36, 41]]], ["Given the intrinsic propensity of ferritin to self-assemble into a highly symmetric and ordered quaternary architecture, the chimeric nanoparticle is generated with the HA epitope (here shown on the right panel in orange, green, and cyan in cartoon-tube format (PDB: 3sm5)) incorporated and projected as a matrix of ordered and surface exposed epitopes ready for their recognition by BCRs, as described recently [93, 94] .", [["surface", "ANATOMY", 328, 335], ["ferritin", "GENE_OR_GENE_PRODUCT", 34, 42], ["tube", "TISSUE", 249, 253], ["matrix", "CELLULAR_COMPONENT", 306, 312], ["BCRs", "GENE_OR_GENE_PRODUCT", 384, 388], ["ferritin", "PROTEIN", 34, 42], ["HA epitope", "PROTEIN", 169, 179], ["epitopes", "PROTEIN", 344, 352], ["BCRs", "PROTEIN", 384, 388], ["a highly symmetric and ordered quaternary architecture", "PROBLEM", 65, 119], ["the HA epitope", "PROBLEM", 165, 179], ["quaternary architecture", "OBSERVATION", 96, 119], ["right", "ANATOMY_MODIFIER", 199, 204]]], ["The figure was prepared using Pymol software (The PyMOL Molecular Graphics System, Version 1.7.6.2, Schr\u00f6dinger, LLC). stem region of the H1 HA glycoprotein, yet was capable of evoking broadly cross-reactive antibodies that, in contrast to plain nanoparticles, protected mice and ferrets against lethal doses of heterosubtypic H5N1 virus [94] .Bacterial protein platformsAnother similar study was also reported by the Nabel team, wherein the conserved receptor-binding domain (a site of vulnerability) of the gp350 antigen from Epstein-Barr virus was presented in a structurally optimized orientation on nanoparticles of ferritin (24 subunits) or encapsulin (60 subunits).", [["encapsulin", "CHEMICAL", 647, 657], ["H1 HA glycoprotein", "GENE_OR_GENE_PRODUCT", 138, 156], ["mice", "ORGANISM", 271, 275], ["ferrets", "ORGANISM", 280, 287], ["heterosubtypic H5N1 virus", "ORGANISM", 312, 337], ["gp350 antigen", "GENE_OR_GENE_PRODUCT", 509, 522], ["Epstein-Barr virus", "ORGANISM", 528, 546], ["ferritin", "GENE_OR_GENE_PRODUCT", 621, 629], ["encapsulin", "GENE_OR_GENE_PRODUCT", 647, 657], ["H1 HA glycoprotein", "PROTEIN", 138, 156], ["cross-reactive antibodies", "PROTEIN", 193, 218], ["conserved receptor-binding domain", "PROTEIN", 442, 475], ["gp350 antigen", "PROTEIN", 509, 522], ["ferritin", "PROTEIN", 621, 629], ["24 subunits", "PROTEIN", 631, 642], ["encapsulin", "PROTEIN", 647, 657], ["60 subunits", "PROTEIN", 659, 670], ["mice", "SPECIES", 271, 275], ["ferrets", "SPECIES", 280, 287], ["heterosubtypic H5N1 virus", "SPECIES", 312, 337], ["H1", "SPECIES", 138, 140], ["mice", "SPECIES", 271, 275], ["ferrets", "SPECIES", 280, 287], ["heterosubtypic H5N1 virus", "SPECIES", 312, 337], ["Epstein-Barr virus", "SPECIES", 528, 546], ["Version", "TEST", 83, 90], ["the H1 HA glycoprotein", "PROBLEM", 134, 156], ["evoking broadly cross-reactive antibodies", "PROBLEM", 177, 218], ["heterosubtypic H5N1 virus", "TREATMENT", 312, 337], ["Bacterial protein platforms", "PROBLEM", 344, 371], ["Another similar study", "TEST", 371, 392], ["Barr virus", "PROBLEM", 536, 546], ["nanoparticles of ferritin", "TREATMENT", 604, 629], ["encapsulin", "TREATMENT", 647, 657], ["LLC", "ANATOMY", 113, 116], ["protein platforms", "OBSERVATION", 354, 371], ["Barr virus", "OBSERVATION", 536, 546]]], ["In preclinical studies, the chimeric nanoparticle-gp350 antigens elicited 10-to 100-fold more potent virus-neutralizing antibody titers than the soluble gp350 antigens alone [95] .", [["gp350", "GENE_OR_GENE_PRODUCT", 50, 55], ["gp350 antigens", "GENE_OR_GENE_PRODUCT", 153, 167], ["gp350 antigens", "PROTEIN", 50, 64], ["gp350 antigens", "PROTEIN", 153, 167], ["preclinical studies", "TEST", 3, 22], ["the chimeric nanoparticle-gp350 antigens", "TEST", 24, 64], ["neutralizing antibody titers", "TEST", 107, 135]]], ["Importantly, in addition to their immuno-focusing ability to generate high-quality antibody responses, the recombinant nature of these nanoparticle antigens has the benefit of high purity, safety, and tolerability, further strengthening the appropriateness of this vaccination strategy (Table 2) .Bacterial protein platformsAlso, very recent is the work by He et al., describing in silico studies to optimize molecular scaffolds for epitope presentation and leading to the generation of recombinant ferritin nanoparticles displaying epitopescaffolds harboring E1 or E2 epitopes from hepatitis C virus, promising candidates for preclinical studies in the quest for an HCV vaccine [96] .", [["hepatitis C", "DISEASE", 583, 594], ["ferritin", "GENE_OR_GENE_PRODUCT", 499, 507], ["E1", "GENE_OR_GENE_PRODUCT", 560, 562], ["E2", "GENE_OR_GENE_PRODUCT", 566, 568], ["hepatitis C virus", "ORGANISM", 583, 600], ["HCV", "ORGANISM", 667, 670], ["E1", "PROTEIN", 560, 562], ["E2 epitopes", "PROTEIN", 566, 577], ["hepatitis C virus", "SPECIES", 583, 600], ["hepatitis C virus", "SPECIES", 583, 600], ["HCV", "SPECIES", 667, 670], ["these nanoparticle antigens", "PROBLEM", 129, 156], ["this vaccination strategy", "TREATMENT", 260, 285], ["Bacterial protein platforms", "PROBLEM", 297, 324], ["silico studies", "TEST", 382, 396], ["molecular scaffolds", "TREATMENT", 409, 428], ["epitope presentation", "PROBLEM", 433, 453], ["recombinant ferritin nanoparticles", "TREATMENT", 487, 521], ["harboring E1", "PROBLEM", 550, 562], ["E2 epitopes", "PROBLEM", 566, 577], ["hepatitis C virus", "PROBLEM", 583, 600], ["preclinical studies", "TEST", 627, 646], ["an HCV vaccine", "TREATMENT", 664, 678], ["high purity", "OBSERVATION", 176, 187], ["protein platforms", "OBSERVATION", 307, 324]]], ["This recent example applied to HCV builds on the epitope-scaffold rational design strategy that emerged in previous attempts to graft HIV epitopes onto heterologous protein scaffolds [97] , and effectively combines this approach with the multivalent nanoparticle format.Bacterial protein platformsFerritin has also been used as antigen support in the search for potent and safe vaccine tools against HIV [98] , which despite its identification more than 30 years ago remains as one of the most devastating pathogens afflicting the human population.", [["Ferritin", "CHEMICAL", 297, 305], ["HCV", "ORGANISM", 31, 34], ["Ferritin", "GENE_OR_GENE_PRODUCT", 297, 305], ["HIV", "ORGANISM", 400, 403], ["human", "ORGANISM", 531, 536], ["HIV epitopes", "PROTEIN", 134, 146], ["Ferritin", "PROTEIN", 297, 305], ["HIV", "SPECIES", 400, 403], ["human", "SPECIES", 531, 536], ["HCV", "SPECIES", 31, 34], ["HIV", "SPECIES", 134, 137], ["HIV", "SPECIES", 400, 403], ["human", "SPECIES", 531, 536], ["HCV", "PROBLEM", 31, 34], ["the epitope-scaffold rational design strategy", "TREATMENT", 45, 90], ["graft HIV epitopes", "TREATMENT", 128, 146], ["heterologous protein scaffolds", "TREATMENT", 152, 182], ["Bacterial protein platforms", "PROBLEM", 270, 297], ["Ferritin", "TEST", 297, 305], ["antigen support", "TREATMENT", 328, 343], ["potent and safe vaccine", "TREATMENT", 362, 385], ["HIV", "PROBLEM", 400, 403], ["protein platforms", "OBSERVATION", 280, 297]]], ["In order to circumvent the fact that Abs others than the so-called broadly neutralizing antibodies (bNAbs) might occlude highly vulnerable HIV sites, Kwong and coworkers grafted a series of these HIV target motifs into different protein templates and the resultant chimeras were named 'supersite transplants'.", [["chimeras", "ORGANISM", 265, 273], ["Abs", "PROTEIN", 37, 40], ["neutralizing antibodies", "PROTEIN", 75, 98], ["bNAbs", "PROTEIN", 100, 105], ["HIV target motifs", "DNA", 196, 213], ["HIV", "SPECIES", 139, 142], ["HIV", "SPECIES", 196, 199], ["neutralizing antibodies", "TEST", 75, 98], ["these HIV target motifs", "TREATMENT", 190, 213], ["different protein templates", "TREATMENT", 219, 246], ["the resultant chimeras", "PROBLEM", 251, 273]]], ["Transplants bearing a glycopeptide from the variable region 3 on gp120 were recognized by neutralizing antibodies from three different donors, and binding was enhanced by presentation of the transplants on ferritin nanoparticles.Bacterial protein platformsLumazine synthase (LS) represents another example of the inclusion of a bacterial particulate base for the optimization of vaccine candidates, as reported recently by Jardine et al. in their attempts to enhance the immunoreactivity of recombinant gp120 against HIV infection [99] .", [["platformsLumazine", "CHEMICAL", 247, 264], ["HIV infection", "DISEASE", 517, 530], ["gp120", "GENE_OR_GENE_PRODUCT", 65, 70], ["donors", "ORGANISM", 135, 141], ["ferritin nanoparticles", "SIMPLE_CHEMICAL", 206, 228], ["platformsLumazine synthase", "GENE_OR_GENE_PRODUCT", 247, 273], ["gp120", "GENE_OR_GENE_PRODUCT", 503, 508], ["HIV", "ORGANISM", 517, 520], ["gp120", "PROTEIN", 65, 70], ["neutralizing antibodies", "PROTEIN", 90, 113], ["Bacterial protein platformsLumazine synthase", "PROTEIN", 229, 273], ["recombinant gp120", "PROTEIN", 491, 508], ["HIV", "SPECIES", 517, 520], ["HIV", "SPECIES", 517, 520], ["a glycopeptide", "TREATMENT", 20, 34], ["neutralizing antibodies", "PROBLEM", 90, 113], ["the transplants", "TREATMENT", 187, 202], ["ferritin nanoparticles", "TREATMENT", 206, 228], ["Bacterial protein platformsLumazine synthase", "TREATMENT", 229, 273], ["a bacterial particulate base", "TREATMENT", 326, 354], ["vaccine candidates", "TREATMENT", 379, 397], ["HIV infection", "PROBLEM", 517, 530], ["transplants", "OBSERVATION", 191, 202]]], ["As mentioned before, HIV represents a major health problem worldwide.", [["HIV", "SPECIES", 21, 24], ["HIV", "PROBLEM", 21, 24]]], ["With 35 million people carrying the virus worldwide and a yearly morbidity of 1.7 million people (AVERT, http://www.avert.org/worldwidehiv-aids-statistics.htm), the lack of a vaccine is an enormous unmet medical need.", [["people", "ORGANISM", 16, 22], ["people", "ORGANISM", 90, 96], ["people", "SPECIES", 16, 22], ["people", "SPECIES", 90, 96], ["a vaccine", "TREATMENT", 173, 182]]], ["A key challenge in designing an anti-HIV vaccine is the high mutagenic capability of the virus and the unfeasibility of administering attenuated or killed virus because of safety issues.", [["A key challenge", "TREATMENT", 0, 15], ["an anti-HIV vaccine", "TREATMENT", 29, 48], ["the virus", "PROBLEM", 85, 94]]], ["An additional hurdle is the negligible recognition potential of germline precursors of bNAbs, such as VRC01, against the wild-type gp120, the major immunogenic component of the HIV virus envelope.", [["bNAbs", "GENE_OR_GENE_PRODUCT", 87, 92], ["VRC01", "GENE_OR_GENE_PRODUCT", 102, 107], ["gp120", "GENE_OR_GENE_PRODUCT", 131, 136], ["HIV virus envelope", "ORGANISM", 177, 195], ["germline precursors", "CELL_TYPE", 64, 83], ["bNAbs", "PROTEIN", 87, 92], ["VRC01", "PROTEIN", 102, 107], ["wild-type gp120", "PROTEIN", 121, 136], ["HIV virus", "SPECIES", 177, 186], ["HIV virus", "SPECIES", 177, 186], ["germline precursors of bNAbs", "PROBLEM", 64, 92], ["VRC01", "TEST", 102, 107], ["the wild-type gp120", "PROBLEM", 117, 136], ["the HIV virus envelope", "PROBLEM", 173, 195], ["germline precursors", "OBSERVATION", 64, 83], ["HIV virus", "OBSERVATION", 177, 186]]], ["One way to overcome this obstacle was recently reported by Schief and co-workers [99] , who boosted the affinity of the germline antibodies for the viral gp120 glycoprotein by displaying multiple copies of an engineered form of the antigen on a lumazine synthase (LS) nanoparticle.", [["lumazine", "CHEMICAL", 245, 253], ["lumazine", "CHEMICAL", 245, 253], ["lumazine synthase", "GENE_OR_GENE_PRODUCT", 245, 262], ["germline antibodies", "PROTEIN", 120, 139], ["viral gp120 glycoprotein", "PROTEIN", 148, 172], ["lumazine synthase", "PROTEIN", 245, 262], ["the germline antibodies", "TREATMENT", 116, 139], ["the viral gp120 glycoprotein", "TREATMENT", 144, 172], ["a lumazine synthase", "TREATMENT", 243, 262]]], ["LS, which is responsible for the penultimate catalytic step in the biosynthesis of riboflavin, is an enzyme present in a broad variety of organisms, including archaea, bacteria, fungi, plants, and eubacteria [100] .", [["riboflavin", "CHEMICAL", 83, 93], ["riboflavin", "CHEMICAL", 83, 93], ["riboflavin", "SIMPLE_CHEMICAL", 83, 93], ["the penultimate catalytic step", "PROBLEM", 29, 59], ["riboflavin", "TREATMENT", 83, 93], ["an enzyme", "TEST", 98, 107], ["a broad variety of organisms", "PROBLEM", 119, 147], ["archaea", "PROBLEM", 159, 166], ["bacteria", "PROBLEM", 168, 176], ["fungi", "PROBLEM", 178, 183], ["eubacteria", "PROBLEM", 197, 207]]], ["The LS monomer is 150 amino acids long, and consists of beta-sheets along with tandem alpha-helices flanking its sides.", [["amino acids", "CHEMICAL", 22, 33], ["amino acids", "CHEMICAL", 22, 33], ["amino acids", "AMINO_ACID", 22, 33], ["beta", "PROTEIN", 56, 60], ["alpha-helices", "PROTEIN", 86, 99], ["amino acids", "TEST", 22, 33], ["beta-sheets", "TREATMENT", 56, 67], ["tandem alpha-helices flanking its sides", "TREATMENT", 79, 118]]], ["A number of different quaternary structures have been reported for LS, illustrating its morphological versatility: from homopentamers up to symmetrical assemblies of 12 pentamers forming capsids of 150 \u00c5 diameter.", [["quaternary structures", "OBSERVATION", 22, 43]]], ["Even LS cages of more than 100 subunits have been described [101] .Bacterial protein platformsUsing LS from the thermophilic bacterium Aquifex aeolicus as a nanoparticle platform for epitope display, Jardine et al. succeeded in increasing the potency of the immune response and breadth of coverage against HIV.", [["Aquifex aeolicus", "GENE_OR_GENE_PRODUCT", 135, 151], ["HIV", "ORGANISM", 306, 309], ["Aquifex aeolicus", "SPECIES", 135, 151], ["HIV", "SPECIES", 306, 309], ["Aquifex aeolicus", "SPECIES", 135, 151], ["HIV", "SPECIES", 306, 309], ["Bacterial protein platforms", "PROBLEM", 67, 94], ["the thermophilic bacterium Aquifex aeolicus", "TREATMENT", 108, 151], ["a nanoparticle platform", "TREATMENT", 155, 178], ["Jardine et al", "TREATMENT", 200, 213], ["the immune response", "TREATMENT", 254, 273], ["HIV", "PROBLEM", 306, 309], ["protein platforms", "OBSERVATION", 77, 94]]], ["The envelope (Env) glycoprotein is the only HIV surface protein targeted by neutralizing antibodies; it is made of three gp160 precursors that trimerize and are each then cleaved into gp120 and gp41 subunits.", [["surface", "ANATOMY", 48, 55], ["Env", "GENE_OR_GENE_PRODUCT", 14, 17], ["gp160", "GENE_OR_GENE_PRODUCT", 121, 126], ["gp120", "GENE_OR_GENE_PRODUCT", 184, 189], ["gp41", "GENE_OR_GENE_PRODUCT", 194, 198], ["envelope (Env) glycoprotein", "PROTEIN", 4, 31], ["HIV surface protein", "PROTEIN", 44, 63], ["neutralizing antibodies", "PROTEIN", 76, 99], ["gp120", "PROTEIN", 184, 189], ["gp41 subunits", "PROTEIN", 194, 207], ["HIV", "SPECIES", 44, 47], ["The envelope (Env) glycoprotein", "TREATMENT", 0, 31], ["HIV surface protein", "TEST", 44, 63], ["neutralizing antibodies", "TEST", 76, 99], ["three gp160 precursors", "TREATMENT", 115, 137], ["gp120 and gp41 subunits", "TREATMENT", 184, 207]]], ["Jardine et al. engineered LS to display an optimized sub-component (termed, eOD-GT6) of the wild-type gp120 antigen from the Env trimer [99] .", [["gp120 antigen", "GENE_OR_GENE_PRODUCT", 102, 115], ["eOD", "PROTEIN", 76, 79], ["GT6", "PROTEIN", 80, 83], ["wild-type gp120 antigen", "PROTEIN", 92, 115], ["Env trimer", "PROTEIN", 125, 135], ["type gp120 antigen", "PROBLEM", 97, 115], ["the Env trimer", "TEST", 121, 135]]], ["This approach overcame the issue that germline precursors of VRC01 bNAbs show undetectable affinity for wild-type Env.", [["VRC01", "GENE_OR_GENE_PRODUCT", 61, 66], ["VRC01 bNAbs", "PROTEIN", 61, 72], ["VRC01 bNAbs", "TEST", 61, 72]]], ["With additional structural stabilization of the trimer provided by an N-terminal coiled-coil GCN4 domain, the eOD-GT6 immunogen was fused to the C-terminus of the LS gene construct.", [["N", "CHEMICAL", 70, 71], ["eOD", "GENE_OR_GENE_PRODUCT", 110, 113], ["N-terminal coiled-coil GCN4 domain", "PROTEIN", 70, 104], ["eOD", "PROTEIN", 110, 113], ["GT6", "PROTEIN", 114, 117], ["C-terminus", "PROTEIN", 145, 155], ["LS gene construct", "DNA", 163, 180], ["an N-terminal coiled-coil GCN4 domain", "TREATMENT", 67, 104], ["the eOD-GT6 immunogen", "TREATMENT", 106, 127], ["stabilization", "OBSERVATION", 27, 40], ["LS", "ANATOMY", 163, 165]]], ["The resulting recombinant nanoparticle antigens were efficiently obtained from mammalian cells, in stable and homogeneous self-assemblies of 60 LS monomers each presenting a glycosylated eOD-GT6.", [["cells", "ANATOMY", 89, 94], ["mammalian cells", "CELL", 79, 94], ["eOD-GT6", "SIMPLE_CHEMICAL", 187, 194], ["recombinant nanoparticle antigens", "PROTEIN", 14, 47], ["mammalian cells", "CELL_TYPE", 79, 94], ["eOD", "PROTEIN", 187, 190], ["GT6", "PROTEIN", 191, 194], ["The resulting recombinant nanoparticle antigens", "PROBLEM", 0, 47], ["a glycosylated eOD", "TREATMENT", 172, 190], ["mammalian cells", "OBSERVATION", 79, 94], ["stable", "OBSERVATION_MODIFIER", 99, 105]]], ["In contrast with the monomeric eOD-GT6 that did not stimulate B-cell activation, the LS-eOD-GT6 nanoparticles remarkably activated both germline and mature B cells.", [["B-cell", "ANATOMY", 62, 68], ["B cells", "ANATOMY", 156, 163], ["eOD-GT6", "CHEMICAL", 31, 38], ["eOD-GT6", "SIMPLE_CHEMICAL", 31, 38], ["B-cell", "CELL", 62, 68], ["LS-eOD-GT6 nanoparticles", "SIMPLE_CHEMICAL", 85, 109], ["mature B cells", "CELL", 149, 163], ["eOD", "PROTEIN", 31, 34], ["GT6", "PROTEIN", 35, 38], ["germline", "DNA", 136, 144], ["mature B cells", "CELL_TYPE", 149, 163], ["the LS", "TEST", 81, 87], ["GT6 nanoparticles", "TREATMENT", 92, 109], ["cell activation", "OBSERVATION", 64, 79], ["both germline", "OBSERVATION", 131, 144], ["mature B cells", "OBSERVATION", 149, 163]]], ["In accordance with related studies discussed above, Jardine et al. also hypothesize that the ability of the nanoparticles to induce cross-linking with the B-cell receptors was important to promote a successful immune response.Micellar nanoparticlesA method to obtain protein micelles from full-length amphiphilic membrane proteins was developed and used to prepare viral surface proteins as water-soluble particles with a hydrophobic interior and a polar exterior, of relatively homogeneous size: approximately 20-30 nm diameter, depending on the protein [102] .", [["B-cell", "ANATOMY", 155, 161], ["membrane", "ANATOMY", 313, 321], ["surface", "ANATOMY", 371, 378], ["B-cell receptors", "GENE_OR_GENE_PRODUCT", 155, 171], ["B-cell receptors", "PROTEIN", 155, 171], ["full-length amphiphilic membrane proteins", "PROTEIN", 289, 330], ["viral surface proteins", "PROTEIN", 365, 387], ["related studies", "TEST", 19, 34], ["the nanoparticles", "TREATMENT", 104, 121], ["the B-cell receptors", "TREATMENT", 151, 171], ["Micellar nanoparticlesA method", "TREATMENT", 226, 256], ["protein micelles", "TEST", 267, 283], ["full-length amphiphilic membrane proteins", "TREATMENT", 289, 330], ["viral surface proteins", "TEST", 365, 387], ["the protein", "TEST", 543, 554], ["polar", "ANATOMY_MODIFIER", 449, 454], ["relatively", "OBSERVATION_MODIFIER", 468, 478], ["homogeneous", "OBSERVATION_MODIFIER", 479, 490], ["size", "OBSERVATION_MODIFIER", 491, 495]]], ["Therein, Simons et al. predicted several possible applications of the approach, including the opportunity to make virus glycoprotein micelle vaccines.", [["the approach", "TREATMENT", 66, 78], ["virus glycoprotein micelle vaccines", "TREATMENT", 114, 149]]], ["Indeed, a similar approach has been adapted for the preparation of protein nanoparticles comprised of amphiphilic antigens, where the protein micelles are prepared by extraction with non-ionic detergents from Sf9 insect cells expressing the recombinant antigen.", [["cells", "ANATOMY", 220, 225], ["Sf9 insect cells", "CELL", 209, 225], ["amphiphilic antigens", "PROTEIN", 102, 122], ["Sf9 insect cells", "CELL_LINE", 209, 225], ["recombinant antigen", "PROTEIN", 241, 260], ["Sf9", "SPECIES", 209, 212], ["protein nanoparticles", "TREATMENT", 67, 88], ["amphiphilic antigens", "PROBLEM", 102, 122], ["the protein micelles", "TREATMENT", 130, 150], ["non-ionic detergents", "TREATMENT", 183, 203], ["Sf9 insect cells", "TREATMENT", 209, 225], ["amphiphilic antigens", "OBSERVATION", 102, 122]]], ["In a compelling example, a slightly genetically modified full-length form of the RSV fusion (F) surface glycoprotein was extracted and purified from insect cell membranes and used to create protein nanoparticle micelles of 40 nm diameter, where the trimeric F protein assembled into rosettes exposing conformational epitopes similar to those of the post-fusion F conformation and able to raise neutralizing Abs [103] .", [["cell membranes", "ANATOMY", 156, 170], ["rosettes", "ANATOMY", 283, 291], ["RSV", "ORGANISM", 81, 84], ["fusion (F) surface glycoprotein", "GENE_OR_GENE_PRODUCT", 85, 116], ["cell membranes", "CELL", 156, 170], ["RSV fusion (F) surface glycoprotein", "PROTEIN", 81, 116], ["trimeric F protein", "PROTEIN", 249, 267], ["conformational epitopes", "PROTEIN", 301, 324], ["RSV", "SPECIES", 81, 84], ["the RSV fusion", "TREATMENT", 77, 91], ["surface glycoprotein", "PROBLEM", 96, 116], ["insect cell membranes", "TREATMENT", 149, 170], ["protein nanoparticle micelles", "TREATMENT", 190, 219], ["the trimeric F protein", "TEST", 245, 267], ["conformational epitopes", "PROBLEM", 301, 324], ["neutralizing Abs", "TEST", 394, 410], ["RSV fusion", "OBSERVATION", 81, 91], ["insect cell membranes", "OBSERVATION", 149, 170]]], ["In very recent clinical trials, these RSV F antigen nanoparticles appeared safe, promoted immunogenicity, and reduced RSV infections [104] , raising high expectations for a nanoparticle vaccine against RSV.", [["RSV infections", "DISEASE", 118, 132], ["nanoparticle", "CHEMICAL", 173, 185], ["RSV", "DISEASE", 202, 205], ["RSV", "ORGANISM", 38, 41], ["F antigen", "GENE_OR_GENE_PRODUCT", 42, 51], ["RSV", "ORGANISM", 118, 121], ["RSV", "ORGANISM", 202, 205], ["RSV", "SPECIES", 38, 41], ["RSV", "SPECIES", 118, 121], ["RSV", "SPECIES", 202, 205], ["these RSV F antigen nanoparticles", "TREATMENT", 32, 65], ["reduced RSV infections", "PROBLEM", 110, 132], ["a nanoparticle vaccine", "TREATMENT", 171, 193], ["RSV", "PROBLEM", 202, 205], ["reduced", "OBSERVATION_MODIFIER", 110, 117], ["RSV infections", "OBSERVATION", 118, 132]]], ["The micellar nanoparticle approach has also been exploited in the search for vaccines against the Coronaviridae virus (CoV) family, which represents an important group of emerging human pathogens, as witnessed in the severe acute respiratory syndrome SARS-CoV and Middle East respiratory syndrome MERS-CoV outbreaks of 2003 and 2012, respectively.", [["micellar nanoparticle", "CHEMICAL", 4, 25], ["acute respiratory syndrome SARS-CoV and Middle East respiratory syndrome", "DISEASE", 224, 296], ["Coronaviridae virus", "ORGANISM", 98, 117], ["CoV", "ORGANISM", 119, 122], ["human", "ORGANISM", 180, 185], ["Coronaviridae virus", "SPECIES", 98, 117], ["human", "SPECIES", 180, 185], ["Coronaviridae virus", "SPECIES", 98, 117], ["CoV", "SPECIES", 119, 122], ["human", "SPECIES", 180, 185], ["severe acute respiratory syndrome SARS-CoV", "SPECIES", 217, 259], ["Middle East respiratory syndrome MERS-CoV", "SPECIES", 264, 305], ["The micellar nanoparticle approach", "TREATMENT", 0, 34], ["vaccines", "TREATMENT", 77, 85], ["emerging human pathogens", "PROBLEM", 171, 195], ["the severe acute respiratory syndrome SARS", "PROBLEM", 213, 255], ["Middle East respiratory syndrome", "PROBLEM", 264, 296], ["micellar nanoparticle", "OBSERVATION", 4, 25], ["severe", "OBSERVATION_MODIFIER", 217, 223], ["acute", "OBSERVATION_MODIFIER", 224, 229], ["respiratory syndrome", "OBSERVATION", 230, 250], ["Middle", "ANATOMY_MODIFIER", 264, 270], ["respiratory syndrome", "OBSERVATION", 276, 296]]], ["Recombinant full-length forms of the major immunodominant CoV antigen-the amphiphilic spike glycoproteins-both from SARS-CoV and MERS-CoV were successfully obtained via non-ionic detergent-extraction from Sf9 cells.", [["Sf9 cells", "ANATOMY", 205, 214], ["CoV antigen", "GENE_OR_GENE_PRODUCT", 58, 69], ["SARS-CoV", "ORGANISM", 116, 124], ["MERS-CoV", "ORGANISM", 129, 137], ["Sf9 cells", "CELL", 205, 214], ["major immunodominant CoV antigen", "PROTEIN", 37, 69], ["amphiphilic spike glycoproteins", "PROTEIN", 74, 105], ["Sf9 cells", "CELL_LINE", 205, 214], ["SARS-CoV", "SPECIES", 116, 124], ["MERS-CoV", "SPECIES", 129, 137], ["the major immunodominant CoV antigen", "PROBLEM", 33, 69], ["the amphiphilic spike glycoproteins", "PROBLEM", 70, 105], ["SARS", "PROBLEM", 116, 120], ["CoV", "PROBLEM", 134, 137], ["non-ionic detergent-extraction", "TREATMENT", 169, 199], ["Sf9 cells", "OBSERVATION", 205, 214]]], ["The purified spike proteins assembled into nanoparticles of~25 nm diameter that, in adjuvanted formulations tested in mice, were capable of raising high-titer neutralizing antibody responses against the homologous virus [105] .", [["mice", "ORGANISM", 118, 122], ["purified spike proteins", "PROTEIN", 4, 27], ["mice", "SPECIES", 118, 122], ["mice", "SPECIES", 118, 122], ["The purified spike proteins", "PROBLEM", 0, 27], ["adjuvanted formulations", "TREATMENT", 84, 107], ["high-titer neutralizing antibody responses", "PROBLEM", 148, 190], ["the homologous virus", "PROBLEM", 199, 219], ["25 nm", "OBSERVATION_MODIFIER", 60, 65], ["diameter", "OBSERVATION_MODIFIER", 66, 74]]], ["These preclinical examples suggest that this protein nanoparticle approach may be suitable for rapid production of relatively simple but effective vaccines in response to emerging pathogens ( Table 3 ).New protein platformsProposals to perform molecular manipulations that, by exploiting chemical forces in a repetitious fashion, could lead to the production of interesting materials that date back at least to the 1960s [14, 15] .", [["this protein nanoparticle approach", "TREATMENT", 40, 74], ["rapid production", "PROBLEM", 95, 111], ["effective vaccines", "TREATMENT", 137, 155], ["emerging pathogens", "PROBLEM", 171, 189], ["New protein platformsProposals", "TREATMENT", 202, 232], ["molecular manipulations", "TREATMENT", 244, 267], ["protein platforms", "OBSERVATION", 206, 223]]], ["Indeed, in addition to the naturally occurring self-assembling proteins described above, several groups have explored ways to design and produce nanoparticle materials based on non-native polypeptides.", [["nanoparticle materials", "TREATMENT", 145, 167], ["non-native polypeptides", "TREATMENT", 177, 200]]], ["For example, Burkhard and co-workers produced chimeric polypeptides capable of self-assembling into regular polyhedral nanoparticles [106] .", [["chimeric polypeptides", "PROBLEM", 46, 67]]], ["The polypeptide consisted of an N-terminal pentamer-forming subunit derived from the cartilage oligomeric matrix protein (COMP), followed by a de novo-designed trimeric subunit domain.", [["N", "CHEMICAL", 32, 33], ["cartilage oligomeric matrix protein", "GENE_OR_GENE_PRODUCT", 85, 120], ["COMP", "GENE_OR_GENE_PRODUCT", 122, 126], ["N-terminal pentamer-forming subunit", "PROTEIN", 32, 67], ["cartilage oligomeric matrix protein", "PROTEIN", 85, 120], ["COMP", "PROTEIN", 122, 126], ["trimeric subunit domain", "PROTEIN", 160, 183], ["The polypeptide", "TREATMENT", 0, 15], ["an N-terminal pentamer-forming subunit", "TREATMENT", 29, 67], ["a de novo-designed trimeric subunit domain", "TREATMENT", 141, 183], ["cartilage", "ANATOMY", 85, 94], ["oligomeric matrix protein", "OBSERVATION", 95, 120]]], ["Both subunits present oligomeric coiled-coil conformations and importantly, the resultant synthetic molecule was shown to refold and self-assemble into nanoparticles with polyhedral symmetry.", [["oligomeric coiled-coil conformations", "TREATMENT", 22, 58], ["the resultant synthetic molecule", "PROBLEM", 76, 108], ["oligomeric coiled", "OBSERVATION", 22, 39], ["coil conformations", "OBSERVATION", 40, 58], ["polyhedral symmetry", "OBSERVATION", 171, 190]]], ["Alternative oligomerization motifs such as the trimeric foldon domain from fibritin have also been used in such designs [107] .", [["fibritin", "CHEMICAL", 75, 83], ["fibritin", "CHEMICAL", 75, 83], ["fibritin", "GENE_OR_GENE_PRODUCT", 75, 83], ["oligomerization motifs", "PROTEIN", 12, 34], ["trimeric foldon domain", "PROTEIN", 47, 69], ["fibritin", "PROTEIN", 75, 83], ["Alternative oligomerization motifs", "TREATMENT", 0, 34], ["the trimeric foldon domain", "TREATMENT", 43, 69], ["fibritin", "TREATMENT", 75, 83]]], ["The assembly of such nanoparticles gives rise to a multivalent molecular architecture that allows diverse immunogenic epitopes to be repeatedly displayed on the surface of the nanoparticles in a strictly arranged manner, a strategy that appears to be broadly applicable.New protein platformsIndeed, using the polypeptide approach, the Burkhard team fused the C-terminal heptad repeat (HRC) region of the SARS-CoV spike protein in its pre-fusogenic state in frame with the nanoparticle scaffold [108] .", [["surface", "ANATOMY", 161, 168], ["C", "CHEMICAL", 359, 360], ["surface", "CELLULAR_COMPONENT", 161, 168], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 404, 412], ["C-terminal heptad repeat (HRC) region", "PROTEIN", 359, 396], ["SARS-CoV spike protein", "PROTEIN", 404, 426], ["SARS-CoV", "SPECIES", 404, 412], ["such nanoparticles", "PROBLEM", 16, 34], ["a multivalent molecular architecture", "PROBLEM", 49, 85], ["diverse immunogenic epitopes", "PROBLEM", 98, 126], ["New protein platforms", "TEST", 270, 291], ["the polypeptide approach", "TREATMENT", 305, 329], ["the C-terminal heptad repeat (HRC)", "TREATMENT", 355, 389], ["the SARS", "PROBLEM", 400, 408], ["CoV spike protein", "PROBLEM", 409, 426], ["the nanoparticle scaffold", "TREATMENT", 468, 493], ["protein platforms", "OBSERVATION", 274, 291], ["SARS", "OBSERVATION", 404, 408], ["CoV spike", "OBSERVATION", 409, 418], ["nanoparticle scaffold", "OBSERVATION", 472, 493]]], ["This strategy allowed conservation of the trimeric coiled-coil conformation of the spike epitope.", [["trimeric coiled-coil conformation", "PROTEIN", 42, 75], ["spike epitope", "PROTEIN", 83, 96], ["the trimeric coiled-coil conformation", "TREATMENT", 38, 75], ["the spike epitope", "PROBLEM", 79, 96]]], ["Immunization of mice with these SARSnanoparticles successfully elicited neutralizing antibodies specific for the trimeric coiled-coil epitope of the pre-fusogenic HRC.", [["SARSnanoparticles", "CHEMICAL", 32, 49], ["mice", "ORGANISM", 16, 20], ["SARSnanoparticles", "SIMPLE_CHEMICAL", 32, 49], ["HRC", "GENE_OR_GENE_PRODUCT", 163, 166], ["neutralizing antibodies", "PROTEIN", 72, 95], ["trimeric coiled-coil epitope", "PROTEIN", 113, 141], ["pre-fusogenic HRC", "PROTEIN", 149, 166], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["Immunization of mice", "TREATMENT", 0, 20], ["these SARSnanoparticles", "TREATMENT", 26, 49], ["neutralizing antibodies", "TREATMENT", 72, 95], ["the trimeric coiled-coil epitope", "TREATMENT", 109, 141], ["the pre-fusogenic HRC", "PROBLEM", 145, 166], ["pre-fusogenic HRC", "OBSERVATION", 149, 166]]], ["Additional applications of this system targeted an HIV vaccine, by using a nanoparticle made of two covalently linked coiled-coil domains designed to incorporate the membrane proximal external region (MPER) of HIV-1 gp41 [109] .", [["membrane", "ANATOMY", 166, 174], ["membrane", "CELLULAR_COMPONENT", 166, 174], ["HIV-1", "GENE_OR_GENE_PRODUCT", 210, 215], ["coiled-coil domains", "PROTEIN", 118, 137], ["membrane proximal external region", "PROTEIN", 166, 199], ["MPER", "PROTEIN", 201, 205], ["gp41", "PROTEIN", 216, 220], ["HIV-1", "SPECIES", 210, 215], ["HIV", "SPECIES", 51, 54], ["HIV-1", "SPECIES", 210, 215], ["this system", "TREATMENT", 27, 38], ["an HIV vaccine", "TREATMENT", 48, 62], ["two covalently linked coiled-coil domains", "TREATMENT", 96, 137], ["HIV", "TEST", 210, 213], ["membrane", "ANATOMY_MODIFIER", 166, 174], ["proximal", "ANATOMY_MODIFIER", 175, 183], ["external region", "ANATOMY", 184, 199]]], ["However, while high MPER-specific titers were raised by this nanoparticle, none of the sera displayed detectable neutralizing activity against HIV-1.", [["sera", "ANATOMY", 87, 91], ["sera", "ORGANISM_SUBSTANCE", 87, 91], ["HIV-1", "ORGANISM", 143, 148], ["MPER", "PROTEIN", 20, 24], ["HIV-1", "SPECIES", 143, 148], ["HIV-1", "SPECIES", 143, 148], ["the sera", "TEST", 83, 91], ["HIV", "PROBLEM", 143, 146], ["neutralizing activity", "OBSERVATION", 113, 134]]], ["More promisingly, similarly designed polypeptide nanoparticles displaying multiple copies of a rodent malaria epitope from the circumsporozoite protein of Plasmodium berghei elicited a long-lasting immune response [110] .", [["malaria", "DISEASE", 102, 109], ["Plasmodium berghei", "DISEASE", 155, 173], ["circumsporozoite", "ORGANISM", 127, 143], ["Plasmodium berghei", "ORGANISM", 155, 173], ["circumsporozoite protein", "PROTEIN", 127, 151], ["rodent", "SPECIES", 95, 101], ["Plasmodium berghei", "SPECIES", 155, 173], ["Plasmodium berghei", "SPECIES", 155, 173], ["polypeptide nanoparticles", "TREATMENT", 37, 62], ["a rodent malaria epitope", "PROBLEM", 93, 117], ["the circumsporozoite protein", "TEST", 123, 151], ["Plasmodium berghei", "PROBLEM", 155, 173], ["rodent", "OBSERVATION_MODIFIER", 95, 101], ["malaria", "OBSERVATION", 102, 109], ["Plasmodium berghei", "OBSERVATION", 155, 173]]], ["Collectively, this preclinical research suggests that the self-assembling protein nanoparticle (SAPN) approach can generate safe non-native polypeptide antigens approximating the size and multivalent scenario of a virus and thus facilitate the recognition of the antigen by immune receptors.New protein platformsEarly in the 21st century, Yeates and co-workers developed the nanohedra protein-design method, which was subsequently extended by Noble and co-workers [111, 112] .", [["SAPN", "SIMPLE_CHEMICAL", 96, 100], ["polypeptide antigens", "PROTEIN", 140, 160], ["immune receptors", "PROTEIN", 274, 290], ["the self-assembling protein nanoparticle (SAPN) approach", "TREATMENT", 54, 110], ["safe non-native polypeptide antigens", "PROBLEM", 124, 160], ["a virus", "PROBLEM", 212, 219], ["New protein platforms", "TEST", 291, 312], ["size", "OBSERVATION_MODIFIER", 179, 183], ["multivalent scenario", "OBSERVATION", 188, 208], ["protein platforms", "OBSERVATION", 295, 312]]], ["The Yeates team rationally designed genetic fusions of the trimeric bromoperoxidase and the dimeric M1 matrix protein of influenza virus, such that the combination of the two naturally oligomeric proteins generated self-assembling nanostructures, including a 15-nm-wide molecular cage and a 4-nm-wide filamentous superstructure [111, 112] .", [["bromoperoxidase", "GENE_OR_GENE_PRODUCT", 68, 83], ["influenza virus", "ORGANISM", 121, 136], ["trimeric bromoperoxidase", "PROTEIN", 59, 83], ["dimeric M1 matrix protein", "PROTEIN", 92, 117], ["naturally oligomeric proteins", "PROTEIN", 175, 204], ["influenza virus", "SPECIES", 121, 136], ["genetic fusions", "TREATMENT", 36, 51], ["the trimeric bromoperoxidase", "TREATMENT", 55, 83], ["influenza virus", "PROBLEM", 121, 136], ["the two naturally oligomeric proteins", "PROBLEM", 167, 204], ["wide filamentous superstructure", "PROBLEM", 296, 327], ["influenza virus", "OBSERVATION", 121, 136], ["cage", "ANATOMY", 280, 284], ["wide", "OBSERVATION_MODIFIER", 296, 300], ["filamentous superstructure", "OBSERVATION", 301, 327]]], ["Later, a well-ordered tetrahedral cage with 12 subunits was designed and its crystal structure was determined and revealed to closely match the intended design, validating this approach [113] .", [["a well-ordered tetrahedral cage with 12 subunits", "TREATMENT", 7, 55]]], ["The Noble team used proteins with higher symmetry, allowing design of fusions with two or more connections, generating regular molecular arrays that formed protein lattices, but not closed nanohedral particles [114] .", [["protein lattices", "PROTEIN", 156, 172], ["proteins with higher symmetry", "TREATMENT", 20, 49], ["design of fusions", "TREATMENT", 60, 77]]], ["Several subsequent in silico and crystallographic studies have further developed nanostructure design strategies, including the generation of particles over 22 nm in diameter [115] .", [["crystallographic studies", "TEST", 33, 57], ["the generation of particles", "TREATMENT", 124, 151]]], ["Therefore, with the development of these more powerful computational approaches for the ab initio design of new protein-protein interfaces with defined symmetry, geometry, and complementary packing arrangements, and the increasing number of protein structures in the PDB, it is speculated that additional achievements in the field of selfassembling protein design will be possible [96, [115] [116] [117] [118] [119] [120] [121] [122] .", [["[115] [116] [117] [118] [119] [120] [121] [122]", "SIMPLE_CHEMICAL", 386, 433], ["new protein-protein interfaces", "TREATMENT", 108, 138], ["complementary packing arrangements", "TREATMENT", 176, 210], ["packing", "OBSERVATION_MODIFIER", 190, 197], ["PDB", "ANATOMY", 267, 270]]], ["It will be interesting to see if such scaffolds can be fully exploited to display antigenic epitopes suitable for full development into clinically efficacious vaccines.ConclusionsDespite many successes in the field of vaccinology, new breakthroughs are still needed to protect humans from several important life-threatening diseases.", [["humans", "ORGANISM", 277, 283], ["humans", "SPECIES", 277, 283], ["humans", "SPECIES", 277, 283], ["such scaffolds", "PROBLEM", 33, 47], ["antigenic epitopes", "PROBLEM", 82, 100], ["efficacious vaccines", "TREATMENT", 147, 167], ["vaccinology", "TREATMENT", 218, 229], ["new breakthroughs", "PROBLEM", 231, 248], ["threatening diseases", "PROBLEM", 312, 332], ["many", "OBSERVATION_MODIFIER", 187, 191], ["successes", "OBSERVATION", 192, 201]]], ["Here, we have reviewed how a variety of non-infectious biological nanoparticles can offer solutions.", [["non-infectious biological nanoparticles", "TREATMENT", 40, 79]]], ["For example, some plain nanoparticles (e.g. HBsAg or the HPV L1 protein) are simple molecular self-assemblies that are safe and efficacious vaccine antigens licensed for human use.", [["HBsAg", "CHEMICAL", 44, 49], ["HBsAg", "GENE_OR_GENE_PRODUCT", 44, 49], ["human", "ORGANISM", 170, 175], ["HBsAg", "PROTEIN", 44, 49], ["HPV L1 protein", "PROTEIN", 57, 71], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["some plain nanoparticles", "TEST", 13, 37], ["HBsAg", "TEST", 44, 49], ["the HPV L1 protein", "TEST", 53, 71], ["efficacious vaccine antigens", "TREATMENT", 128, 156]]], ["Or, more complex chimeric nanoparticles can be platforms on which pathogen-derived immunogenic motifs can be presented to the host immune system.", [["immune system", "ANATOMICAL_SYSTEM", 131, 144], ["more complex chimeric nanoparticles", "PROBLEM", 4, 39]]], ["These biological scaffolds range from synthetic polypeptides to native macromolecules such as ferritin, lumazine synthase or VLP-forming antigens or lipid-enveloped VLPs.", [["lumazine", "CHEMICAL", 104, 112], ["lumazine", "CHEMICAL", 104, 112], ["ferritin", "GENE_OR_GENE_PRODUCT", 94, 102], ["lumazine synthase", "GENE_OR_GENE_PRODUCT", 104, 121], ["VLP-forming antigens", "GENE_OR_GENE_PRODUCT", 125, 145], ["lipid", "SIMPLE_CHEMICAL", 149, 154], ["VLPs", "ORGANISM", 165, 169], ["ferritin", "PROTEIN", 94, 102], ["lumazine synthase", "PROTEIN", 104, 121], ["VLP-forming antigens", "PROTEIN", 125, 145], ["These biological scaffolds", "TREATMENT", 0, 26], ["synthetic polypeptides", "TREATMENT", 38, 60], ["native macromolecules", "TREATMENT", 64, 85], ["ferritin", "TEST", 94, 102], ["lumazine synthase", "TREATMENT", 104, 121], ["VLP", "PROBLEM", 125, 128], ["scaffolds range", "OBSERVATION", 17, 32]]], ["For some chimeric nanoparticles, there is evidence that the immunogenicity of the platform carrier itself is negligible or low compared to that of the mounted immunogen being presented [93] .", [["some chimeric nanoparticles", "PROBLEM", 4, 31], ["the mounted immunogen", "TREATMENT", 147, 168], ["nanoparticles", "OBSERVATION", 18, 31], ["negligible", "OBSERVATION_MODIFIER", 109, 119], ["low", "OBSERVATION_MODIFIER", 123, 126]]], ["Because these nanoparticles display an ordered matrix of immunogens, they enable more fruitful engagements with the B-cell receptors than single recombinant immunogens can establish.", [["B-cell", "ANATOMY", 116, 122], ["matrix", "CELLULAR_COMPONENT", 47, 53], ["B-cell", "CELL", 116, 122], ["B-cell receptors", "PROTEIN", 116, 132], ["an ordered matrix of immunogens", "TREATMENT", 36, 67], ["the B-cell receptors", "TREATMENT", 112, 132], ["single recombinant immunogens", "TREATMENT", 138, 167]]], ["Several animal models and clinical studies have been reported that exemplify the high efficiency of these nanostructures in eliciting potent and long-lasting immunity.", [["clinical studies", "TEST", 26, 42], ["high efficiency", "OBSERVATION_MODIFIER", 81, 96], ["potent", "OBSERVATION_MODIFIER", 134, 140]]], ["Following successful clinical studies, a recombinant nanoparticle-based vaccine against malaria is emerging, and two vaccines are already available to prevent HPV-related diseases.", [["nanoparticle", "CHEMICAL", 53, 65], ["malaria", "DISEASE", 88, 95], ["malaria", "ORGANISM", 88, 95], ["HPV", "ORGANISM", 159, 162], ["HPV", "SPECIES", 159, 162], ["successful clinical studies", "TEST", 10, 37], ["a recombinant nanoparticle-based vaccine", "TREATMENT", 39, 79], ["malaria", "PROBLEM", 88, 95], ["two vaccines", "TREATMENT", 113, 125], ["HPV", "PROBLEM", 159, 162], ["related diseases", "PROBLEM", 163, 179]]], ["Recent preclinical studies have demonstrated how computational and structural biology can be combined for the rational design of welloriented arrays of the most protective epitopes of a pathogen, in a manner suitable to raise the most desired immune responses.", [["Recent preclinical studies", "TEST", 0, 26], ["a pathogen", "PROBLEM", 184, 194]]], ["Further, the computational ab initio design of self-assembling molecules is becoming ever more possible, thus enriching our molecular repertoire of nanoparticle scaffolds.", [["self-assembling molecules", "PROBLEM", 47, 72], ["nanoparticle scaffolds", "TREATMENT", 148, 170], ["nanoparticle scaffolds", "OBSERVATION", 148, 170]]], ["Consequently, the design of plain or chimeric nanoparticle antigens, and the ability to manufacture these recombinantly in prokaryotic or eukaryotic systems, to make safe and effective immunogens, is becoming a reality.", [["chimeric nanoparticle antigens", "PROTEIN", 37, 67], ["plain or chimeric nanoparticle antigens", "TREATMENT", 28, 67], ["safe and effective immunogens", "TREATMENT", 166, 195]]], ["We have shown that vaccination clinical trials against a broad range of diseases are ongoing.", [["vaccination clinical trials", "TREATMENT", 19, 46], ["a broad range of diseases", "PROBLEM", 55, 80]]], ["While there are established examples of successful vaccines against diseases of viral and parasitic origin (hepatitis B, HPV, malaria), the next decade may consolidate the use of multivalent nanoparticles as a therapeutic tool for the future against infectious diseases of other origins (bacterial, fungal) but also against cancers and other disorders such as hypertension, asthma, or addictions (e.g. smoking).", [["cancers", "ANATOMY", 324, 331], ["diseases of viral and parasitic origin", "DISEASE", 68, 106], ["hepatitis B, HPV, malaria", "DISEASE", 108, 133], ["infectious diseases", "DISEASE", 250, 269], ["cancers", "DISEASE", 324, 331], ["hypertension", "DISEASE", 360, 372], ["asthma", "DISEASE", 374, 380], ["smoking", "CHEMICAL", 402, 409], ["hepatitis B", "ORGANISM", 108, 119], ["HPV", "ORGANISM", 121, 124], ["cancers", "CANCER", 324, 331], ["HPV", "SPECIES", 121, 124], ["successful vaccines", "TREATMENT", 40, 59], ["diseases", "PROBLEM", 68, 76], ["viral and parasitic origin", "PROBLEM", 80, 106], ["hepatitis B", "PROBLEM", 108, 119], ["HPV", "PROBLEM", 121, 124], ["malaria", "PROBLEM", 126, 133], ["multivalent nanoparticles", "TREATMENT", 179, 204], ["infectious diseases", "PROBLEM", 250, 269], ["bacterial, fungal)", "PROBLEM", 288, 306], ["cancers", "PROBLEM", 324, 331], ["other disorders", "PROBLEM", 336, 351], ["hypertension", "PROBLEM", 360, 372], ["asthma", "PROBLEM", 374, 380], ["viral", "OBSERVATION_MODIFIER", 80, 85], ["parasitic", "OBSERVATION_MODIFIER", 90, 99], ["hypertension", "OBSERVATION", 360, 372], ["asthma", "OBSERVATION", 374, 380]]], ["These amazingly versatile tools may also get us closer to universal vaccines against highly variable pathogens such as HIV, influenza, or meningitis.", [["influenza", "DISEASE", 124, 133], ["meningitis", "DISEASE", 138, 148], ["HIV", "ORGANISM", 119, 122], ["HIV", "SPECIES", 119, 122], ["HIV", "SPECIES", 119, 122], ["universal vaccines", "TREATMENT", 58, 76], ["highly variable pathogens", "PROBLEM", 85, 110], ["HIV", "PROBLEM", 119, 122], ["influenza", "PROBLEM", 124, 133], ["meningitis", "PROBLEM", 138, 148], ["meningitis", "OBSERVATION", 138, 148]]], ["Continued efforts are still needed, but there is a well-founded optimism that further studies of nanoparticles and VLPs together with the implementation of structural vaccinology, facilitated by emerging B-cell cloning and antibody production technologies, will be translated into new and second-generation vaccines that will contribute to saving more lives worldwide.Conflicts of interestThe authors are employees of GlaxoSmithKline Vaccines S.r.l., via Fiorentina 1, 53100 Siena, Italy.", [["B-cell", "ANATOMY", 204, 210], ["VLPs", "ORGANISM", 115, 119], ["B-cell", "CELL", 204, 210], ["further studies", "TEST", 78, 93], ["nanoparticles", "TREATMENT", 97, 110], ["VLPs", "TREATMENT", 115, 119], ["emerging B-cell cloning", "TREATMENT", 195, 218], ["antibody production technologies", "TREATMENT", 223, 255], ["second-generation vaccines", "TREATMENT", 289, 315], ["GlaxoSmithKline Vaccines", "TREATMENT", 418, 442]]]], "7dd0f9c59b04f12c2a2b1abc0f5b3d229f0a0531": [["| INTRODUCTIONChanges in our everyday life associated with the COVID-19 pandemic pose great challenges to all of us.", [["the COVID", "TREATMENT", 59, 68]]], ["There is a high awareness that individuals with mental disorders are affected significantly more by external stressors than resilient persons.", [["persons", "ORGANISM", 134, 141], ["persons", "SPECIES", 134, 141], ["a high awareness", "PROBLEM", 9, 25], ["mental disorders", "PROBLEM", 48, 64], ["high", "OBSERVATION_MODIFIER", 11, 15]]], ["One reason for this is that persons with mental disorders in generaland those with eating disorders (EDs) in particulartend to use more dysfunctional emotion regulation or coping strategies than individuals without mental disorders (Aldao, Nolen-Hoeksema, & Schweizer, 2010) .", [["eating disorders", "DISEASE", 83, 99], ["persons", "ORGANISM", 28, 35], ["persons", "SPECIES", 28, 35], ["mental disorders", "PROBLEM", 41, 57], ["eating disorders", "PROBLEM", 83, 99], ["mental disorders", "PROBLEM", 215, 231]]], ["However, there are few data on how patients with EDs cope with the current global crisis.| INTRODUCTIONRecently, an international online survey examined the impact of the COVID-19 pandemic on eating behaviour and physical activity in the general population.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["the current global crisis", "PROBLEM", 63, 88], ["the COVID", "TREATMENT", 167, 176], ["few", "OBSERVATION_MODIFIER", 19, 22], ["crisis", "OBSERVATION", 82, 88]]], ["It was found that physical activity decreased and eating behaviour (type of food consumption, eating out of control, snacks between meals, number of main meals) was more unhealthy during confinement than before (Ammar et al., 2020) .", [["physical activity", "PROBLEM", 18, 35], ["activity", "OBSERVATION_MODIFIER", 27, 35], ["decreased", "OBSERVATION_MODIFIER", 36, 45]]], ["Other studies have documented an increase in anxiety, depression, and loneliness (Killgore, Cloonan, Taylor, & Dailey, 2020; Li et al., 2020) .| INTRODUCTIONIn addition to the effects of the pandemic on the general population's well-being, it has been widely recognised that the pandemic may potentially facilitate symptom deterioration and relapse in patients with EDs in particular (Fernandez-Aranda et al., 2020; Todisco & Donini, 2020; Touyz, Lacey, & Hay, 2020; Weissman, Bauer, & Thomas, 2020) .| INTRODUCTIONIndeed, preliminary data suggest that many patients with EDs show a worsening of their overall ED symptomatology.", [["anxiety", "DISEASE", 45, 52], ["depression", "DISEASE", 54, 64], ["loneliness", "DISEASE", 70, 80], ["patients", "ORGANISM", 352, 360], ["patients", "ORGANISM", 558, 566], ["patients", "SPECIES", 352, 360], ["patients", "SPECIES", 558, 566], ["Other studies", "TEST", 0, 13], ["anxiety", "PROBLEM", 45, 52], ["depression", "PROBLEM", 54, 64], ["symptom deterioration", "PROBLEM", 315, 336], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["anxiety", "OBSERVATION", 45, 52], ["worsening", "OBSERVATION_MODIFIER", 583, 592]]], ["However, estimates vary substantially between studies (between 38% and 87%) and between specific EDrelated behaviours (Branley-Bell & Talbot, 2020; Fernandez-Aranda et al., 2020; Phillipou et al., 2020; Schlegl, Maier, Meule, & Voderholzer, in revision; Termorshuizen et al., 2020) .", [["studies", "TEST", 46, 53], ["Schlegl", "TEST", 203, 210]]], ["Moreover, most of these studies have examined heterogeneous samples or focused on anorexia nervosa (AN).", [["samples", "ANATOMY", 60, 67], ["anorexia nervosa", "DISEASE", 82, 98], ["AN", "DISEASE", 100, 102], ["these studies", "TEST", 18, 31], ["heterogeneous samples", "PROBLEM", 46, 67], ["anorexia nervosa", "PROBLEM", 82, 98], ["heterogeneous", "OBSERVATION_MODIFIER", 46, 59]]], ["Therefore, a gap exists in the extant literature regarding the effects of the pandemic in individuals with bulimia nervosa (BN).| INTRODUCTIONSo, the aim of this brief report is to report on the psychological consequences of the COVID-19 pandemic as well as changes in health care utilisation and the use and usefulness of possible strategies to cope with these times in patients with BN.| Study participantsThe study was approved by the institutional review board of the Medical Faculty of the Ludwig Maximilian University Munich, Germany.", [["bulimia nervosa", "DISEASE", 107, 122], ["BN", "DISEASE", 124, 126], ["patients", "ORGANISM", 371, 379], ["patients", "SPECIES", 371, 379], ["participants", "SPECIES", 396, 408], ["a gap", "TEST", 11, 16], ["bulimia nervosa", "PROBLEM", 107, 122], ["The study", "TEST", 408, 417]]], ["Two hundred and three former inpatients with BN who had received treatment in the Schoen Clinic Roseneck (Prien am Chiemsee, Germany) and who were discharged in 2018 and 2019 were contacted by email and invited to complete an anonymous online survey (lasting approximately 15 min) via www. unipark.com.", [["BN", "DISEASE", 45, 47], ["inpatients", "ORGANISM", 29, 39], ["treatment", "TREATMENT", 65, 74]]], ["Inclusion criteria were (a) having a primary diagnosis of BN (ICD-10: F50.2 or F50.3) at admission, (b) being female, and (c) being at least 13 years old.", [["BN", "DISEASE", 58, 60], ["BN", "PROBLEM", 58, 60], ["ICD", "TEST", 62, 65]]], ["One reminder was sent 1 week later.| InstrumentsWe used a self-developed questionnaire equivalent to the survey of patients with AN (Schlegl et al., in revision) to assess psychological consequences of the COVID-19 pandemic.", [["AN", "DISEASE", 129, 131], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["AN (Schlegl et al.", "TREATMENT", 129, 147], ["revision", "TREATMENT", 152, 160], ["the COVID", "TEST", 202, 211], ["pandemic", "PROBLEM", 215, 223]]], ["It was divided into seven parts: (a) Sociodemographic and other information such as age, sex, current self-reported height and weight, occupational situation during the COVID-19 pandemic, and contact history with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that is, current or previous own confirmed infection or infection of others (yes/no answers); (b) Overall impact of the COVID-19 pandemic on ED symptoms and general well-being, that is, deterioration of symptomatology and quality of life, adverse effects on therapy, incidence of new symptoms (5-point scale with 1 = strongly agree to 5 = strongly disagree); (c) Worries, for example, regarding infections, relapses, food insecurity, finances, and job (5-point scale with 1 = extremely worried to 5 = not at all worried); (d) General psychopathology and interpersonal conflicts (5-point scale with 1 = significantly worsened to 5 = significantly improved); (e) Specific ED symptoms and behaviours (5-point scale from 1 = significantly worsened/much more to 5 = significantly improved/much less); (f) Health care utilisation before and during the COVID-19 pandemic (yes/no answers); (g) Use and helpfulness of strategies as suggested by Fernandez-Aranda et al. (2020) (combination of yes/no answers and a 5-point scale with 1 = not helpful at all to 5 = very helpful).| Statistical analysesResponses to all questions are reported descriptively (relative frequencies, means).", [["acute respiratory syndrome coronavirus", "DISEASE", 220, 258], ["infection", "DISEASE", 318, 327], ["infection", "DISEASE", 331, 340], ["infections", "DISEASE", 670, 680], ["psychopathology", "DISEASE", 809, 824], ["severe acute respiratory syndrome coronavirus", "SPECIES", 213, 258], ["SARS-CoV", "SPECIES", 262, 270], ["the COVID", "TEST", 165, 174], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 213, 258], ["infection", "PROBLEM", 318, 327], ["the COVID", "TEST", 391, 400], ["ED symptoms", "PROBLEM", 416, 427], ["symptomatology", "PROBLEM", 478, 492], ["therapy", "TREATMENT", 533, 540], ["new symptoms", "PROBLEM", 555, 567], ["General psychopathology", "PROBLEM", 801, 824], ["Specific ED symptoms", "PROBLEM", 936, 956], ["behaviours", "TEST", 961, 971], ["severe", "OBSERVATION_MODIFIER", 213, 219], ["acute", "OBSERVATION_MODIFIER", 220, 225], ["respiratory syndrome", "OBSERVATION", 226, 246], ["infection", "OBSERVATION", 318, 327]]], ["That is, percentages of endorsement of each statement refer to the combined percentages of the categories agree/strongly agree, moderately worried/extremely worried, somewhat worsened/significantly worsened, and more /much more.", [["worsened", "OBSERVATION_MODIFIER", 175, 183], ["significantly", "OBSERVATION_MODIFIER", 184, 197], ["worsened", "OBSERVATION_MODIFIER", 198, 206]]], ["All analyses were conducted with IBM SPSS Statistics version 24.| Socio-demographic and other informationIn total, 91 of the 203 former inpatients with BN who were contacted accessed the survey.", [["inpatients", "ORGANISM", 136, 146], ["All analyses", "TEST", 0, 12]]], ["Of these 91 patients, 15 patients only viewed the first page of the survey, 2 patients did not agree to informed consent and 74 patients gave electronic informed consent.", [["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 128, 136]]], ["The final sample comprised the 55 patients (27.1% of the total sample) who completed the online survey.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["Mean age was 24.42 years (SD = 6.36, range: 17-46, n = 2 minors).", [["Mean age", "TEST", 0, 8], ["SD", "TEST", 26, 28], ["range", "TEST", 37, 42]]], ["Mean body mass index was 23.62 kg/m 2 (SD = 4.58).", [["body", "ANATOMY", 5, 9], ["body", "ORGANISM_SUBDIVISION", 5, 9], ["Mean body mass index", "TEST", 0, 20], ["SD", "TEST", 39, 41], ["mass", "OBSERVATION", 10, 14]]], ["During the COVID-19 pandemic, the occupational situation of patients was homeschooling (20.0%), university online classes (20.0%), working from home (10.9%), working at workplace (21.8%), reduced working hours (3.6%), job loss due to the COVID-19 pandemic (3.6%) and others (20.0%).", [["job loss", "DISEASE", 218, 226], ["pandemic", "DISEASE", 247, 255], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["job loss", "PROBLEM", 218, 226], ["the COVID", "TEST", 234, 243], ["pandemic", "PROBLEM", 247, 255]]], ["One patient was infected with SARS-CoV-2, two reported an infection in the household and three reported an infection among related parties.| Impact of the COVID-19 pandemic on patients with BNThe overall impact of the COVID-19 pandemic on ED symptoms and general well-being, worries, the impact on general psychopathology, interpersonal conflicts as well as specific ED symptoms and behaviours are shown in Figures 1-4.", [["SARS", "DISEASE", 30, 34], ["infection", "DISEASE", 58, 67], ["infection", "DISEASE", 107, 116], ["patient", "ORGANISM", 4, 11], ["SARS-CoV-2", "ORGANISM", 30, 40], ["patients", "ORGANISM", 176, 184], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 176, 184], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "PROBLEM", 30, 34], ["an infection", "PROBLEM", 55, 67], ["an infection", "PROBLEM", 104, 116], ["the COVID", "TREATMENT", 151, 160], ["the COVID", "TREATMENT", 214, 223], ["symptoms", "PROBLEM", 242, 250], ["specific ED symptoms", "PROBLEM", 358, 378], ["infected", "OBSERVATION", 16, 24], ["infection", "OBSERVATION", 58, 67], ["infection", "OBSERVATION", 107, 116]]], ["Almost half of patients with BN reported a worsening of their ED symptomatology (49.1%) and 61.8% of their quality of life.", [["BN", "DISEASE", 29, 31], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["worsening", "OBSERVATION_MODIFIER", 43, 52]]], ["Furthermore, 45.5% expressed a significant impairment of current psychotherapy and 40.0% reported that they developed new symptoms.| Impact of the COVID-19 pandemic on patients with BNSadness, loss of energy, inner restlessness, and loneliness were the most pronounced depressive and general psychopathology symptoms (over 75%).", [["BNSadness", "DISEASE", 182, 191], ["loss of energy, inner restlessness", "DISEASE", 193, 227], ["loneliness", "DISEASE", 233, 243], ["depressive", "DISEASE", 269, 279], ["psychopathology", "DISEASE", 292, 307], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["new symptoms", "PROBLEM", 118, 130], ["the COVID", "TREATMENT", 143, 152], ["BNSadness", "TREATMENT", 182, 191], ["loss of energy", "PROBLEM", 193, 207], ["inner restlessness", "PROBLEM", 209, 227], ["loneliness", "PROBLEM", 233, 243], ["the most pronounced depressive and general psychopathology symptoms", "PROBLEM", 249, 316], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["impairment", "OBSERVATION", 43, 53]]], ["Furthermore, shape, weight, and eating concerns as well as fear of gaining weight, body dissatisfaction, and drive for thinness increased in most patients (over 80%).", [["body", "ANATOMY", 83, 87], ["body", "ORGANISM_SUBDIVISION", 83, 87], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["body dissatisfaction", "PROBLEM", 83, 103], ["thinness", "PROBLEM", 119, 127], ["shape", "OBSERVATION_MODIFIER", 13, 18]]], ["A higher drive for activity was prevalent in 61.8% of patients and 61.9% reported a less or much lessregular meal structure.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["a less or much lessregular meal structure", "PROBLEM", 82, 123]]], ["Binge eating increased in 47.3% of patients, self-inducing vomiting in 36.4%, laxative use in 9.1% and diuretic abuse in 7.3% of patients.", [["Binge eating", "DISEASE", 0, 12], ["vomiting", "DISEASE", 59, 67], ["diuretic abuse", "DISEASE", 103, 117], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 129, 137], ["vomiting", "PROBLEM", 59, 67], ["laxative use", "TREATMENT", 78, 90], ["diuretic abuse", "TREATMENT", 103, 117]]], ["On the contrary, a quarter of patients reported more or much more time for meal preparation and more or much more cooking.| Health care utilisationMore than 80% of patients with BN received face-toface therapy before the COVID-19 pandemic (81.8%) compared to 36.4% during the pandemic (i.e., a decrease by 55.5%).", [["BN", "DISEASE", 178, 180], ["face-toface", "CHEMICAL", 190, 201], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 164, 172], ["meal preparation", "TREATMENT", 75, 91], ["face-toface therapy", "TREATMENT", 190, 209], ["the COVID", "TEST", 217, 226], ["pandemic", "PROBLEM", 230, 238]]], ["Use of videoconference-based therapy increased from 3.6% to 21.8% and use of telephone contacts from 18.2% to 38.2%, whereas the use of additional online interventions decreased from 3.6% to 0%.| Health care utilisationF I G U R E 1 Percentages of the overall impact of the COVID-19 pandemic on patients with bulimia nervosa| Use and helpfulness of strategiesEnjoyable activities, virtual social contact with friends and mild physical exercises were the strategies rated as most helpful among those most used.", [["bulimia nervosa", "DISEASE", 309, 324], ["patients", "ORGANISM", 295, 303], ["patients", "SPECIES", 295, 303], ["videoconference-based therapy", "TREATMENT", 7, 36], ["additional online interventions", "TREATMENT", 136, 167], ["the COVID", "TEST", 270, 279], ["bulimia nervosa", "PROBLEM", 309, 324], ["mild physical exercises", "TREATMENT", 421, 444]]], ["Figure 5 shows mean responses to questions on helpfulness of different strategies for patients with BN during the COVID-19 pandemic.| Summary of resultsMore than half of former inpatients with BN experienced a worsening of their ED symptomatology as well as of their quality of life during the crisis.", [["BN", "DISEASE", 100, 102], ["BN", "DISEASE", 193, 195], ["patients", "ORGANISM", 86, 94], ["inpatients", "ORGANISM", 177, 187], ["patients", "SPECIES", 86, 94], ["the COVID", "TEST", 110, 119], ["the crisis", "PROBLEM", 290, 300], ["worsening", "OBSERVATION_MODIFIER", 210, 219]]], ["Furthermore, depressive and general psychopathology symptoms increased in up to 80% of patients.", [["depressive", "DISEASE", 13, 23], ["psychopathology symptoms", "DISEASE", 36, 60], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["depressive", "PROBLEM", 13, 23], ["general psychopathology symptoms", "PROBLEM", 28, 60]]], ["Binge eating increased in nearly half of the patients, self-induced vomiting in one third, laxative use and diuretic abuse in almost 10%.", [["Binge eating", "DISEASE", 0, 12], ["vomiting", "DISEASE", 68, 76], ["diuretic abuse", "DISEASE", 108, 122], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["vomiting", "PROBLEM", 68, 76], ["laxative use", "TREATMENT", 91, 103], ["diuretic abuse", "TREATMENT", 108, 122]]], ["A higher drive for activity was prevalent in more than 60% of patients.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["higher drive", "OBSERVATION", 2, 14]]], ["More than 60% of patients also reported problems with maintaining their established daily routine and regular meal structure.", [["patients", "ORGANISM", 17, 25], ["meal", "ORGANISM_SUBDIVISION", 110, 114], ["patients", "SPECIES", 17, 25]]], ["Furthermore, more than half of patients could not continue their face-to-face therapy.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["face therapy", "TREATMENT", 73, 85]]], ["Yet, only 20% of patients used alternative treatment modalities such as videoconference-based therapy.| Comparison with findings of other studiesCompared to the impact that the COVID-19 pandemic had on former inpatients with AN (Schlegl et al., in revision) -with 42% reporting a worsening of their ED symptomatology and 52% a worsening of their quality of lifethe impact of the crisis on ED symptoms seems even stronger in patients with BN.", [["AN", "DISEASE", 225, 227], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 424, 432], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 424, 432], ["alternative treatment modalities", "TREATMENT", 31, 63], ["videoconference-based therapy", "TREATMENT", 72, 101], ["other studies", "TEST", 132, 145], ["the COVID", "TEST", 173, 182], ["the crisis", "PROBLEM", 375, 385], ["ED symptoms", "PROBLEM", 389, 400], ["worsening", "OBSERVATION_MODIFIER", 280, 289], ["worsening", "OBSERVATION_MODIFIER", 327, 336]]], ["Furthermore, almost twice as many patients with BN than those with AN reported a significant impairment of therapy during the crisis and the development of new symptoms.| Comparison with findings of other studiesCompared to international studies, our value for a worsening of overall symptomatology (49.1%) lies in the middle of the range (38.0%-86.7%) (Branley-Bell & Talbot, 2020; Fernandez-Aranda et al., 2020) .", [["AN", "DISEASE", 67, 69], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["therapy", "TREATMENT", 107, 114], ["the crisis", "PROBLEM", 122, 132], ["new symptoms", "PROBLEM", 156, 168], ["other studies", "TEST", 199, 212], ["international studies", "TEST", 224, 245], ["overall symptomatology", "TEST", 276, 298], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["impairment", "OBSERVATION", 93, 103], ["new", "OBSERVATION_MODIFIER", 156, 159], ["symptoms", "OBSERVATION", 160, 168], ["worsening", "OBSERVATION_MODIFIER", 263, 272], ["middle", "ANATOMY_MODIFIER", 319, 325]]], ["However, we found an almost twofold increase in binge eating and urges to binge compared to the U.S./Netherlands sample F I G U R E 4 Percentages on how eating disorder symptoms and behaviours changed in patients with bulimia nervosa during the COVID-19 pandemic sub-group of patients with BN and Binge eating disorder (47.3% vs. 15%-30%) (Termorshuizen et al., 2020) .", [["binge eating", "DISEASE", 48, 60], ["eating disorder", "DISEASE", 153, 168], ["bulimia nervosa", "DISEASE", 218, 233], ["BN", "DISEASE", 290, 292], ["Binge eating disorder", "DISEASE", 297, 318], ["patients", "ORGANISM", 204, 212], ["patients", "ORGANISM", 276, 284], ["patients", "SPECIES", 204, 212], ["patients", "SPECIES", 276, 284], ["eating disorder symptoms", "PROBLEM", 153, 177], ["bulimia nervosa", "PROBLEM", 218, 233], ["BN", "PROBLEM", 290, 292], ["Binge eating disorder", "PROBLEM", 297, 318], ["almost", "OBSERVATION_MODIFIER", 21, 27], ["twofold", "OBSERVATION_MODIFIER", 28, 35], ["increase", "OBSERVATION_MODIFIER", 36, 44]]], ["This might be at least partially attributable to our survey of a more severely ill sample (former inpatients with a still high health care utilisation rate) compared to the sample of the other study where only half of patients were in treatment at the beginning of the COVID-19 pandemic.| Effects on therapy and use of ehealth treatmentsThe utilisation rate of videoconference-based therapy of only 20% in our German sample is much lower than in the United States and Netherlands where 42%-45% of patients transitioned to online/tele-health care (Termorshuizen et al., 2020) .", [["patients", "ORGANISM", 218, 226], ["patients", "ORGANISM", 497, 505], ["patients", "SPECIES", 218, 226], ["patients", "SPECIES", 497, 505], ["a more severely ill sample", "PROBLEM", 63, 89], ["the other study", "TEST", 183, 198], ["treatment", "TREATMENT", 235, 244], ["the COVID", "TEST", 265, 274], ["therapy", "TREATMENT", 300, 307], ["ehealth treatments", "TREATMENT", 319, 337], ["videoconference-based therapy", "TREATMENT", 361, 390]]], ["Therefore, feasibility and/or acceptance of e-mental health treatments in patients with BN do not seem very high, at least in Germany.| Effects on therapy and use of ehealth treatmentsSeveral suggestions exist on how to deliver evidencebased treatments such as cognitive-behavioural therapy or family-based treatment remotely in times of contact restrictions (Matheson, Bohon, & Lock, 2020; Murphy, Calugi, Cooper, & Dalle Grave, 2020; Touyz et al., 2020; Waller et al., 2020) .", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["e-mental health treatments", "TREATMENT", 44, 70], ["therapy", "TREATMENT", 147, 154], ["ehealth treatments", "TREATMENT", 166, 184], ["evidencebased treatments", "TREATMENT", 228, 252], ["behavioural therapy", "TREATMENT", 271, 290]]], ["Furthermore, there is one randomized controlled trial (RCT) showing a comparable efficacy of telemedicine and face-to-face treatment in patients with BN (Mitchell et al., 2008) .", [["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["telemedicine", "TREATMENT", 93, 105], ["face-to-face treatment", "TREATMENT", 110, 132]]], ["Additionally, online interventions such as \"Overcoming Bulimia Online\"-which has been evaluated in an RCT (S\u00e1nchez-Ortiz et al., 2011 )might in principle be an option, but unfortunately are not available in German.", [["online interventions", "TREATMENT", 14, 34]]], ["Also, the smartphone App \"Recovery Record\" might be a helpful tool, either as self-help or as therapist-guided intervention (Tregarthen et al., 2015) .", [["intervention", "TREATMENT", 111, 123]]], ["One of the main \"Recovery Record\" elements is self-F I G U R E 5 Mean responses to questions on helpfulness of strategies.", [["main", "OBSERVATION_MODIFIER", 11, 15]]], ["Higher scores represent higher helpfulness ratings.", [["higher", "OBSERVATION_MODIFIER", 24, 30]]], ["The values in parentheses reflect the percentages of patients that used the strategies.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["The values", "TEST", 0, 10], ["the strategies", "TREATMENT", 72, 86]]], ["Self-monitoring of meals might help to keep a regular, adequate meal structure, which in turn might help to prevent binge eating and subsequent compensatory behaviour.", [["binge eating", "DISEASE", 116, 128]]], ["As \"Recovery Record\" includes these protocols and inquiries about urges as well as disordered behaviour, both patient and therapist can detect early warning signs of relapse more easily, which allows for timely intervention.| Strengths and limitations of the current studyStrengths of our study were that we investigated a sample with a confirmed clinical diagnosis of BN.", [["BN", "DISEASE", 369, 371], ["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["these protocols", "TREATMENT", 30, 45], ["our study", "TEST", 285, 294], ["BN", "PROBLEM", 369, 371]]], ["Furthermore, we performed a comprehensive query of data regarding a wide range of potential detrimental effects of the COVID-19 pandemic on patients with BN, but we also focused on potential helpful coping strategies.", [["BN", "DISEASE", 154, 156], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["the COVID", "TREATMENT", 115, 124]]], ["However, there are also some limitations that should be considered: The completion rate of 27% was relatively low.", [["The completion rate", "TEST", 68, 87]]], ["It is possible that those who were not considerably affected by the COVID-19 pandemic were less likely to respond.", [["the COVID", "TEST", 64, 73]]], ["However, in a sensitivity analysis (not reported), we found no differences in answers between those who responded to the first invitation or the reminder.", [["a sensitivity analysis", "TEST", 12, 34]]], ["Furthermore, increasing response rates do not necessarily reduce such a bias (Dillman, Eltinge, Groves, & Little, 2002) .", [["increasing response rates", "PROBLEM", 13, 38]]], ["Additionally, further RCTs comparing face-to-face therapies and e-mental-health interventions and/or blended treatments and/or evaluating patients who switched from face-to-face to e-mentalhealth interventions regarding outcome and therapeutic alliance might be highly warranted to ascertain if and to what extent evidence-based therapy can also be provided remotely.", [["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["further RCTs", "TEST", 14, 26], ["face", "TEST", 37, 41], ["face therapies", "TREATMENT", 45, 59], ["e-mentalhealth interventions", "TREATMENT", 181, 209], ["therapeutic alliance", "TREATMENT", 232, 252]]], ["Finally, investigating barriers and facilitating factors for remote therapy seems worth researching since it might be a promising solution to support patients best during such crises.| ConclusionThe current pandemic had and likely continues to have detrimental effects on symptomatology and treatment of patients with BN.", [["BN", "DISEASE", 318, 320], ["patients", "ORGANISM", 150, 158], ["patients", "ORGANISM", 304, 312], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 304, 312], ["remote therapy", "TREATMENT", 61, 75], ["detrimental effects on symptomatology", "PROBLEM", 249, 286], ["treatment", "TREATMENT", 291, 300], ["BN", "PROBLEM", 318, 320]]], ["However, we should not forget that the COVID-19 pandemic might also be a chance for patients with BN to learn key life skills such as coping with life in general, with emotions and stress, to change their way of thinking and to set new goals.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["stress", "PROBLEM", 181, 187]]], ["Being able to offer them evidence-based alternative therapeutic treatment strategies should be a goal for future.CONFLICT OF INTERESTWe have no conflicts of interest to declare.DATA AVAILABILITY STATEMENTThe data that support the findings of this study are available from the corresponding author upon reasonable request.DATA AVAILABILITY STATEMENTORCID Sandra Schlegl https://orcid.org/0000-0003-1791-7379 Adrian Meule https://orcid.org/0000-0002-6639-8977 Ulrich Voderholzer https://orcid.org/0000-0003-0261-3145", [["Meule", "CHEMICAL", 414, 419], ["Voderholzer", "CHEMICAL", 465, 476], ["Meule", "CHEMICAL", 414, 419], ["Voderholzer", "SPECIES", 465, 476], ["alternative therapeutic treatment strategies", "TREATMENT", 40, 84], ["this study", "TEST", 242, 252], ["STATEMENTORCID", "TEST", 339, 353], ["Sandra", "TEST", 354, 360], ["Schlegl", "TEST", 361, 368], ["Voderholzer", "TREATMENT", 465, 476]]]], "be6b959fad04bf39f146696e764814217791c7b6": [["We appreciate the opportunity to respond to the letter from Dr Thachil[1], who provided an interesting physiological explanation for coagulation-fibrinolysis balance shifts of the Broncho-alveolar haemostasis during COVID-19 infection, and speculated that the extravascular fibrinolysis would be a source of elevated D-dimers.", [["alveolar", "ANATOMY", 188, 196], ["extravascular", "ANATOMY", 260, 273], ["COVID-19", "CHEMICAL", 216, 224], ["infection", "DISEASE", 225, 234], ["alveolar", "MULTI-TISSUE_STRUCTURE", 188, 196], ["extravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 260, 273], ["D-dimers", "SIMPLE_CHEMICAL", 317, 325], ["D-dimers", "PROTEIN", 317, 325], ["fibrinolysis balance shifts", "PROBLEM", 145, 172], ["the Broncho-alveolar haemostasis", "PROBLEM", 176, 208], ["COVID-19 infection", "PROBLEM", 216, 234], ["the extravascular fibrinolysis", "PROBLEM", 256, 286], ["elevated D-dimers", "PROBLEM", 308, 325], ["alveolar", "ANATOMY", 188, 196], ["haemostasis", "OBSERVATION", 197, 208], ["infection", "OBSERVATION", 225, 234], ["extravascular fibrinolysis", "OBSERVATION", 260, 286], ["elevated", "OBSERVATION", 308, 316]]]], "PMC7287456": [["IntroductionOn January 7th, 2020, a novel Coronavirus was named and identified as Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV).1 The current pandemic of Coronavirus Disease-19 (COVID-19) began in Wuhan city, China, in December 2019.1 Scientists from Wuhan Institute of Virology, Wuhan, China, initially identified the SARS-CoV-2 by metagenomic analysis of bronchoalveolar lavage fluid from a patient with pneumonia.2,3 This virus is an RNA virus belonging to the family of \u03b2 coronavirus and can cause minor illnesses such as common cold, and fatal conditions like pneumonia, and severe acute respiratory syndrome (SARS).1 The virus has been characterized, and it has three subtypes: A, B, and C.4 'A' subtype is the ancestral type like bat coronavirus.", [["bronchoalveolar lavage fluid", "ANATOMY", 434, 462], ["Acute Respiratory Syndrome Corona Virus", "DISEASE", 89, 128], ["Coronavirus Disease", "DISEASE", 231, 250], ["COVID-19", "CHEMICAL", 255, 263], ["pneumonia", "DISEASE", 483, 492], ["2,3", "CHEMICAL", 493, 496], ["\u03b2 coronavirus", "DISEASE", 551, 564], ["pneumonia", "DISEASE", 642, 651], ["acute respiratory syndrome", "DISEASE", 664, 690], ["SARS", "DISEASE", 692, 696], ["Coronavirus", "CANCER", 42, 53], ["Coronavirus Disease-19", "ORGANISM", 231, 253], ["COVID-19", "CELL", 255, 263], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 434, 462], ["patient", "ORGANISM", 470, 477], ["2,3", "SIMPLE_CHEMICAL", 493, 496], ["\u03b2 coronavirus", "ORGANISM", 551, 564], ["A", "GENE_OR_GENE_PRODUCT", 761, 762], ["B", "GENE_OR_GENE_PRODUCT", 764, 765], ["C.4 'A", "ORGANISM", 771, 777], ["bat coronavirus", "ORGANISM", 814, 829], ["patient", "SPECIES", 470, 477], ["\u03b2 coronavirus", "SPECIES", 551, 564], ["bat coronavirus", "SPECIES", 814, 829], ["Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2", "SPECIES", 82, 142], ["ICTV", "SPECIES", 199, 203], ["Coronavirus Disease-19 (COVID-19", "SPECIES", 231, 263], ["SARS-CoV", "SPECIES", 396, 404], ["\u03b2 coronavirus", "SPECIES", 551, 564], ["bat coronavirus", "SPECIES", 814, 829], ["a novel Coronavirus", "PROBLEM", 34, 53], ["Severe Acute Respiratory Syndrome Corona Virus", "PROBLEM", 82, 128], ["Coronavirus Disease", "PROBLEM", 231, 250], ["COVID", "TEST", 255, 260], ["the SARS", "PROBLEM", 392, 400], ["bronchoalveolar lavage fluid", "TEST", 434, 462], ["pneumonia", "PROBLEM", 483, 492], ["This virus", "PROBLEM", 497, 507], ["an RNA virus", "PROBLEM", 511, 523], ["coronavirus", "PROBLEM", 553, 564], ["minor illnesses", "PROBLEM", 579, 594], ["common cold", "PROBLEM", 603, 614], ["fatal conditions", "PROBLEM", 620, 636], ["pneumonia", "PROBLEM", 642, 651], ["severe acute respiratory syndrome", "PROBLEM", 657, 690], ["The virus", "PROBLEM", 700, 709], ["Severe", "OBSERVATION_MODIFIER", 82, 88], ["Acute", "OBSERVATION_MODIFIER", 89, 94], ["Respiratory Syndrome", "OBSERVATION", 95, 115], ["Coronavirus Disease", "OBSERVATION", 231, 250], ["bronchoalveolar lavage fluid", "OBSERVATION", 434, 462], ["pneumonia", "OBSERVATION", 483, 492], ["RNA virus", "OBSERVATION", 514, 523], ["pneumonia", "OBSERVATION", 642, 651], ["severe", "OBSERVATION_MODIFIER", 657, 663], ["acute", "OBSERVATION_MODIFIER", 664, 669], ["respiratory syndrome", "OBSERVATION", 670, 690], ["virus", "OBSERVATION", 704, 709], ["ancestral type", "OBSERVATION", 794, 808], ["bat coronavirus", "OBSERVATION", 814, 829]]], ["'A' and 'C' subtypes are found in the USA and Europe, and 'B' subtype predominant in East Asia.4 The prevalent hypothesis suggested that this virus came from the bat, possibly through pangolins,5 both of which are consumed in China even in undercooked states.", [["pangolins", "CHEMICAL", 184, 193], ["pangolins", "CHEMICAL", 184, 193], ["C' subtypes", "CELL", 9, 20], ["pangolins", "GENE_OR_GENE_PRODUCT", 184, 193], ["this virus", "PROBLEM", 137, 147], ["virus", "OBSERVATION", 142, 147], ["bat", "ANATOMY", 162, 165]]], ["If this hypothesis is correct, it suggests the gastrointestinal (GI) tract be a route for transmission.", [["gastrointestinal", "ANATOMY", 47, 63], ["GI", "ANATOMY", 65, 67], ["gastrointestinal (GI) tract", "DISEASE", 47, 74], ["gastrointestinal", "ORGANISM_SUBDIVISION", 47, 63], ["the gastrointestinal (GI) tract", "PROBLEM", 43, 74], ["gastrointestinal", "ANATOMY", 47, 63]]], ["Subsequently, the infected patients can transmit the virus in the community through fomites and aerosol (Fig. 1).IntroductionThe Corona Virus Disease (COVID-19) outbreak has become a pandemic and has led to severe consequences to the global economy.1 More than 1,20,897 people died of coronavirus to date in the world, and more than 19,39,801 people have been affected till 14th April 2020.", [["community", "ANATOMY", 66, 75], ["Corona Virus Disease", "DISEASE", 129, 149], ["COVID-19", "CHEMICAL", 151, 159], ["coronavirus", "DISEASE", 285, 296], ["patients", "ORGANISM", 27, 35], ["Corona Virus", "ORGANISM", 129, 141], ["people", "ORGANISM", 270, 276], ["coronavirus", "ORGANISM", 285, 296], ["people", "ORGANISM", 343, 349], ["patients", "SPECIES", 27, 35], ["people", "SPECIES", 270, 276], ["people", "SPECIES", 343, 349], ["Corona Virus Disease (COVID-19", "SPECIES", 129, 159], ["the virus", "PROBLEM", 49, 58], ["The Corona Virus Disease", "PROBLEM", 125, 149], ["COVID", "TEST", 151, 156], ["outbreak", "PROBLEM", 161, 169], ["a pandemic", "PROBLEM", 181, 191], ["coronavirus", "PROBLEM", 285, 296], ["infected", "OBSERVATION", 18, 26], ["Corona Virus Disease", "OBSERVATION", 129, 149], ["severe", "OBSERVATION_MODIFIER", 207, 213], ["global", "OBSERVATION_MODIFIER", 234, 240], ["economy", "OBSERVATION", 241, 248]]], ["The mortality of coronavirus is currently 3% to 6%.", [["coronavirus", "DISEASE", 17, 28], ["coronavirus", "ORGANISM", 17, 28], ["The mortality of coronavirus", "PROBLEM", 0, 28], ["coronavirus", "OBSERVATION", 17, 28]]], ["Fig. 2shows the country-wise number of COVID-19 patients and the number of death as of now, though it is increasing every day.", [["death", "DISEASE", 75, 80], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["increasing", "OBSERVATION_MODIFIER", 105, 115]]], ["Though respiratory symptoms are the most common manifestations of SARS-CoV-2, digestive system involvement is not uncommon.1 This review attempts to give an overview of the spectrum of gastrointestinal system involvement in these patients and its clinical, epidemiological, and public health importance.", [["respiratory", "ANATOMY", 7, 18], ["digestive system", "ANATOMY", 78, 94], ["gastrointestinal system", "ANATOMY", 185, 208], ["respiratory symptoms", "DISEASE", 7, 27], ["SARS", "DISEASE", 66, 70], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 66, 76], ["digestive system", "MULTI-TISSUE_STRUCTURE", 78, 94], ["gastrointestinal system", "ANATOMICAL_SYSTEM", 185, 208], ["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 230, 238], ["SARS-CoV", "SPECIES", 66, 74], ["respiratory symptoms", "PROBLEM", 7, 27], ["SARS", "PROBLEM", 66, 70], ["digestive system involvement", "PROBLEM", 78, 106], ["gastrointestinal system involvement", "PROBLEM", 185, 220], ["digestive system", "ANATOMY", 78, 94], ["not uncommon", "UNCERTAINTY", 110, 122], ["gastrointestinal system", "ANATOMY", 185, 208]]], ["It is crucial mentioning that the understanding of this disease is currently evolving; a lot is yet to be understood.Introduction", [["this disease", "PROBLEM", 51, 63]]]], "996a3bd513fca5b451497f9677f104856c051710": [["IntroductionA novel coronavirus is responsible for the coronavirus disease 2019 pandemic that is currently affecting multiple continents.", [["coronavirus", "DISEASE", 20, 31], ["coronavirus disease", "DISEASE", 55, 74], ["coronavirus", "ORGANISM", 20, 31], ["coronavirus", "ORGANISM", 55, 66], ["IntroductionA novel coronavirus", "PROBLEM", 0, 31], ["the coronavirus disease", "PROBLEM", 51, 74], ["pandemic", "PROBLEM", 80, 88], ["coronavirus", "OBSERVATION", 20, 31]]], ["[1] [2] [3] Recent studies have identified that many persons infected by this virus (the exact number is not known) remain asymptomatic, or display only minor symptoms, which lack specificity for COVID-19.", [["persons", "ORGANISM", 53, 60], ["persons", "SPECIES", 53, 60], ["Recent studies", "TEST", 12, 26], ["this virus", "PROBLEM", 73, 83], ["asymptomatic", "PROBLEM", 123, 135], ["minor symptoms", "PROBLEM", 153, 167], ["COVID", "TEST", 196, 201]]], ["[4] [5] [6] Nevertheless, asymptomatic individuals are capable of transmitting the illness with almost the same infectivity as symptomatic patients.", [["individuals", "ORGANISM", 39, 50], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["asymptomatic individuals", "PROBLEM", 26, 50], ["the illness", "PROBLEM", 79, 90]]], ["7, 8 Exposure to COVID-19 infection can result in a serious illness characterized by a severe acute respiratory syndrome (SARS) that carries an overall mortality estimated between 3.0% and 30%, although the exact number remains uncertain, and its magnitude seems greater in subpopulations of particularly vulnerable individuals and those with multiorgan involvement.", [["multiorgan", "ANATOMY", 343, 353], ["COVID-19", "CHEMICAL", 17, 25], ["infection", "DISEASE", 26, 35], ["acute respiratory syndrome", "DISEASE", 94, 120], ["SARS", "DISEASE", 122, 126], ["multiorgan", "ORGAN", 343, 353], ["COVID-19", "SPECIES", 17, 25], ["COVID", "TEST", 17, 22], ["infection", "PROBLEM", 26, 35], ["a serious illness", "PROBLEM", 50, 67], ["a severe acute respiratory syndrome", "PROBLEM", 85, 120], ["multiorgan involvement", "PROBLEM", 343, 365], ["infection", "OBSERVATION", 26, 35], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["respiratory syndrome", "OBSERVATION", 100, 120], ["greater", "OBSERVATION_MODIFIER", 263, 270]]], ["6, 9 Therefore, reducing exposure of unaffected individuals to those already infected is a critical strategy to reduce the spread of the COVID-19 infection and its associated mortality.", [["infection", "DISEASE", 146, 155], ["COVID-19", "ORGANISM", 137, 145], ["COVID-19", "SPECIES", 137, 145], ["unaffected individuals", "PROBLEM", 37, 59], ["a critical strategy", "TREATMENT", 89, 108], ["the COVID-19 infection", "PROBLEM", 133, 155], ["infection", "OBSERVATION", 146, 155]]], ["[10] [11] [12] Multiple screening schemes have been put into practice across the globe, each taking into consideration the specific scenario in which it is being instituted.", [["Multiple screening schemes", "TREATMENT", 15, 41], ["globe", "ANATOMY", 81, 86]]], ["12 A uniquely vulnerable population is that of the medical professionals involved in acute stroke evaluation, who may be exposed to stroke patients with undiagnosed COVID-19 infection at the time of evaluation, although the exact risk of contracting the disease is presently unknown, with indirect evidence suggesting it may be very low.", [["acute stroke", "DISEASE", 85, 97], ["stroke", "DISEASE", 132, 138], ["infection", "DISEASE", 174, 183], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["acute stroke evaluation", "TEST", 85, 108], ["stroke", "PROBLEM", 132, 138], ["undiagnosed COVID-19 infection", "PROBLEM", 153, 183], ["evaluation", "TEST", 199, 209], ["contracting the disease", "PROBLEM", 238, 261], ["vulnerable", "OBSERVATION_MODIFIER", 14, 24], ["population", "OBSERVATION", 25, 35], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["stroke", "OBSERVATION", 91, 97], ["infection", "OBSERVATION", 174, 183], ["disease", "OBSERVATION", 254, 261], ["low", "OBSERVATION_MODIFIER", 333, 336]]], ["[13] [14] [15] [16] [17] [18] [19] [20] [21] Recent evidence suggests that COVID-19 infection may be present in about 5.0% to 6.0% of stroke patients, and that COVID-19 may in turn increase the risk for stroke.", [["[13] [14] [15] [16] [17] [18] [19] [20", "CHEMICAL", 0, 38], ["COVID-19", "CHEMICAL", 75, 83], ["infection", "DISEASE", 84, 93], ["stroke", "DISEASE", 134, 140], ["COVID-19", "CHEMICAL", 160, 168], ["stroke", "DISEASE", 203, 209], ["COVID-19", "CHEMICAL", 160, 168], ["[13] [14] [15] [16] [17] [18] [19] [20] [21", "SIMPLE_CHEMICAL", 0, 43], ["COVID-19", "GENE_OR_GENE_PRODUCT", 75, 83], ["patients", "ORGANISM", 141, 149], ["COVID-19", "GENE_OR_GENE_PRODUCT", 160, 168], ["patients", "SPECIES", 141, 149], ["COVID", "TEST", 75, 80], ["infection", "PROBLEM", 84, 93], ["COVID", "TEST", 160, 165], ["stroke", "PROBLEM", 203, 209], ["infection", "OBSERVATION", 84, 93], ["risk for", "UNCERTAINTY", 194, 202], ["stroke", "OBSERVATION", 203, 209]]], ["22, 23 Still, the recommendations made to date largely emphasize patient screening, widespread use of personal protective equipment (PPE) (ie, masks, gowns, gloves, etc), and limited face-to-face interactions.", [["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72], ["patient screening", "TEST", 65, 82], ["personal protective equipment", "TREATMENT", 102, 131], ["gowns", "TREATMENT", 150, 155], ["gloves", "TREATMENT", 157, 163]]], ["16, 17, 23 Confirmation of COVID-19 infection requires detection of unique sequences of virus RNA using reverse-transcription polymerase chain reaction (RT-PCR) from oropharyngeal and nasopharyngeal swabs and, depending upon the kit being used and the need for an extramural reference laboratory, this can take 8-72 hours.", [["oropharyngeal", "ANATOMY", 166, 179], ["nasopharyngeal swabs", "ANATOMY", 184, 204], ["infection", "DISEASE", 36, 45], ["COVID-19", "ORGANISM", 27, 35], ["oropharyngeal", "ORGANISM_SUBDIVISION", 166, 179], ["nasopharyngeal swabs", "CANCER", 184, 204], ["virus RNA", "RNA", 88, 97], ["COVID-19", "SPECIES", 27, 35], ["COVID", "TEST", 27, 32], ["19 infection", "PROBLEM", 33, 45], ["virus RNA", "TREATMENT", 88, 97], ["reverse-transcription polymerase chain reaction", "TREATMENT", 104, 151], ["RT-PCR", "TEST", 153, 159], ["oropharyngeal and nasopharyngeal swabs", "TEST", 166, 204], ["the kit", "TEST", 225, 232], ["infection", "OBSERVATION", 36, 45], ["oropharyngeal", "ANATOMY", 166, 179], ["nasopharyngeal", "ANATOMY", 184, 198]]], ["Therefore, the use of RT-PCR to detect COVID-19 infection is not practical in the context of acute stroke management.", [["infection", "DISEASE", 48, 57], ["stroke", "DISEASE", 99, 105], ["COVID-19", "GENE_OR_GENE_PRODUCT", 39, 47], ["COVID-19", "SPECIES", 39, 47], ["RT-PCR", "TEST", 22, 28], ["COVID", "TEST", 39, 44], ["infection", "PROBLEM", 48, 57], ["acute stroke management", "TREATMENT", 93, 116], ["infection", "OBSERVATION", 48, 57], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["stroke", "OBSERVATION", 99, 105]]], ["16, 17, 23 However, increasing evidence suggests that distinct patterns of pulmonary involvement by the COVID-19 infection are identifiable by chest computed tomography (CT) scan in more than 75% of infected patients, with a sensitivity of 97% for early detection.", [["pulmonary", "ANATOMY", 75, 84], ["infection", "DISEASE", 113, 122], ["pulmonary", "ORGAN", 75, 84], ["COVID-19", "ORGANISM", 104, 112], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["COVID-19", "SPECIES", 104, 112], ["pulmonary involvement", "PROBLEM", 75, 96], ["the COVID-19 infection", "PROBLEM", 100, 122], ["chest computed tomography", "TEST", 143, 168], ["CT) scan", "TEST", 170, 178], ["a sensitivity", "TEST", 223, 236], ["early detection", "TEST", 248, 263], ["distinct", "OBSERVATION_MODIFIER", 54, 62], ["pulmonary", "ANATOMY", 75, 84], ["chest", "ANATOMY", 143, 148], ["infected", "OBSERVATION", 199, 207]]], ["[24] [25] [26] [27] [28] [29] These radiographic changes, including characteristic \"ground glass\" opacities and consolidation (Fig 1) , may be present prior to the onset of symptoms, and even predict future symptom onset in individuals who initially test negative by RT-PCR.", [["opacities", "DISEASE", 98, 107], ["[24] [25] [26] [27] [28] [29]", "SIMPLE_CHEMICAL", 0, 29], ["individuals", "ORGANISM", 224, 235], ["These radiographic changes", "TEST", 30, 56], ["characteristic \"ground glass\" opacities", "PROBLEM", 68, 107], ["consolidation", "PROBLEM", 112, 125], ["symptoms", "PROBLEM", 173, 181], ["RT", "TEST", 267, 269], ["PCR", "TEST", 270, 273], ["ground glass", "OBSERVATION", 84, 96], ["opacities", "OBSERVATION", 98, 107], ["consolidation", "OBSERVATION", 112, 125]]], ["[24] [25] [26] [27] [28] [29] Therefore, it seemed reasonable to assess the possible benefit of incorporating a chest CT scan for early detection of COVID-19-related pulmonary changes into the urgent imaging protocol routinely used in the evaluation of all stroke patients.", [["pulmonary", "ANATOMY", 166, 175], ["stroke", "DISEASE", 257, 263], ["[24] [25] [26] [27] [28] [29]", "SIMPLE_CHEMICAL", 0, 29], ["pulmonary", "ORGAN", 166, 175], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 264, 272], ["a chest CT scan", "TEST", 110, 125], ["COVID", "TEST", 149, 154], ["pulmonary changes", "PROBLEM", 166, 183], ["the urgent imaging protocol", "TEST", 189, 216], ["the evaluation", "TEST", 235, 249], ["chest", "ANATOMY", 112, 117], ["pulmonary", "ANATOMY", 166, 175], ["stroke", "OBSERVATION", 257, 263]]], ["The present study explored the utility of a bedside decisionmaking model that includes routinely acquiring a chest CT on every stroke patient.", [["stroke", "DISEASE", 127, 133], ["chest", "ORGANISM_SUBDIVISION", 109, 114], ["patient", "ORGANISM", 134, 141], ["patient", "SPECIES", 134, 141], ["The present study", "TEST", 0, 17], ["a chest CT", "TEST", 107, 117], ["chest", "ANATOMY", 109, 114]]], ["Specifically, we examined the implications on the outcomes of both the stroke patients who may be infected with COVID-19, and on the medical professionals whom they may expose.Literature Search and ReviewWe conducted a search of the English language literature in the National Library of Medicine via PubMed, using permutations of the following search terms: \"Stroke,\" \"myocardial infarction,\" \"asymptomatic,\" \"prodrome,\" \"prodromal,\" \"risk,\" \"hospital,\" \"hospitalization,\" \"CT,\" \"computed tomography,\" \"chest,\" \"quarantine,\" \"mortality,\" \"screening,\" and \"identification\" paired one at a time with one invariable term: \"COVID.\"", [["myocardial", "ANATOMY", 370, 380], ["chest", "ANATOMY", 504, 509], ["stroke", "DISEASE", 71, 77], ["Stroke", "DISEASE", 360, 366], ["myocardial infarction", "DISEASE", 370, 391], ["prodrome", "DISEASE", 411, 419], ["patients", "ORGANISM", 78, 86], ["myocardial", "MULTI-TISSUE_STRUCTURE", 370, 380], ["patients", "SPECIES", 78, 86], ["Stroke", "PROBLEM", 360, 366], ["myocardial infarction", "PROBLEM", 370, 391], ["asymptomatic", "PROBLEM", 395, 407], ["prodrome", "PROBLEM", 411, 419], ["CT", "TEST", 475, 477], ["computed tomography", "TEST", 481, 500], ["myocardial", "ANATOMY", 370, 380], ["infarction", "OBSERVATION", 381, 391], ["chest", "ANATOMY", 504, 509]]], ["Finally, we reviewed the Morbidity and Mortality Weekly Report (MMWR) of the Centers for Disease Control and Prevention (CDC) (ie, https://www.cdc.gov/mmwr/) and further identified applicable publications.", [["Disease Control", "TREATMENT", 89, 104]]], ["Once all relevant publications were selected, we reviewed them with particular attention to the following parameters: (a) risk of stroke patients harboring an asymp-tomatic COVID-19 infection, (B) risk of developing symptomatic COVID-19 infection following exposure, (c) chance of the chest CT being diagnostic (ie, consistent with COVID-19 infection) in asymptomatic COVID-19-infected patients, (d) case fatality rates in asymptomatic COVID-19-infected patients with diagnostic findings on chest CT, (e) case fatality rates in symptomatic COVID-19-infected patients, and (f) proportion of COVID-19 patients who require hospitalization.", [["chest", "ANATOMY", 285, 290], ["chest", "ANATOMY", 491, 496], ["stroke", "DISEASE", 130, 136], ["infection", "DISEASE", 182, 191], ["infection", "DISEASE", 237, 246], ["infection", "DISEASE", 341, 350], ["COVID-19-infected", "DISEASE", 368, 385], ["COVID-19-infected", "DISEASE", 436, 453], ["COVID-19-infected", "DISEASE", 540, 557], ["patients", "ORGANISM", 137, 145], ["chest", "ORGAN", 285, 290], ["COVID-19", "ORGANISM", 368, 376], ["patients", "ORGANISM", 386, 394], ["COVID-19", "ORGANISM", 436, 444], ["patients", "ORGANISM", 454, 462], ["chest", "ORGANISM_SUBDIVISION", 491, 496], ["patients", "ORGANISM", 558, 566], ["patients", "ORGANISM", 599, 607], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 386, 394], ["patients", "SPECIES", 454, 462], ["patients", "SPECIES", 558, 566], ["patients", "SPECIES", 599, 607], ["stroke", "PROBLEM", 130, 136], ["an asymp-tomatic COVID-19 infection", "PROBLEM", 156, 191], ["developing symptomatic COVID-19 infection", "PROBLEM", 205, 246], ["the chest CT", "TEST", 281, 293], ["COVID-19 infection", "PROBLEM", 332, 350], ["asymptomatic COVID", "TEST", 355, 373], ["fatality rates", "TEST", 405, 419], ["asymptomatic COVID", "TEST", 423, 441], ["diagnostic findings", "TEST", 468, 487], ["chest CT", "TEST", 491, 499], ["symptomatic COVID", "TEST", 528, 545], ["symptomatic", "OBSERVATION_MODIFIER", 216, 227], ["infection", "OBSERVATION", 237, 246], ["chest", "ANATOMY", 285, 290], ["chest", "ANATOMY", 491, 496]]], ["We concluded our literature data collection, and began our analysis on April 10, 2020.Clinical Decision ModelWe constructed a probabilistic decision tree to analyze the soundness of routinely incorporating a chest CT scan in the urgent imaging studies for the evaluation of acute stroke patients, in order to identify asymptomatic COVID-19 infections.", [["stroke", "DISEASE", 280, 286], ["infections", "DISEASE", 340, 350], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 287, 295], ["a chest CT scan", "TEST", 206, 221], ["the urgent imaging studies", "TEST", 225, 251], ["the evaluation", "TEST", 256, 270], ["acute stroke", "PROBLEM", 274, 286], ["asymptomatic COVID-19 infections", "PROBLEM", 318, 350], ["chest", "ANATOMY", 208, 213], ["acute", "OBSERVATION_MODIFIER", 274, 279], ["stroke", "OBSERVATION", 280, 286], ["infections", "OBSERVATION", 340, 350]]], ["We did not address those patients who present with signs and symptoms suggestive of a respiratory infection, because completing chest CT under these circumstances is wholly justified based on the existing literature and, therefore, does not require further assessment.", [["respiratory", "ANATOMY", 86, 97], ["respiratory infection", "DISEASE", 86, 107], ["patients", "ORGANISM", 25, 33], ["chest", "ORGAN", 128, 133], ["patients", "SPECIES", 25, 33], ["signs and symptoms", "PROBLEM", 51, 69], ["a respiratory infection", "PROBLEM", 84, 107], ["chest CT", "TEST", 128, 136], ["further assessment", "TEST", 249, 267], ["respiratory", "ANATOMY", 86, 97], ["infection", "OBSERVATION", 98, 107], ["chest", "ANATOMY", 128, 133]]], ["Each one represents the calculated mean (rounded to the nearest multiple of five) of all probabilities found in the literature and these, in turn, encompass the plausible range of values for each variable.", [["all probabilities", "PROBLEM", 85, 102]]], ["The logical arguments we used to choose the baseline values for each input a variable are specified in the following paragraphs.Clinical Decision ModelThe first variable, the probability that any given stroke patient harbors an asymptomatic COVID-19 infection, depends on the proportion of all COVID19-infected individuals who remain asymptomatic, augmented by a factor representative of the relationship between respiratory infection and stroke, as noted above.", [["respiratory", "ANATOMY", 413, 424], ["stroke", "DISEASE", 202, 208], ["infection", "DISEASE", 250, 259], ["respiratory infection", "DISEASE", 413, 434], ["stroke", "DISEASE", 439, 445], ["patient", "ORGANISM", 209, 216], ["COVID19", "GENE_OR_GENE_PRODUCT", 294, 301], ["individuals", "ORGANISM", 311, 322], ["patient", "SPECIES", 209, 216], ["an asymptomatic COVID-19 infection", "PROBLEM", 225, 259], ["asymptomatic", "PROBLEM", 334, 346], ["respiratory infection", "PROBLEM", 413, 434], ["stroke", "PROBLEM", 439, 445], ["infection", "OBSERVATION", 250, 259], ["respiratory", "ANATOMY", 413, 424], ["infection", "OBSERVATION", 425, 434], ["stroke", "OBSERVATION", 439, 445]]], ["22, 23 The magnitude of COVID-19 asymptomatic carriers is not known with certainty, and it is believed to be underestimated.", [["COVID", "TEST", 24, 29], ["believed to be", "UNCERTAINTY", 94, 108], ["underestimated", "OBSERVATION", 109, 123]]], ["3 The published data suggest that the proportion is between 1.5% and 17.9%, averaging 3.5%, which corresponds to the value we assigned it in our decision tree (ie, baseline value = .035 and plausible range = .015-.05).", [["The published data", "TEST", 2, 20], ["baseline value", "TEST", 164, 178]]], ["4,30-40 Next, we extrapolated the risk of developing symptomatic COVID-19 infection following exposure, considering the various levels of exposure risk and the estimated transmissibility of COVID-19, expressed in part by its basic reproductive number (R 0 ).", [["infection", "DISEASE", 74, 83], ["COVID-19", "CHEMICAL", 190, 198], ["developing symptomatic COVID-19 infection", "PROBLEM", 42, 83], ["exposure risk", "PROBLEM", 138, 151], ["COVID", "TEST", 190, 195], ["symptomatic", "OBSERVATION_MODIFIER", 53, 64], ["infection", "OBSERVATION", 74, 83]]], ["1, [18] [19] [20] [21] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] We reasoned that, considering the ongoing systematic precautions being instituted across medical facilities, the average risk could be estimated at 10% across all levels of exposure, although it would clearly be higher in very specific high-risk scenarios, and perhaps even lower if some of the recent reports are accurate.", [["1, [18] [19] [20] [21] [31] [32] [33", "CHEMICAL", 0, 36], ["[18] [19] [20] [21] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40", "SIMPLE_CHEMICAL", 3, 71], ["the ongoing systematic precautions", "TREATMENT", 103, 137]]], ["[18] [19] [20] Thus, we expressed this risk as a baseline value = .10 plus a plausible range = .05-.60.Clinical Decision ModelThe chance of a chest CT scan being diagnostic (ie, consistent with COVID-19 infection) in an asymptomatic COVID-19-infected patient varies between 10% and 100%.", [["chest", "ANATOMY", 142, 147], ["infection", "DISEASE", 203, 212], ["COVID-19-infected", "DISEASE", 233, 250], ["chest", "ORGAN", 142, 147], ["COVID-19", "ORGANISM", 233, 241], ["patient", "ORGANISM", 251, 258], ["patient", "SPECIES", 251, 258], ["a chest CT scan", "TEST", 140, 155], ["COVID-19 infection", "PROBLEM", 194, 212], ["an asymptomatic COVID", "TEST", 217, 238], ["chest", "ANATOMY", 142, 147]]], ["[24] [25] [26] [27] [28] [29] Based on this information, and considering larger clinical 1, 4, 25, 30, 34, 44 It also seemed reasonable to expect that any given asymptomatic CODIV-19-infected patient would likely expose all staff members (with varying magnitude) with whom he came in contact, unless appropriate preventive measures were instituted.", [["[24] [25] [26] [27] [28] [29", "SIMPLE_CHEMICAL", 0, 28], ["CODIV-19", "ORGANISM", 174, 182], ["patient", "ORGANISM", 192, 199], ["patient", "SPECIES", 192, 199]]], ["10, [15] [16] [17] 23, 45 That is, the proportion of medical professionals exposed to an infected, yet asymptomatic, patient would likely have a baseline value = 1.0 and a plausible range = .10-1.00, the latter accounting for the widespread precautions instituted in most hospitals, including the use of PPE.", [["[15] [16] [17] 23", "SIMPLE_CHEMICAL", 4, 21], ["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["asymptomatic", "PROBLEM", 103, 115], ["the widespread precautions", "TREATMENT", 226, 252], ["PPE", "TREATMENT", 304, 307], ["infected", "OBSERVATION", 89, 97]]], ["10, [15] [16] [17] 23, 45 We then hypothesized that the identification of the COVID-19 infection by the chest CT scan would reduce the chances of exposure by half (ie, proportion of staff exposed = .50).Clinical Decision ModelThe decision tree outcomes (ie, the utility values of the terminal nodes) were quantified in quality-adjusted life months (QALM) of the survivors, rather than quality-adjusted life years due to the paucity of data on the long-term outcomes of COVID-19 infection.", [["chest", "ANATOMY", 104, 109], ["terminal nodes", "ANATOMY", 284, 298], ["infection", "DISEASE", 87, 96], ["COVID-19", "CHEMICAL", 469, 477], ["infection", "DISEASE", 478, 487], ["[15] [16] [17] 23", "SIMPLE_CHEMICAL", 4, 21], ["chest", "ORGAN", 104, 109], ["terminal nodes", "MULTI-TISSUE_STRUCTURE", 284, 298], ["COVID-19", "ORGANISM", 469, 477], ["COVID-19", "SPECIES", 469, 477], ["the COVID-19 infection", "PROBLEM", 74, 96], ["the chest CT scan", "TEST", 100, 117], ["COVID-19 infection", "PROBLEM", 469, 487], ["infection", "OBSERVATION", 87, 96], ["chest", "ANATOMY", 104, 109], ["terminal", "ANATOMY_MODIFIER", 284, 292], ["nodes", "ANATOMY", 293, 298], ["infection", "OBSERVATION", 478, 487]]], ["6, 9, [46] [47] [48] [49] The utility values were assigned using the following arguments: (a) the QALM of individuals not infected by COVID-19 is at least 12.0, allowing disease-free sur-vival up to the subsequent season (if, in fact COVID-19 turns out to be a seasonal virus); (b) the QALM of patients who test positive for COVID-19, and are either asymptomatic or do not require hospitalization, is probably around 11.00, having lost 1 month due to either quarantine or the known time course of the illness; 1,34,38,39,50 (c) the QALM of patients infected with COVID-19, and who require hospitalization, probably averages 9.0, having lost 3 months (conservatively) due to the impact of the illness, 1,34,38,39,50 and (d) the QALM of patients who die from COVID-19 infection is .0.Clinical Decision ModelOnce the results of \"folding back\" the decision tree became available, in order to minimize the risk of structural and programming errors negatively affecting them, we conducted individual univariate sensitivity analyses of all variables over their entire range, evaluating them graphically and specifically comparing the slopes of the different strategies and the rank order of the extreme values.", [["6, 9, [46] [47", "CHEMICAL", 0, 14], ["COVID-19", "CHEMICAL", 134, 142], ["illness", "DISEASE", 501, 508], ["illness", "DISEASE", 692, 699], ["infection", "DISEASE", 766, 775], ["[46] [47] [48] [49]", "SIMPLE_CHEMICAL", 6, 25], ["patients", "ORGANISM", 294, 302], ["patients", "ORGANISM", 540, 548], ["patients", "ORGANISM", 735, 743], ["patients", "SPECIES", 294, 302], ["patients", "SPECIES", 540, 548], ["patients", "SPECIES", 735, 743], ["The utility values", "TEST", 26, 44], ["COVID", "TEST", 134, 139], ["COVID", "TEST", 234, 239], ["a seasonal virus", "PROBLEM", 259, 275], ["COVID", "TEST", 325, 330], ["the illness", "PROBLEM", 497, 508], ["COVID", "TEST", 563, 568], ["COVID", "TEST", 757, 762], ["infection", "PROBLEM", 766, 775], ["structural and programming errors", "PROBLEM", 909, 942], ["infected", "OBSERVATION", 549, 557], ["illness", "OBSERVATION", 692, 699], ["infection", "OBSERVATION", 766, 775]]], ["All of the decision tree calculations (ie, \"folding back\") and sensitivity analyses were carried out using dedicated computer software (TreePlan TM v.2.03 and SensIt TM v.1.53.", [["sensitivity analyses", "TEST", 63, 83], ["SensIt TM", "TEST", 159, 168]]], ["51, 52ResultsThe results of the decision tree analysis are presented in Figure 2 .", [["the decision tree analysis", "TEST", 28, 54]]], ["The utility of incorporating a chest CT scan into the urgent stroke imaging is superior to not doing so (12.00 QALM vs 11.99 QALM, respectively), when the probability of detecting asymptomatic COVID-19 infection by chest CT scan in a stroke patient is 3.5%, the proportion of medical professionals exposed is 100% if the infection remains unidentified, and if such an exposure is reduced by 50% due to early detection of COVID-19 infection by chest CT scan.", [["chest", "ANATOMY", 31, 36], ["stroke", "DISEASE", 61, 67], ["infection", "DISEASE", 202, 211], ["stroke", "DISEASE", 234, 240], ["infection", "DISEASE", 321, 330], ["infection", "DISEASE", 430, 439], ["chest", "ORGAN", 31, 36], ["chest", "ORGAN", 215, 220], ["patient", "ORGANISM", 241, 248], ["chest", "ORGAN", 443, 448], ["patient", "SPECIES", 241, 248], ["a chest CT scan", "TEST", 29, 44], ["the urgent stroke imaging", "TEST", 50, 75], ["asymptomatic COVID-19 infection", "PROBLEM", 180, 211], ["chest CT scan", "TEST", 215, 228], ["the infection", "PROBLEM", 317, 330], ["COVID-19 infection", "PROBLEM", 421, 439], ["chest CT scan", "TEST", 443, 456], ["chest", "ANATOMY", 31, 36], ["chest", "ANATOMY", 215, 220], ["infection", "OBSERVATION", 321, 330], ["chest", "ANATOMY", 443, 448]]], ["These results appear fairly robust, as evidenced by the sensitivity analyses displayed in Table 2 .", [["the sensitivity analyses", "TEST", 52, 76], ["fairly", "OBSERVATION_MODIFIER", 21, 27], ["robust", "OBSERVATION", 28, 34]]], ["In fact, only one of the eight variables (ie, the risk of developing symptomatic COVID-19 infection following exposure) was found to have a threshold value within its plausible range, indicating that variations in this particular parameter directly affect the results of the decision tree (Table 2 and Fig 3A) .", [["infection", "DISEASE", 90, 99], ["symptomatic COVID-19 infection", "PROBLEM", 69, 99]]], ["The finding suggests that, at values greater than the threshold (ie, 16% chance of becoming symptomatic following exposure), the incorporation of a chest CT scan loses the beneficial effect.", [["chest", "ANATOMY", 148, 153], ["chest", "ORGAN", 148, 153], ["a chest CT scan", "TEST", 146, 161], ["chest", "ANATOMY", 148, 153]]], ["The tornado chart (Fig 3B) demonstrates how this same variable has the greatest swing and, therefore, introduces the greatest degree of uncertainty when interpreting the value of decision tree.", [["greatest swing", "OBSERVATION_MODIFIER", 71, 85]]], ["Interestingly, the input variable of the proportion of medical professionals exposed to COVID-19-infected patients has a degree of swing of comparable magnitude but in the opposite direction (Fig 3B) .", [["COVID-19-infected", "DISEASE", 88, 105], ["COVID-19", "ORGANISM", 88, 96], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["COVID", "TEST", 88, 93]]], ["These findings support incorporating a chest CT scan during acute stroke evaluation to reduce exposure to COVID-19 infection.", [["acute stroke", "DISEASE", 60, 72], ["COVID-19", "CHEMICAL", 106, 114], ["infection", "DISEASE", 115, 124], ["COVID-19", "CHEMICAL", 106, 114], ["a chest CT scan", "TEST", 37, 52], ["acute stroke evaluation", "TEST", 60, 83], ["COVID", "TEST", 106, 111], ["19 infection", "PROBLEM", 112, 124], ["chest", "ANATOMY", 39, 44], ["infection", "OBSERVATION", 115, 124]]], ["This is particularly noticeable when comparing the effect of marginal changes of the input variables on the decision tree results (Fig 3C) .", [["marginal", "OBSERVATION_MODIFIER", 61, 69]]], ["The proportion of medical professionals exposed to an asymptomatic COVID-19-infected patient continued to have the largest effect when expressed as a function of percentage changes from the baseline value (ie, the steepest slope in Fig 3C) .DiscussionThe value of incorporating a chest CT scan into acute stroke management protocols has to be interpreted with the understanding of the number of stroke patients who have concurrent COVID-19 infection, and the exposure risk to medical professionals.", [["COVID-19-infected", "DISEASE", 67, 84], ["stroke", "DISEASE", 305, 311], ["stroke", "DISEASE", 395, 401], ["infection", "DISEASE", 440, 449], ["COVID-19", "ORGANISM", 67, 75], ["patient", "ORGANISM", 85, 92], ["chest", "ORGAN", 280, 285], ["patients", "ORGANISM", 402, 410], ["patient", "SPECIES", 85, 92], ["patients", "SPECIES", 402, 410], ["an asymptomatic COVID", "TEST", 51, 72], ["percentage changes", "PROBLEM", 162, 180], ["a chest CT scan", "TEST", 278, 293], ["acute stroke management protocols", "TREATMENT", 299, 332], ["concurrent COVID-19 infection", "PROBLEM", 420, 449], ["largest", "OBSERVATION_MODIFIER", 115, 122], ["chest", "ANATOMY", 280, 285], ["acute", "OBSERVATION_MODIFIER", 299, 304], ["stroke", "OBSERVATION", 305, 311], ["infection", "OBSERVATION", 440, 449]]], ["A recent estimation suggests that approximately 35,867 stroke patients who also have a COVID-19 infection may be seen worldwide.", [["stroke", "DISEASE", 55, 61], ["infection", "DISEASE", 96, 105], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["A recent estimation", "TEST", 0, 19], ["a COVID-19 infection", "PROBLEM", 85, 105], ["infection", "OBSERVATION", 96, 105]]], ["23 Moreover, recent data from the CDC show that approximately 20% of COVID-19-infected persons in the United States have been medical professionals, highlighting the high exposure risk within hospitals.", [["COVID-19-infected", "DISEASE", 69, 86], ["COVID-19", "ORGANISM", 69, 77], ["persons", "ORGANISM", 87, 94], ["persons", "SPECIES", 87, 94], ["COVID", "TEST", 69, 74]]], ["Therefore, exposure to COVID-19 infection within the hospital remains an important issue.", [["COVID-19", "CHEMICAL", 23, 31], ["infection", "DISEASE", 32, 41], ["COVID-19", "ORGANISM", 23, 31], ["COVID", "TEST", 23, 28], ["infection", "PROBLEM", 32, 41], ["infection", "OBSERVATION", 32, 41]]], ["Nevertheless, the question that remains unanswered is \"what is the actual risk of contracting COVID-19 infection after being exposed in the hospital, particularly to an asymptomatic or mildly symptomatic patient?\"", [["COVID-19", "CHEMICAL", 94, 102], ["infection", "DISEASE", 103, 112], ["COVID-19", "ORGANISM", 94, 102], ["patient", "ORGANISM", 204, 211], ["patient", "SPECIES", 204, 211], ["contracting COVID-19 infection", "PROBLEM", 82, 112], ["mildly symptomatic patient", "PROBLEM", 185, 211]]], ["Counterbalancing the CDC data mentioned above, recent publications suggest that this risk may be quite small.", [["may be quite", "UNCERTAINTY", 90, 102], ["small", "OBSERVATION_MODIFIER", 103, 108]]], ["[18] [19] [20] [21] On the other hand, these represent small retrospective series, with multiple limitations, including a failure to take into account that the sensitivity of RT-PCR testing for COVID-19 has a considerably high rate of false-negative results (ie, about 30%).", [["COVID-19", "CHEMICAL", 194, 202], ["small retrospective series", "PROBLEM", 55, 81], ["a failure", "PROBLEM", 120, 129], ["RT-PCR testing", "TEST", 175, 189], ["COVID", "TEST", 194, 199], ["small", "OBSERVATION_MODIFIER", 55, 60], ["failure", "OBSERVATION", 122, 129]]], ["24 The uncertainty surrounding this issue is illustrated by the sensitivity analysis of our decision model, although the threshold value of the input variable being higher than the baseline value suggests that lower than average risks would have little effect on the results.", [["the sensitivity analysis", "TEST", 60, 84], ["lower", "OBSERVATION_MODIFIER", 210, 215]]], ["The urgent management of acute stroke patients, some of whom may have unrecognized COVID-19 infection, has multiple challenges.", [["stroke", "DISEASE", 31, 37], ["infection", "DISEASE", 92, 101], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["The urgent management", "TREATMENT", 0, 21], ["acute stroke", "PROBLEM", 25, 37], ["unrecognized COVID-19 infection", "PROBLEM", 70, 101], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["stroke", "OBSERVATION", 31, 37], ["infection", "OBSERVATION", 92, 101], ["multiple", "OBSERVATION_MODIFIER", 107, 115]]], ["16, 17, 45 Acute stroke care is very timesensitive, requiring rapid clinical and imaging assessments, which may not allow time-consuming COVID-19 infection screening procedures.", [["stroke", "DISEASE", 17, 23], ["infection", "DISEASE", 146, 155], ["Acute stroke care", "PROBLEM", 11, 28], ["very timesensitive", "PROBLEM", 32, 50], ["imaging assessments", "TEST", 81, 100], ["COVID", "TEST", 137, 142], ["infection screening procedures", "TREATMENT", 146, 176], ["Acute", "OBSERVATION_MODIFIER", 11, 16], ["stroke", "OBSERVATION", 17, 23]]], ["16, 17, 45 Also, the history of exposure and symptoms suggestive of COVID-19 infection may not be reliably ascertained due to aphasia, altered consciousness, and other neurologic deficits inherent to the stroke syndrome.", [["neurologic", "ANATOMY", 168, 178], ["infection", "DISEASE", 77, 86], ["aphasia", "DISEASE", 126, 133], ["altered consciousness", "DISEASE", 135, 156], ["neurologic deficits", "DISEASE", 168, 187], ["stroke", "DISEASE", 204, 210], ["symptoms", "PROBLEM", 45, 53], ["COVID-19 infection", "PROBLEM", 68, 86], ["aphasia", "PROBLEM", 126, 133], ["altered consciousness", "PROBLEM", 135, 156], ["other neurologic deficits", "PROBLEM", 162, 187], ["the stroke syndrome", "PROBLEM", 200, 219], ["infection", "OBSERVATION", 77, 86], ["stroke syndrome", "OBSERVATION", 204, 219]]], ["Moreover, the exposure risk is not limited to the emergency department but extends to other sites such as angiographic suites if endovascular intervention is necessary and/or intensive care units when patients require multimodal monitoring.", [["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 129, 141], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209], ["endovascular intervention", "TREATMENT", 129, 154], ["multimodal monitoring", "TEST", 218, 239]]], ["Therefore, early identification of stroke patients who have COVID-19 infection may considerably reduce the exposure of medical professionals working at multiple hospital locations.", [["stroke", "DISEASE", 35, 41], ["infection", "DISEASE", 69, 78], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["stroke", "PROBLEM", 35, 41], ["COVID-19 infection", "PROBLEM", 60, 78], ["infection", "OBSERVATION", 69, 78]]], ["The acquisition of a chest CT scan concurrently with a head CT scan has been recommended for the evaluation of acute stroke patients during the COVID-19 infection pandemic, but such suggestion has been based on expert opinion, and the need for a data-driven assessment of this issue has been acknowledged.", [["head", "ANATOMY", 55, 59], ["stroke", "DISEASE", 117, 123], ["infection", "DISEASE", 153, 162], ["head", "ORGANISM_SUBDIVISION", 55, 59], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["a chest CT scan", "TEST", 19, 34], ["a head CT scan", "TEST", 53, 67], ["the evaluation", "TEST", 93, 107], ["acute stroke", "PROBLEM", 111, 123], ["the COVID", "TEST", 140, 149], ["infection pandemic", "PROBLEM", 153, 171], ["a data", "TEST", 244, 250], ["driven assessment", "TEST", 251, 268], ["chest", "ANATOMY", 21, 26], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["stroke", "OBSERVATION", 117, 123], ["infection", "OBSERVATION", 153, 162]]], ["23 Presently, however, prospective clinical studies addressing this question are not available, thereby limiting the information from which to derive practical guidance.", [["prospective clinical studies", "TEST", 23, 51]]], ["51, 52 The results of our decision tree demonstrate that incorporating a chest CT scan within the urgent imaging protocol used to evaluate acute stroke patients constitutes a better strategy than not performing such a scan.", [["stroke", "DISEASE", 145, 151], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["a chest CT scan", "TEST", 71, 86], ["the urgent imaging protocol", "TEST", 94, 121], ["acute stroke", "PROBLEM", 139, 151], ["a scan", "TEST", 216, 222], ["chest", "ANATOMY", 73, 78], ["acute", "OBSERVATION_MODIFIER", 139, 144], ["stroke", "OBSERVATION", 145, 151]]], ["However, the value of this approach is small and appears sensitive to (a) attributes that would influence the risk of transmission of the COVID-19 infection following exposure and (b) the proportion of medical professionals inadvertently exposed to patients with unidentified COVID-19 infection (Table 2 and Fig 3) .", [["COVID-19", "CHEMICAL", 138, 146], ["infection", "DISEASE", 147, 156], ["infection", "DISEASE", 285, 294], ["COVID-19", "ORGANISM", 138, 146], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 249, 257], ["the COVID-19 infection", "PROBLEM", 134, 156], ["unidentified COVID-19 infection", "PROBLEM", 263, 294], ["small", "OBSERVATION_MODIFIER", 39, 44], ["infection", "OBSERVATION", 285, 294]]], ["Thus, as the risk of developing symptomatic COVID-19 infection increases, the benefit of screening stroke patients with a chest CT scan is reduced, probably due to the effect of increased infectivity of those with nondiagnostic chest CT studies, with a greater tendency for the infection to spread within the hospitalized population (Figs 3A and 3B).DiscussionOur clinical decision model has inherent limitations that must be considered in the interpretation of the results.", [["COVID", "DISEASE", 44, 49], ["infection", "DISEASE", 53, 62], ["stroke", "DISEASE", 99, 105], ["infection", "DISEASE", 278, 287], ["patients", "ORGANISM", 106, 114], ["chest", "ORGAN", 122, 127], ["patients", "SPECIES", 106, 114], ["developing symptomatic COVID-19 infection", "PROBLEM", 21, 62], ["screening stroke", "TREATMENT", 89, 105], ["a chest CT scan", "TEST", 120, 135], ["increased infectivity", "PROBLEM", 178, 199], ["nondiagnostic chest CT studies", "TEST", 214, 244], ["a greater tendency", "PROBLEM", 251, 269], ["the infection", "PROBLEM", 274, 287], ["symptomatic", "OBSERVATION_MODIFIER", 32, 43], ["infection", "OBSERVATION", 53, 62], ["chest", "ANATOMY", 122, 127], ["increased", "OBSERVATION_MODIFIER", 178, 187], ["infectivity", "OBSERVATION", 188, 199], ["chest", "ANATOMY", 228, 233], ["greater tendency", "OBSERVATION_MODIFIER", 253, 269], ["infection", "OBSERVATION", 278, 287]]], ["First, we used somewhat conservative baseline estimations of the variables, thereby increasing the burden of proof that incorporating a chest CT scan would be of any benefit.", [["chest", "ORGAN", 136, 141], ["a chest CT scan", "TEST", 134, 149], ["chest", "ANATOMY", 136, 141]]], ["For example, using a 50% reduction of medical professionals' exposure following early identification of infected patients by a diagnostic chest CT scan does not reflect the use of comprehensive isolation protocols, which may reduce exposure to 80% or more (ie, at rates comparable to those specified earlier) and may result in a higher magnitude of benefit.", [["patients", "ORGANISM", 113, 121], ["chest", "ORGAN", 138, 143], ["patients", "SPECIES", 113, 121], ["medical professionals' exposure", "TREATMENT", 38, 69], ["a diagnostic chest CT scan", "TEST", 125, 151], ["comprehensive isolation protocols", "TREATMENT", 180, 213], ["infected", "OBSERVATION_MODIFIER", 104, 112], ["chest", "ANATOMY", 138, 143]]], ["Second, our decision tree modeling is an oversimplification of the true pattern of spread of such an infective virus, because it selectively focuses on patient-to-medical professionals' exposure, and does not consider the subsequent exposure from one medical professional to another, as predicted by the exponential growth rate and the R 0 of the infection, originally estimated at .1-.14/day and 2.2-2.7, respectively.", [["infection", "DISEASE", 347, 356], ["patient", "ORGANISM", 152, 159], ["patient", "SPECIES", 152, 159], ["an infective virus", "PROBLEM", 98, 116], ["the exponential growth rate", "TEST", 300, 327], ["the infection", "PROBLEM", 343, 356], ["infective", "OBSERVATION_MODIFIER", 101, 110], ["virus", "OBSERVATION", 111, 116], ["infection", "OBSERVATION", 347, 356]]], ["32, 34, 36, [38] [39] [40] Therefore, any beneficial effect of an intervention destined to reduce exposure would be underestimated, by not accounting for second-degree exposures.", [["an intervention", "TREATMENT", 63, 78], ["second-degree exposures", "PROBLEM", 154, 177]]], ["This underestimation becomes even more pronounced when considering more recent data that suggest that the true R 0 of COVID-19 may be within the 5.0-7.0 interval.", [["COVID", "TEST", 118, 123], ["more pronounced", "OBSERVATION_MODIFIER", 34, 49]]], ["38, 54 A third limitation is that the model does not take into account the effect on the actual stroke patient whose urgent imaging protocol will incorporating a chest CT scan, particularly with regard to the time-sensitive therapeutic decisions required in this clinical scenario.", [["stroke", "DISEASE", 96, 102], ["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110], ["urgent imaging protocol", "TEST", 117, 140], ["a chest CT scan", "TEST", 160, 175], ["chest", "ANATOMY", 162, 167]]], ["16, 17, 45 However, chest CT scans can be presently completed in just a few minutes following any other neurologic CT studies, without removing the patient from the table.", [["neurologic", "ANATOMY", 104, 114], ["patient", "ORGANISM", 148, 155], ["patient", "SPECIES", 148, 155], ["chest CT scans", "TEST", 20, 34], ["any other neurologic CT studies", "TEST", 94, 125], ["chest", "ANATOMY", 20, 25]]], ["Such an addition is unlikely to interfere with treatment algorithms for intravenous thrombolysis and/or endovascular techniques.", [["intravenous", "ANATOMY", 72, 83], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 83], ["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 104, 116], ["treatment algorithms", "TREATMENT", 47, 67], ["intravenous thrombolysis", "TREATMENT", 72, 96], ["endovascular techniques", "TREATMENT", 104, 127]]], ["Finally, we are compelled to address the magnitude of the gain of incorporating a chest CT scan in the evaluation of every single patient.", [["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 130, 137], ["a chest CT scan", "TEST", 80, 95], ["the evaluation", "TEST", 99, 113], ["chest", "ANATOMY", 82, 87]]], ["Although decision-analytic purists have argued that it does not matter, 55 such a small margin could also be interpreted as either of the two courses of action being \"notinferior\" to the other.DiscussionIn conclusion, incorporating a chest CT into the urgent imaging protocol of acute stroke patients seems to reduce exposure of medical professionals, with a beneficial effect measurable in QALMs.", [["chest", "ANATOMY", 234, 239], ["stroke", "DISEASE", 285, 291], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 292, 300], ["a chest CT", "TEST", 232, 242], ["the urgent imaging protocol", "TEST", 248, 275], ["acute stroke", "PROBLEM", 279, 291], ["chest", "ANATOMY", 234, 239], ["acute", "OBSERVATION_MODIFIER", 279, 284], ["stroke", "OBSERVATION", 285, 291]]], ["The clinical impact of this benefit, however, is questionable, although it is likely to be magnified when comprehensive isolation techniques applied to patients identified by chest CT scan lead to greater than 80% reduction of the chance of exposure of medical professionals.", [["patients", "ORGANISM", 152, 160], ["chest", "ORGAN", 175, 180], ["patients", "SPECIES", 152, 160], ["comprehensive isolation techniques", "TREATMENT", 106, 140], ["chest CT scan", "TEST", 175, 188], ["likely to be", "UNCERTAINTY", 78, 90], ["chest", "ANATOMY", 175, 180]]]], "cb6479e01b1a54a8c2515dca7cf0d793b79a2261": [["gious virus, the Veterans Health Administration (VHA) was well positioned to provide virtual care at scale.", [["gious virus", "ORGANISM", 0, 11], ["gious virus", "SPECIES", 0, 11], ["gious virus", "PROBLEM", 0, 11], ["virtual care at scale", "TREATMENT", 85, 106]]]]}